CA1042792A - Fluorescence quenching with immunological pairs in immunoassays - Google Patents
Fluorescence quenching with immunological pairs in immunoassaysInfo
- Publication number
- CA1042792A CA1042792A CA233,197A CA233197A CA1042792A CA 1042792 A CA1042792 A CA 1042792A CA 233197 A CA233197 A CA 233197A CA 1042792 A CA1042792 A CA 1042792A
- Authority
- CA
- Canada
- Prior art keywords
- ligand
- receptor
- assay solution
- amount
- fluorescer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/18—Water
- G01N33/1826—Water organic contamination in water
- G01N33/1833—Oil in water
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/80—Fluorescent dyes, e.g. rhodamine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/816—Alkaloids, amphetamines, and barbiturates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
Abstract
FLUORESCENCE QUENCHING WITH
IMMUNOLOGICAL PAIRS IN IMMUNOASSAYS
ABSTRACT OF THE DISCLOSURE
Immunoassays arc provided employing antibodies and fluorescer-quencher (F-Q) chromophoric pair, wherein one or both of the chromophoric pair are bonded to antibodies.
Depending on the particular ligand of interest, various reagent combinations can be employed, where the amount of quenching is directly related to the amount of ligand present in the assay medium.
In carrying out the assay, the unknown and antibody specific for the ligand of interest to which is bound one of the F-Q pair, are combined in an aqueous buffered medium.
Depending on the protocol, different assay reagents are employed in the aqueous buffered medium: (1) ligand analog bonded to the other of the F-Q pair; (2) antibodies specific for the ligand to which is bound the other of the F-Q pair or; finally, (3) a combination of a plurality of ligands bonded together through linking groups to a hub molecule, usually a polymer, in combination with antibody bound to the other of the F-Q pair. The composition is irradiated with light at a wavelength, absorbed by the fluorescing molecule and the amount of fluorescence determined. By employing appropriate standards, the presence and amount of the ligand can be determined.
IMMUNOLOGICAL PAIRS IN IMMUNOASSAYS
ABSTRACT OF THE DISCLOSURE
Immunoassays arc provided employing antibodies and fluorescer-quencher (F-Q) chromophoric pair, wherein one or both of the chromophoric pair are bonded to antibodies.
Depending on the particular ligand of interest, various reagent combinations can be employed, where the amount of quenching is directly related to the amount of ligand present in the assay medium.
In carrying out the assay, the unknown and antibody specific for the ligand of interest to which is bound one of the F-Q pair, are combined in an aqueous buffered medium.
Depending on the protocol, different assay reagents are employed in the aqueous buffered medium: (1) ligand analog bonded to the other of the F-Q pair; (2) antibodies specific for the ligand to which is bound the other of the F-Q pair or; finally, (3) a combination of a plurality of ligands bonded together through linking groups to a hub molecule, usually a polymer, in combination with antibody bound to the other of the F-Q pair. The composition is irradiated with light at a wavelength, absorbed by the fluorescing molecule and the amount of fluorescence determined. By employing appropriate standards, the presence and amount of the ligand can be determined.
Description
iO4Z73;~ 1 ~l ~AC~(:R()llNI)_OF TIII INV~:NTION
2 II'icld of Lhc Invcntlon ¦ TllCIC i5 a couLinuing nccd for rapid scnsitive 4¦ n~ctllods for dctcr-ninillg miIlutc nmounts of org~nic compounds.
51 ~ number Or tcchniques have bccn dcvcloped towortl this end.
61 AmonE the commcrcially availab1e tcchniques arc radioimmuno-7 assay, spin-labelcd immuno.lssay, for which rcagcnts are sold 8 undcr the tradcmark F~AT~, homogcneous enzyme imlounoassay, I for which reagents are sold undcr thc tradcmar~ E~II ~, and 10 I hemagglutination (III). These techniques are effective for 11 ¦ determining amounts of materials in the rangc of l0 to 12 ~ lO l M or less;~
¦ These techniques all involve the ability of a 14 ¦ receptor molecule, uqually an antibody, to be able to re-I cognize a specific spatial and polar organization of a 16 molecule. Except for hemagglutination, the techniques 17 ¦ depend upon providing a reagent wl-ich can compete with the 18 ¦ molecule being assayed for the receptor. By being able to 19 ¦ distinguish between the reagent which is bound to receptor 20 I and reagent which is unbound, one can determine the amount 21 ¦ of the compound of interest which is present.
22 ¦ In developing immunoassays, one is limited by the 23 ¦ availability and properties of an appropriate receptor.
24 j However, as for the other reagents and the technique of 25 ¦ measurement, there are a number of different considerations 26 ¦ which make for a more accurate, convenient or commercially 27 I desirable assay. First, it is desirable that there be a 28 ~ minimum number of measUrementS of the various reagents, as
51 ~ number Or tcchniques have bccn dcvcloped towortl this end.
61 AmonE the commcrcially availab1e tcchniques arc radioimmuno-7 assay, spin-labelcd immuno.lssay, for which rcagcnts are sold 8 undcr the tradcmark F~AT~, homogcneous enzyme imlounoassay, I for which reagents are sold undcr thc tradcmar~ E~II ~, and 10 I hemagglutination (III). These techniques are effective for 11 ¦ determining amounts of materials in the rangc of l0 to 12 ~ lO l M or less;~
¦ These techniques all involve the ability of a 14 ¦ receptor molecule, uqually an antibody, to be able to re-I cognize a specific spatial and polar organization of a 16 molecule. Except for hemagglutination, the techniques 17 ¦ depend upon providing a reagent wl-ich can compete with the 18 ¦ molecule being assayed for the receptor. By being able to 19 ¦ distinguish between the reagent which is bound to receptor 20 I and reagent which is unbound, one can determine the amount 21 ¦ of the compound of interest which is present.
22 ¦ In developing immunoassays, one is limited by the 23 ¦ availability and properties of an appropriate receptor.
24 j However, as for the other reagents and the technique of 25 ¦ measurement, there are a number of different considerations 26 ¦ which make for a more accurate, convenient or commercially 27 I desirable assay. First, it is desirable that there be a 28 ~ minimum number of measUrementS of the various reagents, as
3'1 -2-:~'' .
:
:
... . .. ._.__.. _ ._.. ~ .. _._;. _.. _~._.. _ .. __.. .... _,.__.. _ _ .. __ .. _ _. _.. .. _.. _.. ___.. _._ .. . ~
:
)4'~79Z
1 well a5 transfcrs of tllc varLous reagents. Scconlly, the 2 cquipment for measuring ;houl(l be reasonnbly ec~nomical, so 3 as to bc acccssible to a broad rnn~e of users. Thirdly, the reagents cmploycd sllould bc rclatively stable, 90 as to be ccpable of stor~ge and shipmelt. ~`ourthly, tle method 6 should not be sul-jcct to siglificant interfcrcnce from other 7 matcrials which may be adventiously present in the snmple to 8 be assayed. Other considcrations are ease of training of 9 tcclnicans, absencc of health hil~.a~ds, scns-;tivity, repro-ducibility, and applicability to a wide variety of ligands.
11 The subJcct invention is predicated on the phenom~non 12 ¦ of energy transfer between two chromophores. ~hen a fluorescing 13 clromophor is irradiated with light absorbed by the chromophore, 14 ¦ the fluorescing chromoplore can dissipate the ener~y of the absorbed light by emitting light of longer wavelength, that 16 1 is, fluorescing. If anot}er chromophore is within less than lOOA of the fluorescer and absorbs light at the wavelength 18 I of emission, there is a probability, depending upon other 19 factors, that the fluorescer will transfer to the other chromophore the energy which uould otherwise have been 21 emitted as light, in effect, quenching the fluorescer.
23 Description of the Prior Art 24 U. S. Patent No. 3,709,868 is exemplary of a radioimmunoassay. U. S. Patent No 3,690,834 is exemplary 26 of a spin immunoassay. U. S. Patent Nos. 3,654,090 and 27 3,817,837 are exemplary of en~yme immunoassays. Articles of 28 interest include an article by Ludwig Brand and James R.
233gl ¦ Goh1ke, CDt i ed, Y1~=re Bc~nce Probo for Str~ttl--e, Ao~=al ¦.
:` . .
": . ' .' . _ .. .. _ _.. .. _ _ _ ...... , __.. _ ._ _.. _.. ,.. _ .. .... ... , .... . .. .. _.. , _.. ..
. . '.
- ~14Z79'~, _evio~ c i~ioch~n~ try, 41, 843-~6~ (197~); and SLrycr, Sciencc, 162, S26 (1~6~). -___ _ SUIIMAI~Y O~` TIII. I~VI.~rIO~
_ _ _ _ _ _ _ _ _ _ _ A metlIod is prov:lded for determlnlIlg thc presenceor amount of arI o~ganic coMpound to ~hich a rcceptor, us~taLly antibody, is availablc or can be preparcd. The organic compound will be hcreinafter referred to as a ligand.
In carrying o~t the assay, two chromoph.ores are employed which are a fluorescer-quencher pair. The amount of fluorescer wIthin quenching distance of quencher is affected by the amount of ligand present in the assay medium.
One chromophore is introduced into the assay medium covalently bonded to a receptor composition which specifically binds to the ligand. The second chromophore can be introduced into the assay medium in different ways:
(1) covalently bonded to a receptor composition which is the same or different from the receptor composition conjugated to the first chro~ophore, but in both instances specifically binds to the ligand, and in the presence or absence of polyligand; or covalently bonded to ligand analog, where the : . .
ligand analog can compete with ligand for the receptor composition. The choice of modes of introduction will depend to a significant degree on the number of independent epltopic or haptenic sit~s present in the lieand.
. ~ .
:
:
... . .. ._.__.. _ ._.. ~ .. _._;. _.. _~._.. _ .. __.. .... _,.__.. _ _ .. __ .. _ _. _.. .. _.. _.. ___.. _._ .. . ~
:
)4'~79Z
1 well a5 transfcrs of tllc varLous reagents. Scconlly, the 2 cquipment for measuring ;houl(l be reasonnbly ec~nomical, so 3 as to bc acccssible to a broad rnn~e of users. Thirdly, the reagents cmploycd sllould bc rclatively stable, 90 as to be ccpable of stor~ge and shipmelt. ~`ourthly, tle method 6 should not be sul-jcct to siglificant interfcrcnce from other 7 matcrials which may be adventiously present in the snmple to 8 be assayed. Other considcrations are ease of training of 9 tcclnicans, absencc of health hil~.a~ds, scns-;tivity, repro-ducibility, and applicability to a wide variety of ligands.
11 The subJcct invention is predicated on the phenom~non 12 ¦ of energy transfer between two chromophores. ~hen a fluorescing 13 clromophor is irradiated with light absorbed by the chromophore, 14 ¦ the fluorescing chromoplore can dissipate the ener~y of the absorbed light by emitting light of longer wavelength, that 16 1 is, fluorescing. If anot}er chromophore is within less than lOOA of the fluorescer and absorbs light at the wavelength 18 I of emission, there is a probability, depending upon other 19 factors, that the fluorescer will transfer to the other chromophore the energy which uould otherwise have been 21 emitted as light, in effect, quenching the fluorescer.
23 Description of the Prior Art 24 U. S. Patent No. 3,709,868 is exemplary of a radioimmunoassay. U. S. Patent No 3,690,834 is exemplary 26 of a spin immunoassay. U. S. Patent Nos. 3,654,090 and 27 3,817,837 are exemplary of en~yme immunoassays. Articles of 28 interest include an article by Ludwig Brand and James R.
233gl ¦ Goh1ke, CDt i ed, Y1~=re Bc~nce Probo for Str~ttl--e, Ao~=al ¦.
:` . .
": . ' .' . _ .. .. _ _.. .. _ _ _ ...... , __.. _ ._ _.. _.. ,.. _ .. .... ... , .... . .. .. _.. , _.. ..
. . '.
- ~14Z79'~, _evio~ c i~ioch~n~ try, 41, 843-~6~ (197~); and SLrycr, Sciencc, 162, S26 (1~6~). -___ _ SUIIMAI~Y O~` TIII. I~VI.~rIO~
_ _ _ _ _ _ _ _ _ _ _ A metlIod is prov:lded for determlnlIlg thc presenceor amount of arI o~ganic coMpound to ~hich a rcceptor, us~taLly antibody, is availablc or can be preparcd. The organic compound will be hcreinafter referred to as a ligand.
In carrying o~t the assay, two chromoph.ores are employed which are a fluorescer-quencher pair. The amount of fluorescer wIthin quenching distance of quencher is affected by the amount of ligand present in the assay medium.
One chromophore is introduced into the assay medium covalently bonded to a receptor composition which specifically binds to the ligand. The second chromophore can be introduced into the assay medium in different ways:
(1) covalently bonded to a receptor composition which is the same or different from the receptor composition conjugated to the first chro~ophore, but in both instances specifically binds to the ligand, and in the presence or absence of polyligand; or covalently bonded to ligand analog, where the : . .
ligand analog can compete with ligand for the receptor composition. The choice of modes of introduction will depend to a significant degree on the number of independent epltopic or haptenic sit~s present in the lieand.
. ~ .
-4-.
- !l 104'~79Z
1 1 Wllcrc thc lignncl hns only one indcpcndcnt cpitoplc 2 ¦ site (monocpitopic), lls~mlly onc chron\opllorc will hc covalcntly 3 bondcd to a reccptor Eor li~and, nnd the othcr chromophore 4 will bc provided as covalcntly bondcd to a lip~and analoE or n combinntion of poly(ligand annlo~) and the chromopllore 6 covalcnl:ly bonded to reccptor for lignnd.
7 Whcrc thc ligalld has n plllrality of indcpendent 8 epitopic si-es (polyepitopic), thc mode.~ indicatcd ahove may be uscd in addition to the following modes. In one mode, the two chromol11ores are individually bonded to receptor for 11 ligand. In another mode, receptor for llgand is obtained 12 from different species end one chromopllore is bonded to 13 receptor for the ligand-rcceptor from one species and the 14 other chromophore bonded to receptor for ligand-receptor 1~ from the other species. The latter method expands the 16 versatility of the subject assay in allo~ing for colrimon I7 reagents for a wide variety of assays, siinplifies purifi-;~ cation procedures, and allows for the determination of the 19 presence of assemblages, as distinct from the co~ponent parts.
'~ I
32 -4a-104Z79~
1 ¦ Thc varlous matcrLnls n-c brousllt eogcthor in an 2 ¦a~ucous bu~cred mc(lium, incut~nted nnd trrDdiatcd with light 3 ¦al)sorbed by thc fluorcsccr molcculcs. By dctcrminlng the 4 ¦amount of fluorescence, nfter incubation for a predetcrmined
- !l 104'~79Z
1 1 Wllcrc thc lignncl hns only one indcpcndcnt cpitoplc 2 ¦ site (monocpitopic), lls~mlly onc chron\opllorc will hc covalcntly 3 bondcd to a reccptor Eor li~and, nnd the othcr chromophore 4 will bc provided as covalcntly bondcd to a lip~and analoE or n combinntion of poly(ligand annlo~) and the chromopllore 6 covalcnl:ly bonded to reccptor for lignnd.
7 Whcrc thc ligalld has n plllrality of indcpendent 8 epitopic si-es (polyepitopic), thc mode.~ indicatcd ahove may be uscd in addition to the following modes. In one mode, the two chromol11ores are individually bonded to receptor for 11 ligand. In another mode, receptor for llgand is obtained 12 from different species end one chromopllore is bonded to 13 receptor for the ligand-rcceptor from one species and the 14 other chromophore bonded to receptor for ligand-receptor 1~ from the other species. The latter method expands the 16 versatility of the subject assay in allo~ing for colrimon I7 reagents for a wide variety of assays, siinplifies purifi-;~ cation procedures, and allows for the determination of the 19 presence of assemblages, as distinct from the co~ponent parts.
'~ I
32 -4a-104Z79~
1 ¦ Thc varlous matcrLnls n-c brousllt eogcthor in an 2 ¦a~ucous bu~cred mc(lium, incut~nted nnd trrDdiatcd with light 3 ¦al)sorbed by thc fluorcsccr molcculcs. By dctcrminlng the 4 ¦amount of fluorescence, nfter incubation for a predetcrmined
5 ¦time intcrval or a~ter thc system hns approache(l cquilibrlum,
6 ¦and comparLns thc results obtaincd with onc or more known
7 standnrds, thc prescncc or amount of ligand cnn be detcrmined.
9 DF~s~r~ r-oN OF Tlll srll~cIFIc E~IBODI~I_NTS
Dcfinitions 11 Ligand--an organic molccule or assemblage, nornally 12 greater than 100 molecular weight and having at least one 13 functionality, normally polar, for which a receptor is either 1~. naturally nvailable or can be prepnred.
Ligand analog--a mono- or polyvalent radical a sub-16 stantial proportion of wllich has the same spatial and polar 17 organization as the ligand to define one or morc determinant 18 or epitopic sites capable of competing with the ligand for 19 the binding sites of a receptor, and differs from the ligand in the absence of an atom or functional group at the site of 21 binding to another molecule or in having a linking group which 22 has been introduced in place of one or more atoms originally 23 present in the ligand. The ligand analog procursor is the 24 compound employed for conJugating ligand or ligand analog to another molccule, e.g. chromophore.
26 Assemblage--a combination of organic molecules bound 27 to~ether by other than covalent bonds, genernlly hnving mole-28 cular weights exceeding 600, usunlly exceeding l,OOO and 29 may be l,OOO,OOO or more, for which receptor is cithor naturally 32 ¦available or c be r reppred illuotraeive as~pmb]pge Is .
'~' ~ ' ' .
:~ . . .
-:
1~4Z792 1 ¦~n nntlr~cn an(l alltii~o(ly) or, a molcculc ~rcpnrcd from two 2 ¦diacrcte entitics, normnlly jo:~nctl togethcr by wenk bonds, 3 sucll as polnr bon(ls or di.slllfidc bonds, wllich undcr the 4 con(litions o the systcm nrc cnpablc of be:i.ng in cqullibrtum : 5 wiL11 thc indivi(lual entities. .
6 ChrolDopllorc--a f1uorcscer or quellchcr molccule; in 7 tlle subjcct invcnt:ion, ~hc fluoresccr and quencller are intcr-
9 DF~s~r~ r-oN OF Tlll srll~cIFIc E~IBODI~I_NTS
Dcfinitions 11 Ligand--an organic molccule or assemblage, nornally 12 greater than 100 molecular weight and having at least one 13 functionality, normally polar, for which a receptor is either 1~. naturally nvailable or can be prepnred.
Ligand analog--a mono- or polyvalent radical a sub-16 stantial proportion of wllich has the same spatial and polar 17 organization as the ligand to define one or morc determinant 18 or epitopic sites capable of competing with the ligand for 19 the binding sites of a receptor, and differs from the ligand in the absence of an atom or functional group at the site of 21 binding to another molecule or in having a linking group which 22 has been introduced in place of one or more atoms originally 23 present in the ligand. The ligand analog procursor is the 24 compound employed for conJugating ligand or ligand analog to another molccule, e.g. chromophore.
26 Assemblage--a combination of organic molecules bound 27 to~ether by other than covalent bonds, genernlly hnving mole-28 cular weights exceeding 600, usunlly exceeding l,OOO and 29 may be l,OOO,OOO or more, for which receptor is cithor naturally 32 ¦available or c be r reppred illuotraeive as~pmb]pge Is .
'~' ~ ' ' .
:~ . . .
-:
1~4Z792 1 ¦~n nntlr~cn an(l alltii~o(ly) or, a molcculc ~rcpnrcd from two 2 ¦diacrcte entitics, normnlly jo:~nctl togethcr by wenk bonds, 3 sucll as polnr bon(ls or di.slllfidc bonds, wllich undcr the 4 con(litions o the systcm nrc cnpablc of be:i.ng in cqullibrtum : 5 wiL11 thc indivi(lual entities. .
6 ChrolDopllorc--a f1uorcscer or quellchcr molccule; in 7 tlle subjcct invcnt:ion, ~hc fluoresccr and quencller are intcr-
8 rclntcd. rhc .f].uoresce~r moleculc is a cllromopllore which is
9 nl>le to absorb light at one wavelength nnd emit li~,ht at 0 a longer wavclcngth. The qucncher molecule is cnp.lble of 11 inhibiting fluoresccnce, w1lt:n within a short distance, 13 usually le6s than about lOOA, of the fluorescer : 14 : 15 .. 10 . .
.
' 2Z . .
:~ 23 .
24 .
. 26 . .
; 27 . 29 3l .
~, 32 -5a-'"''~: . .
, . ~ ' .
-- .
.
' ,' :
:~
-...................................... . . .
1, ,,,, 16)~792 1 mnlecule, by .acccpLillg tlle cnergy which would otherw~se be 2 clnitted as fluore~scent ligllt. As fnr as thc molecule or 3 ComposlLion to whlcll the chromopllores are ~oined, in most 4 instance3, the fluorescer anù quencher will be interchan~eable, alehough there will frequently be some preference. Tberefore, 6 for purposes of generality, the two molecules will be referred 7 to as chro~ophores, ~lld individ~nlly referred to as Chl and ~3 Cl~2-9 Ligand analog-chroloopllore (ligand analog-(Ch2) )--ligand analog is covalently bound to one or more fluorescent 11 molecules or quencher molecules. With small ligands, those 12 below about 10,000 molecular weight, usually below about 13 2,000 molecular weight, the ligand analog will usually be 14 joined to fewer than 10 chromophores, usually from 1 to 10 chromophores, not more than about 1 chromophore per 1,000 16 molecular weight. With a large ligand, at least 2,000 17 molecular weight, usually at least about 10,000 molecular 18 weight, a plurality of chromophores may be covalently bound 19 to ligand analog. The number of chromophores present will be limited by the number which may be introduced without 21 masking too many epitopic sites of the ligand and the desire 2Z to have a sufficient number of chromophores to insure a 23 substantial a-nount of quenching when receptor-Chl is bound 24 to the ligand analog-(Chz)x.
Poly(ligand analog)-poly(chromophore)[poly(ligand 26 analog)-poly(Ch2)]--ligand analog and chromophore are bnnded 27 to a high molecular weight (as comrared to the ligand analog 29 and chromopllore) water soluble polyfunctionalized hub or
.
' 2Z . .
:~ 23 .
24 .
. 26 . .
; 27 . 29 3l .
~, 32 -5a-'"''~: . .
, . ~ ' .
-- .
.
' ,' :
:~
-...................................... . . .
1, ,,,, 16)~792 1 mnlecule, by .acccpLillg tlle cnergy which would otherw~se be 2 clnitted as fluore~scent ligllt. As fnr as thc molecule or 3 ComposlLion to whlcll the chromopllores are ~oined, in most 4 instance3, the fluorescer anù quencher will be interchan~eable, alehough there will frequently be some preference. Tberefore, 6 for purposes of generality, the two molecules will be referred 7 to as chro~ophores, ~lld individ~nlly referred to as Chl and ~3 Cl~2-9 Ligand analog-chroloopllore (ligand analog-(Ch2) )--ligand analog is covalently bound to one or more fluorescent 11 molecules or quencher molecules. With small ligands, those 12 below about 10,000 molecular weight, usually below about 13 2,000 molecular weight, the ligand analog will usually be 14 joined to fewer than 10 chromophores, usually from 1 to 10 chromophores, not more than about 1 chromophore per 1,000 16 molecular weight. With a large ligand, at least 2,000 17 molecular weight, usually at least about 10,000 molecular 18 weight, a plurality of chromophores may be covalently bound 19 to ligand analog. The number of chromophores present will be limited by the number which may be introduced without 21 masking too many epitopic sites of the ligand and the desire 2Z to have a sufficient number of chromophores to insure a 23 substantial a-nount of quenching when receptor-Chl is bound 24 to the ligand analog-(Chz)x.
Poly(ligand analog)-poly(chromophore)[poly(ligand 26 analog)-poly(Ch2)]--ligand analog and chromophore are bnnded 27 to a high molecular weight (as comrared to the ligand analog 29 and chromopllore) water soluble polyfunctionalized hub or
10~'~7~2' 1¦ nnclcus moleculc, Lo provide a plurallLy of lieand analo~
2 ¦ ~roups a11(1 chro1no~ orc ~rou1)G spaccd on thc surfacc of thc 3 ¦molcculc, so t11at wllen rcceptor-Chl is bo-lnd to liga11~
¦ ana~og, somc C1~l ~roups will bc prcscnt wiî:1-L11 q1lcnc11ing 5 ¦ dLstancc of Ch2 ~roups.
6 1 l'oly(ligand analog)--ligan(1 anslog grou1,s arc 7 bondcd to a hir,h molccular weight (a3 comparcd to ligand 8 a11alog) wntcr solul-lc polyfunct;ou.1lizcd lm-b or nuclcus 9 molecule, so thnt therc are a sufficicnt nu1nbcr of ligand 10 analogs per unit area for quenching to occur when the ll poly(li~and analoz) i9 saturated with receptor-Chl and 12 rcceptor-Ch2 in appropriate proportions.
t3 Receptor-chromophorc (receptor-Chl and receptor-l4 Ch2)--a receptor is a molecule which is capable of distin-guishing an epitopic site and bindinz to such site. Usually 16 receptors will have binding constants in excess of 104, 17 frequently, in excess of lO6. For the most part, receptors 18 are antibodies, although enzymes, nucleic acids, and ccrtain 9 globulins, may also act as receptors. In the sub~ect invention, for the most part, the receptors will be antibodies to which 21 one or more, usually at lcast two or more, chromophore 22 groups will be bound.
23 Reccptor composition--receptor composition is a 2~ homogcneous or heterogeneous composition capable of specific non-covalent binding to li~,and and ligand analog and includes 26 a composition which specifically recognizeS the lisand(anti-27 ligand) and a combination of ~nti-ligand and a composition 28 whLch specifically recognizes the anti-li~,and (anti(anti-ligand)).
31 ~ _7 '~ `., ' . ' .
'.
~ 1 104Z79~ l l ¦Gentrnl Stn~cmcnt of thc Invcl~tion ¦ The mctho(l is predLcated on Lhe employment of two 3 ¦chromopllores which form a flllorcscer-qucncher pnir. ~y 4 ¦havin~ a composition (rcceptor~ whlcll specificnlly rccognizes 5 ¦ or billds to n ligand to which one of the chromopllores ls 6 ¦ covalently bOIIClCCI~ alld hllVing thc .second chromophore bonded 7 ¦ to ligand a~ log or rcccpLor, the nmoullt of lignncl present 8 in the assay solutLon will affect the al~ount of quencher 9 within quenching distance of fluorescer. The a3say may be carried out competitively, whorc ligand analog competes with
2 ¦ ~roups a11(1 chro1no~ orc ~rou1)G spaccd on thc surfacc of thc 3 ¦molcculc, so t11at wllen rcceptor-Chl is bo-lnd to liga11~
¦ ana~og, somc C1~l ~roups will bc prcscnt wiî:1-L11 q1lcnc11ing 5 ¦ dLstancc of Ch2 ~roups.
6 1 l'oly(ligand analog)--ligan(1 anslog grou1,s arc 7 bondcd to a hir,h molccular weight (a3 comparcd to ligand 8 a11alog) wntcr solul-lc polyfunct;ou.1lizcd lm-b or nuclcus 9 molecule, so thnt therc are a sufficicnt nu1nbcr of ligand 10 analogs per unit area for quenching to occur when the ll poly(li~and analoz) i9 saturated with receptor-Chl and 12 rcceptor-Ch2 in appropriate proportions.
t3 Receptor-chromophorc (receptor-Chl and receptor-l4 Ch2)--a receptor is a molecule which is capable of distin-guishing an epitopic site and bindinz to such site. Usually 16 receptors will have binding constants in excess of 104, 17 frequently, in excess of lO6. For the most part, receptors 18 are antibodies, although enzymes, nucleic acids, and ccrtain 9 globulins, may also act as receptors. In the sub~ect invention, for the most part, the receptors will be antibodies to which 21 one or more, usually at lcast two or more, chromophore 22 groups will be bound.
23 Reccptor composition--receptor composition is a 2~ homogcneous or heterogeneous composition capable of specific non-covalent binding to li~,and and ligand analog and includes 26 a composition which specifically recognizeS the lisand(anti-27 ligand) and a combination of ~nti-ligand and a composition 28 whLch specifically recognizes the anti-li~,and (anti(anti-ligand)).
31 ~ _7 '~ `., ' . ' .
'.
~ 1 104Z79~ l l ¦Gentrnl Stn~cmcnt of thc Invcl~tion ¦ The mctho(l is predLcated on Lhe employment of two 3 ¦chromopllores which form a flllorcscer-qucncher pnir. ~y 4 ¦havin~ a composition (rcceptor~ whlcll specificnlly rccognizes 5 ¦ or billds to n ligand to which one of the chromopllores ls 6 ¦ covalently bOIIClCCI~ alld hllVing thc .second chromophore bonded 7 ¦ to ligand a~ log or rcccpLor, the nmoullt of lignncl present 8 in the assay solutLon will affect the al~ount of quencher 9 within quenching distance of fluorescer. The a3say may be carried out competitively, whorc ligand analog competes with
11 ligand for receptor, ligand analog bcing present as poly-l?. (ligand analog) or covalently bonded to chromophore. The 13 assay may also be carricd out non-competitively with ligands 14 having a plurality of epitopic sites, where receptor having each of the chromophcres binds to ligand.
I7 Compositions 18 Depending upon the particular protocol employed 19 and the ligand of interest, one or more of the following reagent compositions will be employed in the assay medium:
22 ligand analog-chromophore, poly~ligand analog)-poly(chromophore), 32 -7a-.
1 poly(ltgnnd allalog)~ one or two recep~ors ~nd one or t~o 2 receptor-chromo~llorcs Tbe first comrosi~ioll ~o he eonsidered 3 will be the ligand analog-cllromo~hore.
Ligand Al~log-CIIromollore and roly(l.i~an~ An~l_g)-6 Poly(Chrolllophore) 7 The liga-ld all~log-cllromorhore mny be subdivided 8 into two groupg. 1`be first grotlp is where the ligand ana]og-9 chromophore has a single lig~nd nnalog and a single cllro~ophore joined togethe1- by a relativcly short linl;ing group. In 11 these instances, the ligand analog for the most part will be !2 haptenie, rather than antigenic, and generally be less than 13 about lO,000 moleeular weight, more usually less than about 14 6,000 molecular weight, and freqllently in ~he range of about 125 to l,000 moleeular weight, excluding the linking group 16 employed for linking to the chromophore. ~`or the most part, 17 the ligand analog will differ from the ligand in having a lo partieular functionality replaeed by a bond, a hydrogen 19 replaeed by a bond, or a short carbon chain replaeed by a bond (by bond, it is in'tended to inelude multiple bonds, as 21 ~ well as single bonds) to join to the linking group for 22 linking to the chromophore. The various hzptenie or low 23 molecular we'ïght ligands will be discussed subsequently.
24 The linking group will normally have not more than about lO atoms in the c}lain between the lip,and and the 26 ehromophore, more usually having either a bond or from about 27 l to 6 atoms in the chain. The ato-ns for the most part will 28 be earbon, oxy8en~ nitrogen and sulfur, particularly earbon, o~ygen, and nitrogen.
. ' ~`'`' . ~
` . 1 . ..... , .. ... , .. . .. . . . .... .. ... ... , .. ..... .
. .
- '' ' . - :
' ' lO~Z79~
1 The ~unction~lltics involvcd in thc llnkillg group 2 w~ll normally ~c non-o~:o carl)ollyl (i~lcluclin~ imino nnd 3 thiollocarbonyl) oxy, nmino tparticulnrly tcr~iary amino or 4 qu~tcrnary) or combinations thercof, ~.g. amido~ carbamyl, and amidino.
6 lhc two clm-olnol-hores, ei~hcr flllorcsccr or quencher, 7 will normally hnve citllcr nn amino or alcohol function for 8 rcncting witll a non-oxo carbonyl function (lncluding the 9 nitrogcn and sulfur nnalogs thcrcof) or have n non-oY~o carbonyl function, which can be rcactcd with an amine or Il elcohol functionality.
I7 Compositions 18 Depending upon the particular protocol employed 19 and the ligand of interest, one or more of the following reagent compositions will be employed in the assay medium:
22 ligand analog-chromophore, poly~ligand analog)-poly(chromophore), 32 -7a-.
1 poly(ltgnnd allalog)~ one or two recep~ors ~nd one or t~o 2 receptor-chromo~llorcs Tbe first comrosi~ioll ~o he eonsidered 3 will be the ligand analog-cllromo~hore.
Ligand Al~log-CIIromollore and roly(l.i~an~ An~l_g)-6 Poly(Chrolllophore) 7 The liga-ld all~log-cllromorhore mny be subdivided 8 into two groupg. 1`be first grotlp is where the ligand ana]og-9 chromophore has a single lig~nd nnalog and a single cllro~ophore joined togethe1- by a relativcly short linl;ing group. In 11 these instances, the ligand analog for the most part will be !2 haptenie, rather than antigenic, and generally be less than 13 about lO,000 moleeular weight, more usually less than about 14 6,000 molecular weight, and freqllently in ~he range of about 125 to l,000 moleeular weight, excluding the linking group 16 employed for linking to the chromophore. ~`or the most part, 17 the ligand analog will differ from the ligand in having a lo partieular functionality replaeed by a bond, a hydrogen 19 replaeed by a bond, or a short carbon chain replaeed by a bond (by bond, it is in'tended to inelude multiple bonds, as 21 ~ well as single bonds) to join to the linking group for 22 linking to the chromophore. The various hzptenie or low 23 molecular we'ïght ligands will be discussed subsequently.
24 The linking group will normally have not more than about lO atoms in the c}lain between the lip,and and the 26 ehromophore, more usually having either a bond or from about 27 l to 6 atoms in the chain. The ato-ns for the most part will 28 be earbon, oxy8en~ nitrogen and sulfur, particularly earbon, o~ygen, and nitrogen.
. ' ~`'`' . ~
` . 1 . ..... , .. ... , .. . .. . . . .... .. ... ... , .. ..... .
. .
- '' ' . - :
' ' lO~Z79~
1 The ~unction~lltics involvcd in thc llnkillg group 2 w~ll normally ~c non-o~:o carl)ollyl (i~lcluclin~ imino nnd 3 thiollocarbonyl) oxy, nmino tparticulnrly tcr~iary amino or 4 qu~tcrnary) or combinations thercof, ~.g. amido~ carbamyl, and amidino.
6 lhc two clm-olnol-hores, ei~hcr flllorcsccr or quencher, 7 will normally hnve citllcr nn amino or alcohol function for 8 rcncting witll a non-oxo carbonyl function (lncluding the 9 nitrogcn and sulfur nnalogs thcrcof) or have n non-oY~o carbonyl function, which can be rcactcd with an amine or Il elcohol functionality.
12 ~here the ligand is of at least 2,000 molecular
13 wcigllt, a plurality of chromophore groups may be bound to
14 the ligand. Usually, there will be at least onc chromophore group per 20,000 molecular wcight, more usually at least one 16 chromophore group per 10,000 molecular weigllt and not uore 17 than one chromophorc group per 1,000 molecular weight, more 18 usually not more tllan one chromophore group per 2,000 molecular 19 weight. The considerations concerning the number of chromophores conjugated to the ligand have been previously enumerated.
21 The linking groups will be as previously described. Usually, 22 the ligand will be an antigenic polypeptide or protein 23 having a plurality of amino groups. Active halogen or non-24 oxo carbonyl (including nitrogen and sulfur analogs) can be used for conjugation to form a covalent bond or amides, amidines, 26 thionoamides, ureas, guanidines and thioureas.
27 Alternativcly, the ligand snd chromophore (Chl or 28 Ch2) may be linked to a hub molecule (poly(ligand analog)-29 poly(chromophore). The hub molecule or nuclcus molecule can 32 _9_ . ' ' ~ I 104Z79~ 1 1 ¦bc cmploycd witll ndv~nta~,c ror n varLcty of rc.~30ns~ Thc 2 ¦ nucleus molcclllc will. gcncr.nl1y bc a polyllleric molccu].c of 3 ¦rclatlvcly higl- molccular wcigllt, norm.tlly in exccss o~
4 20,000 molecul~r wcight, frc(lucntly 6(),000 molccular weiEht, an(l may bc 10 n~illion or higller. Thc nuclclls molcc~le will 6 norm.tlly bc waLer ~olublc or diDpersiblc in An .a(lllcous medium 7 to provide a sLablc dispcrsLon, wherc thc dis~crsiblc material 8 does not lnterfere wit:h th(~ absorl)tion or irr.~diation of light.
9 The nuclcus moleculc may be a naturally occurring material, a modified naturally occurring matcrial, or synthetic. Included 11 among nucleus moleculcs are polypeptldes, protein~, poly-12 sacchAridcs, synthetic polymcrs, and the like. The nature of 13 the hub molcculc may bc widely varied, so long as it is 14 sufficiently functionalizcd to permit the introduction of the ligand and the chromophorc molecules.
16 Among proteins which can find u~e are albumins, 17 globulins, protcoglycans, and tlle like; among polysaccharidcs 18 are amylose, cellulose, agarose, dextrans, or the like, either 19 as obtained or partially degraded; among synthctic polymers, polyvinylalcohol, acrylates, copolymers thereof or the like 21 may be employed.
22 ~ormally, there will be not less than about one 23 conjugate (ligand analog or chromophorc) molccule per 50,000 24 molecular weight, more usually not less than about one con-jugatc molecule per 25,000 molecular weight, and usual~y not 26 more than aboùt one conjugate mo~ecule per 1,000 molecular 27 weight, more usually not morc thnn about one conjugate 28 molccule pcr 2,000 molecular weight.
`'`~,v . , ~ ' .
. .
.
` .
.
1 ~ lO~Z79Z
1 Thc ratio o~ cl-romphorc molcculcs to ligand will 2 gcncr,ltly be from nbnuc 0.05-20:1, morc u-;ually from about 3 0.5-20:1, preferably from a~out l-lO:l, and more prefcrably 4 from about 2-8:1.
l~here the chromorllore is the fluorcsccr molecule - 6 for thc purposes of this invcntion, gcnerally thcre will be 7 at lcast about 0.5-20, morc usually from about 1-10, and 8 prefcrably f:-om about 2-7 Cluorescing molecules pcr ligand ~ molecule. Where the chromopllore is the quencher molecule, lO ¦ the number of qucncher molecules pcr ligand will gcnerally 11 ¦ be from about 0.5-20, more usually from about 1-20, and 12 ¦ preferably from about 2-l;5 per ligand molecule.
13 ¦ The conjugates to the hub molecule will have the 14 ¦ same type of linkinG group as was employed for jolning the 1~ ¦ chromophorc to the ligand. The particular choice of func-16 ¦ tionality will depend upon the available functional groups 17 1 on the nucleus molecule.
19 Reccptor-Chromophore ~, 20 Since in most instances the receptor i5 antibody, 21 the present description will refer to antibody as exemplary 22 of receptor. Antibodies have a number of active amino 23 groups which can be used for covalently conjugating the 24 chromophore to the antibody. Conveniently, the chromophore can have a non-oxo carbonyl functionality tincluding the 26 nitrogen and sulfur analogs thereof) or active a-halocarbonyl 27 functionality. Illustrative functionalities for lin~ing the 29 chromophorc to the antlbody include acyl halides, mixed 32 -Il-.
'lZ7~ l 1 nnllydridc~ lidatc al~yl cstcrs, isotllLocyallntc, cl~loro-2 hromo- or indoaccLyl~ au~l thc like.
3 The conditions or conjll~ation cmploy modcratc -empcrature~ 0 to 40C, in aqucous mcdia at modcratc pl{.
; 5 ConjuEation of chromopllores to ~rotcin is known in the art.
6 The, ct al., Immllno]or,y, 18, 865 (l970); Ceb~a, ct al., J.
7 Immunol., 95, 230 (l9G5); Goldman, Fluorescellt Antibody 8 ~lethods, ~cadcmic Press, New Yor~ (1968).
9 Thc nur,lbcr of chrolnopllore gro-lps which are con-jugatcd to the antibody may be varicd over a relatively ll broad range, depending on the chromophore involved. There 12 uill be at least one chromophore group per antibody, and 13 usually on the average, from about 2 to 30, more usually 14 from about 3 to 25 chromophore groups per antibody. llhere the chromophore is the fluorescer, the averagc number of 16 chromophore groups per antibody will be from about l to 20, 17 usually 2 to 15 znd more usually 2 to lO. Where the chromo-"` 18 phorc is the quencher, the average number of chromophore l9 groups per antibody uill be from about 2 to 30, usually 3 to 25, and more usually 5 to 25.
21 It should also be noted that when antibodies are 22 prepared for a ligand having a plurality of cpitopic sites, 23 the reccptor composition is not homogeneous. That is, the receptor will have antibodies uhich recognize different cpitopic sites. In rcferring to receptor, it i5 intended to 26 include all the antibodies which are capablc of specifically-27 binding to any of the cpitopic sites of thc ligand.
~ 228 .
.1 . . . .
.
- ~ 104Z79Z
'~IY(I_&-~d A~ o~.) 2 The poly(1ignnd analog) diffcrs frol~ tllc ligand 3 analog-chromophorc arld poly(ligand analog)-poly(cllromopllorc) in tbat no chromophore i9 prcsent, only ligand analo~. Thc same types oi nuclcus molcculcs and thc samc depree of 6 conjugation apply ior thc poly(ligand analor,) as for the 7 poly(liEand analog)-poly(chromophorc). I~owever, the ligand 8 analog may be prescnL in much lligher ratio than the hub 9 nucleus can accomodate receptor. Therefore, while a minimum number of ligand ~nalog groups are essential, the maximum 11 number is one of cxpedience. Thc significant factor is that 12 receptor molecules when bound to poly(ligand analog) can 13 come sufficiently close to allo~ the chromophores to come 14 within quenching distance.
In choosing a nucleus molecule, A number of 16 considerations will bear on the choice. ~hile it is not 17 essential that the nucleus molecule be water soluble, in 18 most instances, it ~ill be desirable. In any event, the 19 nucleus molecule or composition will be capable of stable dispersion in an aqueous medium. Secondly, the nucleus 21 molecule should not absorb light at the emission wavelength 22 of the fluorescer to cause significant qucnching. Thirdly, 23 the nucleus molecule should not fluoresce at the emission 24 wavelengths oI the fluorescer when irradiated with the exciting light. Therefore, any si~nificant absorption by 2b the nucleus molecule si-ould be belo-~ about 520nm, preferably 28 below about 450nm. .
.
-13- .
.
10~279Z
1 Thc- nuclcus n~oleculc ~hollld bc IILghly function-2 allzcd, prcfcral,ly with amino or hy<lroxyl groups, althou~ll 3 other reactive ~unction.11itics arc also uscful, c.g. carboxy.
lourthly, thc nuclcus molccule should be stable uncler conditions of storage ancl use. F:lfthly, the nucleus molecule 6 slloulll be inert to fullctionalities prescnt in thc chromophore 7 nnd ligancl, othcr than Lhe functiollality for lin~ing.
8 Ylnally, the nucleus molcculc should not interferc with the 9 immunoassay, for examl)le, by having naturally occurring receptors which may be present in physiological fluids which 11 are studied.
12 While any size of molcculc. may be employed, very .
13 large molecules or cells will create practical problems.
14 Yor example, a very large molecule passing through the light beam of the fluorometer could provide a sudden increase in 16 the peak height. Therefore, the signal obtained would have 17 to be averaged over a reasonable period of time. Large 18 molecules will also result in increased scatter, but the 19 scatter could be compensated for by an appropriate optical system. Preferably, for the most part, molacules will be 21 employed whicl- are less than about 10 million molecular 22 weight, more preferably from about 30,000 to 1,000,000 23 molecular weight.
Chromophore 28 Since -~ntibodies are nor~ally present in the assay 27 medium, and proteins absorb light of wavelengths up to about 28 310nm, the fluorescer will have substantial absorption 10~;~792 l higl)cr ~hnn 3101lm, normnlly lli~llcr than 3501lm, and prcfcrnbly 2 hl~hcr th;ll~ ouc l,OOnm. Thc choicc of fluorcscer will also 3 bc govcrned l.y thc pal-ticlllnr lignnd of intcrcst. Thc 4 ¦ fluorcscer shoulA ab:iorb ligllt at a hisller wavelcngth than 5 ¦ the ligalld or ligalld alm~log of intcrcst. A lligll cxtinction G ¦ co-efficient is dcnirnl>lc, grcatly tn exccss of 10, prcfcr.lbly 7 ¦ in excess of 10 , and pnrticulArly l)refcrrcd in cxcess of lO . A good ~m~ntum yicld should be availablc in thC nqllcous 9 ¦ medium for the fluoresccr. As a ;nnttcr of convcl~icncc, thc lO ¦ absorption pea~ of the fluorcsccr should no~ vary significnntly 11 ¦ with variation in the ligand.
12 ¦ A number of different fluorescers are describcd in 13 ¦ the articles previously noted; namely, Stryer, ~æ~, and l4 ¦ Brand, et al., supra.
21 The linking groups will be as previously described. Usually, 22 the ligand will be an antigenic polypeptide or protein 23 having a plurality of amino groups. Active halogen or non-24 oxo carbonyl (including nitrogen and sulfur analogs) can be used for conjugation to form a covalent bond or amides, amidines, 26 thionoamides, ureas, guanidines and thioureas.
27 Alternativcly, the ligand snd chromophore (Chl or 28 Ch2) may be linked to a hub molecule (poly(ligand analog)-29 poly(chromophore). The hub molecule or nuclcus molecule can 32 _9_ . ' ' ~ I 104Z79~ 1 1 ¦bc cmploycd witll ndv~nta~,c ror n varLcty of rc.~30ns~ Thc 2 ¦ nucleus molcclllc will. gcncr.nl1y bc a polyllleric molccu].c of 3 ¦rclatlvcly higl- molccular wcigllt, norm.tlly in exccss o~
4 20,000 molecul~r wcight, frc(lucntly 6(),000 molccular weiEht, an(l may bc 10 n~illion or higller. Thc nuclclls molcc~le will 6 norm.tlly bc waLer ~olublc or diDpersiblc in An .a(lllcous medium 7 to provide a sLablc dispcrsLon, wherc thc dis~crsiblc material 8 does not lnterfere wit:h th(~ absorl)tion or irr.~diation of light.
9 The nuclcus moleculc may be a naturally occurring material, a modified naturally occurring matcrial, or synthetic. Included 11 among nucleus moleculcs are polypeptldes, protein~, poly-12 sacchAridcs, synthetic polymcrs, and the like. The nature of 13 the hub molcculc may bc widely varied, so long as it is 14 sufficiently functionalizcd to permit the introduction of the ligand and the chromophorc molecules.
16 Among proteins which can find u~e are albumins, 17 globulins, protcoglycans, and tlle like; among polysaccharidcs 18 are amylose, cellulose, agarose, dextrans, or the like, either 19 as obtained or partially degraded; among synthctic polymers, polyvinylalcohol, acrylates, copolymers thereof or the like 21 may be employed.
22 ~ormally, there will be not less than about one 23 conjugate (ligand analog or chromophorc) molccule per 50,000 24 molecular weight, more usually not less than about one con-jugatc molecule per 25,000 molecular weight, and usual~y not 26 more than aboùt one conjugate mo~ecule per 1,000 molecular 27 weight, more usually not morc thnn about one conjugate 28 molccule pcr 2,000 molecular weight.
`'`~,v . , ~ ' .
. .
.
` .
.
1 ~ lO~Z79Z
1 Thc ratio o~ cl-romphorc molcculcs to ligand will 2 gcncr,ltly be from nbnuc 0.05-20:1, morc u-;ually from about 3 0.5-20:1, preferably from a~out l-lO:l, and more prefcrably 4 from about 2-8:1.
l~here the chromorllore is the fluorcsccr molecule - 6 for thc purposes of this invcntion, gcnerally thcre will be 7 at lcast about 0.5-20, morc usually from about 1-10, and 8 prefcrably f:-om about 2-7 Cluorescing molecules pcr ligand ~ molecule. Where the chromopllore is the quencher molecule, lO ¦ the number of qucncher molecules pcr ligand will gcnerally 11 ¦ be from about 0.5-20, more usually from about 1-20, and 12 ¦ preferably from about 2-l;5 per ligand molecule.
13 ¦ The conjugates to the hub molecule will have the 14 ¦ same type of linkinG group as was employed for jolning the 1~ ¦ chromophorc to the ligand. The particular choice of func-16 ¦ tionality will depend upon the available functional groups 17 1 on the nucleus molecule.
19 Reccptor-Chromophore ~, 20 Since in most instances the receptor i5 antibody, 21 the present description will refer to antibody as exemplary 22 of receptor. Antibodies have a number of active amino 23 groups which can be used for covalently conjugating the 24 chromophore to the antibody. Conveniently, the chromophore can have a non-oxo carbonyl functionality tincluding the 26 nitrogen and sulfur analogs thereof) or active a-halocarbonyl 27 functionality. Illustrative functionalities for lin~ing the 29 chromophorc to the antlbody include acyl halides, mixed 32 -Il-.
'lZ7~ l 1 nnllydridc~ lidatc al~yl cstcrs, isotllLocyallntc, cl~loro-2 hromo- or indoaccLyl~ au~l thc like.
3 The conditions or conjll~ation cmploy modcratc -empcrature~ 0 to 40C, in aqucous mcdia at modcratc pl{.
; 5 ConjuEation of chromopllores to ~rotcin is known in the art.
6 The, ct al., Immllno]or,y, 18, 865 (l970); Ceb~a, ct al., J.
7 Immunol., 95, 230 (l9G5); Goldman, Fluorescellt Antibody 8 ~lethods, ~cadcmic Press, New Yor~ (1968).
9 Thc nur,lbcr of chrolnopllore gro-lps which are con-jugatcd to the antibody may be varicd over a relatively ll broad range, depending on the chromophore involved. There 12 uill be at least one chromophore group per antibody, and 13 usually on the average, from about 2 to 30, more usually 14 from about 3 to 25 chromophore groups per antibody. llhere the chromophore is the fluorescer, the averagc number of 16 chromophore groups per antibody will be from about l to 20, 17 usually 2 to 15 znd more usually 2 to lO. Where the chromo-"` 18 phorc is the quencher, the average number of chromophore l9 groups per antibody uill be from about 2 to 30, usually 3 to 25, and more usually 5 to 25.
21 It should also be noted that when antibodies are 22 prepared for a ligand having a plurality of cpitopic sites, 23 the reccptor composition is not homogeneous. That is, the receptor will have antibodies uhich recognize different cpitopic sites. In rcferring to receptor, it i5 intended to 26 include all the antibodies which are capablc of specifically-27 binding to any of the cpitopic sites of thc ligand.
~ 228 .
.1 . . . .
.
- ~ 104Z79Z
'~IY(I_&-~d A~ o~.) 2 The poly(1ignnd analog) diffcrs frol~ tllc ligand 3 analog-chromophorc arld poly(ligand analog)-poly(cllromopllorc) in tbat no chromophore i9 prcsent, only ligand analo~. Thc same types oi nuclcus molcculcs and thc samc depree of 6 conjugation apply ior thc poly(ligand analor,) as for the 7 poly(liEand analog)-poly(chromophorc). I~owever, the ligand 8 analog may be prescnL in much lligher ratio than the hub 9 nucleus can accomodate receptor. Therefore, while a minimum number of ligand ~nalog groups are essential, the maximum 11 number is one of cxpedience. Thc significant factor is that 12 receptor molecules when bound to poly(ligand analog) can 13 come sufficiently close to allo~ the chromophores to come 14 within quenching distance.
In choosing a nucleus molecule, A number of 16 considerations will bear on the choice. ~hile it is not 17 essential that the nucleus molecule be water soluble, in 18 most instances, it ~ill be desirable. In any event, the 19 nucleus molecule or composition will be capable of stable dispersion in an aqueous medium. Secondly, the nucleus 21 molecule should not absorb light at the emission wavelength 22 of the fluorescer to cause significant qucnching. Thirdly, 23 the nucleus molecule should not fluoresce at the emission 24 wavelengths oI the fluorescer when irradiated with the exciting light. Therefore, any si~nificant absorption by 2b the nucleus molecule si-ould be belo-~ about 520nm, preferably 28 below about 450nm. .
.
-13- .
.
10~279Z
1 Thc- nuclcus n~oleculc ~hollld bc IILghly function-2 allzcd, prcfcral,ly with amino or hy<lroxyl groups, althou~ll 3 other reactive ~unction.11itics arc also uscful, c.g. carboxy.
lourthly, thc nuclcus molccule should be stable uncler conditions of storage ancl use. F:lfthly, the nucleus molecule 6 slloulll be inert to fullctionalities prescnt in thc chromophore 7 nnd ligancl, othcr than Lhe functiollality for lin~ing.
8 Ylnally, the nucleus molcculc should not interferc with the 9 immunoassay, for examl)le, by having naturally occurring receptors which may be present in physiological fluids which 11 are studied.
12 While any size of molcculc. may be employed, very .
13 large molecules or cells will create practical problems.
14 Yor example, a very large molecule passing through the light beam of the fluorometer could provide a sudden increase in 16 the peak height. Therefore, the signal obtained would have 17 to be averaged over a reasonable period of time. Large 18 molecules will also result in increased scatter, but the 19 scatter could be compensated for by an appropriate optical system. Preferably, for the most part, molacules will be 21 employed whicl- are less than about 10 million molecular 22 weight, more preferably from about 30,000 to 1,000,000 23 molecular weight.
Chromophore 28 Since -~ntibodies are nor~ally present in the assay 27 medium, and proteins absorb light of wavelengths up to about 28 310nm, the fluorescer will have substantial absorption 10~;~792 l higl)cr ~hnn 3101lm, normnlly lli~llcr than 3501lm, and prcfcrnbly 2 hl~hcr th;ll~ ouc l,OOnm. Thc choicc of fluorcscer will also 3 bc govcrned l.y thc pal-ticlllnr lignnd of intcrcst. Thc 4 ¦ fluorcscer shoulA ab:iorb ligllt at a hisller wavelcngth than 5 ¦ the ligalld or ligalld alm~log of intcrcst. A lligll cxtinction G ¦ co-efficient is dcnirnl>lc, grcatly tn exccss of 10, prcfcr.lbly 7 ¦ in excess of 10 , and pnrticulArly l)refcrrcd in cxcess of lO . A good ~m~ntum yicld should be availablc in thC nqllcous 9 ¦ medium for the fluoresccr. As a ;nnttcr of convcl~icncc, thc lO ¦ absorption pea~ of the fluorcsccr should no~ vary significnntly 11 ¦ with variation in the ligand.
12 ¦ A number of different fluorescers are describcd in 13 ¦ the articles previously noted; namely, Stryer, ~æ~, and l4 ¦ Brand, et al., supra.
15 ¦ One group of fluorescers having a number of the l6 ¦ desirable properties described previously are the xanthene 17 ¦ dyes, ~hich include the fluoresceins derived from 3,6-18 ¦ dihydroxy-9-phenyl-xanthhydrol and rosamines and rhodamines, ¦ derived from 3,6-diamino-9-phenylxanthhydrol. The rhodamines 20 ¦ and fluoresccins have a 9-o-carboxyphenyl group, and are derivatives of 9-o-carboxyphenylxanthhydrol.
2Z ¦ These compounds are commercially available with 23 ¦ substituents on the phenyl group which can be used as the 24 ¦ site for bonding or as the bonding functionality. For 25 ¦ example, amino and isothiocyanate substituted fluorescein 26 ¦ compounds arc available.
27 Another group of fluorescent compounds are the 28 naphthylamines, having an amino ~roup in the alpha or beta 2~
:
32 -lS-.:
' :-':
,' ' . ' ' ~
~. .
104,'~:79Z
1 po-;itinn, usu.llly nlph.1 pos1tion. Includc(l n1nong the 2 naphthyl3lllLno comro~ (1s arc 1-dlmct11ylnminon~1pllthyl-5-3 ;ulfonntc, 1-anilll1o-8-na1)lltllalcne sulfonatc nl1d 2-~-~, toluidinyl-6-na~ tllalcllc sulfonate.
~ Other dyes includc 3-phc1lyl-7-isocyanntocoumarin, 6 acridines, such as 9-isoL1-iocyanatoncridine and ncridine 7 orange; N-(p-(2-ben7oxE1zolyl)pl1enyl)maleimidc; benzoxa-8 (liazoles, sllc11 as ll-cl1loro-7-lli.~rnbcn7.o-2-oxa-l,3-diazole 9 and 7-(p-methoxybcnzyl.lmil1o)--4-nitroben7.o-2-oxa-l,3-diazolc;
stilbenes, suc21 as /I-dllllcthylalllino-l~-isothiocyanatostilbenc 11 ~nd ~I-dimethylamino-/~-maleimidostilbene; N,N~-dioctadecyloxa-12 carbocyanine p-toluenesulfo1late; pyrenes, such as 8-hydroxy-13 1,3,6-pyrenetrisulfonic acid, and l-pyrenebutyric acid, l4 merocyanine 540, rose bengal, 2,4-diphenyl-3(211)-furanone, as well as other readily available fluorescing molecules.
These dyes, either l1ave active functionalities or such 17 functionalities may be rcadily introduced.
18 Similar considerations involved with the fluorescer 19 molecule are applicab]e to the quenching molecule, except that a good fluorescent quantum yield is not requircd where 21 fluorescence of the fluorescer is bein~ measured. ~n additional 22 consideration Ior the quenching molecule i6 that it has its 23 absorption at an emission wavelength of the fluorescer.
24 Good overlap of the fluorescer emission and quencher absorption is desirable.
26 It should bc noted that both the absorption and 27 emission charnctcristics of the dye may vary from being free 29 ln solution nnd being bound to a prote:in or ligand. Thereforc, 33l .. . .. ., _.. ............. .. . .. ................. , . .. .. _ .. .. .. .. ;~. .. ........... , ... ..
.~ ' ' .
' ~)4'~79'~
1 I wllon reEerrLnE to ~he varlous ran~es nnd char.lcteri :tics oE
2 ¦ the dye~;, it is iuccode(l to Ln(lientu the dye as eml>loyed and 3 ¦ not the dye whlch 1:; uneonju~ated and charzlclerized in an ¦ arbitrary solvent. In the area of overlap between fluorescence 5 ¦ and quencllin&, thc quellcller should have extLnctlon coefficients 6 ¦ of the :alne order or higller than those ~;et forLIl for absoll tion 7 by tlle f]uorscing nolecule.
9 _i~
As indicated, the ligand will vary wide]y, normally 11 having a molecular weight oi at least llO, more usually at 12 least 125 with the maximum molecular weight unlimited, althougl 13 usually not exceeding 10 million. For the most part~ the 14 signifiesnt factor coneerning a ligand is that a receptor ean l5 be made to the ligand or is available. Normal]y, receptors
2Z ¦ These compounds are commercially available with 23 ¦ substituents on the phenyl group which can be used as the 24 ¦ site for bonding or as the bonding functionality. For 25 ¦ example, amino and isothiocyanate substituted fluorescein 26 ¦ compounds arc available.
27 Another group of fluorescent compounds are the 28 naphthylamines, having an amino ~roup in the alpha or beta 2~
:
32 -lS-.:
' :-':
,' ' . ' ' ~
~. .
104,'~:79Z
1 po-;itinn, usu.llly nlph.1 pos1tion. Includc(l n1nong the 2 naphthyl3lllLno comro~ (1s arc 1-dlmct11ylnminon~1pllthyl-5-3 ;ulfonntc, 1-anilll1o-8-na1)lltllalcne sulfonatc nl1d 2-~-~, toluidinyl-6-na~ tllalcllc sulfonate.
~ Other dyes includc 3-phc1lyl-7-isocyanntocoumarin, 6 acridines, such as 9-isoL1-iocyanatoncridine and ncridine 7 orange; N-(p-(2-ben7oxE1zolyl)pl1enyl)maleimidc; benzoxa-8 (liazoles, sllc11 as ll-cl1loro-7-lli.~rnbcn7.o-2-oxa-l,3-diazole 9 and 7-(p-methoxybcnzyl.lmil1o)--4-nitroben7.o-2-oxa-l,3-diazolc;
stilbenes, suc21 as /I-dllllcthylalllino-l~-isothiocyanatostilbenc 11 ~nd ~I-dimethylamino-/~-maleimidostilbene; N,N~-dioctadecyloxa-12 carbocyanine p-toluenesulfo1late; pyrenes, such as 8-hydroxy-13 1,3,6-pyrenetrisulfonic acid, and l-pyrenebutyric acid, l4 merocyanine 540, rose bengal, 2,4-diphenyl-3(211)-furanone, as well as other readily available fluorescing molecules.
These dyes, either l1ave active functionalities or such 17 functionalities may be rcadily introduced.
18 Similar considerations involved with the fluorescer 19 molecule are applicab]e to the quenching molecule, except that a good fluorescent quantum yield is not requircd where 21 fluorescence of the fluorescer is bein~ measured. ~n additional 22 consideration Ior the quenching molecule i6 that it has its 23 absorption at an emission wavelength of the fluorescer.
24 Good overlap of the fluorescer emission and quencher absorption is desirable.
26 It should bc noted that both the absorption and 27 emission charnctcristics of the dye may vary from being free 29 ln solution nnd being bound to a prote:in or ligand. Thereforc, 33l .. . .. ., _.. ............. .. . .. ................. , . .. .. _ .. .. .. .. ;~. .. ........... , ... ..
.~ ' ' .
' ~)4'~79'~
1 I wllon reEerrLnE to ~he varlous ran~es nnd char.lcteri :tics oE
2 ¦ the dye~;, it is iuccode(l to Ln(lientu the dye as eml>loyed and 3 ¦ not the dye whlch 1:; uneonju~ated and charzlclerized in an ¦ arbitrary solvent. In the area of overlap between fluorescence 5 ¦ and quencllin&, thc quellcller should have extLnctlon coefficients 6 ¦ of the :alne order or higller than those ~;et forLIl for absoll tion 7 by tlle f]uorscing nolecule.
9 _i~
As indicated, the ligand will vary wide]y, normally 11 having a molecular weight oi at least llO, more usually at 12 least 125 with the maximum molecular weight unlimited, althougl 13 usually not exceeding 10 million. For the most part~ the 14 signifiesnt factor coneerning a ligand is that a receptor ean l5 be made to the ligand or is available. Normal]y, receptors
16 can be made for most organic compounds having a polar fune-
17 tionalit~. Compounds for whieh antibodies ean be formed by 13 bonding the compound to a compound having antigenie properties 19 are referred to as haptens. Those compounds whieh elieit 20 antibody formation without ehemiea] modifieation are referred 21 to as antigens. See Kabat, et al., Experimental Immunochemistry, 22 Charles C. Thomas, Springfield, Illinois, 1967.
23 The non-polymerie ligands of interest will normally 24 be of from about 125 to 2,000 molecular weight. These eompounds 2~ involve a wide variety of eompounds of varying strueture, 26 Eunetionality, and physiological properties. 5he eompounds 27 may be aeyelic, alieyelie or heteroeyelie, both mono- and 28 polyeyelie. The heteroatoms involved inelude o~:yE;en, nitrogen, 29 sulfur, halogen tEluorine~ ehlorine, bromine and iodine) boron, 30 phosphorous, metal eations of Groups lA and 2A of the Periodie ` 32 Chnrt, transition metals, and the like.
`~ -17-.' ~.
1~)4~79~
1 Thc functionnl.ltics include nlcollols, ethers, cnrboxylic nc:ids~ e.qtcrs an(l nmides, amines ~primnry, 3 secondnry, tertiary and quaternar~) hnlo, nitrilo, merenpto~
4 and tlle ].ike. Normally, the compounds will be composed solely oE carbon, hydrogen, oxygen, nitrogen, halogen and : 6 phosp1lorous, particu].arl.y carbon, hydro~en, oxy~,en, and nitrosen and whcl-e salts are involved, the nppropriate metal 8 counter:ion or n~ oni~ collnterion, 9 Heteroeycl:ic r:ings ~hich are present inelude pyrrole, pyridine, piperidine, indole, thiazole, piperazine, 11 pyran, coumarin, pyrimidine, purinc, triazine, imidazole, 12 and the like.
.` 13 Because of the wide variety of compounds which can 14 be determined in aecordance with the subject assay, the different groups will be broken down into various, fre-16 quently artificial, eategories, either by the presenee of a 17 partieular functionality or ring strueture, or beeause of 13 sharing a partieulnr f unction or beeause of being reeognized as a class.
20 The first class of compounds of interest are those .
21 having an amino ~roup, either as a heterocyclie member, o~
22 as a funetionality on an aliphatic ehain. These componnds 23 will normally be of from about llO to 800 molecular weight, : more usually of about 125 to 650 moleeular weight. These .25 compounds frequently hnve an amino group separated by 2 to 3 26 aliphatie earbon atoms from a benzene ring.
27 The first Eroup of eompounds of interest are the 28 alkaloids and the metabolites of those alkaloids whicb aFc : 31 .
32 -18^
'~. .
`~ 104'~79~ 1 1 illlestcd. Thc first group of .importallt a].knlolds arc <tlhaloi~s 2 of thc morplline groltp. Includc(l ln tl-is groltp Are morphine, 3 cocleine, hcroin, morpllinc ~lucuronide nnd thc likc.
Thc next Eroup of nlkaloids arc the cocaine alk.-tloids, whicll includcs, pnrticulnrly as ntetabolite~, bcn~oyl cc~oninc 6 and ecgonine.
7 Anotller group of alkrtloids are the cincltona alkaloi.ds 8 which inc:Ludes quinine.
9 Tlle :Lsoquitlol:ille grottp of n].kaloids i.ncludes 10 mescaline . ' 11 The benzylisoquinoline alkaloid group includes 12 papaverine.
13 The phthalide isoquinoline alkaloid group includes 14 narcotine, narceine, and cotarnine.
The indolopyridocoline alkaloid group includes 16 yohimbine and reserpine.
17 The ergot alkaloid group includes ergotamine and
23 The non-polymerie ligands of interest will normally 24 be of from about 125 to 2,000 molecular weight. These eompounds 2~ involve a wide variety of eompounds of varying strueture, 26 Eunetionality, and physiological properties. 5he eompounds 27 may be aeyelic, alieyelie or heteroeyelie, both mono- and 28 polyeyelie. The heteroatoms involved inelude o~:yE;en, nitrogen, 29 sulfur, halogen tEluorine~ ehlorine, bromine and iodine) boron, 30 phosphorous, metal eations of Groups lA and 2A of the Periodie ` 32 Chnrt, transition metals, and the like.
`~ -17-.' ~.
1~)4~79~
1 Thc functionnl.ltics include nlcollols, ethers, cnrboxylic nc:ids~ e.qtcrs an(l nmides, amines ~primnry, 3 secondnry, tertiary and quaternar~) hnlo, nitrilo, merenpto~
4 and tlle ].ike. Normally, the compounds will be composed solely oE carbon, hydrogen, oxygen, nitrogen, halogen and : 6 phosp1lorous, particu].arl.y carbon, hydro~en, oxy~,en, and nitrosen and whcl-e salts are involved, the nppropriate metal 8 counter:ion or n~ oni~ collnterion, 9 Heteroeycl:ic r:ings ~hich are present inelude pyrrole, pyridine, piperidine, indole, thiazole, piperazine, 11 pyran, coumarin, pyrimidine, purinc, triazine, imidazole, 12 and the like.
.` 13 Because of the wide variety of compounds which can 14 be determined in aecordance with the subject assay, the different groups will be broken down into various, fre-16 quently artificial, eategories, either by the presenee of a 17 partieular functionality or ring strueture, or beeause of 13 sharing a partieulnr f unction or beeause of being reeognized as a class.
20 The first class of compounds of interest are those .
21 having an amino ~roup, either as a heterocyclie member, o~
22 as a funetionality on an aliphatic ehain. These componnds 23 will normally be of from about llO to 800 molecular weight, : more usually of about 125 to 650 moleeular weight. These .25 compounds frequently hnve an amino group separated by 2 to 3 26 aliphatie earbon atoms from a benzene ring.
27 The first Eroup of eompounds of interest are the 28 alkaloids and the metabolites of those alkaloids whicb aFc : 31 .
32 -18^
'~. .
`~ 104'~79~ 1 1 illlestcd. Thc first group of .importallt a].knlolds arc <tlhaloi~s 2 of thc morplline groltp. Includc(l ln tl-is groltp Are morphine, 3 cocleine, hcroin, morpllinc ~lucuronide nnd thc likc.
Thc next Eroup of nlkaloids arc the cocaine alk.-tloids, whicll includcs, pnrticulnrly as ntetabolite~, bcn~oyl cc~oninc 6 and ecgonine.
7 Anotller group of alkrtloids are the cincltona alkaloi.ds 8 which inc:Ludes quinine.
9 Tlle :Lsoquitlol:ille grottp of n].kaloids i.ncludes 10 mescaline . ' 11 The benzylisoquinoline alkaloid group includes 12 papaverine.
13 The phthalide isoquinoline alkaloid group includes 14 narcotine, narceine, and cotarnine.
The indolopyridocoline alkaloid group includes 16 yohimbine and reserpine.
17 The ergot alkaloid group includes ergotamine and
18 lysergic acid.
19 Other groups of alkaloids are strychnine alkaloids, pyridine alkaloids, piperidine alkaloids, py.rrolizidine alkaloids, and the like.
22 The alkaloids of primar~ intercst are those which 23 corme within the category of drugs of abuse, such ns morphine, 2~ cocaine, mescaline, and lysergic acid, ~Jhich may be analyzed for the compound or its metaholite, depending on the physio-26 logicnl fluid which is analyzed for its presence, 27 A nul~ber of synthetic drugs mimic tll~ physiological 28 properties, in part or in whole, of the naturally occurring 31 . .
''.'.
. ' . -.. . . -~ .
.
- 104Z79'~
l ¦ dru~-s of a~usc. Incl~l(lcd alllong ~hc3c drugs nre mcthil(lone, ¦ 2 ¦ mcpcridlnc, ampl~ct.llninc, l~h.lmpllct-lminc, glutctllimkle, 3 ¦ dipllcnylllyd.lnL~in~ an~ drugs wlllcl~ comc wiLhln the catcgory ¦ of bcnzdin~ocyclollept;lnes, phenotllia7incs and barl>iturates.
¦ I)rugs of intcrcst bccausc of their physiolop.i-al ! 6 ¦ propcrtics nrc thosc i~hich arc rcfcrred to as catecholamines.
¦ Among the catecllol~mines arc cpincphrinc, cphedrinc, L-dopa, 8 I allcl norepinephrine.
9 I Othcr drtlg~ of interest are the tranquilizer 10 ¦ lleprobamatc, Tcrgitol and succini~nides, such as Ethoxsumide.
11 ¦ Other compounds of interest arc tetrahydrocan-12 ¦ nabinol, cannabinol, and derivatives thereof, primarily 1~ ¦ compotlnds dcrived from marijuana, synthetic modifications and metabolites thereof.
15 ¦ Another group of compounds of significant interest ~ 15 I are the steroids. The steroids includc estrogene, gestogens, ; 17 I androgens, adrenocortical hormones, bile acids, cardiotonic ¦ glycoids, algycones, saponins and sapogenins.
19 ¦ Another class of compounds are the vitamins, such ~` 2d I as vitamin A, the B gsoup, e.g. vitamin Bl, ~6~ and B12, E, 21 ¦ ~, and the like.
22 ¦ Another class of co~pounds are the sugars, both 23 ¦ the mono- and polysaccharides, particularly di- and higher 2~ ~ order polysaccharides.
25 I Another class of compounds is the prosta~landins.
26¦ Another class of compounds are the amino acids, 27 ¦ polypeptides and proteins. Polypeptides usually encompass 29 ~ from about 2 to lO0 amino acid units (usually less than ' . .
.
.' ~ ,~ .. - ' :.
. - , ~
104~:79;~ 1 1 ¦ nl~ouL ].2,000 molee~ r we:lrllt:). Laruer poJ.ypepti(les ara ¦ 2 ¦ arbitr~rlly enl].ed protein-: 3ncl are usulll.ly eomposed of from 3 ¦ about 1 to 20 po:lypel)l:l(le ehains. roly(.llnino acid) will be ¦ used as generie to polyp(-ltides an(l proteLns. or partieular . 5 ¦:inlerest alnong c~m.ino ae.ids is thyronines, both tlle trl- and ; 6 ¦ tetra:io~o. Tlle poly(nm:ino ~cid)s employed in th.is Lnvention : 7 employillr, two ant:ibodies as re~nr,ents will generally ran~e 8 Irom al)ollt 5,000 to 107, uslla:Lly 10l to 106 molee~llar ~eight.
9 0f parc:icul.nr :interesL amonr, polylept:ides and proteins [poly(~mino acids)] are hormolles, globulins, antigens and Il cempositi.ons found to have speciEic physlolog:ical. activ.ities.
12 The wide variety of proteins may be considered as 13 to the family oE proteins having similar structural features, 14 protein~s having particular biological funetions, proteins : 15 related to speeifie microorganisms, partieularly d:isease lG eausing mieroorga~i,ms, ete.
17 The following are elasses of proteins related by 18 str~lcture:
19 protamines histones 21 albumins .
22 globlllins 23 scleroproteins 24 phosphoproteins : 25 mucoprotelns 26 chromoproteins 27 lipoproteLns .
28 nucleoproteins 31 .
32 -21^
' ~ -. - . ........ ,,.. ,., . ,.. _.. ,....... ............. ... .................. ..... _ ~1 . .
, ':
104;Z79Z, 1 unclass:l.ficd protcLns, c.g. somAlotropil~, 2 pro:lactin, lnsulin, pepsin 3 A numl~cr of protcins found in thc hllman plasma are import;lnt clinicall~ nnd lncludcs:
rrc~llbumin 6 Albumin 7 l-I.ipoprotcin 8 ~l-Ac:id glycoprotein 9 l-Antitrypsin l-Glycoprotcin :
Transcortln 4.6S-I'ostalbumin 13 Tryptopllan-poor 14 ¦ ~l-glycoprotein 15 ~ X-Glycoprotein lS ¦ Thyroxin-binding globulin 17 ¦ Inter-~-trypsin-inllibitor .
18 I GC_,A,1O~U1i~1 19 ¦ (GC 1-1)
22 The alkaloids of primar~ intercst are those which 23 corme within the category of drugs of abuse, such ns morphine, 2~ cocaine, mescaline, and lysergic acid, ~Jhich may be analyzed for the compound or its metaholite, depending on the physio-26 logicnl fluid which is analyzed for its presence, 27 A nul~ber of synthetic drugs mimic tll~ physiological 28 properties, in part or in whole, of the naturally occurring 31 . .
''.'.
. ' . -.. . . -~ .
.
- 104Z79'~
l ¦ dru~-s of a~usc. Incl~l(lcd alllong ~hc3c drugs nre mcthil(lone, ¦ 2 ¦ mcpcridlnc, ampl~ct.llninc, l~h.lmpllct-lminc, glutctllimkle, 3 ¦ dipllcnylllyd.lnL~in~ an~ drugs wlllcl~ comc wiLhln the catcgory ¦ of bcnzdin~ocyclollept;lnes, phenotllia7incs and barl>iturates.
¦ I)rugs of intcrcst bccausc of their physiolop.i-al ! 6 ¦ propcrtics nrc thosc i~hich arc rcfcrred to as catecholamines.
¦ Among the catecllol~mines arc cpincphrinc, cphedrinc, L-dopa, 8 I allcl norepinephrine.
9 I Othcr drtlg~ of interest are the tranquilizer 10 ¦ lleprobamatc, Tcrgitol and succini~nides, such as Ethoxsumide.
11 ¦ Other compounds of interest arc tetrahydrocan-12 ¦ nabinol, cannabinol, and derivatives thereof, primarily 1~ ¦ compotlnds dcrived from marijuana, synthetic modifications and metabolites thereof.
15 ¦ Another group of compounds of significant interest ~ 15 I are the steroids. The steroids includc estrogene, gestogens, ; 17 I androgens, adrenocortical hormones, bile acids, cardiotonic ¦ glycoids, algycones, saponins and sapogenins.
19 ¦ Another class of compounds are the vitamins, such ~` 2d I as vitamin A, the B gsoup, e.g. vitamin Bl, ~6~ and B12, E, 21 ¦ ~, and the like.
22 ¦ Another class of co~pounds are the sugars, both 23 ¦ the mono- and polysaccharides, particularly di- and higher 2~ ~ order polysaccharides.
25 I Another class of compounds is the prosta~landins.
26¦ Another class of compounds are the amino acids, 27 ¦ polypeptides and proteins. Polypeptides usually encompass 29 ~ from about 2 to lO0 amino acid units (usually less than ' . .
.
.' ~ ,~ .. - ' :.
. - , ~
104~:79;~ 1 1 ¦ nl~ouL ].2,000 molee~ r we:lrllt:). Laruer poJ.ypepti(les ara ¦ 2 ¦ arbitr~rlly enl].ed protein-: 3ncl are usulll.ly eomposed of from 3 ¦ about 1 to 20 po:lypel)l:l(le ehains. roly(.llnino acid) will be ¦ used as generie to polyp(-ltides an(l proteLns. or partieular . 5 ¦:inlerest alnong c~m.ino ae.ids is thyronines, both tlle trl- and ; 6 ¦ tetra:io~o. Tlle poly(nm:ino ~cid)s employed in th.is Lnvention : 7 employillr, two ant:ibodies as re~nr,ents will generally ran~e 8 Irom al)ollt 5,000 to 107, uslla:Lly 10l to 106 molee~llar ~eight.
9 0f parc:icul.nr :interesL amonr, polylept:ides and proteins [poly(~mino acids)] are hormolles, globulins, antigens and Il cempositi.ons found to have speciEic physlolog:ical. activ.ities.
12 The wide variety of proteins may be considered as 13 to the family oE proteins having similar structural features, 14 protein~s having particular biological funetions, proteins : 15 related to speeifie microorganisms, partieularly d:isease lG eausing mieroorga~i,ms, ete.
17 The following are elasses of proteins related by 18 str~lcture:
19 protamines histones 21 albumins .
22 globlllins 23 scleroproteins 24 phosphoproteins : 25 mucoprotelns 26 chromoproteins 27 lipoproteLns .
28 nucleoproteins 31 .
32 -21^
' ~ -. - . ........ ,,.. ,., . ,.. _.. ,....... ............. ... .................. ..... _ ~1 . .
, ':
104;Z79Z, 1 unclass:l.ficd protcLns, c.g. somAlotropil~, 2 pro:lactin, lnsulin, pepsin 3 A numl~cr of protcins found in thc hllman plasma are import;lnt clinicall~ nnd lncludcs:
rrc~llbumin 6 Albumin 7 l-I.ipoprotcin 8 ~l-Ac:id glycoprotein 9 l-Antitrypsin l-Glycoprotcin :
Transcortln 4.6S-I'ostalbumin 13 Tryptopllan-poor 14 ¦ ~l-glycoprotein 15 ~ X-Glycoprotein lS ¦ Thyroxin-binding globulin 17 ¦ Inter-~-trypsin-inllibitor .
18 I GC_,A,1O~U1i~1 19 ¦ (GC 1-1)
20 ¦ (GC 2-1)
21 ¦ (GC 2-2)
22 ¦ 11 aptozlobin
23 ¦ (HP 1-1) 2'~ ¦ (HP 2-1) 25 I (I~P 2-2) 26 ¦ CeruloplasmLn 27 ¦ Cholincstcrase 28 ¦ ~2-LipoprotQin(5) 30 I . .
31 I ~ ~22-'.;` ~ ' '~'.
I
.. .. . . ,,, , . _ , . ,,, ... . , _, . .. . .. .... .
-, , ' ' .
: .' ~ ' ' ' ' ~
1 ` I 104~`~9'~ l nL2-~l.ncroglol,lllln 2 ~-11S-r,lycoprotcin 3 Z~ 2-r,lycoprotcin 4 ~2-Nuuramino-glyco1~rotcin S I.ryLhropoietln 6 ~ ipoprotein 7 Tran~;forr:in 8 llclnol-exill 9 Yibr:;nogen Pla~;mlnogen ll ~2-glycoprotein I
12 ~2-glycoprotcin II
13 In1munoglobulin G
14 (IgG) or yG-globulin Mol. formula:
16 y2K2 or Y2~2 17 Immunoglobulin A (IgA) 18 or yA-globulin 9 Mol. formuln:
(2~2) or (~2A2) 21 Immunoglobulin M
22 (IgM) or yM-globulin 23 Mol. formula:
31 I ~ ~22-'.;` ~ ' '~'.
I
.. .. . . ,,, , . _ , . ,,, ... . , _, . .. . .. .... .
-, , ' ' .
: .' ~ ' ' ' ' ~
1 ` I 104~`~9'~ l nL2-~l.ncroglol,lllln 2 ~-11S-r,lycoprotcin 3 Z~ 2-r,lycoprotcin 4 ~2-Nuuramino-glyco1~rotcin S I.ryLhropoietln 6 ~ ipoprotein 7 Tran~;forr:in 8 llclnol-exill 9 Yibr:;nogen Pla~;mlnogen ll ~2-glycoprotein I
12 ~2-glycoprotcin II
13 In1munoglobulin G
14 (IgG) or yG-globulin Mol. formula:
16 y2K2 or Y2~2 17 Immunoglobulin A (IgA) 18 or yA-globulin 9 Mol. formuln:
(2~2) or (~2A2) 21 Immunoglobulin M
22 (IgM) or yM-globulin 23 Mol. formula:
24 (~2~2) or (~2~2) Immuno~loblllin D(IgD) 26 or yD-Clobulin (yD) 27 Mol. formula:
(~2K2) or (2 2 .
31 .
32 ~ - 22A -.' ~ ' .
'.' . .
, ~. ._ .. , . . . . , . . .... . ,, .. .... ,._, . .. .. , . . , ,, ., . , . . . ,__ _.. .. . . . . .. .. .
' , . ~
"
.. . .
~ '~ ' '.''. ~ . - .''' ' 1 Immnllo~tlol-~lill E (I~,Y) 2 or yE-Glol)ulin (yR) .
3 ~lol, formul;t:
(~2~2) Or (~2~2) Frcc li~ht ch~ins 6 Coml)lement f~ctors:
7 C'.l 8 C'lq 9 C'lr 0 C'ls C'2 12 C'3 13 ~1 14 ct.2D
c~4 lZ c~5 17 c'6 18 c'7 19 c~8 c~g 21 .
n ~ ZZb-1 . .
~.~
~ 104Z79;~ 1 1 ¦Importallt b].oo(1 elottin~ faetors inelude:
3T~lS~.E VII
4~LOOD C1.0TTlNG FACTORS .
_ _ _ _ _ -International ~esi~>nation Name 6 _ _ _ 7 I Fibrino~en II- Prothrombin 8 IIa Thromb~
III T:issue thromLoplastin 9 V and VI Proaccelor~ , accelerator ~lobulil1 0 VII Proconvertin VIII ~ntihe~:wpllilic globul:in (AIIG) IX Cilr:istmas faet or, plasma thromboplastin 12 component (PTC) : X S Luar t-Pro-ier faetor, 13 autoprothrombin III
: XI Plasma thromboplastin i 14 anteeedent (PTA) XII Ha~emann faetor XIII Fibrin-stabilizin~ faetor 16 _ _ 17 ..
~` 18 Important protein hormones inelude:
.i 19 Peptide and Protein Hormones .. ` 20 Parathyroid hormone 21 (parathormone) 22 Thyrocalcitonin . . 23 Insulin 24 Glucagon -. 25 Relaxin 26 Erythropoietin 27 Melanotropin 28 (melanocyte-stimulatlng 29 hormone; intermcdin) 3~ 22e-,.,,.~ .
.~., `~, . . ., .' .
:, ,, , ,. ,, ....... . .... -... - -- ` , : . : :
-: ' ': :' - . ' : - .
:~ ' - ~ ', ,- :~
-, , . , .. `- ~' ~ : ` ' ` I 10~;~79;~ l 1 SomnLotropin 2 (grow~ll hormone) 3 Corticotro~in (ndrcnc-corticotrol)ic hormolle) Thyrotropin 6 Folliclc-st~mulatill~ hormonc 7 Lutcini~.ing hormonc 8 (intcr3t:itial ccll-stimlllatins hormone) IO 1mlteomammotropic hormone ll (luteotropin, prolact:Ln) 12 Gonadotropin 13 (chorionic gonndotropin) 1~ Tissue ~ormones Secretin 16 Gastrin 17 Angiotensin I and II
B,radykinin 19 lluman placental lactogcn Peptide 11Ormones from the NQuroh~pophysis 21 Oxytocin 22 Vasopre~sin 23 Releasing factors (RF) 24 CRF, I,RF, TRF, Somatotropin-RF, GRF, FSII-RF, PIF, MIF
26 Other polymeric matcrials of interest are mucopoly-28 saccharides and poly-:nccharides.
29 . .
31 .
32 ~ -22d-' .
1 ILlustrat-lvt: ant.l~enic polysacch<lrllles derived 2 ~rotn nicroor~ .m~. ar( as ~ollo~s:
4 Slec ee of_~l.croorl2anic~ms _c o_en~:itin Found in 5 Scrcptoco~cus pyogenes rolysaccharide 6 Diplococcus pncllnoni3e Polysaccharide 7 ~cifi~cria men~ g:it:idis Polysaccharide Ne;sseria gonorrlloeae PolyF.accllaride Coryncbactcr;.lln dlpl~ eriae Polysaccharide 9i Actinobacll:l.u~ ma].lei; Crude extract i Act:inobac:illus ~ihitcmori 0 ¦ Francisella tularcnsi.s Liporolysaccharide ¦ ~ol~saccharide Pasteurella pestis 12 Pa3teurella pe.stis Polysaccharide Pasteurclla multocida Capsular anti~cn 13 I Brucella abortus Crudc extract llael~ophilus influenzae Pol.ysacchnri.de lf. llaemophi].us pcrtussis Crude ¦ Treponema reiteri Polysaccllaride 15 ¦ Vei].lonella l.ipopolysaccharide ¦ r.ryF.ipelothrix Pol~saccharide 16 ¦ Listeria monocytogenes Polysaccharide ¦ Chromobncterl-lm Lipopolysaccharide 17 ~Iycobacter:ium tuberculosis Sa].:ine extract of 90 . . rheno]. cxtracted 18 mycobacteria and poly-~ saccharide fraction of : 19¦ eells and tuberculin :~ I
20¦ Klebsiella aerogenes Polysaccharide ; I Klebsiella eloaeae Polysaccharide 21 ¦ Sal~onella typhosa Lipopolysaeeharide ¦ Polysaccharide , 22 ¦ Salmonclla typhi-murium; Polysaeeharide ~ 23 I Salmonella dcrby : ¦ Salmonella pullorum 24 ¦ Shigella dysenteriae Polysaccharide I
(~2K2) or (2 2 .
31 .
32 ~ - 22A -.' ~ ' .
'.' . .
, ~. ._ .. , . . . . , . . .... . ,, .. .... ,._, . .. .. , . . , ,, ., . , . . . ,__ _.. .. . . . . .. .. .
' , . ~
"
.. . .
~ '~ ' '.''. ~ . - .''' ' 1 Immnllo~tlol-~lill E (I~,Y) 2 or yE-Glol)ulin (yR) .
3 ~lol, formul;t:
(~2~2) Or (~2~2) Frcc li~ht ch~ins 6 Coml)lement f~ctors:
7 C'.l 8 C'lq 9 C'lr 0 C'ls C'2 12 C'3 13 ~1 14 ct.2D
c~4 lZ c~5 17 c'6 18 c'7 19 c~8 c~g 21 .
n ~ ZZb-1 . .
~.~
~ 104Z79;~ 1 1 ¦Importallt b].oo(1 elottin~ faetors inelude:
3T~lS~.E VII
4~LOOD C1.0TTlNG FACTORS .
_ _ _ _ _ -International ~esi~>nation Name 6 _ _ _ 7 I Fibrino~en II- Prothrombin 8 IIa Thromb~
III T:issue thromLoplastin 9 V and VI Proaccelor~ , accelerator ~lobulil1 0 VII Proconvertin VIII ~ntihe~:wpllilic globul:in (AIIG) IX Cilr:istmas faet or, plasma thromboplastin 12 component (PTC) : X S Luar t-Pro-ier faetor, 13 autoprothrombin III
: XI Plasma thromboplastin i 14 anteeedent (PTA) XII Ha~emann faetor XIII Fibrin-stabilizin~ faetor 16 _ _ 17 ..
~` 18 Important protein hormones inelude:
.i 19 Peptide and Protein Hormones .. ` 20 Parathyroid hormone 21 (parathormone) 22 Thyrocalcitonin . . 23 Insulin 24 Glucagon -. 25 Relaxin 26 Erythropoietin 27 Melanotropin 28 (melanocyte-stimulatlng 29 hormone; intermcdin) 3~ 22e-,.,,.~ .
.~., `~, . . ., .' .
:, ,, , ,. ,, ....... . .... -... - -- ` , : . : :
-: ' ': :' - . ' : - .
:~ ' - ~ ', ,- :~
-, , . , .. `- ~' ~ : ` ' ` I 10~;~79;~ l 1 SomnLotropin 2 (grow~ll hormone) 3 Corticotro~in (ndrcnc-corticotrol)ic hormolle) Thyrotropin 6 Folliclc-st~mulatill~ hormonc 7 Lutcini~.ing hormonc 8 (intcr3t:itial ccll-stimlllatins hormone) IO 1mlteomammotropic hormone ll (luteotropin, prolact:Ln) 12 Gonadotropin 13 (chorionic gonndotropin) 1~ Tissue ~ormones Secretin 16 Gastrin 17 Angiotensin I and II
B,radykinin 19 lluman placental lactogcn Peptide 11Ormones from the NQuroh~pophysis 21 Oxytocin 22 Vasopre~sin 23 Releasing factors (RF) 24 CRF, I,RF, TRF, Somatotropin-RF, GRF, FSII-RF, PIF, MIF
26 Other polymeric matcrials of interest are mucopoly-28 saccharides and poly-:nccharides.
29 . .
31 .
32 ~ -22d-' .
1 ILlustrat-lvt: ant.l~enic polysacch<lrllles derived 2 ~rotn nicroor~ .m~. ar( as ~ollo~s:
4 Slec ee of_~l.croorl2anic~ms _c o_en~:itin Found in 5 Scrcptoco~cus pyogenes rolysaccharide 6 Diplococcus pncllnoni3e Polysaccharide 7 ~cifi~cria men~ g:it:idis Polysaccharide Ne;sseria gonorrlloeae PolyF.accllaride Coryncbactcr;.lln dlpl~ eriae Polysaccharide 9i Actinobacll:l.u~ ma].lei; Crude extract i Act:inobac:illus ~ihitcmori 0 ¦ Francisella tularcnsi.s Liporolysaccharide ¦ ~ol~saccharide Pasteurella pestis 12 Pa3teurella pe.stis Polysaccharide Pasteurclla multocida Capsular anti~cn 13 I Brucella abortus Crudc extract llael~ophilus influenzae Pol.ysacchnri.de lf. llaemophi].us pcrtussis Crude ¦ Treponema reiteri Polysaccllaride 15 ¦ Vei].lonella l.ipopolysaccharide ¦ r.ryF.ipelothrix Pol~saccharide 16 ¦ Listeria monocytogenes Polysaccharide ¦ Chromobncterl-lm Lipopolysaccharide 17 ~Iycobacter:ium tuberculosis Sa].:ine extract of 90 . . rheno]. cxtracted 18 mycobacteria and poly-~ saccharide fraction of : 19¦ eells and tuberculin :~ I
20¦ Klebsiella aerogenes Polysaccharide ; I Klebsiella eloaeae Polysaccharide 21 ¦ Sal~onella typhosa Lipopolysaeeharide ¦ Polysaccharide , 22 ¦ Salmonclla typhi-murium; Polysaeeharide ~ 23 I Salmonella dcrby : ¦ Salmonella pullorum 24 ¦ Shigella dysenteriae Polysaccharide I
25 ¦ Shigella flcxneri .
26 ¦ Shi~ella sonnei Crude polysaecharide.
¦ Rickcttsiae Crudc extract
¦ Rickcttsiae Crudc extract
27 ¦ Candida albieans Polysaecharide .~ 2~ Entamoeba hi~tolyti~a Crude extraet `~ 31 .
32 -22e- .
.. .
:.:' " ' . . : '' : .
, ~ , ::
.
' 104'~79X, 1 ~notl~er group oi compourlds arc tlle nntibloties ~ such ns pen;cillJIl~ actino(nycil~ lorolllyeetin, and the 3 llke.
4 Indivi(llu~l compollllds of interest are serotonin, spermlne, an(l pllenylpyruvic Dcid.
6 ~ina:L:ly, compoulld3 whicll are pestici-les, sucll as 7 funr,icides, insecticide-;, bactericides, and nemcltocides, may 8 also be of interest for assaying.
9 Or11er (:llau compound3 of interest, cells, viruses, 0 and other biological aggrep,atiolls whicll are nnLigenic or to 11 which naturally oceurring receptors can be fo~lnd mny also be 12 assayed for.
13 ¦ The microorganisms which are assayed may be intact, 14 ¦ lysed, ground or otherwise fragmented, and the resulting 15 ¦ eomposition or portion, e g. by e~traetion, assayed. Micro-16 I organisms of interest inelude:
17 ¦ Corynebacter:ia 18 ¦ Corynebacterium diptheriae " 19 I
20 I Pneumococci 21 ¦ Diplocoeeus pneumoniae 22 1- .
23 ¦ Streptoeoeei 24 I Streptococcus pyogenes 25 ¦ Strcptococcus salivarus 27 ¦ Stapllylococci
32 -22e- .
.. .
:.:' " ' . . : '' : .
, ~ , ::
.
' 104'~79X, 1 ~notl~er group oi compourlds arc tlle nntibloties ~ such ns pen;cillJIl~ actino(nycil~ lorolllyeetin, and the 3 llke.
4 Indivi(llu~l compollllds of interest are serotonin, spermlne, an(l pllenylpyruvic Dcid.
6 ~ina:L:ly, compoulld3 whicll are pestici-les, sucll as 7 funr,icides, insecticide-;, bactericides, and nemcltocides, may 8 also be of interest for assaying.
9 Or11er (:llau compound3 of interest, cells, viruses, 0 and other biological aggrep,atiolls whicll are nnLigenic or to 11 which naturally oceurring receptors can be fo~lnd mny also be 12 assayed for.
13 ¦ The microorganisms which are assayed may be intact, 14 ¦ lysed, ground or otherwise fragmented, and the resulting 15 ¦ eomposition or portion, e g. by e~traetion, assayed. Micro-16 I organisms of interest inelude:
17 ¦ Corynebacter:ia 18 ¦ Corynebacterium diptheriae " 19 I
20 I Pneumococci 21 ¦ Diplocoeeus pneumoniae 22 1- .
23 ¦ Streptoeoeei 24 I Streptococcus pyogenes 25 ¦ Strcptococcus salivarus 27 ¦ Stapllylococci
28 ¦ Staphylococcus aurcus 2~ ¦ Stapllylococcus alb~lg 30 I .
31 I . . I .
32 ~ -23-'. . ....... ... ...... , ... _ .. . ... . .. ..... ... . ........
` I 104Z79,'~: l 1 Nei.qseriae 2 Neisscria mcnin~itidis 3 Neisser:La gonorrheac '~ ~
Enteroblcteri~ciae ~ __ c __, 6 Eschcrich;a coli 7 Aerobactcr acrogcncs The coliform bacteria 8 Kle.bsiella pne-unonile .
9 Salmonella ty?llosa 0 Salmonella choleracsuis ~ Tbc Salmonell.ae l ¦ Salmonella ty~himurium ¦ Shigella dysenteriae 13 ¦ Shigella schmit7.ii 14 ¦ Shigclla arabinotarda The Shigellae .
15 ¦ Shigella flexneri 16 ¦ Shigella boyùii .
17 ¦ Shigella Sonnei . .
18 I . .
19 ¦ Other enteric bacilli 20 ¦ Proteus vulgaris . -¦ Proteus mirabilis Proteus species 22 ¦ Proteus morgni 23 ¦ Pscudomonas aeruginosa 24 ¦ Alcaligenes faecalis Vlbrio cholerae 27 I .
28 I .
:' I .
.. I .
.
:, , .
: ,, ,. ~ ' . : ' :
: : -: . ' ' : .
: : -, , --. , .
: :
, ., ~ .
1~4~79 u~ C ~ r )u~
2 ¦ llcmol)hilu~3 lnflucnzllc, 11, ducrcyi 3 Il. hcmophilus ~ ~1. acr,yptlcus S , ~1. paraiu~lucnzac 6 Pordctclln pcrtussi3 o Paste~rellac 9 Pastcurclkl pcstls Pnstcurell;l tulareusis 12 P,rucellae 13 Brucella melitensis 14 Brucella abortus Brucella suis 17 Aerobic Spore-fornnin~ Bacilli 18 Bacillus anthracis 9 Bacillus subtilis Bacillus megaterium 21 Bacilllls cereus 23 Anaerobic Spore-forming ~acilli . Clostridium botulinum .
Clostridlum tetani 26 Clostrldium perfringcns 27 Clostridium novyi Clostridium septicum .
31 .
32 ~ -23b-~_ , . .. ,, ...... ~ _ ,. . . ........ .. ................. . ..... .
.~ ' ' . .
~ 104279'~
1 ¦ Clnstri(llnlm llistolyticllm 2 ¦ Clou~rl(lium tcrtium 3 ¦ Clo~tridLum bifcrmcntnns . C]ostridium sporocnes .
6 I~__o_~cteria 7 ~Iycob.lcter;llm tubcrculosis llominLs ~Iycobactel-iulD bovis ~Iycobncter:ium nviun ~Iycobacterlum leprac ~Iycobacterium paracuberculosis 2 . .
13 ~ctinnmycetes tfungus-like bacteria) 14 Actillomyces i~sraelii Actinomyces bovis 16 ~ctinomyces naeslundii 17 ~ocardia asteroides 18 Nocardia brasillensis The Spirochetes.
21 Treponema pallidum Spirillum minus 22 Treponema pertenue Streptobacillus moniliformis 23 Treponema carateum 24 ~orrelia recurrentis Leptospira icterohemorrha~iae .
ZB ¦ Le splro c~nicola 32 ~ -2~c-. . '" .
.~ 1 ~
.: : .
:-:-:: -' ' ' ; - :' "~ : : : . :
.. . .. . ..
.. :- :. :: -. ' , : : ' ~ . :
104'~792 1 I ~Iyco~nsmas I ~
2 ¦ ~Iycoplasmn pncllmoniae Other patho ~ens Listeria monocytogclles 6 Erysipelothli~ rhllsiopatlllae 7 Strel)tobac:illus moniliEormis 8 Donvnnia p>rall-llomatis 9 ~arconella bacilliformis ~ 11 Rickettsiae (bncteria-like parasi~es) .
12 Riclcettsia prol~azekii 13 Rickettsia mooseri 14 Riekettsin rickettsii Riclcettsia conori 16 Rickettsia australis 17 Rickettsia sibiricus 18 Rickettsia akari 19 Rickettsia tsutsugnmushi Rickettsia burnetii 21 Rickettsia quintana 23 Chlamydin (unclassifiable parasites bacterial/viral) 24 Chlamydia aS~ents (naming uncertain) .
2~
26 Funp,i 27 Crypcococcus neoformans 28 blastomyces dermntidis
31 I . . I .
32 ~ -23-'. . ....... ... ...... , ... _ .. . ... . .. ..... ... . ........
` I 104Z79,'~: l 1 Nei.qseriae 2 Neisscria mcnin~itidis 3 Neisser:La gonorrheac '~ ~
Enteroblcteri~ciae ~ __ c __, 6 Eschcrich;a coli 7 Aerobactcr acrogcncs The coliform bacteria 8 Kle.bsiella pne-unonile .
9 Salmonella ty?llosa 0 Salmonella choleracsuis ~ Tbc Salmonell.ae l ¦ Salmonella ty~himurium ¦ Shigella dysenteriae 13 ¦ Shigella schmit7.ii 14 ¦ Shigclla arabinotarda The Shigellae .
15 ¦ Shigella flexneri 16 ¦ Shigella boyùii .
17 ¦ Shigella Sonnei . .
18 I . .
19 ¦ Other enteric bacilli 20 ¦ Proteus vulgaris . -¦ Proteus mirabilis Proteus species 22 ¦ Proteus morgni 23 ¦ Pscudomonas aeruginosa 24 ¦ Alcaligenes faecalis Vlbrio cholerae 27 I .
28 I .
:' I .
.. I .
.
:, , .
: ,, ,. ~ ' . : ' :
: : -: . ' ' : .
: : -, , --. , .
: :
, ., ~ .
1~4~79 u~ C ~ r )u~
2 ¦ llcmol)hilu~3 lnflucnzllc, 11, ducrcyi 3 Il. hcmophilus ~ ~1. acr,yptlcus S , ~1. paraiu~lucnzac 6 Pordctclln pcrtussi3 o Paste~rellac 9 Pastcurclkl pcstls Pnstcurell;l tulareusis 12 P,rucellae 13 Brucella melitensis 14 Brucella abortus Brucella suis 17 Aerobic Spore-fornnin~ Bacilli 18 Bacillus anthracis 9 Bacillus subtilis Bacillus megaterium 21 Bacilllls cereus 23 Anaerobic Spore-forming ~acilli . Clostridium botulinum .
Clostridlum tetani 26 Clostrldium perfringcns 27 Clostridium novyi Clostridium septicum .
31 .
32 ~ -23b-~_ , . .. ,, ...... ~ _ ,. . . ........ .. ................. . ..... .
.~ ' ' . .
~ 104279'~
1 ¦ Clnstri(llnlm llistolyticllm 2 ¦ Clou~rl(lium tcrtium 3 ¦ Clo~tridLum bifcrmcntnns . C]ostridium sporocnes .
6 I~__o_~cteria 7 ~Iycob.lcter;llm tubcrculosis llominLs ~Iycobactel-iulD bovis ~Iycobncter:ium nviun ~Iycobacterlum leprac ~Iycobacterium paracuberculosis 2 . .
13 ~ctinnmycetes tfungus-like bacteria) 14 Actillomyces i~sraelii Actinomyces bovis 16 ~ctinomyces naeslundii 17 ~ocardia asteroides 18 Nocardia brasillensis The Spirochetes.
21 Treponema pallidum Spirillum minus 22 Treponema pertenue Streptobacillus moniliformis 23 Treponema carateum 24 ~orrelia recurrentis Leptospira icterohemorrha~iae .
ZB ¦ Le splro c~nicola 32 ~ -2~c-. . '" .
.~ 1 ~
.: : .
:-:-:: -' ' ' ; - :' "~ : : : . :
.. . .. . ..
.. :- :. :: -. ' , : : ' ~ . :
104'~792 1 I ~Iyco~nsmas I ~
2 ¦ ~Iycoplasmn pncllmoniae Other patho ~ens Listeria monocytogclles 6 Erysipelothli~ rhllsiopatlllae 7 Strel)tobac:illus moniliEormis 8 Donvnnia p>rall-llomatis 9 ~arconella bacilliformis ~ 11 Rickettsiae (bncteria-like parasi~es) .
12 Riclcettsia prol~azekii 13 Rickettsia mooseri 14 Riekettsin rickettsii Riclcettsia conori 16 Rickettsia australis 17 Rickettsia sibiricus 18 Rickettsia akari 19 Rickettsia tsutsugnmushi Rickettsia burnetii 21 Rickettsia quintana 23 Chlamydin (unclassifiable parasites bacterial/viral) 24 Chlamydia aS~ents (naming uncertain) .
2~
26 Funp,i 27 Crypcococcus neoformans 28 blastomyces dermntidis
29 32 ~ -23d-., ~
104;~9Z
1 ¦ lli9toplnstml cnl)slll;ltum 2 CoccidtoLdeF immi t i9 Pnracoecidioides brasiliensis Cnndid;l nlbicnns AspergilluF. f~lmigntus 6 Mucor corymbifer (Absidia corymbifera) 7 ~llizol-us oryzae 8 Rhizoplls arrhizus ~ I'hycomycetes 9 Rhizopus nigricnns ) Sporotrichum schenl;ii 11 Fonsecaea pedrosoi 12 Fonsecaea compaeta Fonsecaea dermatitidis 14 Cladosporium carrionii Phialophora verrueosa 16 Aspergillus nidulans 17 ~5adurella myeetomi 18 Madurella grisea 19 Alleseheria boydii Phialosphora jeanselmei 21 Mierosporum gypseum 22 Triehophyton mentagrophytes 23 Keratinomyees ajelloi 24 MierosporulD eanis Triehophyton rubrum 26 Mierosporum andouini 2i 2~ Viruses 3e_ .'. ":~" . .
' .~.. . , . , ' . .
:. - , . :
: ., : . :
: .
~04'~
l A enovirusos 2 llcrpo~ vlruses 3 llcrpe3 simplex 4 Vnricc.lln ~ icken pox) llorpes %oster (Shillgles) Virus B
Cy torncgalovirus 9 Pox Viruses 0 Variola (smallpox) 11 Vaccinia 12 Poxvirus bovis 13 Par~vaccinia 14 Molluscum contagiosum 16 Picornaviruses 17 Poliovirus lo Coxsackievirus 9 Echoviruses Rhinoviruses 22 ~:yxoviruses 23 Inflnenza (A, B, and C) 24 Parainfluenza (1-4) llumps Virus 26 l~cwcastle Disease Virus 27 Measlos Virus 29 RiDderpest Virus . .
~2 ~ -23~-' ~04279~
1 Caninc Distcmpcr Virus 2 Rcspir~tory Syncyti~l Virus 3 Rubc].l.l Virus ~ ..
~tbovir scs 6¦ Eastern Equlne Eucepllalitls Virus 7¦ Wcstern Eq~inc Euceph:llitls Virus 81 Sindbis V:irus ¦ Chilcun~unya Virus 0 ¦ Semliki Forcst Virus 11 ¦ ~ayora Virus 12 ¦ St. Louis l.ncephalitis Virus 13 ¦ Cal:i~ornia FncephAlitis Virus 14 ¦ Colorado Tick Fever Virus 15 ¦ Yellow Fever Virus 16 ¦ Den~ue Vi us 17 ..
18 ¦ Reoviruses 9 ¦ Reovirus Types 1-3 . .
21 ¦ ~lep~titis 22 ¦ . Hepatitis ~ Virus 23 ¦ Nepatitis B Virus 2~ I
25 I umor Viruse.s 26 ¦ Rauscher Le--kemia Virus 27 ¦ Gross Virus 28 ¦ ~aloney l.cukemia Virus .-32 ¦ * -23E- ¦ .
,'', , I .
I
'.' . I . .
- .. .. . . . . .. ... .
':~':'' . ' ',:`,,~' "'.
. ,. ~ .
.: :
,: , , . ' : ' :., , ~ ::, :
.
104'~'79~ l Fricn~l l,cu~emia Virus 2 ~lousc ~lammnry Tulllor Vlrus 3 Avinn l,cucosi~ Virus 4 ~ou~q Snrcoma Virus Polyoma Virus 6 Simian Virn~ l~o 7 Papi:lloma virng 8 ¦ Preparatiolls of m.icroorganifims include:
9 ¦ Strcptococcus pyogelles, protcin 10 ¦ Pasteurclla pestifi, protein toxin 11 ¦ Clostridium tetani, toxoid 12 ¦ Clostridium perfringens, ~-lecithinsse 13 ¦ ~scherichia coli, filtrates 14 ¦ Treponema reiteri, protein extract l~ ¦ Corynebacterium diphther1ae, toxin, toxoid Ilycobacterinm tuberculosis, protein 17 ¦ M. tuberculosis, cytoplasm 1 18 ¦ M. tuberculosis, culture filtrate and tuberculin lg ¦ Mycoplasm~ pneumoniae, "crude" antigen . .
21 ¦ Immunoassay 22 ¦ The subject immunoassays are based on the degree of 23 1 quenching occurring in a solution where fluorescent molecules 2~, arc irradiated with light absorbed by the fluorcscer, pre-ferably within the absorption peal;, as a function of the 2u amount of li.gand in the medium. Thus, tllc number of fluoresccr 27 and quencller molecules 17hich arc brougllt together to within 2~ a distancc where qucnching can occur is related to the amount : 29 of ligand present in the assay medium.
3l 3,1 ~ -33h-.~ ' . "
' . ,' ' , ~ ' :
1 Tllc afisay cnn bc cs~rr:lcd out wl.th rcccptors for the 2 li~,nlld (allti. ligancl) conJug~Lcd to ~hc cllro~opllore (nntl-3 ].i~alld)-chrolDo~ orc or rccel)tor for tllC nnti-ligand (anti-4 (nllti-llgan(l)) conju~nted to tlle cllromophorc (nnL:i(anti-ligand)-chromopllore). For rcasons which will bc dlscusscd subscquently, tl~e latter teclllliqlle (tlle doub1.c rcccptor tcchn:lqllc) prov:Ldcs .
7 procedural advnnt2lscs, ns wcll as providing assay capabllitics 8 not nvailable !~ith thc sin~,lc reccptor technique. The double receptor tcchniquc binds rcceptor-chromopllore indirectly lo to the ligand throtlgh a receptor (nnti-li.and) intermediary, 11 whlch now allows Eor an addit:ional de~ree of freedom in 12 varying the re.igents.
13 In carrying out the assay employing the single 1~ receptor technique, the ligand analog reagent has ligand analog bound cither directly (covalently) to a chromophore, 16 ligand analog-(Ch2)x or poly(ligand analog)-poly(Ch2), or 17 indirectly (througll receptor-Ch2) to a chromophorc (Ch2).
lô The assay is then carried out by combining in the assay 19 medium, the ligand bound to Ch2, receptor-Chl, and the 20 unknown. Various orders of addition are permissible. l~here .
21 ligand analog is to be bound indirectly to Ch2, receptor-Ch 22 and receptor-Ch2, may be added stepwise or substnDtlally 23 simultaneously.
24 Conve1licntly, the receptor-Chl and rcceptor-Ch2 may be comb.tncd togetller as a single rea~cnt at tl-e proper 26 ratio. In this manner, the ratio of the two common receptors 27 can be carefully controlled and accuratcly added to the 2B assay Dlixture. The mi~ture can be a dry lyophili~ed mixture 33o 32 ~ -23i-'. -: .
1 , :~. :' . . ' ': : ' . , ' ', ~
' : ' ' ' ', ' ' , ,~ ' :
~'' ' ~ . : ~"' 1 104~:79Z
1 or an a~ucous, nor1n;l11y bufrcred (pll 5~-1(); usually 6.5-8.5) 2 solotion of any desLre(l conccntrat~on.
3 Thc conccntration of ligan(l of lntcrest wlll gencrally rnnr,e from about 10 to 10 , morc usually from about 10 6 to 10 1 ~I, mose usually 10 6 to 10 1 1l. The 6 concentrations of reaents will reflcct tho concentration of 7 interest o~ the l.lgand.
8 ¦ Tlle medLum will normally be aqueous, hav:ing from 0 9 ¦ to llo, more usunlly from 0 to 20 volume percent of a polar 10 ¦ organic solvent. Illustrative polar org,anic solvents include li ¦ ethylcne glycol, ethanol, carbitol, dimethylformamide, 12 dir,latllylsulfoxide and the like. Preferably, the aqueous 13 medium will be substantially free of other polar solvents.
1~ The medium will normally be buffered in the range of about 5 to 10, preferably from about 6.5 to 8.5, and more preferred 16 from about 7 to 8.5. Various buffers may be used, such as 17 borate, phosphate, carbonate, barbituric acid, tris, and the 18 like. The particular buffer employed is not critical to this invention, but in particular assays, one buffer may be preferred over another. The buffer concentration will 21 nor;nally range from about 0.005M to 0.5M, more usually from 22 about O.OlM to about O.lM.
23 During the assay, moderate temperatures normally 24 will be employed, ~enerally ranging from about 0C to 45C, m~re usually ranging from about 15C to 40C. The particular te~perature choscn will depenù on convenicncc, and on the 27 ef'ect of temperature on fluorescence efficiency, and on the 29 binding constant of the rcc ptor to the ligand. The assay 32 ~ -23~-. .
`1`` .
... . _ ..........
:, :
10~'~79'~
pcrformnIlce.will be iIllprovcd at ].ower temper.Itllrec;~ slnec 2 bo~h fluore~;cenee effi.ci.cncy nIl(I l-:Lnd:ing constants arc 3 cnhnIleed.
4 For convcnieIlce, the sin~le receptor assay~
be divided into tho~3c whc!re li~nIld is bound covalently to 6 chromopIIore and tho~c w1Icrc lig:Ind is bound indircctly : 7 through reccptor to chromophorc.
8 The first ass;ly to be co~ls.idercd wil]. bc witII
9 those composttions whcre chromopllore i9 cova].ently bound to 0 ligand. As previously :indicated, a singlc chromopllore may 11 be bound to .3 singlc ligand or by employing a nucleus molecule, 12 a plurality of ligands may bc bound to a plurality of chromo-~: phore groups. Alternatively, with large ligands sueh as 14 protcins, a plurality of chromophorc groups may be bound to 16 the ligand.
: lg . .
2~
32 -23k-~ 11 I
', ' ~ - ' ' ' , ~
. ~ .
~ . ' ' - ' '' I ~ ~ 104;~79Z
1 ¦ Thc lil;~n~ o~ o~-cllrolllophort wll~ ~cnorDlly bc at 2 ¦ a conccntr;~tioll not ~rcatcr th.ln lO0 timcs thc hi~llcst 3 ¦ concentration and not less thnll 0.01 timcs thc lowcst concen-¦ trat:ion of thc conccllLration ran~e of :inLcrcst, more usually 5 j bcitlg in thc rnn~c ~rolll thc higllest conccntration of interest 6 ¦ to not le~ss thall O.l tilncs the lo~est conccnCraLion of .~ ¦ ;ntcrest, and prcfernbly witllin ~n ordcr of magnitucle or a 8 ¦ factor oE ]0 of the ~.owesL concentration o~ intcrest. The 9 ¦ receptor-chrolnophore concentration is thcn dc~crmined by 10 ¦ adding a sufficicnt amount of the rcceptor to obtain at 11 ¦ least lO percent quenching, preferably at least 20 percent 12 ¦ quenching, and Ip to lO0 pcrcent yuenching, usually from 13 ¦ about 20 to 80 perccnt quenching, and preferably fro~ about 14 1 50 to 80 percent qucnchin~. The amo~-nt of receptor-chromo-15 ¦ phore employed will be related to the binding COJIStant, the 1O ¦ concentration of interest which affects the concentration of 17 1 the ligand-chrornop11orc, the sensitivity of the instrurnent, lo ¦ and the like.
19 ¦ While the chromophore bound to the ligand may be 20 ¦ quencher, for the most part, the chromophore bound to ligand l will be fluorescer. This is not a matter of operability, 22 ¦ but rather expedience. In most cases, the receptor is 23 ¦ antibody, which will be a complex protein mixture, containing 2~ ¦ antibody lor the ligand, as well as other antibodies and 25 1 proteins. When the antibody composition is labeled with 26 ¦ chromophorc, a substantial proportion of tl-e chromophore 27 1 will be bound to protein other tllan the antibody for the 2$ ~ ligand (anti-lisand). Therefore, if fluorescer was bound to 104~'Z79Z
l rcccp~or, thl~; wotll(l re!;ult iu a la-gc b.lck~ro~ fluorcsccncc 2 in thc a8~:.1y Ill~.~iUnl. ~1~crnlltivl~1y, WllCn a relatlvcly purc 3 :;amlllc of an(i-llgllld is availal)lc, thc prefcrrcd proccdurc 4 woulcl bc ~o biltd ligand to qucnchcr, rathcr than fluoresccr.
Thc particular order of aùdition of thc variolls 6 materials to the ASSny medium is not critical to this invention.
7 ~he unkno~n al-d ligall(l analog-chromophore may be combined 8 simllltnlleously with reccptor-chro;llol)hore or the material~s 9 nd(led seqllentially. Prcfcrably, thc unknown is combined with thc rcceptor-chromo~-horc and incobated for a sufficicnt Il tiTlle, SO 2S to approach equilibrium. Therefore, the availablc 12 binding sites of the receptor arc reduced in proportion to 13 the amount of unknown present in the assay medium. The 14 liP~and analog-chromophorc may then be added and incubated and the solution then transierred to a fluorometer and the 16 fluorescence intensity determined on exciting Wit}l li~ht at 17 a wavelength or wavelengths absorbed by the fluorescer.
18 Incubation times will be dependent upon the tem-perature employed, the binding constant of the receptor and tne concentrations o f the materials present in the assay 21 medium. Normally, incubation times will be at least about 5 22 sec and preferably not e~ceeding about 6 hours, more usually 23 being in the range of about 30 sec to 2 hours, preferably, 1 24 to 30 min. Temperatures of incubation will generally vary from about 15 to 40C.
26 by employing a scries of solutions havin~ known 27 concentrations of ligand, one can provide a standard curve rclatin~ fluorescence or percent qucncllin~ to concentration 3i ~ .
.
.. .. ... ................. . .. , ... ........ .. ............ ... . . . ~., .. ., .. .
~04Z79Z
l of ligalld. Tllc fluo~ ccncc rcsultl1lg from all ass.1y mcdi(lm 2 with an un~nown can tll{n bc dircct1y rclatcd to th~ con-3 ccntrntion of thc un~llown in thc assny ~l~edium.
In a scconcl mode, in which lignnd is bound indirectly to a chrornophore, thc an~i-ligand is divided into two pnrts 6 and onc part c~niugaec(l wit11 fluorcsccr and thc otller part 7 conjugated wi-h qucncller. This mode rcquires eithcr that 8 thc ]igand have a plurality o dctcrrlinant or cp;topic 9 sites, or alternnt:ivcly, that ~here the ligan(1 ha-: only one or ~wo cpitopic sitcs, a poly(ligand nnalog) bc prcpared.
11 'rhat is, thè li&and can only accommodatc a fcw, usually from 12 about l to 2 antibodics simllleaneollsly. As prcvio~sly 13 ¦ indicated, poly(ligand ~nalog) is prepared by conjugating 14 ¦ ligand analog to a nucleus molecule of high molecular weight.
15 ¦ In the assay where the ligand is covalcntly con-16 1 jugated to chromophore, tlle assay response in going from no ¦ ligand to increasing concentrations of ligand lS a smooth 18 1 curve with increasing fluorescence, until tlle maY.imum amount 19 1 of fluoresccnce is obtained. A similar result is observed 20 ¦ when one emp]oys poly(ligand analog) to measure ligand and 21 ¦ recePtor-fiuorcscer and receptor-4uencher. 11Owevcr, with an 22 1 antigen, which has a plurality of determinant sites and only 23 ¦ receptor-quencher and receptor-fluorescer are added to the 24 ¦ unknown to be assayed, at zero antigen conccntration, therc !
25 1 is a ma~i~num fluorescence whicl1 diminishcs with increasing 26 ¦ antip,en concentration to reach a minimum and then increases 27 ¦ a$:in to m,$ mu~ e1uoresoe=ce.
... ...... ,. ,,,, ., ..... . . ......... ,... ,.... .. . , ...... . . ......
- :
''~ : - :
. : : . -10~ 9;~
~ ¦ The C.11191` of thi~ ip~ s:lc rc.slllt is ~;tr~ligllt-2 ~ rorwartl. As ~nt~l~s~ll is ~ llc~cr nl~d f]llorcsccr arc 3 ¦ broll~ht tolctl)er on Lllc surfacc o~ thc anti~cn, ;o that some ¦ qllencl~ occurs. I~ith incre~sill~ anti~rn concentrAtion, 5 ¦ mor~ nnd more o~ the ~wo reccptors nrc brousllt to~ether at 6 ¦ thc surfacc of thc anti~cn with incrcnsing quenchin~.
7 ~}lo~ever, nt some concentr~Lion, ~ucnchtng reaches a maximum 8 ¦ (f:Luorcscencc rcaclles a minimum). ~ith iucrc~ls;n~ antigen, 9 ¦ the nmount of reccptor bound to any onc anti~en diminishes so that thc amount of (lu(!nchin~ also ùiminishcs. Finally, 11 1 at higll conccntrations of ~nti~en, the amount of reccptor 12 ¦ bound to any one autigen is insufficicnt to provide quenching.
13 ¦ Therefore, ~then assaying for antigen, it is necessary to 1~ ¦ carry out the assay at two differen1: dilutions of the anti~cn.
15 ¦ In this way one can determinc whether one is on the declining 16 ¦ portion or increasins portion of the curve.
17 ¦ The concentration of poly(ligand analog~, based on 18 ¦ available ligand analog, will fall within the same ranges 19 1 indicated for the ligand covalently bound to chromophore.
20 ¦ In carryinE out the assay with the two conjugated 21¦ receptors, e.g. antibodies, the antigen is combined with the 22 1 antibodies usually in the presence of about O.l to lmglml of 23 I a protein, e.g. albumin, and incubated for a sufficient 2~ time, gcnerally from about 5 sec to 6 hours, more usually 25 1 from about l/2 nin to 2 hourfi, preferably one to 30 min, at 26 ¦ a temperature in the range of about 15 to 40C. The consid-27 1 erations detcrminin~ the time for incubation havc been 28 I dl~cussed prcviously.
104;~9Z
1 ¦ lli9toplnstml cnl)slll;ltum 2 CoccidtoLdeF immi t i9 Pnracoecidioides brasiliensis Cnndid;l nlbicnns AspergilluF. f~lmigntus 6 Mucor corymbifer (Absidia corymbifera) 7 ~llizol-us oryzae 8 Rhizoplls arrhizus ~ I'hycomycetes 9 Rhizopus nigricnns ) Sporotrichum schenl;ii 11 Fonsecaea pedrosoi 12 Fonsecaea compaeta Fonsecaea dermatitidis 14 Cladosporium carrionii Phialophora verrueosa 16 Aspergillus nidulans 17 ~5adurella myeetomi 18 Madurella grisea 19 Alleseheria boydii Phialosphora jeanselmei 21 Mierosporum gypseum 22 Triehophyton mentagrophytes 23 Keratinomyees ajelloi 24 MierosporulD eanis Triehophyton rubrum 26 Mierosporum andouini 2i 2~ Viruses 3e_ .'. ":~" . .
' .~.. . , . , ' . .
:. - , . :
: ., : . :
: .
~04'~
l A enovirusos 2 llcrpo~ vlruses 3 llcrpe3 simplex 4 Vnricc.lln ~ icken pox) llorpes %oster (Shillgles) Virus B
Cy torncgalovirus 9 Pox Viruses 0 Variola (smallpox) 11 Vaccinia 12 Poxvirus bovis 13 Par~vaccinia 14 Molluscum contagiosum 16 Picornaviruses 17 Poliovirus lo Coxsackievirus 9 Echoviruses Rhinoviruses 22 ~:yxoviruses 23 Inflnenza (A, B, and C) 24 Parainfluenza (1-4) llumps Virus 26 l~cwcastle Disease Virus 27 Measlos Virus 29 RiDderpest Virus . .
~2 ~ -23~-' ~04279~
1 Caninc Distcmpcr Virus 2 Rcspir~tory Syncyti~l Virus 3 Rubc].l.l Virus ~ ..
~tbovir scs 6¦ Eastern Equlne Eucepllalitls Virus 7¦ Wcstern Eq~inc Euceph:llitls Virus 81 Sindbis V:irus ¦ Chilcun~unya Virus 0 ¦ Semliki Forcst Virus 11 ¦ ~ayora Virus 12 ¦ St. Louis l.ncephalitis Virus 13 ¦ Cal:i~ornia FncephAlitis Virus 14 ¦ Colorado Tick Fever Virus 15 ¦ Yellow Fever Virus 16 ¦ Den~ue Vi us 17 ..
18 ¦ Reoviruses 9 ¦ Reovirus Types 1-3 . .
21 ¦ ~lep~titis 22 ¦ . Hepatitis ~ Virus 23 ¦ Nepatitis B Virus 2~ I
25 I umor Viruse.s 26 ¦ Rauscher Le--kemia Virus 27 ¦ Gross Virus 28 ¦ ~aloney l.cukemia Virus .-32 ¦ * -23E- ¦ .
,'', , I .
I
'.' . I . .
- .. .. . . . . .. ... .
':~':'' . ' ',:`,,~' "'.
. ,. ~ .
.: :
,: , , . ' : ' :., , ~ ::, :
.
104'~'79~ l Fricn~l l,cu~emia Virus 2 ~lousc ~lammnry Tulllor Vlrus 3 Avinn l,cucosi~ Virus 4 ~ou~q Snrcoma Virus Polyoma Virus 6 Simian Virn~ l~o 7 Papi:lloma virng 8 ¦ Preparatiolls of m.icroorganifims include:
9 ¦ Strcptococcus pyogelles, protcin 10 ¦ Pasteurclla pestifi, protein toxin 11 ¦ Clostridium tetani, toxoid 12 ¦ Clostridium perfringens, ~-lecithinsse 13 ¦ ~scherichia coli, filtrates 14 ¦ Treponema reiteri, protein extract l~ ¦ Corynebacterium diphther1ae, toxin, toxoid Ilycobacterinm tuberculosis, protein 17 ¦ M. tuberculosis, cytoplasm 1 18 ¦ M. tuberculosis, culture filtrate and tuberculin lg ¦ Mycoplasm~ pneumoniae, "crude" antigen . .
21 ¦ Immunoassay 22 ¦ The subject immunoassays are based on the degree of 23 1 quenching occurring in a solution where fluorescent molecules 2~, arc irradiated with light absorbed by the fluorcscer, pre-ferably within the absorption peal;, as a function of the 2u amount of li.gand in the medium. Thus, tllc number of fluoresccr 27 and quencller molecules 17hich arc brougllt together to within 2~ a distancc where qucnching can occur is related to the amount : 29 of ligand present in the assay medium.
3l 3,1 ~ -33h-.~ ' . "
' . ,' ' , ~ ' :
1 Tllc afisay cnn bc cs~rr:lcd out wl.th rcccptors for the 2 li~,nlld (allti. ligancl) conJug~Lcd to ~hc cllro~opllore (nntl-3 ].i~alld)-chrolDo~ orc or rccel)tor for tllC nnti-ligand (anti-4 (nllti-llgan(l)) conju~nted to tlle cllromophorc (nnL:i(anti-ligand)-chromopllore). For rcasons which will bc dlscusscd subscquently, tl~e latter teclllliqlle (tlle doub1.c rcccptor tcchn:lqllc) prov:Ldcs .
7 procedural advnnt2lscs, ns wcll as providing assay capabllitics 8 not nvailable !~ith thc sin~,lc reccptor technique. The double receptor tcchniquc binds rcceptor-chromopllore indirectly lo to the ligand throtlgh a receptor (nnti-li.and) intermediary, 11 whlch now allows Eor an addit:ional de~ree of freedom in 12 varying the re.igents.
13 In carrying out the assay employing the single 1~ receptor technique, the ligand analog reagent has ligand analog bound cither directly (covalently) to a chromophore, 16 ligand analog-(Ch2)x or poly(ligand analog)-poly(Ch2), or 17 indirectly (througll receptor-Ch2) to a chromophorc (Ch2).
lô The assay is then carried out by combining in the assay 19 medium, the ligand bound to Ch2, receptor-Chl, and the 20 unknown. Various orders of addition are permissible. l~here .
21 ligand analog is to be bound indirectly to Ch2, receptor-Ch 22 and receptor-Ch2, may be added stepwise or substnDtlally 23 simultaneously.
24 Conve1licntly, the receptor-Chl and rcceptor-Ch2 may be comb.tncd togetller as a single rea~cnt at tl-e proper 26 ratio. In this manner, the ratio of the two common receptors 27 can be carefully controlled and accuratcly added to the 2B assay Dlixture. The mi~ture can be a dry lyophili~ed mixture 33o 32 ~ -23i-'. -: .
1 , :~. :' . . ' ': : ' . , ' ', ~
' : ' ' ' ', ' ' , ,~ ' :
~'' ' ~ . : ~"' 1 104~:79Z
1 or an a~ucous, nor1n;l11y bufrcred (pll 5~-1(); usually 6.5-8.5) 2 solotion of any desLre(l conccntrat~on.
3 Thc conccntration of ligan(l of lntcrest wlll gencrally rnnr,e from about 10 to 10 , morc usually from about 10 6 to 10 1 ~I, mose usually 10 6 to 10 1 1l. The 6 concentrations of reaents will reflcct tho concentration of 7 interest o~ the l.lgand.
8 ¦ Tlle medLum will normally be aqueous, hav:ing from 0 9 ¦ to llo, more usunlly from 0 to 20 volume percent of a polar 10 ¦ organic solvent. Illustrative polar org,anic solvents include li ¦ ethylcne glycol, ethanol, carbitol, dimethylformamide, 12 dir,latllylsulfoxide and the like. Preferably, the aqueous 13 medium will be substantially free of other polar solvents.
1~ The medium will normally be buffered in the range of about 5 to 10, preferably from about 6.5 to 8.5, and more preferred 16 from about 7 to 8.5. Various buffers may be used, such as 17 borate, phosphate, carbonate, barbituric acid, tris, and the 18 like. The particular buffer employed is not critical to this invention, but in particular assays, one buffer may be preferred over another. The buffer concentration will 21 nor;nally range from about 0.005M to 0.5M, more usually from 22 about O.OlM to about O.lM.
23 During the assay, moderate temperatures normally 24 will be employed, ~enerally ranging from about 0C to 45C, m~re usually ranging from about 15C to 40C. The particular te~perature choscn will depenù on convenicncc, and on the 27 ef'ect of temperature on fluorescence efficiency, and on the 29 binding constant of the rcc ptor to the ligand. The assay 32 ~ -23~-. .
`1`` .
... . _ ..........
:, :
10~'~79'~
pcrformnIlce.will be iIllprovcd at ].ower temper.Itllrec;~ slnec 2 bo~h fluore~;cenee effi.ci.cncy nIl(I l-:Lnd:ing constants arc 3 cnhnIleed.
4 For convcnieIlce, the sin~le receptor assay~
be divided into tho~3c whc!re li~nIld is bound covalently to 6 chromopIIore and tho~c w1Icrc lig:Ind is bound indircctly : 7 through reccptor to chromophorc.
8 The first ass;ly to be co~ls.idercd wil]. bc witII
9 those composttions whcre chromopllore i9 cova].ently bound to 0 ligand. As previously :indicated, a singlc chromopllore may 11 be bound to .3 singlc ligand or by employing a nucleus molecule, 12 a plurality of ligands may bc bound to a plurality of chromo-~: phore groups. Alternatively, with large ligands sueh as 14 protcins, a plurality of chromophorc groups may be bound to 16 the ligand.
: lg . .
2~
32 -23k-~ 11 I
', ' ~ - ' ' ' , ~
. ~ .
~ . ' ' - ' '' I ~ ~ 104;~79Z
1 ¦ Thc lil;~n~ o~ o~-cllrolllophort wll~ ~cnorDlly bc at 2 ¦ a conccntr;~tioll not ~rcatcr th.ln lO0 timcs thc hi~llcst 3 ¦ concentration and not less thnll 0.01 timcs thc lowcst concen-¦ trat:ion of thc conccllLration ran~e of :inLcrcst, more usually 5 j bcitlg in thc rnn~c ~rolll thc higllest conccntration of interest 6 ¦ to not le~ss thall O.l tilncs the lo~est conccnCraLion of .~ ¦ ;ntcrest, and prcfernbly witllin ~n ordcr of magnitucle or a 8 ¦ factor oE ]0 of the ~.owesL concentration o~ intcrest. The 9 ¦ receptor-chrolnophore concentration is thcn dc~crmined by 10 ¦ adding a sufficicnt amount of the rcceptor to obtain at 11 ¦ least lO percent quenching, preferably at least 20 percent 12 ¦ quenching, and Ip to lO0 pcrcent yuenching, usually from 13 ¦ about 20 to 80 perccnt quenching, and preferably fro~ about 14 1 50 to 80 percent qucnchin~. The amo~-nt of receptor-chromo-15 ¦ phore employed will be related to the binding COJIStant, the 1O ¦ concentration of interest which affects the concentration of 17 1 the ligand-chrornop11orc, the sensitivity of the instrurnent, lo ¦ and the like.
19 ¦ While the chromophore bound to the ligand may be 20 ¦ quencher, for the most part, the chromophore bound to ligand l will be fluorescer. This is not a matter of operability, 22 ¦ but rather expedience. In most cases, the receptor is 23 ¦ antibody, which will be a complex protein mixture, containing 2~ ¦ antibody lor the ligand, as well as other antibodies and 25 1 proteins. When the antibody composition is labeled with 26 ¦ chromophorc, a substantial proportion of tl-e chromophore 27 1 will be bound to protein other tllan the antibody for the 2$ ~ ligand (anti-lisand). Therefore, if fluorescer was bound to 104~'Z79Z
l rcccp~or, thl~; wotll(l re!;ult iu a la-gc b.lck~ro~ fluorcsccncc 2 in thc a8~:.1y Ill~.~iUnl. ~1~crnlltivl~1y, WllCn a relatlvcly purc 3 :;amlllc of an(i-llgllld is availal)lc, thc prefcrrcd proccdurc 4 woulcl bc ~o biltd ligand to qucnchcr, rathcr than fluoresccr.
Thc particular order of aùdition of thc variolls 6 materials to the ASSny medium is not critical to this invention.
7 ~he unkno~n al-d ligall(l analog-chromophore may be combined 8 simllltnlleously with reccptor-chro;llol)hore or the material~s 9 nd(led seqllentially. Prcfcrably, thc unknown is combined with thc rcceptor-chromo~-horc and incobated for a sufficicnt Il tiTlle, SO 2S to approach equilibrium. Therefore, the availablc 12 binding sites of the receptor arc reduced in proportion to 13 the amount of unknown present in the assay medium. The 14 liP~and analog-chromophorc may then be added and incubated and the solution then transierred to a fluorometer and the 16 fluorescence intensity determined on exciting Wit}l li~ht at 17 a wavelength or wavelengths absorbed by the fluorescer.
18 Incubation times will be dependent upon the tem-perature employed, the binding constant of the receptor and tne concentrations o f the materials present in the assay 21 medium. Normally, incubation times will be at least about 5 22 sec and preferably not e~ceeding about 6 hours, more usually 23 being in the range of about 30 sec to 2 hours, preferably, 1 24 to 30 min. Temperatures of incubation will generally vary from about 15 to 40C.
26 by employing a scries of solutions havin~ known 27 concentrations of ligand, one can provide a standard curve rclatin~ fluorescence or percent qucncllin~ to concentration 3i ~ .
.
.. .. ... ................. . .. , ... ........ .. ............ ... . . . ~., .. ., .. .
~04Z79Z
l of ligalld. Tllc fluo~ ccncc rcsultl1lg from all ass.1y mcdi(lm 2 with an un~nown can tll{n bc dircct1y rclatcd to th~ con-3 ccntrntion of thc un~llown in thc assny ~l~edium.
In a scconcl mode, in which lignnd is bound indirectly to a chrornophore, thc an~i-ligand is divided into two pnrts 6 and onc part c~niugaec(l wit11 fluorcsccr and thc otller part 7 conjugated wi-h qucncller. This mode rcquires eithcr that 8 thc ]igand have a plurality o dctcrrlinant or cp;topic 9 sites, or alternnt:ivcly, that ~here the ligan(1 ha-: only one or ~wo cpitopic sitcs, a poly(ligand nnalog) bc prcpared.
11 'rhat is, thè li&and can only accommodatc a fcw, usually from 12 about l to 2 antibodics simllleaneollsly. As prcvio~sly 13 ¦ indicated, poly(ligand ~nalog) is prepared by conjugating 14 ¦ ligand analog to a nucleus molecule of high molecular weight.
15 ¦ In the assay where the ligand is covalcntly con-16 1 jugated to chromophore, tlle assay response in going from no ¦ ligand to increasing concentrations of ligand lS a smooth 18 1 curve with increasing fluorescence, until tlle maY.imum amount 19 1 of fluoresccnce is obtained. A similar result is observed 20 ¦ when one emp]oys poly(ligand analog) to measure ligand and 21 ¦ recePtor-fiuorcscer and receptor-4uencher. 11Owevcr, with an 22 1 antigen, which has a plurality of determinant sites and only 23 ¦ receptor-quencher and receptor-fluorescer are added to the 24 ¦ unknown to be assayed, at zero antigen conccntration, therc !
25 1 is a ma~i~num fluorescence whicl1 diminishcs with increasing 26 ¦ antip,en concentration to reach a minimum and then increases 27 ¦ a$:in to m,$ mu~ e1uoresoe=ce.
... ...... ,. ,,,, ., ..... . . ......... ,... ,.... .. . , ...... . . ......
- :
''~ : - :
. : : . -10~ 9;~
~ ¦ The C.11191` of thi~ ip~ s:lc rc.slllt is ~;tr~ligllt-2 ~ rorwartl. As ~nt~l~s~ll is ~ llc~cr nl~d f]llorcsccr arc 3 ¦ broll~ht tolctl)er on Lllc surfacc o~ thc anti~cn, ;o that some ¦ qllencl~ occurs. I~ith incre~sill~ anti~rn concentrAtion, 5 ¦ mor~ nnd more o~ the ~wo reccptors nrc brousllt to~ether at 6 ¦ thc surfacc of thc anti~cn with incrcnsing quenchin~.
7 ~}lo~ever, nt some concentr~Lion, ~ucnchtng reaches a maximum 8 ¦ (f:Luorcscencc rcaclles a minimum). ~ith iucrc~ls;n~ antigen, 9 ¦ the nmount of reccptor bound to any onc anti~en diminishes so that thc amount of (lu(!nchin~ also ùiminishcs. Finally, 11 1 at higll conccntrations of ~nti~en, the amount of reccptor 12 ¦ bound to any one autigen is insufficicnt to provide quenching.
13 ¦ Therefore, ~then assaying for antigen, it is necessary to 1~ ¦ carry out the assay at two differen1: dilutions of the anti~cn.
15 ¦ In this way one can determinc whether one is on the declining 16 ¦ portion or increasins portion of the curve.
17 ¦ The concentration of poly(ligand analog~, based on 18 ¦ available ligand analog, will fall within the same ranges 19 1 indicated for the ligand covalently bound to chromophore.
20 ¦ In carryinE out the assay with the two conjugated 21¦ receptors, e.g. antibodies, the antigen is combined with the 22 1 antibodies usually in the presence of about O.l to lmglml of 23 I a protein, e.g. albumin, and incubated for a sufficient 2~ time, gcnerally from about 5 sec to 6 hours, more usually 25 1 from about l/2 nin to 2 hourfi, preferably one to 30 min, at 26 ¦ a temperature in the range of about 15 to 40C. The consid-27 1 erations detcrminin~ the time for incubation havc been 28 I dl~cussed prcviously.
30 I
31 I
32 -27-I . .
J . . .. ~ ........ .. ... . .............. ...........
.
10427gz l ¦ Witl~ ~)nly(lLunn(l allalo~), the two con~ugate(l anti-2 ¦I.odics are combine~(l w;LII thc unlillo~n to l-c assayed, incubated, 3 ¦and the poly(li~nlld annlog) added and the mixtllrc furthér ¦ ;nc~lbnted The timcs ancl tcmpcratures previou-:ly indieated 5 ¦are nlso al~plicable i~l th~s ~s~ny.
6 ~hc sumrlc i9 thcll introduced into n flllorometer, 7 nnd the fluores(~cnce dctermined upon exc;t~ wiLI) light of the appropriate ~avclen~th. The [~uorescence m.~ be from the fluore-;ccr or quellcl)er depending upon the ~avelcngtll band mcasured. The assay can bc carried out manually or 11 be automatcd.
12 The subject method is readily adaptable to determine 13 the presence of antibo(lies or antigens in human physiological ~ Eluid usinE a two step method and recepcor-chromophores 1~ (Chl and Ch2) for gamma globulin, e.g. human. One can readily 16 differentiate by the difference in molecular weight hetween 17 the agEregation of antibodies or other receptor molecules 18 ¦which are bound to an antigen and thc antibodies or other 19 ¦ receptors which are free in solution.
20 ¦ Depending on vhether one wishes to determine the 21 ¦ presence or absence of an antigen or antibodies in a human 22 physiological fluid, e.g. blood, one would add the com~le-23 ¦ mentary material, usually in substantial excess to the maxlmum 2~ ¦ concentration of intercst. For example, if one wished to 25 ¦ determine the prcsencc of antibodies in serum to a particular 26 ¦ antigen, one would add the antiEen to the physi.ological fluid 27 ¦ and separate components having molecular ueiEIIts Ereater than 28 the antibody moloeulnr weight (>160,000), for exan~ple, by 29 centrifuEat:i.on. Afeer separating the precipitste from the supernatant, the prccipitste i~ rcdlspersed and assayed in 32 ~ -28-~ .
~ ' . ' . .
-:: - : , :~.
:~
.:
:. :
:~ . , :. - ....... :
1 ¦ accordancc ~Ltll the invelltlon for thc presence of hllman 2 ¦ galllma ~lobulill. On].y i.l~ the prc-:cnce of nntile~ il]. human 3 ¦ ~amma globulin bc prcscnt ln the prccipitatc. Tl~ercfore, the ~rcsencc o~ h~ an g.l~lma glob~llin in thc precipltate indicates the presencc of nntibodies to the antigen in the 6 scrum 7 ¦ The t~o stcp mcthod c.nn be uscd for detcrmining a 8 ¦~idc varict)~ of antigclls and alltibodics usin~ the same 91 rec(!ptor-chromol)hores. The metllod providcs a d:iLcct deter-0¦ mination of antibodies to spccific antigells. Antigens can 111 be indirectly determilled by addillo antibo(lies to the fluid 12 ¦ suspeetcd of containin~ the antigen and then assnying for ¦ the presence of antibodies in thc precipitate after separation of bound and unbound antibodies.
5l¦ The double receptor technique is a homogeneous ! technique which allo~ls for the determination of haptens, 17`~ antigens, and anti-ligand, particularly ~here the ligand is g;l a polyepitopic antigen.
9¦¦ In tlle simplest mode, for detection of a ligand, 201 the ligand ~ould be conjugated to a chromopllore, particularly 21 ¦ fluorescer and anti-ligand and anti(anti-ligand)-chromophore, 22 ¦ particu].arly quencher, added to the assay solution. In this 23 ¦ manner, one could bind a larger number o~ quenc1ler molecules to the ligand, enhancing the opportunity Ior quenching, In 251 cffcct, the nnti-ligand provides for increasing the number 20¦ of qucnchcr molecules capable of being bound to the ligand.
27l The concentrations of the reagents vill parallel 29 the analo~ous reagen-s for the sinEle receptor technique 31 ~
32 ~ -28a-'I .... .. . ... ...... .... . .... . ....... ... . . . ...... .. ... . .. ... .
~ 104~79~ 1 wltll Lllc .lnLi(~ ti~ cl~rol~lol)ll(Jrc b~ n Inol;lr CXCCS8 2 to the antl-llgalld, gcllcralLy ~he mole rnLlo heing Erom 3 about 1.5 to 10:1. If clcsired, indlv.idll.ll F b units can be employcd rathcr tl-an in~act I~G.
The next mode llas both chroll~ol-hores ind-ircctly 6 bound to ligalld. In this mode, only anti-l-igan(l an(l anti-7 (anti-l:igalld)-Chl all(l anti(nllLi-ll~nnd)-Ch2 nre employed.
o llowever, prior to Intro(luctioll of these reagent6, .3 portion 9 of Che anti-l;gnn(l will bc coml-ined witll anti(antl-]igand)-Chl and another port:ion witll anti(anti-ligalld)-C1l2, so as to 1l become bound. Desirab]y, the anti(anti-ligand) ~ill be 12 monofunctionnl, e.g. l 1. The anti(anti-ligan(l)-Chl and 13 -Ch2 bound to anti-ligand provides comparable reagen~ to 14 receptor-Chl and receptor-Ch2 respectively. Similar ratios of anti(anti-ligand)-chromophores to anti-l:igand may be l~ employed as previously indicated.
17 In a preferred embodiment, anti-ligand from two 18 different species, e.g. mammalian species, are employed, for 19 example, sheep and CONS. In this s:ituation, the epitopic or haptenic sites are different for the two anti-ligands for 21 the same ligand. In referring to anti-ligand from two 22 different sourees, anti-]igand will be preceded by a small 23 letter, e.g. a-(ant:i-ligand). In this mode, the anti-ligand 2~ and anti(anti-ligand)-chromophore need not be precombined, 2~ The ratios of the various reagents would parallel the analogolls 26 reagents in the previously described assays.
27 The chromophore rengents would be anti(a-anti-28 ligand)-Chl and anti(h-tnti-li~nnd)-C112. Thus, Chl would be 29 associated with only a-(anti-ligand) and Ch2 with b-(anti-ligand).
32 ~ -28~-.
.`
,.
~ 104279Z
1 ~rhiS tcchni,luc ullows ror the deter~lnation of 2 nssem~lages in solnLIon, whert! men~ber. Or the assemblnge 3 di~fer by at lenst Onc epitopic site. One ean prepare a-(anti-ligand) for onc me-nbcr of the assemblaEe and b-(anti-lignnd) for allotller member of ~hc asserlblape. Quencher and 6 flllorescer ~ould be brouEht togetl~er only when the two 7 meMbers arc boun(l togetller.
8 ¦ ~sing anti~ ,alld from ~o di~ferent source.s ean 9 ¦ uls.o be employed w;th advantage with a ligand to nvoid 10 ¦ having to precombine nnti-ligand ~ith the nnti(anti-ligand)-ll chromopllore and in situations where covalent linliage is 12 1 oeeurring between two entities which can exist independently, 13 ¦ e.g. undergoing n ehemieal reaetion.
I4 ¦ The reagents can bc provided in separate vials or 15 ¦ mixed in a dry lyophili~ed state or an aqueous, normally 16 ¦ buffered (pH 5-lO; usually 6.5-8.5) solution of any desired 17 1 eoncentration. Preferably, anti(a-anti-ligand) would not be lS ¦ eombined with a-(anti-ligand) in solution as a reùgent for a 19 ¦ long period prior to use. Conveniently, the two anti-20 ¦ ligands eould be eombined and the two anti(anti-ligand)s.
21 ¦ A partieular advantage of using the double receptor 22 ¦ is that the same pair of (anti(anti-liEand)-ehron!ophore)s 23 ¦ can be employed irrespective of the ligand, only the pairs 24 ¦ of anti-ligand varying with the ligand.
25 ¦ For determinin~ the presence of ~ntil)odies to a 26 ¦ partieular antigen, one would earry out the assay as if one 27 ¦ was determining the antigen, except that a knol~n an~ount of 23 ¦ antigen would be added to the assay medium. Any antibody 31 l 32 ~ -zee-. ~ . .
~ 1~)4Z792 1 present in tllC ullkl)own would aet to diminisll tlle nmount of 2 the all~i(allti-lLgal~ cllromo~ orc bound to tlle antigell and 3 thlls dimillisl- the alnount of quellclllllg whLell would oceur in 4 the al-sence of alltibody. ~f conrsc, the anti-ligand would ~ be from different species (other than mammalian~ Lllan the 6 antibody to be determined.
7 Thc followillg exam~les are offered by way of illustration alld not by way of limltaticn.
9 .
EXPF.RI~IRNTAL
___ 11 (All temperatures not otherwise indicated are in 12 Centi~,rade. All parts not othcrwisc indicated are parts by 13 weight. All buffer solutions are aqueous buffer. All 14 symbols not otherwise defined are intended to have their normal meaning.) 16 The following symbols are employed:
17 IgG - gamma-globulin;
18 IgG(x) - anti-x;
9 R - tetramethylrhodamine, e.g. RIgG(x) tetramethyl-rhodamine eonjugated to anti-x;
21 F - fluoreseein, e.g. FIgG(x) fluorescein conjugated 22 to anti-x; and 23 hIgG - human gamma-globulin.
2~
32 -20~-~, ' : , , : `
~' i ' , :~ . :.' ' ,' : , :
. ' ' . '::, ~: ~ .
:' , -~ 104~79~, I EXAMI'I.E I 1 luorc-:c~ rotIIlo~ya ~.~te (1~ t r~ . on~ te ! to n 3-.-n~! noethylInorLIIlin~ IOIS') 3 ¦ A. Fluor<-:ccin ami.ne (0.5~) (S.i~ma, isomer I, ~1 ~ pure, tlc ~ieOH/CllC13 1:3) wa6 dissolved in 20ml of dry 5 I acetone (dr.ied on anh. K2C03) and addl-d drop~ise at room G I temperature to 3ml of thiopIIos~(:ne in 5ml of ncetone wi~h 7 1' stron~ stirr:iltg (1/2 hr). Stirr:i.n ~ wns continned for t hour 8 ~, and the re-;ultin~ prce:iritate cooled with an ice-bath to 9 1 5~ wag r;Il-idly filtered throeh a fine sintered y].ass 10 . funnel. The precipital:e was washed with dry acetone (3ml) Il and then with 5 ~: 5ml 6N IICl whi].c crushi.nR wi~h a spatt1la !2 until it all turned deep red, followed by dryin~ _n vacuo 13I (80 KOll) overnight. The isothiocyanate o1-tained was pure 14 I (tlc 50Z I~leOH/D.lF). .
15~
16 1 B. O -aminoethylmorphine (lOOmg) is dissolved in 17 I 5ml of acetone and added to a mixture of acetone (20ml), 18~ water (5ml), and triethylamine (0.07ml). To this solution 19 ! is added a solution c f FITC (lOO;ng) in aeetone (5ml) dropwise 20 with st:Lrring during 15 min. Stirring is eontinued for an 21 j additional 80 min, while adjusting the pH oE the reaction 22 ¦ mi~:ture to 9.5 with drops of dilute triethylalnine solution 231 in aeetor-e (l.4ml/lOml aeetone). The aeetone is then partially 2$ I removed with a rotary evaporator at room temperature. The 251 produet is then precipitated by bubbling C02 throug1I the 261 solution with simultaneous addition of H20 (up to lOml) 27i until the pH drops to 6-6.5. The precipitate is rapidly 281 filtered on a sintered :lass funnel and was1-ed with }IzC03 29 ` .
31 ~ .
32 -29- .
. . .
.,, ~ . .
. 104'~79Z
I ¦-:olution (2ml, 111 6.0). Ylcld 601n~. Tl~c filtrtlte and w;lsliinEs 2 arc col~billc(l and n !;eCOn(l crop is obtninc(l by repcntinr, the 3 ¦l~ubblins Of C02 as dcscri~cd. Yield 2/mr,. Thc pro~uct is ¦ dried overnlr,llt undtr vacutlm at 80 over 1'205. Totnl 87mg, ¦ Tbe product shows a single slot on tlc (50~ Tncthanol in 6 1 dime~hylforlla-.n;de), Rf = O.~S.
~ ¦ ~XA~IPLE II Pur_fLca~ion and labelin~_of ~! r~lline 9 I Ant:ibo(ly (Tp,~l)) witll Tctramc(:llylrhc~damine I __ __ __ _ _ _._~_____ _ ¦ Isotl1Locy~l.lte (TRITC) 11 ¦ A. (a) Preparat o1_ot__l_r~hine - Jm1n~_nadsorb nt 12 1 Cyanogen bromide activatcd Sepharose 4P, coupled 13 1 with hexamethylenediamine (8-lO ~mole/lml packed gel) was 14 ¦ prepared according to the company's directions (rhar~acia, Upsala). Wet gel (2.5ml) ~as suspended in boratc buffer 16 ¦ (lOml,O.lN, pH 8.8), the mixed anhydride of O -carboxymethyl-17 ¦ morphine and isobutyl chloroformate (O.l mmole, large excess) 18 ¦ in DMF (2ml) added in the cold (0~), and the mixture allowed 19 ¦ to react for 3 hours. The gel was filtered and washed 20 ¦ successlvely with H20 (500ml), O.lM borate buffer pH 9.0 21 ¦ (SOOml), H20 (500ml), dilute HCl ' O.lM NaCl, pH 2.5 (lSOOml), 22 ¦ and H20 (lOOOml). No morphine could be detected at the end 23 I of the washings. The estimation of bound morphine was 2~ I carricd out by a dilute acetic acid hydrolysis method 25 ¦ (Failla, et al., Anal. Bioche~., 52, 363 (1973).. The uv 26 1 spectrum was compared to that of O -carboxymethylmorphine.
27 1 The bound morphine equivalent was 5.05 llmolellml ~ac~ed gel.
., 291 . .
; 32 -30-1- . . ...
: ' ' , : , ~ . . , ,....... ' ' ," , ~ : :
.
-- 1(~4;~79Z
1 (b) P~ clt-~on .~r ~lo~r!l~nc_ nt.Lbody 2 The n~o1rhi~e Scpl~ro~ic conjllr,.lte (2.5ml~ was 3 pac~ed in a 1/4" o.d. columll nnd washed succcssivcly with lOOml ench of boratc hllrfer O.l~l p1l ~ 0~ 1120, dilute 1ICl pl1 l 5~ ll20, alld thc samc l)orat( burfer. Stock s11ecp IEG
6 solution (7ml, 2.18xlO 4~1 linding sitcs) W.lg app]ied to the 7 column fo1lowcd 1)y wash-ing wit11 bol.aLc buffer O.l~l pll 9.0, 8 nntil no ploLcin cou1d be dctcctcd in the eEflnent (uv).
9 All the ant;morplline activity W.IS rCtnine(l by the column as dctermincd by morphine ~piu-label measurement. (See U. S.
11 Patent N'o. 3,690,834). I~ashing was continued with glycine-12 }ICl buffer O.l~ pH 4.0 wllereby no protein was elutcd.
Antibody was then eluted with glycine-HCl buEfer O.lN pl~ 1.5 and 3ml fractions were collected at room tcmperature in tubes containing lml of lN borate buffer pH 9Ø Almost all 16 of the antibody vas collected i,n three fractions which were 17 combined and dialyzed for 24 hours against O.l~l phosphate 18 buffer ph 7.5 (2x2000~1). The anti~orphine activity of the 19 isolated fraction was determined with morph:lne spin-label and accounted for 70% of the initislly bound antimorphine 21 activity. This fraction was 100% pure as determined by the 22 antimorphine activity titer value compared to protein content 23 estimated from the uv spectrum at 280nm.
2~' r.. (a) Purificat:ion of Morphine _ ~ibody-Sephadex Chroma~o&raphy 26 The antimorphine IgG(m) solution (2ml, _50mg/ml 27 total protein) was separatcd on Sephadcx G-200 column (2x30cm) 28 ~ith O.OlM PBS tphosphate buffered saline) pli 7.4 (flow rate 29 lmltlOmin). The IgG clearly separated from the IgM and ,~
, . .. . . . ,.. ~ . . .... .
" , ',: ~
, .
104,'Z79'~, 1 olbumin .Ind fr.lctiolls oE 2~3ml werr. eollected. The obtalned 2 Ig~: sllowed no albumln on eellulosc ncetaLe electro;-lloresi5 3 (Tris-bnrl), buffol-, pl~ 8.8, ~ -- O.l) and ~as 32-35X anti-morplline-rich IgG. Recovery depen(le(l on the cut-w:i(lth of the IgG peak eollected an(l wns: usually 50Z of total anti-6 morrhine activity apl)lied to Lhe column. The co]lected IgG
7 fraetion was dialy~ecl a~ainst 0.01~1 ~llos~)haLe buffer ~ll 7.5.
9 (b) ~ovine Seru~ bo!iin (nS~)-Tm~.llno~(lsorl-ellL Treatment BSA was coupled ~ith (:NBr activated Sepllarose 4B
11 (Pharmacia) aceordinz to the com~any's instrllctions (50~
12 exeess of BSA was used over the reeom~ended an-ount). Five 13 ml of the Sephadex ehromatogrnphed ISG solution (20mg/ml) ~ were applied to the 2~SA-i~munoadsorbent column (lxl5cm) and run through with 0.01~l phosphate buffer pll 7.5. The collected 16 protein eame out in 20ml and was assayed for protein content 17 tuV) and antimorphine aetivity (spin-label method). Recovery 18 of protein was 70~ and recovery of antimorphine aetivity was 19 90-92%.
21 (ej Antimorphine ~gG(m)) Labeled ~ith TRITC (RIgG(~
22 To a solution of IgG(m) (7~n~/0.5ml) in 0.01~
23 phosphate buffer p21 7.5 is added erystalline potassium 24 earbonate up to pH 10.0-10.5 with stirring at room tem-perature. TRITC (tetramethylrhodamine i.sothiocyanate) (15-26 1000 ~g) dissolved in aeetone (3-30 ~l) is then added and 27 stirring is continued for 3 hrs. Initially thc p21 drops to 28 9.0 and then stays stable, and is maintained nt 9.0-9.5 if . .. ~....... . .. ... . ...... ........ .....
. .
::
., .
:
. ~ .
:
. . .
~ 104;~79Z
l ncccss.lry, by carcful n(l~lition of crysLallinc potn.~ um 2 cnrbonntc. Tl~e rcacLion ~ixture is thcn ~pplleù ~o a Scphndcx 3 G-25(~1) column (lxl5cm) ~lth O.Ol~l phosl)l)atc b~lffcr pil 7.5 4 and clution of thc first colorctl bnnd wllich separat:cs completely from other ballds is col.lccted in 10--15 min. The scparation 6 is repcatcù t~ice in order to cnsure completc removal of 7 free dyc. In case of formntion of a prec:ip:itatc, the prec:ip:Ltnt~
8 i5 rcmovcd by centr:ifllgation prior to the scparat:ion on Seplllldex. The following tablc describcs thc prcparation of conjugatcs with vnrious degrces of labeling by thc above Il procedure:
13 P~otein Concentration Dye (TRITC) D/P* % Activit l4 (% Antimorphine) mg/0.5ml)Jg (M/l-l) Recovere 15 IgG (45) 7.1 15 0.9 86 16 IgG (45) 7.1 .50 2.2 89 17 IgG (45) 7.1 150 .4.4 75 18 IgG (45) 7.1 400 15-16 75 l9 I~G (45) 7.1 750 20-23 70 *D~P - Dye/Protein 23 EXAMPLE III Fluorescein Isothiocyan~te (FIrC)-Labeled 24 _rphine Antibody (FIgG
(a) o_ju~ation Procedure 26 Four lml fractions of affinity chroinatographed 27 morphine antibody (3.06mg pro-ein/ml) (See EY.ample II) in 28 O.OlM phosphate buffer pH 7.5, were brought to p~l 9.5 ~ith 32 . -33-.'~ ' ': . -104279Z' 1 crystnllinc rodium c.rl)-)natc (Na2C03). 10, 20, 30, and 50 2 of an acctol~e sol~Liol~ of IITC (2~ 001l1) werc ad~cd re:-3 pcctively Lo thc four antibody fractions at room tcmperaturcwith stir-in~,. AEter 3 hrs, thc four rcaction loi~tures werc combin~d, thcn di~idcd into 8 c(lual portions and each pnssed G throu~h Scphn(lex G-25 column (lxl5cm) eqllilibrdted witll 7 0.0]~1 phosl)lmlte buffer pll 7.5. E]ution witll the same buffer yiel(led (the first colorcd balld) the conJIlgate whicll was 9 free of unreactcd dye.
11 (b) Se~ rat_on of FITC Conj_&_te on DFAE-_cll~lose Column 12 (See ~1. Goldman in "Eluorcscent Antibody ~lethods,"
13 ¦ Academic Press ed., 1968, pp. 104-107). The FITC-antimorphine 14 I con~ugate was spplied to a D~AE-cellulose column (lx3cm) 15 ¦ equilibrated with O.OlM phospllate buf f er pM 7.3. Elution 16 ¦ with the same buffer and with increasing NaCl concentration 17 I yielded fractions of increasing dye contcnt. The clye content 18 ¦ D/~ of the various fractions was determined with the Wells' l9 ¦ nomograpll (A.F. Wells, C.E. Miller and M.R. Nadel, Appl.
20 ¦ Microbiol, 14, 271 (1966). The antimorphine activity was 21 ¦ determined as usual with morphine 5pin-label. The f ollowing 22 ¦ fractions were obtained:
l Fraction Protein D/P
24 No. mg mo'1e/mole l 1.75 1.5 26 2 1.3 '3.0 27 . 3 1.15 6.0 ' 28 4 1.42 g.o 32 -3~-.
`. . '.
.... , .. _.. ,., .. ,.. _ ,~_ .. , .,. ., .. ... , ,, , ,,, , ,,, . ., ~ _ .. . .
: ' ' ~ ' ' ~, ' ' ' :
. . . . ,: --. ~ ~ , , . ' , .,: . . ~ . : :
' 104~79Z' 1 ~X~ IV l'ul-LEJcatioll of ~ltihod~ to llulaall Gnmma~
2 G1,obulin (I~G(hI~C~) nn(l Con~u&_tion witl 3 FITC (Ft~G(llIsG) _ nd TI~ITC (RI~G(IlI~G)) ~ (n) l~uri~tc;ltioll of Antibo(ly to llumnn I&~
A ~ y Cl-romnto~rae~y 6 Scpharose-~B (2~) was couplcd witll 18mg human 7 gamma-globulilt (hlgG) as described in thc compally manual 8 (~harmacia, Upsnla). ~abbit antiserum (50ml) to h'LgG (5mg 9 antibody/ml~ (IEG(hIgC)) was obtained from Antibodies Incorpornted. A column (lx3cmj of the above Sel)llarose-hIEG
ll conju~te was prepared with O.OlM borate bufEer p~ 8Ø The 12 antiserum was passed throllgh the column, followed by washing l3 with the same buffcr until no protein could be detected in the eluent. The column was further washed wiLh 0.1~1 glycine-llCl bui'fer pH 5Ø The antibody was then eluted with O.lM
16 glycine-}lCl buffer pll 2.5; fractions of 3ml were collected and immediately neutralized with 0.5M borate buffcr 9Ø
18 The total volume of antibody solution thus collected was 19 30ml. The antibody solution was dialyzed overnight against 0.05M phosphate buffer pH 8.0, then concentrated with Aquacide and dialyzed again. The final volume was 11M1 and ehe 22 protein-antibody content 3.76mglml as determined from the 23 absorption spectrum at 280nm. Antibody recovered was 83~.
(b) rre~aration of FIgG(hlgG) 26 , (i) The above antibody solution (lml) in 0.05M
27 p}losphate buffer pH 8.0 was brought to pH 9.5 with crystalline 28 Na2C03. FITC (lOOIlg) in 10~1 of acetone was addcd at room ,29 .. . . ' ' ' ,.......... .
' , .
1~79Z
l tcml)crature and sti~rcd for 3 hrs. Thc conjugal:e was than 2 sepnratcd on Sepllnclcx C-25(~1) (lxlOcm) cqllllil)ratcù with 3 0.05M phospllatc buffcr pll 8Ø Tl~e conjugate was collecta~
in l.5ml; i~ had D/r e 4~3 (~ 1) (dyc/~rol:c;ll) nnd 2.05mg/lnl S as detcrmined with thc ~ lls' nomoEral~h.
7 (c) I`rclm~r~_ion of -r~-I &G(h_~) 8 (i) The above dcscribed nntibody solution (lml) 9 in 0.05M phospllate bllffcr pll 8.0 was broup,ht to pll 9.5 with lO crystalline Na2C03. TRITC (0.5mg) ln acetone (20-30~1) was ll added at room temperature and the mixtll7-e e,tirrcd for 3 hrs.
12 A precipieate formed which was removed hy centrifugation and 13 discarded. The conjugate was then separated twice on Sephadex 14 G-25 column (lxlOcm) equilibrated with 0.05M phosphatc lS buffer pH 8.0, The product was recovered :in a 2ml voluDe 16 and had D/P = 10 and 0.7mg/ml as determined from the absorption 17 spectrum at 280 and 516nm.
18 (ii) DEAE-cellulose separated IgG fraction (27.6mg¦ml) 19 of Rabbit antiserum to hIgG (6.4m~ antibody/ml) ras obtained from Antibodies Inc. The above protein solution (O.Sml~ was 21 brought to pll 9.5 with crystalline Na2C03, and 3mg of TRITC
22 in 50~1 of acetone + 0.5ml H20 were added with stirring in 23 the cold (4~). After 3 hrs, a precipitate occurred an~ wa:~
2~ filtered off. The resulein~ viD]et solution was separated successivel~ twice on Sephadex G-25(~l) column (2x30cm) 26 equilibrated with 0.05M phospl-ate buffer pll 8Ø The resulting 27 conjugate was O.lmg antibody/ml and had D/P -- 12-15 (M/M) as 28 calculated rom the absorption spectrum.
~ --.
1 . ~ , .
.
.' : . .
- " " ' . , ' ' ' . ' .' . ' - , ' ' '~
:: .
J 10~7'~Z
1 ~XAMrLE V Conj~ L_ of 11~"".~" ~._mm.l-Clol~ulin .
2 (hl~(~) Lo 111~orel:co:Ln (ihIU~
_ _ __,____ _ 3 Onc mg of IllgG (~ m.ln IgG) di.s.solvcd in 0.4ml of 4 0.lM phos~hntc buffer pll 7.5, was brougllt to pll 9.5 with crystalline Na2Cn3. A solution (101ll) of FITC (70~1g) in 6 acc~one was adde-l with stirring alld mixcd for 3 hr.s at room 7 tempernturc. The rcsultlng solution was separnted two times o on Sephadex ~-25(~1) colum.l~ 15cr;1) equilibrated witll 0.05M
9 phospllate buffer pll 8Ø Thc clutcd 1ITC-hIgG conjugate solution was 0.58mg/ml in concentration and had D/P = 5.5 11 (M/M) as determined by the ~ells' nomograph.
13 EXAMPLE VI Morphine Conju~ated to Bovine Serum ~lbumin 1~ (BSA-44m) 0 -Carboxymethyl morphine (3.43g) and l.31m].
16 isobutyl chloroformate were combined in 30ml DMF at 0. The 17 resulting clear solution was then added to a stirrin~ solution 18 of 2.88g BSA and l3f~ Na1~C03 in 600ml of water at 0. Addition 19 was carried out by means of a syringe with its tip below the solution surface. The solution was stirred in a cold room -21 overnight.
22 ~fter passin~ the solution through a lar~e Sephadex 23 column, the effluent was concentrated to 60ml with Dow liFn/l 24 overnight and lyophilized to yield 3. 1P.. By uv analysis the product was shown to have an average of about 44 mor~hine 26 ~ g rou p G .
29 .
104;~79Z
1 In ordcr to dr)nonserntc thc erfcctivcncss o~ thc 2 subJect assays ~Isins quellchillr, of fluorcsccncc as a method of mcasurlll/, the presence of a ligclnd, a numl~cr of diffcrcnt 3ssnys wcrc cnrried out cmplo~ing diffcrcnt protocols.
The first assay to bc considcrcd is Lhe assay for 6 1ilorp2line and codclnc cmployill~ thc fluorcsceln isoLhiocyalla~c 7 conjugate to 0 -~minocthylmorpllinc (FLUMO'S').
~ s a iirst parL of this assay, a number of antibody 9 conju~,ates havins varying degrees of labeling of rhodaminc wcre combined with FLU~IO'S' to detcrmine thc maximal qucnching.
ll The FLUMO'S' was at a concentrAtion of 1.83xlO M in 0.05M
12 boratc buffer pH 8Ø Fluoresccnce rclative intensity at 13 F = 516-518nm was recorded by scanninE from 490nm to 14 530n~, excitation line ~as 462-464nm and slits were adjusted with a sensitivity knob to keep the peak on scalc with a Perkin-Elmer Model MPF-2A fluoresccnce spectrophotometer.
17 The spectrophotolDeter cell, lcm path length (3ml in volume), 18 was installed in a two mirror combination-base. The conjugated 19 antibody was allowed to incubate with FLUMO'S' at room temperature in pyreY. vials for 30-40 min before takin~ the 21 fluorescence reading.
22 The dyelprotein ratio (D/P) (M/~l) for the conjugates 23 was 0.9, 2.2, 4.4, 15-16, and 20-22. The results reported 24 for relative elricicncy (1/2 of the maximum quenching in ~
dividcd by thc corresponding number of binding site equivalents) 26 werc rcspectivcly 6, 16.4, 24, 51.4, and 31.5.
27 In carrying out the assay, the following reagents 28 were cmp]oyed: FLUMO'S'-1.38xlO M; RIgG(~) D/P 30, 4.58xlO 7M;
33l ~2 -38-~.,, ., ~r.J
' 1 .. ... .... , ...... ,.. ,,.. _. .
`:''~' ' ' . ~ : ' . ` ' : -: ~, ' ' ' .
~_ 1042792 1 bornte buf~cr 0.05M p~1 ~.0; ~itand;1rd ~orphinc ~olutions 2 (l.5xlO 3-l.5xlO 7~). Incubation was in glass tubes.
3 Proccdure: cqunl nmouuts of RIgC(m) (~O~Il) worc dilutoc1 with 0.05~1 boraLe buffer, p11 8.0 (2~1~0-2990~l) and incubated at roo~ tcm~crature with increasing amounts of 6 morphine (S-lO~l oE thc standard morp1)ine solutions) for one 7 hour. FLUMO'S' (lO1~l) was thcn addcd and thc 1nixture 8 incubated for an additional onc ho11r. The flnal voll1me of 9 each tube was 3ml. The final concentration of FLU~IO'S' was 4.6xlO lOM and that of RIgG(m) 6.1xlO 9~1 in binding sites.
ll The results are reported in the following tablc as fluoresccnce 12 intensity increase as percent o maximum fluorcscence possible 13 (FLUMO~S' without quenching antibody).
`,' 1~ . .
TABLE I
morphinc signal % of F
16 (molarity) intensity max 17 0 27 33.33 18 2.5xlO-9 28 34,5 19 SxlO-9 29.5 36.4 2.5xlO-8 35 43.2 -8 38 16.9 22 2.5xlO- 54 66.6 23 5x10-7 60 74 2~ 2.5xlO-6 74 9l.3 5xlO-6 78 96.3 26 ' 27 Thc study was repeated except ehat codeine was 28 employed in place of ~orphine. The following table indicates 29 the results.
, ' .
,. .... . ....... _.. . .. . ..... , .... , ._ .. ~_, . _ .. _ .. _ _. ......... . .... .. .. ...... .... . ........ _.
... . .
.:
: ' . - :' ~ . : ' - - : . ": . ..
: :. : - :
104Z7C~2 1 TAnl,~. II
Codeine sl~ncll Y of F
2 (molarity~ intcllslty Itlax _ , _ 3 o 2732.9 2.5xl0-9 30,537.2 5xlO-9 3643.9 6 2.5xlO-8 5162.2 5xlO-8 5870.7 8 5xlO-7 7591.5 9 2,5xlO-6 8097.5 .
Il The aSSRy ~RS repcated, but :insteatl of Lhe rhodamine .2 labelcd morphine antibody (RIgG(m)) having a D/P (dye/protein) I (Il/~) ratio of 30, ~IgG(m) was eiDployed having a D/P of 22.
lfii ¦ ~he follouing are the results employing morphine.
15 ¦ T~BLE III
~ 17 ¦ morphine siEnal ~ of F
-~ ¦ (molarlty) intensity max '`' 1~ 1' ; I o 24.5 29.9 , ,~ -19 1 2.5xlO-1 26.0 31.7 20 1 5xlO-1 26.5 32.3 22 1 2.5xlO- 28.0 34.1 ;~ 1 5xlO-9 29.0 35.4 ~` 23 I lx10-8 33.5 - 40.8 2.5x10-8 40.0 48.8 5xlO- 45.5 55.5 26 lx10-7 53.0 64.6 2.5x10-7 63.0 76.8 28 5Y.10-7 68.0 82.9 ` 29 lx10-6 72.5 88.4 2.5x10-6 80.~ 97.5 `; 31 5x10-6 82.0 100 '~.. . . .
'' - ': .
.,:., , , : , :
'' ' .
.
. ': - ' :
1 Thc ncxt s,tully whlch wa-i cnrr:ic-l out cmployed a 2 polyli~and, namely, morplllllc conjur,nted ~o bovinc scrum 3 alhumin, havillg nn average nllmber of 44 morphincs pcr albumin.
In n first tcst, thc polyllgand was employcd as n syntllctic proteln ;n tl-aL th~ polyliga-ld has a plurali.ty of morphine 6 cpitopic sitcs. In n sccond serics oE tests, the polyligand wafi employe(l in aU assay for morphinc or code:ine. In both thesc assays, ncitllcr chromophore is covalcntly bound to the 9 epitopic site oL i.ntcrest, but rathcr each becomes bound through antibody. Thus, thcre is a random binding of anti.body 11 to morphine on the polylieand. At thc concentrations of 12 interest, in a study not described here, it was found that 13 optimum quenching was obtained where a ratio of quencher as 14 receptor-q--encher to fluorescer as receptor-fluorescer was about 5 to l.
16 In the first test, which is an assay for the 17 poly(ligand analog), a series of tubes were prepared each 18 containing 6.4x10 9M (ln binding sites) of antimorphine 19 having a D/P ratio of fluorescein/antibody of 9 and 3.47xlO M
(in binding sites) of antimorphine having a D/P ratio of 21 rhodamine/antibody of about 22 in 0.05M phospllate buffer, pil 22 8.0, containing 1.2xlO M bovine gamma-globulin. Various 23 amounts of the morphine conjugated bovine serum albumin (approximately 44 morphines per albumin) (0.0].2-l,21~g) 2~ werc added (in 5-lO~l) to each of the tubes so that the 26 final volume was 0.5ml and incuba-ed at room tempcrature for 27 30 min. The fluorcscence of each of thc tubes is then measurcd 29 and cxpresscd in pcrccntagc of maY.imal fluorcscence possible : 30 .
31 .
~ -41-.1 - .. ...... ...
., .
.
:, :
.. " ., ~., . .. ~
~ 1042792 l (Wl~ no mor~ e collJugnted l'iSA ls prc~;cnt). Tl~e res.ults 2 nrc in thc rollowillg tl~ble.
~; TAULE IV
5~ n-1~S~ ~. of F
8O.OL~ 8/l.5 90.024 72 100.0~i8 64.5 11O.OS4 61 120.12 66 130.24 74 140.48 83 151.20 92 16 For assaying for codeinc, the following procedure 17 was employed. Employing the same antimorphine-fluorescein 18 (FIgG(m)) and antim~rphine-rhodamine (RIgG(m)) as cmployed 19 above, 30~1 of the FIgG(m) (2.64xlO M) and 30~1 of the RIgG~m) (1.44xlO M) were diluted in a series oE tube3 ~ith 21 0.05M phosphate buffer, pH 8.0, containing 1.5xlO 6M bovine 22 gamma-globulin (390-430~1) Codeine in incrensing conccntrations 23 (1.5xlO 3-1.5xlO M) is then addcd (10-40~1) and the mixture 24 incubated at room temperature for 0.5 hr. To ench of the tubes is then added 10~1 (0.241l~) of the morplline-bovine 26 serum albumin con~ugate used previously and the tubes incubatéd 27 for an additional one hoùr. The fina] volume in cach tube was 0.5ml. The fluorcscence of cach of the tubes at 518nm ';
''~ 1 .. . . ...... .
. . .
"'': ' :
:
1 was then rccordc~ an(l expressed ns ~ercc~ c o~ maxJmal 2 fluorcscellce possillc (whcn no morpllinc-BSA conJu~ato 18 3 prc~ent). Thc followln~ table in(lica~:er. the results.
TA~LE V
7 Codcine ~ of F
8 3xlO-9 51 9 6x10-9 5~
0 1.2x10-8 56.5 3xlO- 62 23 6x10-8 70 5 1.2xlO 81 3x10-7 90 5 17 1.2xlO 100 18 3x10-6 ~ 100 19 The next two studies involve the nPtural protein human gamma-globulin. In the first study, human gamma-21 globulin-fluorescein (FhIgG) D/P 5.5 was employed for the 22 determination of human gamma-globulin. A series of tubes 23 ~ere prepared, each containing 100~1 of 0.017mg/ml of anti-24 human gamma-globulin-rhodamine conjugate (~IgGthIgG) D/B 12-15 in 0.05~l phosphate buffer, pH 8.0 (330-380ll1) containing 26 BS~ (0.6mg/ml). Increasing amounts of human gamma-globulin 27 (in 15-35~1) were then added and incubated for 30 min at 28 room temperature. To the solutions ~as then added 30~1 of 29 0.014mgtml of FhIgG. The final volume in each case ~as 32 _43_ , .
~: .
`.
~ ' `, ' ' ' ~
i. 104Z7912 I 0.5ml. Thc f:in;ll concolltration of thc FhlgG was 5.4xlO 911, 2 wl~ilc tho couccutrati~ns of h~lm~u ~nmma-~obulin rnnged from 3 ~l.S4xlO t~ 6.45xlO ~1. Aftcr n sccond incubntion pcriod 4 of 30 min, thc fLuorcsccllcc of the tubes at 522nm was r~cordcd QS perccnca~c of maxilllal fluorcsccncc po-:sible. Thc following 6 tablc indicatcs the rcsutts.
8 T~I~LR V.I
9 ll:rgG X of FmaX
o 28 ll 4.84xlO-1 33 12 8.06xlO-1 ~ 36 13 1.13xlO-9 38 1.61xlO-9 46 3.22Y~10-9 68 . l6 4.84xlO-9 81 17 8.06xlO- 91 l~ 1.13x10-8 93 19 1.61x10-8 95.5 3.22x10-8 96 21 6.45x10-8 98 23 In the next determination, the human gamma-globulin 2~, was assayed by employing anti-human gamma-~lobulin-fluorescein (FIgG(hIgG)) conju~ate and anti-human gamma-globul:in-rhodamine 26 conjugate (RIgG~hIgG)). The f]uorescein conju~atc had a D/P
27 of 4.3 and the rhoda~ine conju~ate had a D/P of 10. All 28 rea~ents wcre diluted with 0.05~1 phosphate buffer, p}l 8.0, : 2~ containin~ 0.6mp./ml of bovine scrum albumin. ~ scrics of : 31 ~. ~
~ 1 . . : ~
.
,~
. '.
,~' ' ' ~ ' "
, j 10~'92 1 ¦ tnl~cs wc.rc prc~-arcd, cac~l colltnLnin~ /,001l1 of thc ln~lcntcd 2 ¦ buffcr. To cach of t)~c t~lbcs wa~ ~(ldc(l, 30ll1 of 2-71 3 ¦ of l~ ;G(IIl~G) nn(l 30ll1 o 351lL/ml of ~I~G(III~,C). The t~lbc~
4 ¦ wcrc mix~d alld inCrC;l~Sillg, ~mounts of llnlnan l;amma-~lobulin 5 I atl(lcd in 401ll sol-ltio-l~s and incubatcd at room tcmpcratllrc 6 ¦ for onc hour. The fluorc~sccncc of thc t~lbes was tllcn measurcd 1 7 an(l cxpresscd as pcrccnt o total ]uorcscencc in thc ~hscncc 8 o h-lman ~amm~ ,lob~llin. Thc follo~in~ t~blc in(l:Lc~tcs thc 9 rcsults.
..
Il T~BI.E VII
12 Human IgG % of F
13 3xlO-ll 100 14 6xl0_ll 95 7 1.2xlO-1 93.2.
16 l.8xlO-l 89-5 17 2.4xlO-l 86.5 1~ 3Y.10-l 82.2 lg 6x1O_lo 70 5 1.2xlO-9 60.7 21 l~8x10-9 62 22 2.4xlO-9 60.l 23 3xlO-9 69.3 2~ 6xlO-9 79 1.2xlO.8 87.7 26 1.8xlO-8 88.3 28 2.4xlO-8 93.8 29 . .
31 . .
32 _~5_ : ', ' , ' 1 ~ 104Z79Z
1 ¦ As iF. cvidencc(l fron~ ~hc abovc Tnblc VII, witll 2 ¦ incrcasing hulllall ga~ a-glol>ulin conccntratioll, he fluore~-3 1 ccncc dccrc.ll;cs to a mlnimum alld thcn increnses. Thcreore, 4 ¦ ~itll an ullkllown, it ~ouLd bc n~cessary to carry out: two 5 ¦ dllutions to clctcrminc ~hicll part of the curvc was involved.
6 Thc abovc resulcs dcmon-itraLc tllC exLremc scnsl-7 tivity and wLde rilngc of capabLlity of thc subjcct nssnys.
8 ny clnploying thc fluorcsccr~cc-qllenchin~ phenomcllon, onc can 9 as~ay directly for a wlùc varlety of diffcrcnt compounds, both haptenic and antigenic. Reagents can be cmployed, 11 where the hayten or antigen is covalentl~ bondcd to the 12 chromophore, or altcrnatively, where the comyound of interest 13 has a plurality of epitopic sites, mixtures of ant;bodies 1~ can be employed with a portion of the antibodies bonded to quencher and a portion of the antibodies bonded to fluorescer.
16 In this situation, derivatives of the ligand are not required 17 for preparing reagents, where a naturally occurrlng receptor 18 i8 available or the ligand is antigenic.
19 In addition, reagents can be prepared having a plurality of haptenic or antigenic molecules bonded to a 21 nucleus molccule. Either the nucleus moiccule can bc bonded 22 to a chromophore and antibody employed which is conjugated to the other member of the fluorescer-quencher pair or the miY~ture of antibodies indicated above employed. The assay is relatively rapid, and depending upon the concentrations, 26 various incubation times are required. Furtherlllore, conventional 27 fluorometers can be cmployed which are relativcly inexpensivc 28 and easily read.
~ . .
','., . .
' : ;
.
' ., 1. , ` 10427C~2 Lhour,ll thc forcr,o:inE invcntioll hn5 bcen dcscri.bcd 2 in somc de~nll by w.,y Or illu~.t--aLion nnd c~cnmplc for p~lrpor.c.
3 oC clarity of l~n~lcr~:Lan(i:inr,, i~ will bc obv;ous that certain 4 chanEcs and mod.iflcations may bc prncticcd withln thc scope 7 ~ oi the ;'PI~ claimr.
.-18 . .
. . .
21 . .
2s 1~
29 . .
32 _~17_ ~ ' ~ ., ............ .
J . . .. ~ ........ .. ... . .............. ...........
.
10427gz l ¦ Witl~ ~)nly(lLunn(l allalo~), the two con~ugate(l anti-2 ¦I.odics are combine~(l w;LII thc unlillo~n to l-c assayed, incubated, 3 ¦and the poly(li~nlld annlog) added and the mixtllrc furthér ¦ ;nc~lbnted The timcs ancl tcmpcratures previou-:ly indieated 5 ¦are nlso al~plicable i~l th~s ~s~ny.
6 ~hc sumrlc i9 thcll introduced into n flllorometer, 7 nnd the fluores(~cnce dctermined upon exc;t~ wiLI) light of the appropriate ~avclen~th. The [~uorescence m.~ be from the fluore-;ccr or quellcl)er depending upon the ~avelcngtll band mcasured. The assay can bc carried out manually or 11 be automatcd.
12 The subject method is readily adaptable to determine 13 the presence of antibo(lies or antigens in human physiological ~ Eluid usinE a two step method and recepcor-chromophores 1~ (Chl and Ch2) for gamma globulin, e.g. human. One can readily 16 differentiate by the difference in molecular weight hetween 17 the agEregation of antibodies or other receptor molecules 18 ¦which are bound to an antigen and thc antibodies or other 19 ¦ receptors which are free in solution.
20 ¦ Depending on vhether one wishes to determine the 21 ¦ presence or absence of an antigen or antibodies in a human 22 physiological fluid, e.g. blood, one would add the com~le-23 ¦ mentary material, usually in substantial excess to the maxlmum 2~ ¦ concentration of intercst. For example, if one wished to 25 ¦ determine the prcsencc of antibodies in serum to a particular 26 ¦ antigen, one would add the antiEen to the physi.ological fluid 27 ¦ and separate components having molecular ueiEIIts Ereater than 28 the antibody moloeulnr weight (>160,000), for exan~ple, by 29 centrifuEat:i.on. Afeer separating the precipitste from the supernatant, the prccipitste i~ rcdlspersed and assayed in 32 ~ -28-~ .
~ ' . ' . .
-:: - : , :~.
:~
.:
:. :
:~ . , :. - ....... :
1 ¦ accordancc ~Ltll the invelltlon for thc presence of hllman 2 ¦ galllma ~lobulill. On].y i.l~ the prc-:cnce of nntile~ il]. human 3 ¦ ~amma globulin bc prcscnt ln the prccipitatc. Tl~ercfore, the ~rcsencc o~ h~ an g.l~lma glob~llin in thc precipltate indicates the presencc of nntibodies to the antigen in the 6 scrum 7 ¦ The t~o stcp mcthod c.nn be uscd for detcrmining a 8 ¦~idc varict)~ of antigclls and alltibodics usin~ the same 91 rec(!ptor-chromol)hores. The metllod providcs a d:iLcct deter-0¦ mination of antibodies to spccific antigells. Antigens can 111 be indirectly determilled by addillo antibo(lies to the fluid 12 ¦ suspeetcd of containin~ the antigen and then assnying for ¦ the presence of antibodies in thc precipitate after separation of bound and unbound antibodies.
5l¦ The double receptor technique is a homogeneous ! technique which allo~ls for the determination of haptens, 17`~ antigens, and anti-ligand, particularly ~here the ligand is g;l a polyepitopic antigen.
9¦¦ In tlle simplest mode, for detection of a ligand, 201 the ligand ~ould be conjugated to a chromopllore, particularly 21 ¦ fluorescer and anti-ligand and anti(anti-ligand)-chromophore, 22 ¦ particu].arly quencher, added to the assay solution. In this 23 ¦ manner, one could bind a larger number o~ quenc1ler molecules to the ligand, enhancing the opportunity Ior quenching, In 251 cffcct, the nnti-ligand provides for increasing the number 20¦ of qucnchcr molecules capable of being bound to the ligand.
27l The concentrations of the reagents vill parallel 29 the analo~ous reagen-s for the sinEle receptor technique 31 ~
32 ~ -28a-'I .... .. . ... ...... .... . .... . ....... ... . . . ...... .. ... . .. ... .
~ 104~79~ 1 wltll Lllc .lnLi(~ ti~ cl~rol~lol)ll(Jrc b~ n Inol;lr CXCCS8 2 to the antl-llgalld, gcllcralLy ~he mole rnLlo heing Erom 3 about 1.5 to 10:1. If clcsired, indlv.idll.ll F b units can be employcd rathcr tl-an in~act I~G.
The next mode llas both chroll~ol-hores ind-ircctly 6 bound to ligalld. In this mode, only anti-l-igan(l an(l anti-7 (anti-l:igalld)-Chl all(l anti(nllLi-ll~nnd)-Ch2 nre employed.
o llowever, prior to Intro(luctioll of these reagent6, .3 portion 9 of Che anti-l;gnn(l will bc coml-ined witll anti(antl-]igand)-Chl and another port:ion witll anti(anti-ligalld)-C1l2, so as to 1l become bound. Desirab]y, the anti(anti-ligand) ~ill be 12 monofunctionnl, e.g. l 1. The anti(anti-ligan(l)-Chl and 13 -Ch2 bound to anti-ligand provides comparable reagen~ to 14 receptor-Chl and receptor-Ch2 respectively. Similar ratios of anti(anti-ligand)-chromophores to anti-l:igand may be l~ employed as previously indicated.
17 In a preferred embodiment, anti-ligand from two 18 different species, e.g. mammalian species, are employed, for 19 example, sheep and CONS. In this s:ituation, the epitopic or haptenic sites are different for the two anti-ligands for 21 the same ligand. In referring to anti-ligand from two 22 different sourees, anti-]igand will be preceded by a small 23 letter, e.g. a-(ant:i-ligand). In this mode, the anti-ligand 2~ and anti(anti-ligand)-chromophore need not be precombined, 2~ The ratios of the various reagents would parallel the analogolls 26 reagents in the previously described assays.
27 The chromophore rengents would be anti(a-anti-28 ligand)-Chl and anti(h-tnti-li~nnd)-C112. Thus, Chl would be 29 associated with only a-(anti-ligand) and Ch2 with b-(anti-ligand).
32 ~ -28~-.
.`
,.
~ 104279Z
1 ~rhiS tcchni,luc ullows ror the deter~lnation of 2 nssem~lages in solnLIon, whert! men~ber. Or the assemblnge 3 di~fer by at lenst Onc epitopic site. One ean prepare a-(anti-ligand) for onc me-nbcr of the assemblaEe and b-(anti-lignnd) for allotller member of ~hc asserlblape. Quencher and 6 flllorescer ~ould be brouEht togetl~er only when the two 7 meMbers arc boun(l togetller.
8 ¦ ~sing anti~ ,alld from ~o di~ferent source.s ean 9 ¦ uls.o be employed w;th advantage with a ligand to nvoid 10 ¦ having to precombine nnti-ligand ~ith the nnti(anti-ligand)-ll chromopllore and in situations where covalent linliage is 12 1 oeeurring between two entities which can exist independently, 13 ¦ e.g. undergoing n ehemieal reaetion.
I4 ¦ The reagents can bc provided in separate vials or 15 ¦ mixed in a dry lyophili~ed state or an aqueous, normally 16 ¦ buffered (pH 5-lO; usually 6.5-8.5) solution of any desired 17 1 eoncentration. Preferably, anti(a-anti-ligand) would not be lS ¦ eombined with a-(anti-ligand) in solution as a reùgent for a 19 ¦ long period prior to use. Conveniently, the two anti-20 ¦ ligands eould be eombined and the two anti(anti-ligand)s.
21 ¦ A partieular advantage of using the double receptor 22 ¦ is that the same pair of (anti(anti-liEand)-ehron!ophore)s 23 ¦ can be employed irrespective of the ligand, only the pairs 24 ¦ of anti-ligand varying with the ligand.
25 ¦ For determinin~ the presence of ~ntil)odies to a 26 ¦ partieular antigen, one would earry out the assay as if one 27 ¦ was determining the antigen, except that a knol~n an~ount of 23 ¦ antigen would be added to the assay medium. Any antibody 31 l 32 ~ -zee-. ~ . .
~ 1~)4Z792 1 present in tllC ullkl)own would aet to diminisll tlle nmount of 2 the all~i(allti-lLgal~ cllromo~ orc bound to tlle antigell and 3 thlls dimillisl- the alnount of quellclllllg whLell would oceur in 4 the al-sence of alltibody. ~f conrsc, the anti-ligand would ~ be from different species (other than mammalian~ Lllan the 6 antibody to be determined.
7 Thc followillg exam~les are offered by way of illustration alld not by way of limltaticn.
9 .
EXPF.RI~IRNTAL
___ 11 (All temperatures not otherwise indicated are in 12 Centi~,rade. All parts not othcrwisc indicated are parts by 13 weight. All buffer solutions are aqueous buffer. All 14 symbols not otherwise defined are intended to have their normal meaning.) 16 The following symbols are employed:
17 IgG - gamma-globulin;
18 IgG(x) - anti-x;
9 R - tetramethylrhodamine, e.g. RIgG(x) tetramethyl-rhodamine eonjugated to anti-x;
21 F - fluoreseein, e.g. FIgG(x) fluorescein conjugated 22 to anti-x; and 23 hIgG - human gamma-globulin.
2~
32 -20~-~, ' : , , : `
~' i ' , :~ . :.' ' ,' : , :
. ' ' . '::, ~: ~ .
:' , -~ 104~79~, I EXAMI'I.E I 1 luorc-:c~ rotIIlo~ya ~.~te (1~ t r~ . on~ te ! to n 3-.-n~! noethylInorLIIlin~ IOIS') 3 ¦ A. Fluor<-:ccin ami.ne (0.5~) (S.i~ma, isomer I, ~1 ~ pure, tlc ~ieOH/CllC13 1:3) wa6 dissolved in 20ml of dry 5 I acetone (dr.ied on anh. K2C03) and addl-d drop~ise at room G I temperature to 3ml of thiopIIos~(:ne in 5ml of ncetone wi~h 7 1' stron~ stirr:iltg (1/2 hr). Stirr:i.n ~ wns continned for t hour 8 ~, and the re-;ultin~ prce:iritate cooled with an ice-bath to 9 1 5~ wag r;Il-idly filtered throeh a fine sintered y].ass 10 . funnel. The precipital:e was washed with dry acetone (3ml) Il and then with 5 ~: 5ml 6N IICl whi].c crushi.nR wi~h a spatt1la !2 until it all turned deep red, followed by dryin~ _n vacuo 13I (80 KOll) overnight. The isothiocyanate o1-tained was pure 14 I (tlc 50Z I~leOH/D.lF). .
15~
16 1 B. O -aminoethylmorphine (lOOmg) is dissolved in 17 I 5ml of acetone and added to a mixture of acetone (20ml), 18~ water (5ml), and triethylamine (0.07ml). To this solution 19 ! is added a solution c f FITC (lOO;ng) in aeetone (5ml) dropwise 20 with st:Lrring during 15 min. Stirring is eontinued for an 21 j additional 80 min, while adjusting the pH oE the reaction 22 ¦ mi~:ture to 9.5 with drops of dilute triethylalnine solution 231 in aeetor-e (l.4ml/lOml aeetone). The aeetone is then partially 2$ I removed with a rotary evaporator at room temperature. The 251 produet is then precipitated by bubbling C02 throug1I the 261 solution with simultaneous addition of H20 (up to lOml) 27i until the pH drops to 6-6.5. The precipitate is rapidly 281 filtered on a sintered :lass funnel and was1-ed with }IzC03 29 ` .
31 ~ .
32 -29- .
. . .
.,, ~ . .
. 104'~79Z
I ¦-:olution (2ml, 111 6.0). Ylcld 601n~. Tl~c filtrtlte and w;lsliinEs 2 arc col~billc(l and n !;eCOn(l crop is obtninc(l by repcntinr, the 3 ¦l~ubblins Of C02 as dcscri~cd. Yield 2/mr,. Thc pro~uct is ¦ dried overnlr,llt undtr vacutlm at 80 over 1'205. Totnl 87mg, ¦ Tbe product shows a single slot on tlc (50~ Tncthanol in 6 1 dime~hylforlla-.n;de), Rf = O.~S.
~ ¦ ~XA~IPLE II Pur_fLca~ion and labelin~_of ~! r~lline 9 I Ant:ibo(ly (Tp,~l)) witll Tctramc(:llylrhc~damine I __ __ __ _ _ _._~_____ _ ¦ Isotl1Locy~l.lte (TRITC) 11 ¦ A. (a) Preparat o1_ot__l_r~hine - Jm1n~_nadsorb nt 12 1 Cyanogen bromide activatcd Sepharose 4P, coupled 13 1 with hexamethylenediamine (8-lO ~mole/lml packed gel) was 14 ¦ prepared according to the company's directions (rhar~acia, Upsala). Wet gel (2.5ml) ~as suspended in boratc buffer 16 ¦ (lOml,O.lN, pH 8.8), the mixed anhydride of O -carboxymethyl-17 ¦ morphine and isobutyl chloroformate (O.l mmole, large excess) 18 ¦ in DMF (2ml) added in the cold (0~), and the mixture allowed 19 ¦ to react for 3 hours. The gel was filtered and washed 20 ¦ successlvely with H20 (500ml), O.lM borate buffer pH 9.0 21 ¦ (SOOml), H20 (500ml), dilute HCl ' O.lM NaCl, pH 2.5 (lSOOml), 22 ¦ and H20 (lOOOml). No morphine could be detected at the end 23 I of the washings. The estimation of bound morphine was 2~ I carricd out by a dilute acetic acid hydrolysis method 25 ¦ (Failla, et al., Anal. Bioche~., 52, 363 (1973).. The uv 26 1 spectrum was compared to that of O -carboxymethylmorphine.
27 1 The bound morphine equivalent was 5.05 llmolellml ~ac~ed gel.
., 291 . .
; 32 -30-1- . . ...
: ' ' , : , ~ . . , ,....... ' ' ," , ~ : :
.
-- 1(~4;~79Z
1 (b) P~ clt-~on .~r ~lo~r!l~nc_ nt.Lbody 2 The n~o1rhi~e Scpl~ro~ic conjllr,.lte (2.5ml~ was 3 pac~ed in a 1/4" o.d. columll nnd washed succcssivcly with lOOml ench of boratc hllrfer O.l~l p1l ~ 0~ 1120, dilute 1ICl pl1 l 5~ ll20, alld thc samc l)orat( burfer. Stock s11ecp IEG
6 solution (7ml, 2.18xlO 4~1 linding sitcs) W.lg app]ied to the 7 column fo1lowcd 1)y wash-ing wit11 bol.aLc buffer O.l~l pll 9.0, 8 nntil no ploLcin cou1d be dctcctcd in the eEflnent (uv).
9 All the ant;morplline activity W.IS rCtnine(l by the column as dctermincd by morphine ~piu-label measurement. (See U. S.
11 Patent N'o. 3,690,834). I~ashing was continued with glycine-12 }ICl buffer O.l~ pH 4.0 wllereby no protein was elutcd.
Antibody was then eluted with glycine-HCl buEfer O.lN pl~ 1.5 and 3ml fractions were collected at room tcmperature in tubes containing lml of lN borate buffer pH 9Ø Almost all 16 of the antibody vas collected i,n three fractions which were 17 combined and dialyzed for 24 hours against O.l~l phosphate 18 buffer ph 7.5 (2x2000~1). The anti~orphine activity of the 19 isolated fraction was determined with morph:lne spin-label and accounted for 70% of the initislly bound antimorphine 21 activity. This fraction was 100% pure as determined by the 22 antimorphine activity titer value compared to protein content 23 estimated from the uv spectrum at 280nm.
2~' r.. (a) Purificat:ion of Morphine _ ~ibody-Sephadex Chroma~o&raphy 26 The antimorphine IgG(m) solution (2ml, _50mg/ml 27 total protein) was separatcd on Sephadcx G-200 column (2x30cm) 28 ~ith O.OlM PBS tphosphate buffered saline) pli 7.4 (flow rate 29 lmltlOmin). The IgG clearly separated from the IgM and ,~
, . .. . . . ,.. ~ . . .... .
" , ',: ~
, .
104,'Z79'~, 1 olbumin .Ind fr.lctiolls oE 2~3ml werr. eollected. The obtalned 2 Ig~: sllowed no albumln on eellulosc ncetaLe electro;-lloresi5 3 (Tris-bnrl), buffol-, pl~ 8.8, ~ -- O.l) and ~as 32-35X anti-morplline-rich IgG. Recovery depen(le(l on the cut-w:i(lth of the IgG peak eollected an(l wns: usually 50Z of total anti-6 morrhine activity apl)lied to Lhe column. The co]lected IgG
7 fraetion was dialy~ecl a~ainst 0.01~1 ~llos~)haLe buffer ~ll 7.5.
9 (b) ~ovine Seru~ bo!iin (nS~)-Tm~.llno~(lsorl-ellL Treatment BSA was coupled ~ith (:NBr activated Sepllarose 4B
11 (Pharmacia) aceordinz to the com~any's instrllctions (50~
12 exeess of BSA was used over the reeom~ended an-ount). Five 13 ml of the Sephadex ehromatogrnphed ISG solution (20mg/ml) ~ were applied to the 2~SA-i~munoadsorbent column (lxl5cm) and run through with 0.01~l phosphate buffer pll 7.5. The collected 16 protein eame out in 20ml and was assayed for protein content 17 tuV) and antimorphine aetivity (spin-label method). Recovery 18 of protein was 70~ and recovery of antimorphine aetivity was 19 90-92%.
21 (ej Antimorphine ~gG(m)) Labeled ~ith TRITC (RIgG(~
22 To a solution of IgG(m) (7~n~/0.5ml) in 0.01~
23 phosphate buffer p21 7.5 is added erystalline potassium 24 earbonate up to pH 10.0-10.5 with stirring at room tem-perature. TRITC (tetramethylrhodamine i.sothiocyanate) (15-26 1000 ~g) dissolved in aeetone (3-30 ~l) is then added and 27 stirring is continued for 3 hrs. Initially thc p21 drops to 28 9.0 and then stays stable, and is maintained nt 9.0-9.5 if . .. ~....... . .. ... . ...... ........ .....
. .
::
., .
:
. ~ .
:
. . .
~ 104;~79Z
l ncccss.lry, by carcful n(l~lition of crysLallinc potn.~ um 2 cnrbonntc. Tl~e rcacLion ~ixture is thcn ~pplleù ~o a Scphndcx 3 G-25(~1) column (lxl5cm) ~lth O.Ol~l phosl)l)atc b~lffcr pil 7.5 4 and clution of thc first colorctl bnnd wllich separat:cs completely from other ballds is col.lccted in 10--15 min. The scparation 6 is repcatcù t~ice in order to cnsure completc removal of 7 free dyc. In case of formntion of a prec:ip:itatc, the prec:ip:Ltnt~
8 i5 rcmovcd by centr:ifllgation prior to the scparat:ion on Seplllldex. The following tablc describcs thc prcparation of conjugatcs with vnrious degrces of labeling by thc above Il procedure:
13 P~otein Concentration Dye (TRITC) D/P* % Activit l4 (% Antimorphine) mg/0.5ml)Jg (M/l-l) Recovere 15 IgG (45) 7.1 15 0.9 86 16 IgG (45) 7.1 .50 2.2 89 17 IgG (45) 7.1 150 .4.4 75 18 IgG (45) 7.1 400 15-16 75 l9 I~G (45) 7.1 750 20-23 70 *D~P - Dye/Protein 23 EXAMPLE III Fluorescein Isothiocyan~te (FIrC)-Labeled 24 _rphine Antibody (FIgG
(a) o_ju~ation Procedure 26 Four lml fractions of affinity chroinatographed 27 morphine antibody (3.06mg pro-ein/ml) (See EY.ample II) in 28 O.OlM phosphate buffer pH 7.5, were brought to p~l 9.5 ~ith 32 . -33-.'~ ' ': . -104279Z' 1 crystnllinc rodium c.rl)-)natc (Na2C03). 10, 20, 30, and 50 2 of an acctol~e sol~Liol~ of IITC (2~ 001l1) werc ad~cd re:-3 pcctively Lo thc four antibody fractions at room tcmperaturcwith stir-in~,. AEter 3 hrs, thc four rcaction loi~tures werc combin~d, thcn di~idcd into 8 c(lual portions and each pnssed G throu~h Scphn(lex G-25 column (lxl5cm) eqllilibrdted witll 7 0.0]~1 phosl)lmlte buffer pll 7.5. E]ution witll the same buffer yiel(led (the first colorcd balld) the conJIlgate whicll was 9 free of unreactcd dye.
11 (b) Se~ rat_on of FITC Conj_&_te on DFAE-_cll~lose Column 12 (See ~1. Goldman in "Eluorcscent Antibody ~lethods,"
13 ¦ Academic Press ed., 1968, pp. 104-107). The FITC-antimorphine 14 I con~ugate was spplied to a D~AE-cellulose column (lx3cm) 15 ¦ equilibrated with O.OlM phospllate buf f er pM 7.3. Elution 16 ¦ with the same buffer and with increasing NaCl concentration 17 I yielded fractions of increasing dye contcnt. The clye content 18 ¦ D/~ of the various fractions was determined with the Wells' l9 ¦ nomograpll (A.F. Wells, C.E. Miller and M.R. Nadel, Appl.
20 ¦ Microbiol, 14, 271 (1966). The antimorphine activity was 21 ¦ determined as usual with morphine 5pin-label. The f ollowing 22 ¦ fractions were obtained:
l Fraction Protein D/P
24 No. mg mo'1e/mole l 1.75 1.5 26 2 1.3 '3.0 27 . 3 1.15 6.0 ' 28 4 1.42 g.o 32 -3~-.
`. . '.
.... , .. _.. ,., .. ,.. _ ,~_ .. , .,. ., .. ... , ,, , ,,, , ,,, . ., ~ _ .. . .
: ' ' ~ ' ' ~, ' ' ' :
. . . . ,: --. ~ ~ , , . ' , .,: . . ~ . : :
' 104~79Z' 1 ~X~ IV l'ul-LEJcatioll of ~ltihod~ to llulaall Gnmma~
2 G1,obulin (I~G(hI~C~) nn(l Con~u&_tion witl 3 FITC (Ft~G(llIsG) _ nd TI~ITC (RI~G(IlI~G)) ~ (n) l~uri~tc;ltioll of Antibo(ly to llumnn I&~
A ~ y Cl-romnto~rae~y 6 Scpharose-~B (2~) was couplcd witll 18mg human 7 gamma-globulilt (hlgG) as described in thc compally manual 8 (~harmacia, Upsnla). ~abbit antiserum (50ml) to h'LgG (5mg 9 antibody/ml~ (IEG(hIgC)) was obtained from Antibodies Incorpornted. A column (lx3cmj of the above Sel)llarose-hIEG
ll conju~te was prepared with O.OlM borate bufEer p~ 8Ø The 12 antiserum was passed throllgh the column, followed by washing l3 with the same buffcr until no protein could be detected in the eluent. The column was further washed wiLh 0.1~1 glycine-llCl bui'fer pH 5Ø The antibody was then eluted with O.lM
16 glycine-}lCl buffer pll 2.5; fractions of 3ml were collected and immediately neutralized with 0.5M borate buffcr 9Ø
18 The total volume of antibody solution thus collected was 19 30ml. The antibody solution was dialyzed overnight against 0.05M phosphate buffer pH 8.0, then concentrated with Aquacide and dialyzed again. The final volume was 11M1 and ehe 22 protein-antibody content 3.76mglml as determined from the 23 absorption spectrum at 280nm. Antibody recovered was 83~.
(b) rre~aration of FIgG(hlgG) 26 , (i) The above antibody solution (lml) in 0.05M
27 p}losphate buffer pH 8.0 was brought to pH 9.5 with crystalline 28 Na2C03. FITC (lOOIlg) in 10~1 of acetone was addcd at room ,29 .. . . ' ' ' ,.......... .
' , .
1~79Z
l tcml)crature and sti~rcd for 3 hrs. Thc conjugal:e was than 2 sepnratcd on Sepllnclcx C-25(~1) (lxlOcm) cqllllil)ratcù with 3 0.05M phospllatc buffcr pll 8Ø Tl~e conjugate was collecta~
in l.5ml; i~ had D/r e 4~3 (~ 1) (dyc/~rol:c;ll) nnd 2.05mg/lnl S as detcrmined with thc ~ lls' nomoEral~h.
7 (c) I`rclm~r~_ion of -r~-I &G(h_~) 8 (i) The above dcscribed nntibody solution (lml) 9 in 0.05M phospllate bllffcr pll 8.0 was broup,ht to pll 9.5 with lO crystalline Na2C03. TRITC (0.5mg) ln acetone (20-30~1) was ll added at room temperature and the mixtll7-e e,tirrcd for 3 hrs.
12 A precipieate formed which was removed hy centrifugation and 13 discarded. The conjugate was then separated twice on Sephadex 14 G-25 column (lxlOcm) equilibrated with 0.05M phosphatc lS buffer pH 8.0, The product was recovered :in a 2ml voluDe 16 and had D/P = 10 and 0.7mg/ml as determined from the absorption 17 spectrum at 280 and 516nm.
18 (ii) DEAE-cellulose separated IgG fraction (27.6mg¦ml) 19 of Rabbit antiserum to hIgG (6.4m~ antibody/ml) ras obtained from Antibodies Inc. The above protein solution (O.Sml~ was 21 brought to pll 9.5 with crystalline Na2C03, and 3mg of TRITC
22 in 50~1 of acetone + 0.5ml H20 were added with stirring in 23 the cold (4~). After 3 hrs, a precipitate occurred an~ wa:~
2~ filtered off. The resulein~ viD]et solution was separated successivel~ twice on Sephadex G-25(~l) column (2x30cm) 26 equilibrated with 0.05M phospl-ate buffer pll 8Ø The resulting 27 conjugate was O.lmg antibody/ml and had D/P -- 12-15 (M/M) as 28 calculated rom the absorption spectrum.
~ --.
1 . ~ , .
.
.' : . .
- " " ' . , ' ' ' . ' .' . ' - , ' ' '~
:: .
J 10~7'~Z
1 ~XAMrLE V Conj~ L_ of 11~"".~" ~._mm.l-Clol~ulin .
2 (hl~(~) Lo 111~orel:co:Ln (ihIU~
_ _ __,____ _ 3 Onc mg of IllgG (~ m.ln IgG) di.s.solvcd in 0.4ml of 4 0.lM phos~hntc buffer pll 7.5, was brougllt to pll 9.5 with crystalline Na2Cn3. A solution (101ll) of FITC (70~1g) in 6 acc~one was adde-l with stirring alld mixcd for 3 hr.s at room 7 tempernturc. The rcsultlng solution was separnted two times o on Sephadex ~-25(~1) colum.l~ 15cr;1) equilibrated witll 0.05M
9 phospllate buffer pll 8Ø Thc clutcd 1ITC-hIgG conjugate solution was 0.58mg/ml in concentration and had D/P = 5.5 11 (M/M) as determined by the ~ells' nomograph.
13 EXAMPLE VI Morphine Conju~ated to Bovine Serum ~lbumin 1~ (BSA-44m) 0 -Carboxymethyl morphine (3.43g) and l.31m].
16 isobutyl chloroformate were combined in 30ml DMF at 0. The 17 resulting clear solution was then added to a stirrin~ solution 18 of 2.88g BSA and l3f~ Na1~C03 in 600ml of water at 0. Addition 19 was carried out by means of a syringe with its tip below the solution surface. The solution was stirred in a cold room -21 overnight.
22 ~fter passin~ the solution through a lar~e Sephadex 23 column, the effluent was concentrated to 60ml with Dow liFn/l 24 overnight and lyophilized to yield 3. 1P.. By uv analysis the product was shown to have an average of about 44 mor~hine 26 ~ g rou p G .
29 .
104;~79Z
1 In ordcr to dr)nonserntc thc erfcctivcncss o~ thc 2 subJect assays ~Isins quellchillr, of fluorcsccncc as a method of mcasurlll/, the presence of a ligclnd, a numl~cr of diffcrcnt 3ssnys wcrc cnrried out cmplo~ing diffcrcnt protocols.
The first assay to bc considcrcd is Lhe assay for 6 1ilorp2line and codclnc cmployill~ thc fluorcsceln isoLhiocyalla~c 7 conjugate to 0 -~minocthylmorpllinc (FLUMO'S').
~ s a iirst parL of this assay, a number of antibody 9 conju~,ates havins varying degrees of labeling of rhodaminc wcre combined with FLU~IO'S' to detcrmine thc maximal qucnching.
ll The FLUMO'S' was at a concentrAtion of 1.83xlO M in 0.05M
12 boratc buffer pH 8Ø Fluoresccnce rclative intensity at 13 F = 516-518nm was recorded by scanninE from 490nm to 14 530n~, excitation line ~as 462-464nm and slits were adjusted with a sensitivity knob to keep the peak on scalc with a Perkin-Elmer Model MPF-2A fluoresccnce spectrophotometer.
17 The spectrophotolDeter cell, lcm path length (3ml in volume), 18 was installed in a two mirror combination-base. The conjugated 19 antibody was allowed to incubate with FLUMO'S' at room temperature in pyreY. vials for 30-40 min before takin~ the 21 fluorescence reading.
22 The dyelprotein ratio (D/P) (M/~l) for the conjugates 23 was 0.9, 2.2, 4.4, 15-16, and 20-22. The results reported 24 for relative elricicncy (1/2 of the maximum quenching in ~
dividcd by thc corresponding number of binding site equivalents) 26 werc rcspectivcly 6, 16.4, 24, 51.4, and 31.5.
27 In carrying out the assay, the following reagents 28 were cmp]oyed: FLUMO'S'-1.38xlO M; RIgG(~) D/P 30, 4.58xlO 7M;
33l ~2 -38-~.,, ., ~r.J
' 1 .. ... .... , ...... ,.. ,,.. _. .
`:''~' ' ' . ~ : ' . ` ' : -: ~, ' ' ' .
~_ 1042792 1 bornte buf~cr 0.05M p~1 ~.0; ~itand;1rd ~orphinc ~olutions 2 (l.5xlO 3-l.5xlO 7~). Incubation was in glass tubes.
3 Proccdure: cqunl nmouuts of RIgC(m) (~O~Il) worc dilutoc1 with 0.05~1 boraLe buffer, p11 8.0 (2~1~0-2990~l) and incubated at roo~ tcm~crature with increasing amounts of 6 morphine (S-lO~l oE thc standard morp1)ine solutions) for one 7 hour. FLUMO'S' (lO1~l) was thcn addcd and thc 1nixture 8 incubated for an additional onc ho11r. The flnal voll1me of 9 each tube was 3ml. The final concentration of FLU~IO'S' was 4.6xlO lOM and that of RIgG(m) 6.1xlO 9~1 in binding sites.
ll The results are reported in the following tablc as fluoresccnce 12 intensity increase as percent o maximum fluorcscence possible 13 (FLUMO~S' without quenching antibody).
`,' 1~ . .
TABLE I
morphinc signal % of F
16 (molarity) intensity max 17 0 27 33.33 18 2.5xlO-9 28 34,5 19 SxlO-9 29.5 36.4 2.5xlO-8 35 43.2 -8 38 16.9 22 2.5xlO- 54 66.6 23 5x10-7 60 74 2~ 2.5xlO-6 74 9l.3 5xlO-6 78 96.3 26 ' 27 Thc study was repeated except ehat codeine was 28 employed in place of ~orphine. The following table indicates 29 the results.
, ' .
,. .... . ....... _.. . .. . ..... , .... , ._ .. ~_, . _ .. _ .. _ _. ......... . .... .. .. ...... .... . ........ _.
... . .
.:
: ' . - :' ~ . : ' - - : . ": . ..
: :. : - :
104Z7C~2 1 TAnl,~. II
Codeine sl~ncll Y of F
2 (molarity~ intcllslty Itlax _ , _ 3 o 2732.9 2.5xl0-9 30,537.2 5xlO-9 3643.9 6 2.5xlO-8 5162.2 5xlO-8 5870.7 8 5xlO-7 7591.5 9 2,5xlO-6 8097.5 .
Il The aSSRy ~RS repcated, but :insteatl of Lhe rhodamine .2 labelcd morphine antibody (RIgG(m)) having a D/P (dye/protein) I (Il/~) ratio of 30, ~IgG(m) was eiDployed having a D/P of 22.
lfii ¦ ~he follouing are the results employing morphine.
15 ¦ T~BLE III
~ 17 ¦ morphine siEnal ~ of F
-~ ¦ (molarlty) intensity max '`' 1~ 1' ; I o 24.5 29.9 , ,~ -19 1 2.5xlO-1 26.0 31.7 20 1 5xlO-1 26.5 32.3 22 1 2.5xlO- 28.0 34.1 ;~ 1 5xlO-9 29.0 35.4 ~` 23 I lx10-8 33.5 - 40.8 2.5x10-8 40.0 48.8 5xlO- 45.5 55.5 26 lx10-7 53.0 64.6 2.5x10-7 63.0 76.8 28 5Y.10-7 68.0 82.9 ` 29 lx10-6 72.5 88.4 2.5x10-6 80.~ 97.5 `; 31 5x10-6 82.0 100 '~.. . . .
'' - ': .
.,:., , , : , :
'' ' .
.
. ': - ' :
1 Thc ncxt s,tully whlch wa-i cnrr:ic-l out cmployed a 2 polyli~and, namely, morplllllc conjur,nted ~o bovinc scrum 3 alhumin, havillg nn average nllmber of 44 morphincs pcr albumin.
In n first tcst, thc polyllgand was employcd as n syntllctic proteln ;n tl-aL th~ polyliga-ld has a plurali.ty of morphine 6 cpitopic sitcs. In n sccond serics oE tests, the polyligand wafi employe(l in aU assay for morphinc or code:ine. In both thesc assays, ncitllcr chromophore is covalcntly bound to the 9 epitopic site oL i.ntcrest, but rathcr each becomes bound through antibody. Thus, thcre is a random binding of anti.body 11 to morphine on the polylieand. At thc concentrations of 12 interest, in a study not described here, it was found that 13 optimum quenching was obtained where a ratio of quencher as 14 receptor-q--encher to fluorescer as receptor-fluorescer was about 5 to l.
16 In the first test, which is an assay for the 17 poly(ligand analog), a series of tubes were prepared each 18 containing 6.4x10 9M (ln binding sites) of antimorphine 19 having a D/P ratio of fluorescein/antibody of 9 and 3.47xlO M
(in binding sites) of antimorphine having a D/P ratio of 21 rhodamine/antibody of about 22 in 0.05M phospllate buffer, pil 22 8.0, containing 1.2xlO M bovine gamma-globulin. Various 23 amounts of the morphine conjugated bovine serum albumin (approximately 44 morphines per albumin) (0.0].2-l,21~g) 2~ werc added (in 5-lO~l) to each of the tubes so that the 26 final volume was 0.5ml and incuba-ed at room tempcrature for 27 30 min. The fluorcscence of each of thc tubes is then measurcd 29 and cxpresscd in pcrccntagc of maY.imal fluorcscence possible : 30 .
31 .
~ -41-.1 - .. ...... ...
., .
.
:, :
.. " ., ~., . .. ~
~ 1042792 l (Wl~ no mor~ e collJugnted l'iSA ls prc~;cnt). Tl~e res.ults 2 nrc in thc rollowillg tl~ble.
~; TAULE IV
5~ n-1~S~ ~. of F
8O.OL~ 8/l.5 90.024 72 100.0~i8 64.5 11O.OS4 61 120.12 66 130.24 74 140.48 83 151.20 92 16 For assaying for codeinc, the following procedure 17 was employed. Employing the same antimorphine-fluorescein 18 (FIgG(m)) and antim~rphine-rhodamine (RIgG(m)) as cmployed 19 above, 30~1 of the FIgG(m) (2.64xlO M) and 30~1 of the RIgG~m) (1.44xlO M) were diluted in a series oE tube3 ~ith 21 0.05M phosphate buffer, pH 8.0, containing 1.5xlO 6M bovine 22 gamma-globulin (390-430~1) Codeine in incrensing conccntrations 23 (1.5xlO 3-1.5xlO M) is then addcd (10-40~1) and the mixture 24 incubated at room temperature for 0.5 hr. To ench of the tubes is then added 10~1 (0.241l~) of the morplline-bovine 26 serum albumin con~ugate used previously and the tubes incubatéd 27 for an additional one hoùr. The fina] volume in cach tube was 0.5ml. The fluorcscence of cach of the tubes at 518nm ';
''~ 1 .. . . ...... .
. . .
"'': ' :
:
1 was then rccordc~ an(l expressed ns ~ercc~ c o~ maxJmal 2 fluorcscellce possillc (whcn no morpllinc-BSA conJu~ato 18 3 prc~ent). Thc followln~ table in(lica~:er. the results.
TA~LE V
7 Codcine ~ of F
8 3xlO-9 51 9 6x10-9 5~
0 1.2x10-8 56.5 3xlO- 62 23 6x10-8 70 5 1.2xlO 81 3x10-7 90 5 17 1.2xlO 100 18 3x10-6 ~ 100 19 The next two studies involve the nPtural protein human gamma-globulin. In the first study, human gamma-21 globulin-fluorescein (FhIgG) D/P 5.5 was employed for the 22 determination of human gamma-globulin. A series of tubes 23 ~ere prepared, each containing 100~1 of 0.017mg/ml of anti-24 human gamma-globulin-rhodamine conjugate (~IgGthIgG) D/B 12-15 in 0.05~l phosphate buffer, pH 8.0 (330-380ll1) containing 26 BS~ (0.6mg/ml). Increasing amounts of human gamma-globulin 27 (in 15-35~1) were then added and incubated for 30 min at 28 room temperature. To the solutions ~as then added 30~1 of 29 0.014mgtml of FhIgG. The final volume in each case ~as 32 _43_ , .
~: .
`.
~ ' `, ' ' ' ~
i. 104Z7912 I 0.5ml. Thc f:in;ll concolltration of thc FhlgG was 5.4xlO 911, 2 wl~ilc tho couccutrati~ns of h~lm~u ~nmma-~obulin rnnged from 3 ~l.S4xlO t~ 6.45xlO ~1. Aftcr n sccond incubntion pcriod 4 of 30 min, thc fLuorcsccllcc of the tubes at 522nm was r~cordcd QS perccnca~c of maxilllal fluorcsccncc po-:sible. Thc following 6 tablc indicatcs the rcsutts.
8 T~I~LR V.I
9 ll:rgG X of FmaX
o 28 ll 4.84xlO-1 33 12 8.06xlO-1 ~ 36 13 1.13xlO-9 38 1.61xlO-9 46 3.22Y~10-9 68 . l6 4.84xlO-9 81 17 8.06xlO- 91 l~ 1.13x10-8 93 19 1.61x10-8 95.5 3.22x10-8 96 21 6.45x10-8 98 23 In the next determination, the human gamma-globulin 2~, was assayed by employing anti-human gamma-~lobulin-fluorescein (FIgG(hIgG)) conju~ate and anti-human gamma-globul:in-rhodamine 26 conjugate (RIgG~hIgG)). The f]uorescein conju~atc had a D/P
27 of 4.3 and the rhoda~ine conju~ate had a D/P of 10. All 28 rea~ents wcre diluted with 0.05~1 phosphate buffer, p}l 8.0, : 2~ containin~ 0.6mp./ml of bovine scrum albumin. ~ scrics of : 31 ~. ~
~ 1 . . : ~
.
,~
. '.
,~' ' ' ~ ' "
, j 10~'92 1 ¦ tnl~cs wc.rc prc~-arcd, cac~l colltnLnin~ /,001l1 of thc ln~lcntcd 2 ¦ buffcr. To cach of t)~c t~lbcs wa~ ~(ldc(l, 30ll1 of 2-71 3 ¦ of l~ ;G(IIl~G) nn(l 30ll1 o 351lL/ml of ~I~G(III~,C). The t~lbc~
4 ¦ wcrc mix~d alld inCrC;l~Sillg, ~mounts of llnlnan l;amma-~lobulin 5 I atl(lcd in 401ll sol-ltio-l~s and incubatcd at room tcmpcratllrc 6 ¦ for onc hour. The fluorc~sccncc of thc t~lbes was tllcn measurcd 1 7 an(l cxpresscd as pcrccnt o total ]uorcscencc in thc ~hscncc 8 o h-lman ~amm~ ,lob~llin. Thc follo~in~ t~blc in(l:Lc~tcs thc 9 rcsults.
..
Il T~BI.E VII
12 Human IgG % of F
13 3xlO-ll 100 14 6xl0_ll 95 7 1.2xlO-1 93.2.
16 l.8xlO-l 89-5 17 2.4xlO-l 86.5 1~ 3Y.10-l 82.2 lg 6x1O_lo 70 5 1.2xlO-9 60.7 21 l~8x10-9 62 22 2.4xlO-9 60.l 23 3xlO-9 69.3 2~ 6xlO-9 79 1.2xlO.8 87.7 26 1.8xlO-8 88.3 28 2.4xlO-8 93.8 29 . .
31 . .
32 _~5_ : ', ' , ' 1 ~ 104Z79Z
1 ¦ As iF. cvidencc(l fron~ ~hc abovc Tnblc VII, witll 2 ¦ incrcasing hulllall ga~ a-glol>ulin conccntratioll, he fluore~-3 1 ccncc dccrc.ll;cs to a mlnimum alld thcn increnses. Thcreore, 4 ¦ ~itll an ullkllown, it ~ouLd bc n~cessary to carry out: two 5 ¦ dllutions to clctcrminc ~hicll part of the curvc was involved.
6 Thc abovc resulcs dcmon-itraLc tllC exLremc scnsl-7 tivity and wLde rilngc of capabLlity of thc subjcct nssnys.
8 ny clnploying thc fluorcsccr~cc-qllenchin~ phenomcllon, onc can 9 as~ay directly for a wlùc varlety of diffcrcnt compounds, both haptenic and antigenic. Reagents can be cmployed, 11 where the hayten or antigen is covalentl~ bondcd to the 12 chromophore, or altcrnatively, where the comyound of interest 13 has a plurality of epitopic sites, mixtures of ant;bodies 1~ can be employed with a portion of the antibodies bonded to quencher and a portion of the antibodies bonded to fluorescer.
16 In this situation, derivatives of the ligand are not required 17 for preparing reagents, where a naturally occurrlng receptor 18 i8 available or the ligand is antigenic.
19 In addition, reagents can be prepared having a plurality of haptenic or antigenic molecules bonded to a 21 nucleus molccule. Either the nucleus moiccule can bc bonded 22 to a chromophore and antibody employed which is conjugated to the other member of the fluorescer-quencher pair or the miY~ture of antibodies indicated above employed. The assay is relatively rapid, and depending upon the concentrations, 26 various incubation times are required. Furtherlllore, conventional 27 fluorometers can be cmployed which are relativcly inexpensivc 28 and easily read.
~ . .
','., . .
' : ;
.
' ., 1. , ` 10427C~2 Lhour,ll thc forcr,o:inE invcntioll hn5 bcen dcscri.bcd 2 in somc de~nll by w.,y Or illu~.t--aLion nnd c~cnmplc for p~lrpor.c.
3 oC clarity of l~n~lcr~:Lan(i:inr,, i~ will bc obv;ous that certain 4 chanEcs and mod.iflcations may bc prncticcd withln thc scope 7 ~ oi the ;'PI~ claimr.
.-18 . .
. . .
21 . .
2s 1~
29 . .
32 _~17_ ~ ' ~ ., ............ .
Claims (44)
1. A method for determining in an assay solution, the presence of a ligand in an unknown suspected of containing said ligand, said ligand having at least one opitopic site, wherein two chromophores, Ch1 and Ch2, whcih form a fluorescer-quencher pair are employed as reagents, whereby in said assay solution the amount of fluorescer brought within quenching distance of said quencher is affected by the presence of ligand, which comprises:
(A) combining in an aqueous buffered medium to form an assay solution;
(1) said unknown;
(2) a source of Ch1, as Ch1 covalently bound so a first receptor composition capable of specific non-covalent binding to said ligand;
(3) a source of Ch2, as Ch2 covalently bound to a second receptor composition capable of specific non-covalent binding to said ligand or as Ch2 covalently or non-covalently bound to ligand analog, wherein ligand analog is a mono- or polyvalent radical, a substantial proportion of which defines one or more epitopic sites capable of competing with ligand for the binding sites of said receptor;
(B) incubating said assay solution for a sufficient time for at least a portion of said receptor compositions to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount oh ligand.
(A) combining in an aqueous buffered medium to form an assay solution;
(1) said unknown;
(2) a source of Ch1, as Ch1 covalently bound so a first receptor composition capable of specific non-covalent binding to said ligand;
(3) a source of Ch2, as Ch2 covalently bound to a second receptor composition capable of specific non-covalent binding to said ligand or as Ch2 covalently or non-covalently bound to ligand analog, wherein ligand analog is a mono- or polyvalent radical, a substantial proportion of which defines one or more epitopic sites capable of competing with ligand for the binding sites of said receptor;
(B) incubating said assay solution for a sufficient time for at least a portion of said receptor compositions to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount oh ligand.
2. A method according to Claim 1, wherein said first and second receptor compositions are the same anti-ligand.
3. A method according to Claim 1, wherein said first receptor composition is a combination of anti-ligand from a first species and anti (first anti-ligand) conjugated to Ch1, and said second receptor composition is anti-ligand from a second species and anti (second anti-ligand) conjugated to Ch2.
4. A method according to Claim 1, wherein said ligand is of from about 110-2,000 molecular weight.
5. A method according to Claim 1, wherein said ligand is a poly (amino acid) having a plurality of epitopic sites and of at least about 10,000 molecular weight.
6. A method according to Claim 1, wherein said ligand is of greater than about 2,000 molecular weight and has a plurality of epitopic sites, and said sources of Ch1 and Ch2 are said first and second receptor compositions covalently bonded to Ch1 and Ch2 respectively.
7. A method according to Claim 6, wherein said lignd is a serum protein.
8. A method according to Claim 7, wherein said serum protein is a globulin.
9. A method according to Claim 7, wherein said serum protein is an albumin.
10. A method according to Claim 7, wherein said serum protein is a glycoprotein.
11. A method according to Claim 7, wherein said serum protein is a glycoprotein.
12. A method according to Claim 7, wherein said serum protein is a complement factor.
13. A method according to Claim 7, wherein said serum protein is a blood clotting factor.
14. A method according to Claim 6, wherein said ligand is at least a portion of a microorganism.
15. A method according to Claim 14, wherein said ligand is a portion of the microorganism membrane.
16. A method according to Claim 14, wherein said microorganism is a virus.
17. A method according to Claim 6, wherein said ligand is a poly(amino acid) of greater than about 10,000 molecular weight.
18. A method according to Claim 1, wherein said ligand is an assemblage of an antigen and antibody for said antigen.
19. A method according to Claim 1, wherein said receptor compositions are antibodies, said aqueous medium has from 0 to 20 volume percent of an inert polar organic solvent, said aqueous medium is buffered in the range of from about 5 to 10, the amount of receptor added is suffi-cient to provide from about 20 to 80 percent quenching and the assay solution is incubated at a temperature in the range of about 0° to 45°C.
20. A method for determining in an assay solution, the presence of a ligand in an unknown suspected of containing said ligand, said ligand having one or more epitopic sites;
in which is employed two chromophores, Ch1 and Ch2, which form a fluorescer-quencher pair, one of the chromophores, Ch1, is bound to receptor for ligand to form receptor-Ch1, said receptor having binding sites capable of specifically binding to the epitopic sites of said ligand, the other of the chromophores, Ch2, is bound to receptor for ligand to form receptor-Ch2 or to ligand analog, either a single ligand analog being covalently bound to one or more chromophores to form ligand analog-(Ch2)x, where x is on the average at least one, or a plurality of ligand analogs and chromophores being covalently bound to a polyfunctionalized nucleus molecule to form poly(ligand analog)-poly(Ch2), wherein ligand analog is a mono- or polyvalent radical, a substantial proportion of which defines one or more epitopic sites capable of competing with ligand for the binding sites of said receptor; and wherein the amount of fluoroescer within quenching distance of quencher is related to the amount of ligand present in said assay solution;
which comprises:
(A) combining in an aqueous buffered medium to form an assay solution:
(1) unknown;
(2) receptor-Ch1; and (3) a source of Ch2 capable of binding within quenching distance to receptor-Ch1, as one of the following:
(a) ligand analog-(Ch2)x;
(b) poly(ligand analog)-poly(Ch2);
(c) poly(ligand analog) and receptor-Ch2;
wherein poly(ligand analog) has a plurality of ligand analogs covalently bound to a polyfunctionalized nucleus molecule; or when said ligand has a plurality of epitopic sites, (d) receptor-Ch2;
(B) incubating said assay solution for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
in which is employed two chromophores, Ch1 and Ch2, which form a fluorescer-quencher pair, one of the chromophores, Ch1, is bound to receptor for ligand to form receptor-Ch1, said receptor having binding sites capable of specifically binding to the epitopic sites of said ligand, the other of the chromophores, Ch2, is bound to receptor for ligand to form receptor-Ch2 or to ligand analog, either a single ligand analog being covalently bound to one or more chromophores to form ligand analog-(Ch2)x, where x is on the average at least one, or a plurality of ligand analogs and chromophores being covalently bound to a polyfunctionalized nucleus molecule to form poly(ligand analog)-poly(Ch2), wherein ligand analog is a mono- or polyvalent radical, a substantial proportion of which defines one or more epitopic sites capable of competing with ligand for the binding sites of said receptor; and wherein the amount of fluoroescer within quenching distance of quencher is related to the amount of ligand present in said assay solution;
which comprises:
(A) combining in an aqueous buffered medium to form an assay solution:
(1) unknown;
(2) receptor-Ch1; and (3) a source of Ch2 capable of binding within quenching distance to receptor-Ch1, as one of the following:
(a) ligand analog-(Ch2)x;
(b) poly(ligand analog)-poly(Ch2);
(c) poly(ligand analog) and receptor-Ch2;
wherein poly(ligand analog) has a plurality of ligand analogs covalently bound to a polyfunctionalized nucleus molecule; or when said ligand has a plurality of epitopic sites, (d) receptor-Ch2;
(B) incubating said assay solution for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
21. A method according to Claim 20, wherein said ligand is of from about 110 to 2,000 molecular weight, and said receptor is antibody.
22. A method according to Claim 20, wherein said ligand is a poly(amino acid) having n plurality of epitopic sites and of at least about 10,000 molucular weight.
23. A method according to Claim 20, wherein said ligand is of greater than about 2,000 molecular weight and has a plurality of epitopic sites, said receptor is antibody, and said source of Ch2 is receptor-Ch2.
24. A method for determining in an assay solution, the presence of a ligand in an unknown suspected of containing said ligand, said ligand having one epitopic site, in which is employed two chromophores, Ch1 and Ch2, which form a fluorescer-quencher pair, one of the chromophores, Ch1 is bound to receptor for ligand to form receptor-Ch1, said receptor having a binding site capable of specifically binding to the epitopic site of said ligand, the other of the chromophores is covalently bound to ligand analog to form ligand analog-Ch2, wherein ligand analog is a monovalent radical, a substantial proportion of which defines an epitopic site capable of competing with ligand for a binding site of said receptor; and wherein the amount of fluorescer within quenching distance of quencher is related to the amount of ligand present in said assay solution:
which comprises:
(A) combining in an aqueous buffered medium at a pH in the range of about 5 to 10 to form an assay solution;
(1) unknown:
(2) receptor-Ch1;
(3) ligand analog-Ch2;
the concentration of receptor-Ch1 and ligand analog-Ch2 providing from about 20 to 80% quenching of the fluorescence in the absence of ligand;
(B) incubating said assay solution at a temperature in the range of about 0-45°C for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared Lo an assay solution having a known amount of ligand.
which comprises:
(A) combining in an aqueous buffered medium at a pH in the range of about 5 to 10 to form an assay solution;
(1) unknown:
(2) receptor-Ch1;
(3) ligand analog-Ch2;
the concentration of receptor-Ch1 and ligand analog-Ch2 providing from about 20 to 80% quenching of the fluorescence in the absence of ligand;
(B) incubating said assay solution at a temperature in the range of about 0-45°C for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared Lo an assay solution having a known amount of ligand.
25. A method according, to Claim 24, wherein said ligand is of from about 110 to 2,000 molecular wherein and is a drug having a benzene ring separated from an amino group by from 2 to 3 aliphatic carbon atoms.
26. A method according to Claim 24, wherein said ligand is a steroid.
27. A method for determining in an assay solution, the presence of a ligand in an unknown suspected of containing said ligand, said ligand having a plurality of epitopic sites, in which is employed two chromophores, Ch1 and Ch2, which form a fluorescer-quencher pair, one of the chromophores, Ch1 is bound to receptor for ligand to form receptor-Ch1, said receptor having binding sites capable of specifically binding to the epitopic sites of said ligand, the other of the chromophores is bound to receptor for ligand to form receptor-Ch2;
wherein the amount of fluorescer within quenching distance of quencher is related to the amount of ligand present in said assay solution;
which comprises:
(A) combining in an aqueous buffered medium at a pH in the range of about 5 to 10, to form an assay solution;
(1) unknown;
(2) receptor-Ch1;
(3) receptor-Ch2;
(B) incubating said assay solution at a temperature in the range of about 0-45°C for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
wherein the amount of fluorescer within quenching distance of quencher is related to the amount of ligand present in said assay solution;
which comprises:
(A) combining in an aqueous buffered medium at a pH in the range of about 5 to 10, to form an assay solution;
(1) unknown;
(2) receptor-Ch1;
(3) receptor-Ch2;
(B) incubating said assay solution at a temperature in the range of about 0-45°C for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any ligand present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
28. A method according to Claim 27, wherein said ligand is a poly(amino acid) of at least about 10,000 molecular weight.
29. A method for determining in an assay solution, the presence of a ligand in an unknown suspected of containing said ligand, said ligand having one or more epitopic sites, in which is employed two chromophores, Ch1 and Ch2, which form a fluorescer-quencher pair, one of the chromophores, Ch1, is bound to receptor for ligand to form receptor-Ch1, said receptor having binding sites capable of specifically binding to the epitopic sites of said ligand, the other of the chromophores is bound to receptor for ligand to form receptor-Ch2;
wherein the amount of flulorescer within quenching distance of quencher is related to the amount of ligand present in said assay solution;
which comprises:
(A) combining in an aqueous buffered medium at a pH in the range of 5 to 10 to form an assay solution;
(1) unknown;
(2) receptor-Ch1;
(3) poly(ligand analog) and receptor-Ch2, wherein ligand analog is a mono- or polyvalent radical, a substantial proportion of which defines one or more epitopic sites capable of competing with ligand for the binding sites of said receptor and poly(ligand analog) has a plurality of ligand analogs covalently bound to a polyfunctionalized nucleus molecule;
(B) incubating said assay solution at a temperature in the range of about 0-45°C for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any liquid present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
wherein the amount of flulorescer within quenching distance of quencher is related to the amount of ligand present in said assay solution;
which comprises:
(A) combining in an aqueous buffered medium at a pH in the range of 5 to 10 to form an assay solution;
(1) unknown;
(2) receptor-Ch1;
(3) poly(ligand analog) and receptor-Ch2, wherein ligand analog is a mono- or polyvalent radical, a substantial proportion of which defines one or more epitopic sites capable of competing with ligand for the binding sites of said receptor and poly(ligand analog) has a plurality of ligand analogs covalently bound to a polyfunctionalized nucleus molecule;
(B) incubating said assay solution at a temperature in the range of about 0-45°C for a sufficient time for at least a portion of the receptor present to combine with at least a portion of any liquid present;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
30. A method according to Claim 29, wherein said ligand has one epitopic site and is of a molecular weight in the range of about 110 to 2,000.
31. A method according to Claim 30, wherein said ligand is a drug having a benzene ring separated by from 2 to 3 aliphatic carbon atoms from an amino group.
32. A method according to Claim 30, wherein said ligand is a steroid.
33. A method according to Claim 29, wherein said polyfunctionalized nucleus molecule is a poly(amino acid) of at least 30,000 molecular weight.
34. A method for determining in an assay solution the presence of a ligand or anti-ligand in an unknown suspected of containing said ligand or anti-ligand, said ligand and anti-ligand having a plurality of epitopic sites;
in which is employed anti(anti-ligand), a portion of which is bound to Ch1 and a portion of which is bound to Ch2, wherein Ch1 and Ch2 form a fluoescer-quencher pair;
combining with said unknown (1) anti-ligand for the determination of the presence of ligand, or (2) ligand for the determination of the presence of anti-ligand;
separating anti-ligand bound to ligand from unbound anti-ligand;
combining in an aqueous buffered assay solution said bound anti-ligand with said anti(anti-ligand)s;
irradiating said assay solution with light at a wavelength within the absorption spectrum of said fluorescer;
and measuring, the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand or anti-ligand.
in which is employed anti(anti-ligand), a portion of which is bound to Ch1 and a portion of which is bound to Ch2, wherein Ch1 and Ch2 form a fluoescer-quencher pair;
combining with said unknown (1) anti-ligand for the determination of the presence of ligand, or (2) ligand for the determination of the presence of anti-ligand;
separating anti-ligand bound to ligand from unbound anti-ligand;
combining in an aqueous buffered assay solution said bound anti-ligand with said anti(anti-ligand)s;
irradiating said assay solution with light at a wavelength within the absorption spectrum of said fluorescer;
and measuring, the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand or anti-ligand.
35. A method for determining in an assay solution the presence of a ligand in an unknown suspected of containing said ligand, said ligand having a plurality of epitopic sites, in which method is employed a-(anti-ligand), b-(anti-ligand), anti(a-(anti-ligand)-Ch1 and anti(b-(anti-ligand)-Ch2, wherein a and b designate a different species source for the anti-ligand and Ch1 and Ch2 form a fluorescer-quencher pair, wherein the amount of fluorescer within quenching distance of quencher is related to the amount of ligand present in said assay solution, which comprises:
(A) combining in an aqueous buffered medium to form an assay solution:
(1) unknown;
(2) a-(anti-ligand);
(3) b-(anti-ligand);
(4) anti(a-(anti-ligand)-Ch1; and (5) anti(b-(anti-ligand)-Ch2;
(B) incubating said assay solution for a sufficient time for at least a portion of the anti-ligands and anti(anti-ligand)s to combine with ligand and anti-ligand respectively;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
(A) combining in an aqueous buffered medium to form an assay solution:
(1) unknown;
(2) a-(anti-ligand);
(3) b-(anti-ligand);
(4) anti(a-(anti-ligand)-Ch1; and (5) anti(b-(anti-ligand)-Ch2;
(B) incubating said assay solution for a sufficient time for at least a portion of the anti-ligands and anti(anti-ligand)s to combine with ligand and anti-ligand respectively;
(C) irradiating said incubated assay solution with light at a wavelength within the absorption spectrum of said fluorescer; and (D) measuring the amount of fluorescence from said assay solution as compared to an assay solution having a known amount of ligand.
36. A method for determining in an assay solution, the presence of anti-ligand for a ligand in an unknown suspected of containing said anti-ligand, in said method is employed (anti-ligand)-Ch1 and (anti-ligand)-Ch2, wherein Ch1 and Ch2 form a fluorescer-quencher pair;
wherein anti-ligand present in the unknown diminishes the amount of quenching of said fluorescer by said quencher;
and which comprises:
combining in an aqueous buffered assay medium;
(1) said unknown;
(2) said ligand, when said ligand is polyepitopic, or poly(ligand analog) hen said ligand is monoepitopic;
(3) (anti-ligand)-Ch1; and (4) (anti-ligand)-Ch2;
irradiating said assay solution with light at a wavelength within the absorption spectrum of said fluorescer;
and measuring the amount of fluorescence from said assay solution as compared to an assay solution having a know amount of anti-ligand.
wherein anti-ligand present in the unknown diminishes the amount of quenching of said fluorescer by said quencher;
and which comprises:
combining in an aqueous buffered assay medium;
(1) said unknown;
(2) said ligand, when said ligand is polyepitopic, or poly(ligand analog) hen said ligand is monoepitopic;
(3) (anti-ligand)-Ch1; and (4) (anti-ligand)-Ch2;
irradiating said assay solution with light at a wavelength within the absorption spectrum of said fluorescer;
and measuring the amount of fluorescence from said assay solution as compared to an assay solution having a know amount of anti-ligand.
37. In combination, anti(a-anti-ligand)-Ch1 and anti(b-anti-ligand)-Ch2 wherein a and b designate anti-ligand from two different species for the same ligand, said ligand having a plurality of epitopic sites, and Ch1 and Ch2 designate a fluorescer-quencher pair.
38. A combination according to claim 37, including a-(anti-ligand) and b-(anti-ligand).
39. A ligand analog-chromophore conjugate for use in an immunoassay for determining a ligand having a molecular weight in the range of about 110 to 800, wherein said ligand analog and said ligand can specifically bind to the same receptor, said ligand analog-chromophore conjugate having an haptenic compound con-jugated to a fluorescing chromophore having absorption of at least 10 at a wavelength greater than about 400nm, wherein said haptenic compound is an alkaloid, methadone, meperidine, amphetamine, methamphetamine, glutethimide, diphenylhydantoin, benzdiazocyclo-heptane, phenothiazine, barbiturate, catecholamine drug, meprobamate, tegretol, succinimide drug, cannabinol, tetrahydrocannabinol, steroid, cardiotonic glycoside or aglycone, saponin or sapogonin, mono- or polysaccharide, or polyiodothyronine.
40. Morphine-fluorescein.
41. Tetraiodothyronine-fluorescein.
42. Diphenylhydantoin-fluorescein.
43. Barbiturate-fluorescein.
44. Cardiotonic glycoside or aglycone-fluorescein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49716774A | 1974-08-12 | 1974-08-12 | |
US05/591,386 US3996345A (en) | 1974-08-12 | 1975-06-30 | Fluorescence quenching with immunological pairs in immunoassays |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1042792A true CA1042792A (en) | 1978-11-21 |
Family
ID=27052409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA233,197A Expired CA1042792A (en) | 1974-08-12 | 1975-08-11 | Fluorescence quenching with immunological pairs in immunoassays |
Country Status (13)
Country | Link |
---|---|
US (1) | US3996345A (en) |
JP (1) | JPS6018940B2 (en) |
AU (1) | AU501140B2 (en) |
BR (1) | BR7505107A (en) |
CA (1) | CA1042792A (en) |
CH (1) | CH621873A5 (en) |
DE (1) | DE2535574C2 (en) |
ES (1) | ES440173A1 (en) |
FR (1) | FR2282115A1 (en) |
GB (2) | GB1526241A (en) |
IL (1) | IL47835A (en) |
NL (1) | NL185423C (en) |
SE (2) | SE427504B (en) |
Families Citing this family (1763)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630328B2 (en) | 1909-07-15 | 2003-10-07 | Genencor International, Inc. | Increasing production of proteins in gram-positive microorganisms |
US4199559A (en) * | 1974-08-12 | 1980-04-22 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4174384A (en) * | 1975-06-30 | 1979-11-13 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4160818A (en) * | 1976-04-15 | 1979-07-10 | Technicon Instruments Corporation | Fluorimetric immunoassay for diphenylhydantoin |
GB1573212A (en) * | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
JPS5836308B2 (en) * | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | Antibody production method |
IT1079045B (en) * | 1977-05-16 | 1985-05-08 | Syva Co | DOUBLE RECEPTOR FLUORESCENT IMUUNOLOGICAL ANALYSIS |
FR2394085A1 (en) * | 1977-06-10 | 1979-01-05 | Syva Co | Fluorimetric analysis of physiologically active cpds. - such as alkaloid(s), medicaments, steroid(s), vitamin(s), sugars, prostaglandin(s), antibiotics and pesticides |
US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US4160645A (en) * | 1977-07-14 | 1979-07-10 | Syva Company | Catalyst mediated competitive protein binding assay |
USRE34394E (en) * | 1978-01-23 | 1993-09-28 | Baxter Diagnostics Inc. | Method and composition for double receptor, specific binding assays |
US4215102A (en) * | 1979-01-05 | 1980-07-29 | Lee Sin H | Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues |
US4331590A (en) * | 1978-03-13 | 1982-05-25 | Miles Laboratories, Inc. | β-Galactosyl-umbelliferone-labeled protein and polypeptide conjugates |
US4220450A (en) * | 1978-04-05 | 1980-09-02 | Syva Company | Chemically induced fluorescence immunoassay |
US4193983A (en) * | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
US4235869A (en) * | 1978-05-16 | 1980-11-25 | Syva Company | Assay employing a labeled Fab-fragment ligand complex |
US4318707A (en) * | 1978-11-24 | 1982-03-09 | Syva Company | Macromolecular fluorescent quencher particle in specific receptor assays |
US4238195A (en) * | 1979-01-18 | 1980-12-09 | Miles Laboratories, Inc. | Fluorescer-labeled specific binding assays |
CA1121345A (en) * | 1979-03-05 | 1982-04-06 | Robert A. Yoshida | Method for competitive protein binding assays inhibiting non-specific interference |
US4256834A (en) * | 1979-04-09 | 1981-03-17 | Syva Company | Fluorescent scavenger particle immunoassay |
US4284412A (en) * | 1979-07-13 | 1981-08-18 | Ortho Diagnostics, Inc. | Method and apparatus for automated identification and enumeration of specified blood cell subclasses |
US4287300A (en) * | 1979-07-26 | 1981-09-01 | Syva Company | Charge effects in enzyme immunoassays |
US4351760A (en) * | 1979-09-07 | 1982-09-28 | Syva Company | Novel alkyl substituted fluorescent compounds and polyamino acid conjugates |
US4329461A (en) * | 1980-01-11 | 1982-05-11 | Syva Company | Fluorescent thyroid hormone conjugates and their uses |
NL8000173A (en) * | 1980-01-11 | 1981-08-03 | Akzo Nv | USE OF WATER-DISPERSIBLE HYDROPHOBIC DYES AS LABELS IN IMMUNOCHEMICAL TESTS. |
US4401764A (en) * | 1980-02-07 | 1983-08-30 | Technicon Instruments Corporation | Immunoassays employing labeled reagent and a conjugate having two binding sites |
US4318981A (en) * | 1980-04-24 | 1982-03-09 | Miles Laboratories, Inc. | Homogeneous specific binding assay employing an intramolecularly modulated photogenic enzyme substrate label |
US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
EP0050684B1 (en) * | 1980-10-27 | 1986-01-22 | Syva Company | Novel ether substituted fluorescein compounds as fluorescers and quenchers |
JPS5782387A (en) * | 1980-10-29 | 1982-05-22 | Syva Co | Novel ether substituted fluorescein compound |
US4385126A (en) * | 1980-11-19 | 1983-05-24 | International Diagnostic Technology, Inc. | Double tagged immunoassay |
US4785080A (en) * | 1981-03-30 | 1988-11-15 | Baker Instruments Corporation | Labeled analytes |
US4378458A (en) | 1981-03-30 | 1983-03-29 | Baker Instruments Corporation | Novel chromogenic and/or fluorogenic substrates for monitoring catalytic or enzymatic activity |
US4378428A (en) * | 1981-03-30 | 1983-03-29 | Baker Instruments Corporation | Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays |
US4442218A (en) * | 1981-05-27 | 1984-04-10 | Corning Glass Works | Method of measuring degree of partitioning |
JPS585659A (en) * | 1981-06-24 | 1983-01-13 | ハイブリテツク インコ−ポレ−テツド | Immunological inhibition test using single clone property antigen |
AU9094982A (en) * | 1982-02-01 | 1983-08-11 | Miles Laboratories Inc. | Photogenic labels to alleviate quenching in immuno assays |
US4472301A (en) * | 1982-05-27 | 1984-09-18 | Miles Laboratories, Inc. | Propranolol immunogen and antibodies |
US4687732A (en) * | 1983-06-10 | 1987-08-18 | Yale University | Visualization polymers and their application to diagnostic medicine |
US4719176A (en) * | 1983-10-31 | 1988-01-12 | Klotz Irving M | Enzyme-free diagnostic binding reagents |
US4865997A (en) * | 1984-02-23 | 1989-09-12 | Becton Dickinson And Company | Assay for ligands by separating bound and free tracer from sample |
US4708929A (en) * | 1984-10-29 | 1987-11-24 | Microgenics Corporation | Methods for protein binding enzyme complementation assays |
US4645828A (en) | 1984-03-23 | 1987-02-24 | Oncogen | Platelet related growth regulator |
US4791068A (en) * | 1984-06-22 | 1988-12-13 | Scripps Clinic And Research Foundation | Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators |
US4666862A (en) * | 1984-08-14 | 1987-05-19 | Ortho Diagnostic Systems Inc. | Fluorescent energy transfer with phycobiliproteins |
US5238808A (en) * | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5221605A (en) * | 1984-10-31 | 1993-06-22 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5310687A (en) * | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US4743561A (en) * | 1985-03-05 | 1988-05-10 | Abbott Laboratories | Luminescent assay with a reagent to alter transmitive properties of assay solution |
IE64785B1 (en) | 1985-04-08 | 1995-09-06 | Genetic Systems Corp | Expression of immunologically reactive viral proteins |
JPH0672883B2 (en) * | 1985-06-19 | 1994-09-14 | コニカ株式会社 | Analytical element |
FR2585836B1 (en) * | 1985-08-02 | 1987-11-27 | Commissariat Energie Atomique | HOMOGENEOUS METHOD FOR LUMINESCENCE DETECTION AND / OR DETERMINATION OF AN ANALYTE IN A MEDIUM CONTAINING IT |
US5279943A (en) * | 1985-08-02 | 1994-01-18 | Compagnie Oris Industrie | Homogeneous process for the detection and/or determination by luminescence of an analyte in a medium in which it may be present |
US4689397A (en) * | 1985-08-12 | 1987-08-25 | Scripps Clinic And Research Foundation | Synthetic polypeptides for detecting mycobacterial infections |
US4777128A (en) * | 1986-05-27 | 1988-10-11 | Ethigen Corporation | Fluorescence immunoassay involving energy transfer between two fluorophores |
FR2617974B1 (en) * | 1987-07-07 | 1992-11-13 | Stabiligen | IMMUNOLOGICAL ASSAY PROCESS BY BIO- OR CHEMIO-LUMINESCENCE |
US5384241A (en) * | 1987-09-11 | 1995-01-24 | Enzo Diagnostics, Inc. | Specific binding assay compound with inhibitive self-quenching characteristics |
US5334513A (en) * | 1988-05-17 | 1994-08-02 | Syntex (U.S.A.) Inc. | Method for immunochromatographic analysis |
US5039607A (en) * | 1988-05-17 | 1991-08-13 | Syntex (U.S.A.) Inc. | Method for immunochromatographic analysis |
US5053054A (en) * | 1988-09-12 | 1991-10-01 | Ortho Pharmaceutical Corporation | Methods and reagents for staining intracellular components |
US5135863A (en) * | 1988-12-23 | 1992-08-04 | Syntex (U.S.A.) Inc. | Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine |
US5132432A (en) * | 1989-09-22 | 1992-07-21 | Molecular Probes, Inc. | Chemically reactive pyrenyloxy sulfonic acid dyes |
AU6602890A (en) * | 1989-10-05 | 1991-04-28 | Exoxemis, Inc. | Haloperoxidase acid optimum chemiluminescence assay system |
US5108899A (en) * | 1989-10-31 | 1992-04-28 | Exoxemis, Inc. | Chemiluminescence assay of in vivo inflammation |
US5532138A (en) * | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
US5578498A (en) * | 1991-05-22 | 1996-11-26 | Behringwerke Ag | Metal chelate containing compositions for use in chemiluminescent assays |
US5340716A (en) * | 1991-06-20 | 1994-08-23 | Snytex (U.S.A.) Inc. | Assay method utilizing photoactivated chemiluminescent label |
US5279937A (en) * | 1992-04-30 | 1994-01-18 | Detechnology Canada | Use of macroglobulins to improve the signal-to-background ratio in affinity binding assays |
ES2113547T3 (en) * | 1992-07-31 | 1998-05-01 | Behringwerke Ag | PHOTOACTIVABLE CHEMIOLUMINISCENT MATRICES. |
US5874423A (en) * | 1992-09-10 | 1999-02-23 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Digitalis-like compounds |
US6033898A (en) * | 1992-12-30 | 2000-03-07 | Abbott Laboratories | Enhanced yeast expression using regulatory control sequences from yeast sorbitol dehydrogenase gene |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US6953573B1 (en) | 1993-03-17 | 2005-10-11 | University Of Washington | Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated |
AU679008B2 (en) * | 1993-05-06 | 1997-06-19 | Chiron Diagnostics Corporation | Mixed luminescent conjugate test assays |
US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
US20040259113A1 (en) * | 1993-07-22 | 2004-12-23 | Mayo Foundation For Medical Education And Research, Hybritech Incorporated | Method for detection of metastatic prostate cancer |
US6103237A (en) * | 1993-07-22 | 2000-08-15 | Hybritech Incorporated | Stable variant hK2 polypeptide |
US5684144A (en) * | 1993-07-28 | 1997-11-04 | University Of North Texas | Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof |
US6238931B1 (en) * | 1993-09-24 | 2001-05-29 | Biosite Diagnostics, Inc. | Fluorescence energy transfer in particles |
US6251687B1 (en) | 1993-09-24 | 2001-06-26 | Biosite Diagnostics, Inc. | Fluorescence energy transfer and intramolecular energy transfer in particles using novel compounds |
US5824799A (en) * | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
US7322927B2 (en) | 1993-09-24 | 2008-01-29 | Biosite, Inc. | Hybrid phthalocyanine derivatives and their uses |
US7083984B2 (en) | 1993-09-24 | 2006-08-01 | Biosite, Inc. | Hybrid phthalocyanine derivatives and their uses |
US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
WO1995030758A1 (en) * | 1994-05-10 | 1995-11-16 | Mayo Foundation For Medical Education And Research | Recombinant hk2 polypeptide |
WO1995034640A1 (en) * | 1994-06-13 | 1995-12-21 | Henry Ford Health System | A novel neuronal-neonatal gene: neuronatin |
DK0705902T3 (en) | 1994-08-12 | 2002-03-11 | Univ Utah Res Found | 17q-linked breast and ovarian cancer predisposition gene |
CA2196797C (en) | 1994-08-12 | 2000-10-10 | Donna M. Shattuck-Eidens | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
US8236493B2 (en) | 1994-10-21 | 2012-08-07 | Affymetrix, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
US6974666B1 (en) * | 1994-10-21 | 2005-12-13 | Appymetric, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
US6531277B2 (en) | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
US6692920B1 (en) * | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
PT796280E (en) * | 1994-12-28 | 2003-08-29 | Univ Kentucky | ANTI-IDIOTIPIC MONOCLONAL 3H1 ANTIBODY OF MURINOS |
US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
CN1100258C (en) * | 1995-02-02 | 2003-01-29 | 中外制药株式会社 | Method of assaying specimen substance by controlling dose of chemiluminescence |
US7005509B1 (en) | 1995-02-17 | 2006-02-28 | Incyte Corporation | Chemokine PANEC-1 polynucleotides and compositions and methods related thereto |
US5728807A (en) * | 1995-05-16 | 1998-03-17 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Mutated proteins associated with ataxia-telangiectasia |
US5858661A (en) | 1995-05-16 | 1999-01-12 | Ramot-University Authority For Applied Research And Industrial Development | Ataxia-telangiectasia gene and its genomic organization |
US5777093A (en) * | 1995-05-16 | 1998-07-07 | Ramot-University Authority For Applied Research & Industrial Development Ltd. | cDNAs associated with ataxia-telangiectasia |
GB0112226D0 (en) * | 2001-05-18 | 2001-07-11 | Danisco | Method of improving dough and bread quality |
CA2245835A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
DE69625678T3 (en) | 1995-12-18 | 2006-11-09 | The University Of Utah Research Foundation, Salt Lake City | Chromosome 13 associated breast cancer susceptibility gene BRCA2 |
US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
US5741662A (en) * | 1995-12-18 | 1998-04-21 | Quidel Corporation | Direct stain specific binding assays for microorganisms |
US20040210045A1 (en) * | 1996-01-23 | 2004-10-21 | Mcgall Glenn | Nucleic acid labeling compounds |
US20010018514A1 (en) * | 1998-07-31 | 2001-08-30 | Mcgall Glenn H. | Nucleic acid labeling compounds |
US7282327B2 (en) * | 1996-01-23 | 2007-10-16 | Affymetrix, Inc. | Nucleic acid labeling compounds |
US7291463B2 (en) * | 1996-01-23 | 2007-11-06 | Affymetrix, Inc. | Nucleic acid labeling compounds |
US6864059B2 (en) * | 1996-01-23 | 2005-03-08 | Affymetrix, Inc. | Biotin containing C-glycoside nucleic acid labeling compounds |
EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | Nucleic acid analysis techniques |
US6965020B2 (en) | 1996-01-23 | 2005-11-15 | Affymetrix, Inc. | Nucleic acid labeling compounds |
US7423143B2 (en) * | 1996-01-23 | 2008-09-09 | Affymetrix. Inc. | Nucleic acid labeling compounds |
EP1728875A3 (en) | 1996-02-08 | 2007-05-09 | Affymetrix, Inc. | Chip-based speciation and phenotypic characterization of microorganisms |
WO1997029212A1 (en) | 1996-02-08 | 1997-08-14 | Affymetrix, Inc. | Chip-based speciation and phenotypic characterization of microorganisms |
US6924094B1 (en) | 1996-02-08 | 2005-08-02 | Affymetrix, Inc. | Chip-based species identification and phenotypic characterization of microorganisms |
WO1997032212A1 (en) * | 1996-03-01 | 1997-09-04 | Beckman Instruments, Inc. | System for simultaneously conducting multiple ligand binding assays |
AU742668B2 (en) * | 1996-03-22 | 2002-01-10 | Morehouse School Of Medicine | Immunogenic compositions comprising porphyromonas gingivalis peptides and methods |
US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US6942862B2 (en) * | 1996-04-01 | 2005-09-13 | University Of Washington | Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins |
US6162931A (en) | 1996-04-12 | 2000-12-19 | Molecular Probes, Inc. | Fluorinated xanthene derivatives |
DK0912738T3 (en) * | 1996-05-22 | 2008-11-17 | Viventia Biotech Inc | Antigen-binding fragments that specifically detect cancer cells, nucleotides encoding the fragments and their use for the prophylaxis and detection of cancers |
US6063908A (en) * | 1996-07-02 | 2000-05-16 | Roche Diagnostics Corporation | Reagents for lysergic acid diethylamide immunoassay |
US6342349B1 (en) | 1996-07-08 | 2002-01-29 | Burstein Technologies, Inc. | Optical disk-based assay devices and methods |
US20050069923A1 (en) * | 1996-07-08 | 2005-03-31 | Mullis Kary Banks | Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus |
JP2002514046A (en) | 1996-07-08 | 2002-05-14 | バースタイン テクノロジーズ,インコーポレイティド | Devices and methods for cleavable signaling factors |
US6331275B1 (en) | 1996-07-08 | 2001-12-18 | Burstein Technologies, Inc. | Spatially addressable, cleavable reflective signal elements, assay device and method |
US5866336A (en) * | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
US6117635A (en) * | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
ATE250768T1 (en) * | 1996-07-18 | 2003-10-15 | Dade Behring Marburg Gmbh | REAGENTS FOR TESTING FOR MYCOPHENOLIC ACID |
CA2231775A1 (en) | 1996-07-18 | 1998-01-29 | Behringwerke Aktiengesellschaft | Reagents for assays for ligands |
US5853990A (en) * | 1996-07-26 | 1998-12-29 | Edward E. Winger | Real time homogeneous nucleotide assay |
EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
US20070299005A1 (en) * | 1996-09-24 | 2007-12-27 | Tanox, Inc. | Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
DK0932678T4 (en) * | 1996-09-24 | 2010-07-12 | Genentech Inc | A family of genes encoding apoptosis-related peptides, peptides encoded therein, and methods for their use |
US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
US6808880B2 (en) * | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
DE69723531T3 (en) | 1996-10-01 | 2012-09-06 | Geron Corp. | Catalytic subunit of human telomerase |
GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
US6479263B1 (en) | 1996-11-14 | 2002-11-12 | Baylor College Of Medicine | Method for detection of micrometastatic prostate cancer |
EP1114864B9 (en) | 1996-12-13 | 2013-05-08 | Schering Corporation | Mammalian cell surface antigens, related reagents |
US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
EP2172478A3 (en) | 1997-02-07 | 2010-07-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Activity-dependent neurotrophic factor III (ADNF III) |
CA2281205A1 (en) | 1997-02-12 | 1998-08-13 | Eugene Y. Chan | Methods and products for analyzing polymers |
US20050013825A1 (en) * | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
US7413864B2 (en) * | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
US7622549B2 (en) * | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US6103536A (en) | 1997-05-02 | 2000-08-15 | Silver Lake Research Corporation | Internally referenced competitive assays |
AU740333B2 (en) | 1997-05-07 | 2001-11-01 | Schering Corporation | Human receptor proteins; related reagents and methods |
US7115722B1 (en) | 1997-05-22 | 2006-10-03 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US7314711B2 (en) * | 1997-05-23 | 2008-01-01 | Bioveris Corporation | Assays employing electrochemiluminescent labels and electrochemiluminescence quenchers |
US20020098190A1 (en) * | 1997-06-13 | 2002-07-25 | Malaya Chatterjee | Compositions and methods for treating tumors bearing HMFG and CEA antigens |
AU8259798A (en) | 1997-06-20 | 1999-01-04 | George G Klee | Method for detection of breast cancer |
US20020122807A1 (en) * | 1998-07-07 | 2002-09-05 | Dan Michael D. | Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
AR014891A1 (en) | 1997-07-09 | 2001-04-11 | Schering Corp | ISOLATED GENES OF MAMPHERE MEMBRANE PROTEINS; RELATED REAGENTS |
US6228638B1 (en) | 1997-07-11 | 2001-05-08 | University Of North Texas, Health Science Center At Fort Worth | Escherichia coli CSRB gene and RNA encoded thereby |
US6506579B1 (en) | 1997-07-15 | 2003-01-14 | Genencor International, Inc. | Increasing production of proteins in gram-positive microorganisms using SecG |
US20030157642A1 (en) * | 1997-07-15 | 2003-08-21 | Caldwell Robert M. | Increasing production of proteins in gram-positive microorganisms |
US6723550B1 (en) * | 1997-07-15 | 2004-04-20 | Genencor International, Inc. | Proteases from gram-positive organisms |
US6762039B2 (en) * | 1997-07-15 | 2004-07-13 | Genencor International, Inc. | Bacillus subtillis with an inactivated cysteine protease-1 |
US6521421B1 (en) * | 1997-07-16 | 2003-02-18 | Genencor International, Inc. | Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same |
PE20000183A1 (en) | 1997-07-25 | 2000-03-11 | Schering Corp | MAMMAL CYTOKINES AND RELATED REAGENTS |
US6180411B1 (en) | 1997-08-01 | 2001-01-30 | The Regents Of The University Of California | Light-triggered indicators that memorize analyte concentrations |
PT1003861E (en) | 1997-08-01 | 2007-01-31 | Schering Corp | Mammalian cell membrane proteins; related reagents |
US5929049A (en) | 1997-08-08 | 1999-07-27 | Dade Behring Marburg Gmbh | Polysaccharide conjugates of biomolecules |
US20030104973A1 (en) * | 1997-08-21 | 2003-06-05 | Quark Biotech, Inc. | Hypoxia-regulated genes |
US7973156B2 (en) * | 1997-08-21 | 2011-07-05 | Quark Pharmaceuticals Inc. | Hypoxia-regulated genes |
WO1999009046A1 (en) | 1997-08-21 | 1999-02-25 | Quark Biotech, Inc. | Hypoxia-regulated genes |
US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
US7745142B2 (en) | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
US7632651B2 (en) | 1997-09-15 | 2009-12-15 | Mds Analytical Technologies (Us) Inc. | Molecular modification assays |
US7070921B2 (en) | 2000-04-28 | 2006-07-04 | Molecular Devices Corporation | Molecular modification assays |
US6521440B1 (en) | 1997-09-15 | 2003-02-18 | Genencor International, Inc. | Proteases from gram-positive organisms |
US6300117B1 (en) * | 1997-09-15 | 2001-10-09 | Genencor International, Inc. | Proteases from gram-positive organisms |
US7378244B2 (en) * | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
EP1029244A4 (en) * | 1997-10-02 | 2003-07-23 | Aclara Biosciences Inc | Capillary assays involving separation of free and bound species |
US6284496B1 (en) | 1997-10-03 | 2001-09-04 | University Of South Florida | DNA vector for determining the presence of out-of-reading-frame mutations |
DE19745001A1 (en) * | 1997-10-11 | 1999-05-06 | Evotec Biosystems Ag | Affinity-labelling of oligomers or polymers |
MXPA00003705A (en) | 1997-10-17 | 2002-04-17 | Univ South Florida | Method to diagnose and monitor cellular immune deficiencies. |
US6607829B1 (en) * | 1997-11-13 | 2003-08-19 | Massachusetts Institute Of Technology | Tellurium-containing nanocrystalline materials |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
GB9724627D0 (en) | 1997-11-20 | 1998-01-21 | Genencor Int Bv | Gram positive microorganism formate pathway |
US6316241B1 (en) * | 1997-11-20 | 2001-11-13 | Genencor International, Inc. | Alpha/beta hydrolase-fold enzymes |
GB9724629D0 (en) * | 1997-11-20 | 1998-01-21 | Genencor Int Bv | Alpha/beta hydrolase-fold enzymes |
US6306642B1 (en) | 1997-11-24 | 2001-10-23 | Quidel Corporation | Enzyme substrate delivery and product registration in one step enzyme immunoassays |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6207392B1 (en) * | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6699723B1 (en) | 1997-11-25 | 2004-03-02 | The Regents Of The University Of California | Organo luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
DE19756782A1 (en) | 1997-12-19 | 1999-06-24 | Dade Behring Marburg Gmbh | Detection and determination of solid phase associated factors |
DE19756773A1 (en) | 1997-12-19 | 1999-06-24 | Dade Behring Marburg Gmbh | New procedure and diagnostic tool for hemostasis diagnostics |
AU1944699A (en) * | 1997-12-23 | 1999-07-12 | Vicam, L.P. | Generic signalling mechanism for detection of analytes |
US6599731B1 (en) * | 1997-12-30 | 2003-07-29 | Genencor International, Inc. | Proteases from gram positive organisms |
GB9727470D0 (en) | 1997-12-30 | 1998-02-25 | Genencor Int Bv | Proteases from gram positive organisms |
US6465186B1 (en) * | 1997-12-30 | 2002-10-15 | Genecor International, Inc. | Proteases from gram positive organisms |
US6528255B1 (en) * | 1997-12-30 | 2003-03-04 | Genencor International, Inc. | Proteases from gram positive organisms |
US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
US6780609B1 (en) | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
WO2000018885A1 (en) | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US6596501B2 (en) | 1998-02-23 | 2003-07-22 | Fred Hutchinson Cancer Research Center | Method of diagnosing autoimmune disease |
WO1999045124A2 (en) | 1998-03-04 | 1999-09-10 | Genencor International, Inc. | Modified forms of pullulanase |
WO1999047934A2 (en) | 1998-03-20 | 1999-09-23 | The Curators Of The University Of Missouri | Early pregnancy diagnosis using pags (pregnancy-associated glycoproteins) |
US8062908B2 (en) * | 1999-03-29 | 2011-11-22 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
US6303081B1 (en) | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
EP1086372B1 (en) | 1998-03-30 | 2006-05-31 | OraSure Technologies, Inc. | Collection device for single step assay of oral fluids |
AU3217599A (en) * | 1998-03-31 | 1999-10-18 | Genzyme Corporation | Methods for the diagnosis and treatment of lung cancer |
US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
US7715989B2 (en) * | 1998-04-03 | 2010-05-11 | Elitech Holding B.V. | Systems and methods for predicting oligonucleotide melting temperature (TmS) |
US7045610B2 (en) * | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
US6949367B1 (en) | 1998-04-03 | 2005-09-27 | Epoch Pharmaceuticals, Inc. | Modified oligonucleotides for mismatch discrimination |
US7108968B2 (en) * | 1998-04-03 | 2006-09-19 | Affymetrix, Inc. | Mycobacterial rpoB sequences |
US6538129B1 (en) | 1999-04-07 | 2003-03-25 | Ewald A. Terpetschnig | Luminescent compounds |
US20030235846A1 (en) * | 1998-04-08 | 2003-12-25 | Terpetschnig Ewald A. | Luminescent compounds |
AU3386399A (en) * | 1998-04-08 | 1999-10-25 | Ewald A. Terpetschnig | Luminescent compounds |
US7411068B2 (en) * | 1998-04-08 | 2008-08-12 | Terpetschnig Ewald A | Luminescent compounds |
US7250517B2 (en) * | 1998-04-08 | 2007-07-31 | Ewald A. Terpetschnig | Luminescent compounds |
US6699969B1 (en) | 1998-04-14 | 2004-03-02 | The Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
US6872537B1 (en) | 1998-04-14 | 2005-03-29 | Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
WO1999053295A1 (en) | 1998-04-14 | 1999-10-21 | The Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
US7875440B2 (en) | 1998-05-01 | 2011-01-25 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US6780591B2 (en) | 1998-05-01 | 2004-08-24 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
US6153442A (en) * | 1998-05-20 | 2000-11-28 | Dade Behring Inc. | Reagents and methods for specific binding assays |
US6303325B1 (en) | 1998-05-29 | 2001-10-16 | Dade Behring Inc. | Method for detecting analytes |
CA2329948A1 (en) * | 1998-06-09 | 1999-12-16 | Vijay Kumar | Solution-phase elisa |
GB9814506D0 (en) * | 1998-07-03 | 1998-09-02 | Stanley Christopher J | Optical sensor for insitu measurement of analytes |
USRE38525E1 (en) | 1998-07-03 | 2004-06-08 | Torsana Diabetes Diagnostics A/S | Optical sensor for in situ measurement of analytes |
AU757642B2 (en) | 1998-07-03 | 2003-02-27 | Medtronic Minimed, Inc. | Optical sensor for in situ measurement of analytes |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
AU4994899A (en) | 1998-07-13 | 2000-02-01 | University Of South Florida | Modulation of the phospholipase a2 pathway as a therapeutic |
WO2000005582A2 (en) * | 1998-07-21 | 2000-02-03 | Burstein Laboratories, Inc. | Optical disc-based assay devices and methods |
ES2188190T5 (en) | 1998-07-21 | 2007-11-16 | Danisco A/S | FOOD PRODUCT. |
AU8662598A (en) | 1998-07-22 | 2000-02-14 | Syntron Bioresearch, Inc. | Multiple analyte assay device |
US6187563B1 (en) | 1998-08-07 | 2001-02-13 | Yale University | βIV-spectrin-polypeptides and nucleic acids encoding same |
SE9803099D0 (en) | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
US6617583B1 (en) | 1998-09-18 | 2003-09-09 | Massachusetts Institute Of Technology | Inventory control |
US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
EP1115867A1 (en) | 1998-09-21 | 2001-07-18 | Schering Corporation | Human interleukin-b50. therapeutic uses |
JP4630459B2 (en) * | 1998-09-24 | 2011-02-09 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | Water-soluble luminescent quantum dots and biomolecular conjugates thereof |
EP0997476A3 (en) | 1998-09-25 | 2000-07-19 | Schering-Plough | Antibodies to a mammalian Langerhans cell antigen and their uses |
US6153411A (en) * | 1998-10-30 | 2000-11-28 | American Water Works Company, Inc. | Methods and kits for detection of Cryptosporidium parvum using immunomagnetic separation and amplification |
JP2002534122A (en) | 1999-01-11 | 2002-10-15 | シェーリング コーポレイション | Interleukin-17-related mammalian cytokines, polynucleotides encoding the same, uses |
EP2208782B1 (en) | 1999-02-04 | 2017-05-31 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
US6156515A (en) * | 1999-02-09 | 2000-12-05 | Urocor, Inc. | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
JP2003500010A (en) | 1999-03-11 | 2003-01-07 | シェリング・コーポレーション | Mammalian cytokines; related reagents and methods |
IL146093A0 (en) | 1999-04-20 | 2002-07-25 | Target Discovery Inc | Method of separating a polypeptide or protein from a solution containing a plurality thereof |
KR20110102476A (en) | 1999-05-13 | 2011-09-16 | 메디칼 리서취 카운실 | Ox2 receptor homologs |
AU5011400A (en) | 1999-05-14 | 2000-12-05 | Arbor Vita Corporation | Molecular interactions in t cells |
US6440682B1 (en) * | 1999-05-28 | 2002-08-27 | Detroit R&D Inc. | Detection of hypertension using immunoreactive metabolic products |
US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
EP2258849A1 (en) | 1999-06-01 | 2010-12-08 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
GB9914210D0 (en) | 1999-06-17 | 1999-08-18 | Danisco | Promoter |
US6262265B1 (en) | 1999-06-18 | 2001-07-17 | Microgenics Corporation | Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay |
EP1190082A4 (en) * | 1999-06-25 | 2003-07-02 | Yissum Res Dev Co | Method of inducing angiogenesis by micro-organs |
US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
EP1196398A4 (en) | 1999-07-06 | 2002-11-06 | Surromed Inc | Bridged fluorescent dyes, their preparation and their use in assays |
WO2001009176A2 (en) | 1999-07-30 | 2001-02-08 | Schering Corporation | Mammalian cytokines; related reagents |
US6875582B1 (en) | 1999-08-19 | 2005-04-05 | Omniscience Pharmaceuticals, Inc. | Methods and targets of antibiotic resistance |
US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US7101839B1 (en) | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
EP1905832A3 (en) | 1999-09-09 | 2009-09-09 | Schering Corporation | Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
DE60030466T2 (en) * | 1999-11-19 | 2007-08-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | ASPERGILLUS NIGER BETA-GLUCOSIDASE GENE, PROTEIN, AND USES THEREOF |
EP1232185A2 (en) | 1999-11-24 | 2002-08-21 | Schering Corporation | Methods of inhibiting metastasis |
EP2336775A3 (en) | 1999-12-06 | 2013-03-20 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
US6544792B1 (en) * | 1999-12-21 | 2003-04-08 | Genencor International, Inc. | Production of secreted polypeptides |
ATE356874T1 (en) * | 1999-12-22 | 2007-04-15 | Dade Behring Marburg Gmbh | HUMAN PROCALCITONIN SOLUTIONS |
ATE395364T1 (en) | 1999-12-22 | 2008-05-15 | Dade Behring Marburg Gmbh | ANTIBODIES DIRECTED AGAINST PROCALCITONIN, THEIR PRODUCTION AND USE |
US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
US7230088B2 (en) * | 2001-07-03 | 2007-06-12 | Mallinckrodt, Inc. | Compounds for dual photodiagnosis and therapy |
US7385106B2 (en) * | 2000-01-24 | 2008-06-10 | Ramot At Tel Aviv University Ltd. | Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
DE10003734A1 (en) * | 2000-01-28 | 2001-08-02 | Bosch Gmbh Robert | Detection method and device |
WO2001062942A2 (en) * | 2000-02-25 | 2001-08-30 | Ludwig Institute For Cancer Research | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
EP1944310A3 (en) | 2000-03-01 | 2008-08-06 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
WO2001064958A2 (en) | 2000-03-01 | 2001-09-07 | Epoch Bioscienecs, Inc. | Modified oligonucleotides for mismatch discrimination |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
EP1264181B1 (en) | 2000-03-06 | 2007-06-06 | Dade Behring Marburg GmbH | Carriers coated with polysaccharides, their preparation and use |
US8288128B2 (en) * | 2004-11-18 | 2012-10-16 | Eppendorf Array Technologies S.A. | Real-time quantification of multiple targets on a micro-array |
US7875442B2 (en) * | 2000-03-24 | 2011-01-25 | Eppendorf Array Technologies | Identification and quantification of a plurality of biological (micro)organisms or their components |
US7829313B2 (en) * | 2000-03-24 | 2010-11-09 | Eppendorf Array Technologies | Identification and quantification of a plurality of biological (micro)organisms or their components |
DE60142475D1 (en) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | UNIFORM CLASS I (MHC-I) UNIFORM MAJOR HISTORICITY COMPATIBILITY COMPOUNDS, ENCODING CONSTRUCTS, AND METHODS OF THEIR PRODUCTION |
US20030108927A1 (en) * | 2000-04-03 | 2003-06-12 | Kathryn Leishman | Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases |
DE60136921D1 (en) | 2000-04-18 | 2009-01-22 | Schering Corp | Medical use of IL-174 agonists and antagonists |
IL135884A (en) * | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
WO2001084157A2 (en) | 2000-05-04 | 2001-11-08 | Dade Behring Marburg Gmbh | Compositions for detection of multiple analytes |
US7019129B1 (en) | 2000-05-09 | 2006-03-28 | Biosearch Technologies, Inc. | Dark quenchers for donor-acceptor energy transfer |
PT1287130E (en) | 2000-05-10 | 2008-09-01 | Schering Corp | Mammalian cytokine receptor subunit proteins, related reagents and methods |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
EP1433792A3 (en) | 2000-05-25 | 2004-11-17 | Schering Corporation | Human receptor proteins, related reagents and methods |
WO2005000087A2 (en) * | 2003-06-03 | 2005-01-06 | Chiron Corporation | Gene products differentially expressed in cancerous colon cells and their methods of use ii |
WO2001094609A1 (en) | 2000-06-07 | 2001-12-13 | Li-Cor, Inc. | Charge-switch nucleotides |
US6936702B2 (en) | 2000-06-07 | 2005-08-30 | Li-Cor, Inc. | Charge-switch nucleotides |
US7846733B2 (en) | 2000-06-26 | 2010-12-07 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
GB0016841D0 (en) | 2000-07-07 | 2000-08-30 | Stanley Christopher J | Optical device for measurement of analytes in tears |
US6958214B2 (en) * | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
HUP0300810A2 (en) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Artifical vascular grafts, and methods of producing and using same |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
EP2359854B1 (en) | 2000-08-08 | 2013-10-09 | Technion Research and Development Foundation, Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis |
GB0020498D0 (en) | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
EP1683874A3 (en) | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
DE60142840D1 (en) | 2000-09-08 | 2010-09-30 | Univ Texas | BY PHAGENDISPLAY IDENTIFIED TARGET PEPTIDES OF HUMANS AND MOUSE |
ATE549347T1 (en) | 2000-09-08 | 2012-03-15 | Schering Corp | MAMMAL GENES, AND ASSOCIATED REAGENTS, METHODS |
US6673623B1 (en) | 2000-09-12 | 2004-01-06 | Novocure, Inc. | Methods and compositions that control lipid production |
AU2001292749A1 (en) * | 2000-09-18 | 2002-03-26 | Genencor International, Inc. | Twin-arginine translocation in bacillus |
US20070281037A9 (en) * | 2000-09-28 | 2007-12-06 | Nanocyte Inc. | Sterile preparations and compositions including stinging capsules and methods of producing and using same |
US7632522B2 (en) * | 2000-09-28 | 2009-12-15 | Nanocyte Inc. | Use of stinging cells/capsules for the delivery of active agents to keratinous substances |
AU2001295850A1 (en) * | 2000-09-28 | 2002-04-08 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
US6815164B2 (en) | 2000-10-06 | 2004-11-09 | Nugen Technologies, Inc. | Methods and probes for detection and/or quantification of nucleic acid sequences |
GB0025147D0 (en) | 2000-10-13 | 2000-11-29 | Torsana Diabetes Diagnostics A | Optical sensor for in situ measurement of analytes |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
EP2479578A1 (en) | 2000-10-19 | 2012-07-25 | Target Discovery, Inc. | Mass defect labeling for the determination of oligomer sequences |
US6890734B2 (en) | 2000-11-10 | 2005-05-10 | Schering Corporation | Nucleic acids encoding a cytokine receptor complex |
IL155940A0 (en) | 2000-11-17 | 2003-12-23 | Vascular Biogenics Ltd | Promoters exhibiting endothelial cell specificity and method of using same |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
EP1341543A4 (en) | 2000-11-24 | 2009-09-02 | Vascular Biogenics Ltd | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
AU2002252773A1 (en) * | 2000-11-29 | 2002-06-11 | Lynkeus Boitech Gmbh | Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 |
KR20030067696A (en) | 2000-11-30 | 2003-08-14 | 모렉큐랄 스킨케어 리미티드 | Diagnosis and treatment of disease |
IL155941A0 (en) * | 2000-11-30 | 2003-12-23 | Yeda Res & Dev | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
NO20006130D0 (en) * | 2000-12-01 | 2000-12-01 | Erling Sundrehagen | Reagent and assay method |
WO2002044425A2 (en) | 2000-12-01 | 2002-06-06 | Visigen Biotechnologies, Inc. | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity |
US20020165149A1 (en) * | 2000-12-08 | 2002-11-07 | Kranz David M. | Mutated class II major histocompatibility proteins |
WO2002048402A2 (en) | 2000-12-13 | 2002-06-20 | Nugen Technologies, Inc. | Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof |
DE10064827A1 (en) * | 2000-12-22 | 2002-06-27 | Dade Behring Marburg Gmbh | Sandwich assay for detecting analyte, useful e.g. for hormones, with detection or correction of the hook effect by measuring detection signals twice |
KR20040101889A (en) * | 2001-01-17 | 2004-12-03 | 라모트 앳 텔-아비브 유니버시티 리미티드 | Chitinases, derived from carnivorous plants polynucleotide sequences encoding thereof, and methods of isolating and using same |
GB0101762D0 (en) * | 2001-01-23 | 2001-03-07 | Medical Res Council | Method |
US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
AU2002230061A1 (en) * | 2001-01-31 | 2002-08-12 | Tolaren | Induction of tolerance by apoptotic and/or necrotic cells |
ZA200210369B (en) | 2001-03-09 | 2004-07-08 | Nugen Technologies Inc | Methods and compositions for amplification or RNA sequences. |
CA2440615A1 (en) | 2001-03-12 | 2002-09-19 | Affymetrix, Inc. | Nucleic acid labeling compounds |
CA2440754A1 (en) | 2001-03-12 | 2002-09-19 | Stephen Quake | Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension |
US20030104410A1 (en) * | 2001-03-16 | 2003-06-05 | Affymetrix, Inc. | Human microarray |
US20030003454A1 (en) | 2001-03-23 | 2003-01-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer |
US20030220475A1 (en) * | 2001-04-03 | 2003-11-27 | Fields Howard A. | Neutralizing immunogenic hev polypepetides |
US7618789B2 (en) * | 2001-04-06 | 2009-11-17 | The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Use of semenogelin in the diagnosis, prognosis and treatment of cancer |
AU2002339115B2 (en) | 2001-05-18 | 2007-03-15 | Dupont Nutrition Biosciences Aps | Method of preparing a dough with an enzyme |
WO2002094985A2 (en) | 2001-05-22 | 2002-11-28 | Merck & Co., Inc. | Beta-secretase substrates and uses thereof |
US7118907B2 (en) * | 2001-06-06 | 2006-10-10 | Li-Cor, Inc. | Single molecule detection systems and methods |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
US20070190534A1 (en) * | 2001-06-11 | 2007-08-16 | Genesis Genomics Inc. | Mitochondrial sites and genes associated with prostate cancer |
AU2002327184A1 (en) * | 2001-06-27 | 2003-03-03 | The Uab Research Foundation | Biophotonic sensors and methods of use thereof |
WO2003003015A2 (en) * | 2001-06-28 | 2003-01-09 | Advanced Research And Technology Institute, Inc. | Methods of preparing multicolor quantum dot tagged beads and conjugates thereof |
GB0116853D0 (en) | 2001-07-10 | 2001-09-05 | Torsana Diabetes Diagnostics A | Optical sensor containing particles for in SITU measurement of analytes |
MXPA04000397A (en) * | 2001-07-19 | 2004-03-18 | Yissum Res Dev Co | Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof. |
US20030031627A1 (en) * | 2001-07-31 | 2003-02-13 | Mallinckrodt Inc. | Internal image antibodies for optical imaging and therapy |
DE60237696D1 (en) * | 2001-08-01 | 2010-10-28 | Univ Utah | AT N-TERMINUS TRUNCATED ISOFORMS OF CYCLIC PHOSPHODIESTERASES PDE3A |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
US20030082596A1 (en) * | 2001-08-08 | 2003-05-01 | Michael Mittmann | Methods of genetic analysis of probes: test3 |
US20060073530A1 (en) * | 2001-08-15 | 2006-04-06 | Olaf Schneewind | Methods and compositions involving sortase B |
WO2003017817A2 (en) | 2001-08-16 | 2003-03-06 | Bar Ilan University | Diagnosis, prevention and treatment of cancer |
US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
EP1438583B1 (en) | 2001-09-20 | 2009-09-16 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
AU2002330102A1 (en) * | 2001-09-28 | 2003-04-14 | Aspenbio, Inc. | Bovine pregnancy test |
GB0212544D0 (en) * | 2002-05-30 | 2002-07-10 | Microsens Biophage Ltd | Methods for detection of target molecules and molecular interactions |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US8323903B2 (en) * | 2001-10-12 | 2012-12-04 | Life Technologies Corporation | Antibody complexes and methods for immunolabeling |
US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
AU2002334997A1 (en) | 2001-10-12 | 2003-04-22 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
CN100506284C (en) | 2001-10-19 | 2009-07-01 | 脉管生物生长有限公司 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
US20040054162A1 (en) * | 2001-10-30 | 2004-03-18 | Hanna Michelle M. | Molecular detection systems utilizing reiterative oligonucleotide synthesis |
US7045319B2 (en) * | 2001-10-30 | 2006-05-16 | Ribomed Biotechnologies, Inc. | Molecular detection systems utilizing reiterative oligonucleotide synthesis |
US7175983B2 (en) * | 2001-11-02 | 2007-02-13 | Abmaxis, Inc. | Adapter-directed display systems |
DE10153829A1 (en) * | 2001-11-05 | 2003-05-28 | Bayer Ag | Assay based on doped nanoparticles |
WO2003042697A1 (en) * | 2001-11-14 | 2003-05-22 | Genospectra, Inc. | Biochemical analysis system with combinatorial chemistry applications |
AU2002366097B2 (en) | 2001-11-20 | 2008-09-18 | Monsanto Technology Llc | Compositions and methods for accurate early pregnancy diagnosis |
US6952704B2 (en) * | 2001-11-26 | 2005-10-04 | Microsoft Corporation | Extending a directory schema independent of schema modification |
US9575070B2 (en) * | 2001-12-04 | 2017-02-21 | Wayne State University | Neoepitope detection of disease using protein arrays |
US8178128B2 (en) * | 2001-12-05 | 2012-05-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles containing polymeric nucleic acid homologs |
US20050085432A1 (en) * | 2001-12-26 | 2005-04-21 | Aviva Lapidot | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
EP2077277A1 (en) | 2002-02-01 | 2009-07-08 | Schering Corporation | Use of mammalian cytokine; related reagents |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
SI1487972T1 (en) | 2002-02-21 | 2016-03-31 | Institute Of Virology Slovak Academy Of Sciences | Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use |
US7053188B2 (en) | 2002-02-22 | 2006-05-30 | Purdue Research Foundation | Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase |
WO2003072799A2 (en) | 2002-02-22 | 2003-09-04 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Brother of the regulator of imprinted sites (boris) |
WO2003078567A2 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
US7611723B2 (en) * | 2002-03-26 | 2009-11-03 | Nanocyte Inc. | Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue |
DE10214019A1 (en) * | 2002-03-30 | 2003-10-16 | Detlef Mueller-Schulte | Luminescent, spherical, non-autofluorescent silica gel particles with variable emission intensities and frequencies |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
EP1497304B1 (en) | 2002-04-12 | 2014-06-25 | Catalyst Assets LLC | Dual-labeled nucleotides |
US7534580B2 (en) * | 2002-05-01 | 2009-05-19 | Ambrilia Biopharma Inc. | PSP94 diagnostic reagents and assays |
CA2391438A1 (en) * | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
US7842513B2 (en) * | 2002-05-02 | 2010-11-30 | Aspenbio Pharma, Inc. | Pregnancy detection |
EP1501863A4 (en) * | 2002-05-03 | 2007-01-24 | Sequenom Inc | Kinase anchor protein muteins, peptides thereof, and related methods |
US20040121442A1 (en) * | 2002-05-05 | 2004-06-24 | Ilan Chet | Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof |
US20050221349A1 (en) * | 2002-05-30 | 2005-10-06 | Stuart Wilson | Methods of detecting target molecules and molecular interactions |
WO2003102595A1 (en) * | 2002-05-31 | 2003-12-11 | Genetype Pty Ltd | Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood |
WO2003102239A2 (en) * | 2002-05-31 | 2003-12-11 | Secretary, Department Of Atomic Energy | Met/fret based method of target nucleic acid detection whereby the donor/acceptor moieties are on complementary strands |
US7504215B2 (en) | 2002-07-12 | 2009-03-17 | Affymetrix, Inc. | Nucleic acid labeling methods |
JP2005533102A (en) * | 2002-07-12 | 2005-11-04 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | Method and apparatus for inducing biological processes by micro-organs |
US20040175378A1 (en) | 2002-07-15 | 2004-09-09 | Board Of Regents, The University Of Texas System | Selected antibody compositions and methods for binding to aminophospholipids |
US6916474B2 (en) | 2002-07-15 | 2005-07-12 | Board Of Regents, The University Of Texas System | Antibodies with increased affinities for anthrax antigens |
US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
EP2561889A3 (en) | 2002-08-01 | 2013-04-03 | Yeda Research and Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
EA200500330A1 (en) * | 2002-08-10 | 2006-06-30 | Йейл Юниверсити | ANTAGONISTS NOGO RECEPTORS |
BR0314155A (en) | 2002-09-09 | 2005-07-05 | Arbor Vita Corp | Methods to Diagnose Cervical Cancer |
AU2003278832A1 (en) * | 2002-09-13 | 2004-04-30 | Carnegie Mellon University | Optical biosensors and methods of use thereof |
US20050042621A1 (en) * | 2002-09-27 | 2005-02-24 | Affymetrix, Inc. | Method for preparing a nucleic acid sample for hybridization to an array |
US7267981B2 (en) | 2002-10-07 | 2007-09-11 | Technion Research & Development Foundation Ltd. | Human foreskin fibroblasts for culturing ES cells |
WO2004033101A1 (en) * | 2002-10-11 | 2004-04-22 | Zbx Corporation | Diagnostic devices |
WO2004038369A2 (en) * | 2002-10-21 | 2004-05-06 | Discoverx, Inc. | Ip3 protein binding assay |
JP2006514614A (en) | 2002-10-24 | 2006-05-11 | ステリックス リミテッド | 11β-hydroxysteroid dehydrogenase type 1 and type 2 inhibitors |
AU2003284968A1 (en) * | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
EP2295980A1 (en) | 2002-10-30 | 2011-03-16 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Molecules and methods using same for measuring non-transferrin bound iron |
US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
FI20022048A0 (en) * | 2002-11-18 | 2002-11-18 | Valtion Teknillinen | Non-competitive immunoassay for small assays |
AU2002352938B8 (en) * | 2002-11-26 | 2009-10-08 | The University Of Chicago | Materials and methods for preventing and treating microbe-mediated epithelial disorders |
AU2003302701A1 (en) * | 2002-11-29 | 2004-06-23 | Technion Research And Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
AU2003298706A1 (en) | 2002-12-04 | 2004-06-23 | Applera Corporation | Multiplex amplification of polynucleotides |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
AU2003286410A1 (en) | 2002-12-12 | 2004-06-30 | R.B.T (Rakuto Bio Technologies) Ltd. | Methods of producing lignin peroxidase and its use in skin and hair lightening |
ES2571355T3 (en) | 2002-12-16 | 2016-05-24 | Technion Res & Dev Foundation | Culture system without feeder cells or xenocontaminants for human embryonic stem cells |
ATE546548T1 (en) | 2003-01-02 | 2012-03-15 | Rappaport Family Inst For Res | METHOD FOR PREDICTING THE BENEFIT OF ANTI-OXIDATION THERAPY FOR PREVENTING CARDIOVASCULAR DISEASE IN HYPERGLYCEMIC PATIENTS |
US20040229245A1 (en) * | 2003-01-06 | 2004-11-18 | Anton Bittner | Methods and algorithms for performing quality control during gene expression profiling on DNA microarray technology |
WO2004060791A1 (en) | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
CN102021205A (en) | 2003-01-17 | 2011-04-20 | 丹尼斯科公司 | Method of producing a protein ester and a protein subunit ester |
US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
MXPA05007653A (en) | 2003-01-17 | 2005-09-30 | Danisco | Method. |
US20050196766A1 (en) | 2003-12-24 | 2005-09-08 | Soe Jorn B. | Proteins |
US20050014249A1 (en) * | 2003-02-21 | 2005-01-20 | Norbert Staimer | Chromatographic analysis on optical bio-discs and methods relating thereto |
US7786071B2 (en) | 2003-03-04 | 2010-08-31 | Yeda Research And Development Co. Ltd. | Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same |
EP1599608A4 (en) * | 2003-03-05 | 2007-07-18 | Genetic Technologies Ltd | Identification of fetal dna and fetal cell markers in maternal plasma or serum |
CA2517959A1 (en) * | 2003-03-07 | 2004-09-16 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
EP1603511B1 (en) | 2003-03-07 | 2011-01-26 | New England Medical Center Hospitals, Inc. | Treatment of igai deposition diseases |
US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
ATE517926T1 (en) | 2003-04-04 | 2011-08-15 | Yeda Res & Dev | ANTIBODIES TO INHIBIT THE ACTIVITY OF MMP-2 AND MMP-9 |
CA2520023C (en) | 2003-04-08 | 2013-02-05 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to sdf-1 and methods of generating and using same |
FR2853551B1 (en) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM |
WO2004092418A2 (en) | 2003-04-14 | 2004-10-28 | Nugen Technologies, Inc. | Global amplification using a randomly primed composite primer |
EA009643B1 (en) * | 2003-04-16 | 2008-02-28 | Йейл Юниверсити | Treatment of conditions involving amyloid plaques |
US7917298B1 (en) | 2003-04-17 | 2011-03-29 | Nanosys, Inc. | Nanocrystal taggants |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US7554007B2 (en) | 2003-05-22 | 2009-06-30 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants |
RU2350653C2 (en) | 2003-05-22 | 2009-03-27 | Эводжин Лтд. | Methods of abiotic stress tolerance enhancement and/or biomass increase for plants, and plants obtained by method |
AU2005234725B2 (en) * | 2003-05-22 | 2012-02-23 | Evogene Ltd. | Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby |
EP1636333A4 (en) * | 2003-06-19 | 2007-10-24 | Evogene Ltd | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
US8129514B2 (en) * | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
EP2719394B1 (en) | 2003-06-30 | 2015-07-29 | Tel Aviv University Future Technology Development L.P. | Peptides for treating amyloid-associated diseases |
CA2542984A1 (en) * | 2003-07-07 | 2005-01-27 | David H. Wagner | Methods for predicting development of auto-immune diseases and treatment of same |
US8454566B2 (en) * | 2003-07-10 | 2013-06-04 | Medtronic Minimed, Inc. | Methods and compositions for the inhibition of biofilms on medical devices |
US20090088337A1 (en) * | 2003-07-10 | 2009-04-02 | Ronald Gill | RET-Based Analyte Detection |
WO2005014795A2 (en) | 2003-08-08 | 2005-02-17 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
US20050064479A1 (en) * | 2003-08-12 | 2005-03-24 | Affymetrix, Inc. | Compounds and methods for post incorporation labeling of nucleic acids |
CA2535901A1 (en) | 2003-08-14 | 2005-02-24 | Exelixis, Inc. | Ups as modifiers of the beta catenin pathway and methods of use |
JP2007518394A (en) * | 2003-08-14 | 2007-07-12 | ザ バイオ バランス コーポレイション | Bacterial strain, composition containing the bacterial strain, and use of probiotics thereof |
JP4711963B2 (en) | 2003-09-15 | 2011-06-29 | オクラホマ メディカル リサーチ ファウンデーション | Methods using cytokine assays to diagnose, treat and evaluate inflammatory and autoimmune diseases |
WO2005050206A2 (en) * | 2003-09-17 | 2005-06-02 | Molecular Probes, Inc. | Competitive immunoassay |
US20050064435A1 (en) * | 2003-09-24 | 2005-03-24 | Xing Su | Programmable molecular barcodes |
WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
CA2541535C (en) | 2003-10-07 | 2013-12-10 | Yeda Research And Development Co. Ltd. | Antibodies to nik, their preparation and use |
BRPI0415742A (en) * | 2003-10-23 | 2006-12-19 | Pfizer Producs Inc | vaccine for periodontal disease |
US20050227251A1 (en) | 2003-10-23 | 2005-10-13 | Robert Darnell | Method of purifying RNA binding protein-RNA complexes |
CN101068934A (en) * | 2003-10-29 | 2007-11-07 | 里伯米德生物技术公司 | Compositions, methods and detection technologies for reiterative oligonucleotide synthesis |
AR046833A1 (en) | 2003-11-10 | 2005-12-28 | Schering Corp | ANTI-INTERLEUQUINA ANTIBODIES-10 |
US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
JP3615752B1 (en) | 2003-11-18 | 2005-02-02 | 淳 高橋 | Small diameter resin twist brush |
CA2547459C (en) | 2003-11-30 | 2013-10-08 | Yeda Research And Development Co. Ltd | Modulators of nik-siva complex formation for treating immune disorders |
WO2005062048A1 (en) * | 2003-12-01 | 2005-07-07 | Dade Behring Marburg Gmbh | Homogeneous detection method |
US20050118727A1 (en) * | 2003-12-01 | 2005-06-02 | Carsten Schelp | Conjugates and their use in detection methods |
US8039642B2 (en) | 2003-12-09 | 2011-10-18 | Life Technologies Corporation | Pyrenyloxysulfonic acid fluorescent agents |
AU2003296419A1 (en) * | 2003-12-09 | 2005-07-21 | Molecular Probes, Inc. | Pyrenyloxysulfonic acid fluorescent agents |
WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
US20100221233A1 (en) * | 2003-12-15 | 2010-09-02 | University Of South Florida | Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
US7022492B2 (en) | 2003-12-15 | 2006-04-04 | Dade Behring Inc. | Ecstasy haptens and immunogens |
US6991911B2 (en) | 2003-12-15 | 2006-01-31 | Dade Behring Inc. | Assay for entactogens |
WO2005061018A1 (en) | 2003-12-22 | 2005-07-07 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring protein backbone |
AU2004308964B2 (en) | 2003-12-23 | 2010-09-16 | Arbor Vita Corporation | Antibodies for oncogenic strains of HPV and methods of their use |
US7718408B2 (en) * | 2003-12-24 | 2010-05-18 | Danisco A/S | Method |
GB0716126D0 (en) * | 2007-08-17 | 2007-09-26 | Danisco | Process |
WO2008090395A1 (en) | 2007-01-25 | 2008-07-31 | Danisco A/S | Production of a lipid acyltransferase from transformed bacillus licheniformis cells |
KR101169265B1 (en) | 2003-12-24 | 2012-08-02 | 대니스코 에이/에스 | Proteins |
US8007847B2 (en) | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
US20050186646A1 (en) * | 2004-01-26 | 2005-08-25 | Cruz Miguel A. | Rapid assay to detect ADAMTS-13 activity |
EP1713900A4 (en) * | 2004-01-27 | 2009-06-17 | Compugen Ltd | Methods and systems for annotating biomolecular sequences |
US20070178462A1 (en) * | 2004-02-18 | 2007-08-02 | Uebele Victor N | Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof |
EP2248911A1 (en) | 2004-02-19 | 2010-11-10 | Helicos Biosciences Corporation | Methods and kits for analyzing polynucleotide sequences |
GB0403864D0 (en) | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
WO2005085475A1 (en) | 2004-03-01 | 2005-09-15 | Applera Corporation | Methods, compositions and kits for use in polynucleotide amplification |
JP2007526337A (en) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | ALK7 and myostatin inhibitors and uses thereof |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
GB0405637D0 (en) | 2004-03-12 | 2004-04-21 | Danisco | Protein |
JP2007533755A (en) * | 2004-04-20 | 2007-11-22 | ザ ユニヴァーシティ オヴ シカゴ | Therapeutic drug delivery system comprising high molecular weight PEG-like compounds |
WO2006083269A2 (en) * | 2004-05-14 | 2006-08-10 | Florida Atlantic University | Luminescent nanosensors |
EP2400030B1 (en) | 2004-05-18 | 2016-01-20 | The Board of Trustees of the Leland Stanford Junior University | Detection of protein translocation by beta-galactosidase reporter fragment complementation |
US7476734B2 (en) | 2005-12-06 | 2009-01-13 | Helicos Biosciences Corporation | Nucleotide analogs |
WO2006007207A2 (en) | 2004-05-25 | 2006-01-19 | Helicos Biosciences Corporation | Methods and devices for nucleic acid sequence determination |
JP4651663B2 (en) | 2004-05-28 | 2011-03-16 | アジェンシス,インコーポレイテッド | Antibodies and related molecules that bind to PSCA proteins |
ES2665463T3 (en) | 2004-06-14 | 2018-04-25 | Evogene Ltd. | Polynucleotides and polypeptides involved in the development of plant fiber and methods of use thereof |
US8034553B2 (en) | 2004-06-24 | 2011-10-11 | Kimberly-Clark Worldwide, Inc. | Biomarkers for wound healing |
JP4796059B2 (en) * | 2004-06-30 | 2011-10-19 | ディスカヴァーエックス コーポレイション | Analysis of intracellular modification |
US8680062B2 (en) * | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
US7635598B2 (en) * | 2004-07-08 | 2009-12-22 | Biosearch Technologies, Inc. | Inducible fluorescence assay |
WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
EP2267108A1 (en) | 2004-07-16 | 2010-12-29 | Danisco A/S | Enzymatic oil-degumming method |
CA2579790A1 (en) * | 2004-07-30 | 2006-02-09 | Mount Sinai School Of Medicine Of New York University | Npc1l1 and npc1l1 inhibitors and methods of use thereof |
US20060073168A1 (en) * | 2004-08-11 | 2006-04-06 | Stephens David S | Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions |
DE102005026163A1 (en) * | 2004-08-24 | 2006-03-02 | Dade Behring Marburg Gmbh | Antibodies directed against the Marburg I polymorphism of Factor VII activating protease (FSAP), their production and use |
WO2006021894A2 (en) | 2004-08-26 | 2006-03-02 | Engeneic Gene Therapy Pty Limited | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
FI20050753A (en) | 2004-09-03 | 2006-03-04 | Licentia Oy | New peptides |
ES2345993T3 (en) | 2004-09-14 | 2010-10-07 | The Regents Of The University Of Colorado, A Body Corporate | METHOD FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC ADDRESSING. |
WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
CN101043891A (en) | 2004-09-18 | 2007-09-26 | 巴尔的摩马里兰大学 | Therapeutic agents targeting the nc ca-atp channel and methods of use thereof |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
SI1797127T1 (en) * | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modified fc molecules |
US20060067889A1 (en) * | 2004-09-27 | 2006-03-30 | Light Sciences Corporation | Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents |
EP1805319B1 (en) * | 2004-09-29 | 2014-09-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Recombinant human t2 rnase and uses thereof |
CN101065491B (en) | 2004-09-29 | 2012-01-11 | 胶原植物有限公司 | Collagen producing plants and methods of generating and using same |
GB0422052D0 (en) | 2004-10-04 | 2004-11-03 | Dansico As | Enzymes |
US7390489B2 (en) * | 2004-10-08 | 2008-06-24 | Komed Co., Ltd. | Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody |
US7781402B2 (en) * | 2004-10-12 | 2010-08-24 | Closed Loop Therapies Ltd. | Methods and implantable devices for treating supraventricular arrhythmias |
GB0423139D0 (en) | 2004-10-18 | 2004-11-17 | Danisco | Enzymes |
JP5525689B2 (en) * | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Compositions and methods for treating hyperproliferative disorders |
GB0424940D0 (en) | 2004-11-11 | 2004-12-15 | Danisco | Transcription factors |
WO2006055635A2 (en) * | 2004-11-15 | 2006-05-26 | Mount Sinai School Of Medicine Of New York University | Compositions and methods for altering wnt autocrine signaling |
EP1812594B1 (en) | 2004-11-18 | 2013-01-09 | Eppendorf Array Technologies | Real-time quantification of multiple targets on a micro-array |
IL165484A0 (en) | 2004-11-30 | 2006-01-15 | Applied Research Systems | Production of proteins |
DE602005025685D1 (en) | 2004-12-03 | 2011-02-10 | Schering Corp | BIOLOGICAL MARKERS FOR THE PRESELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY |
US7504769B2 (en) * | 2004-12-16 | 2009-03-17 | E. I. Du Pont De Nemours + Company | Aromatic chalcogen compounds and their use |
US20060134680A1 (en) * | 2004-12-22 | 2006-06-22 | Alexander Kotlyar | Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof |
US7220549B2 (en) * | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
EP1844403A4 (en) | 2005-01-16 | 2010-06-23 | Zlango Ltd | Iconic communication |
WO2007080558A2 (en) | 2006-01-16 | 2007-07-19 | Zlango Ltd. | Communications network system and methods for using same |
US7482120B2 (en) | 2005-01-28 | 2009-01-27 | Helicos Biosciences Corporation | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
EP3028765B1 (en) | 2005-01-31 | 2020-01-08 | Realbio Technologies Ltd. | Method of sequentially transferring liquids through a lateral flow capillary device |
CN103497993A (en) | 2005-02-07 | 2014-01-08 | 基因信息公司 | Mild osteoarthritis biomarkers and uses thereof |
EP2316441A1 (en) | 2005-02-17 | 2011-05-04 | Hadasit Medical Research Services And Development | Bisphosphonates for treating endometriosis |
GB0503546D0 (en) * | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
EP1871402B1 (en) | 2005-02-25 | 2017-07-26 | State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (A.R.O.), Volcani Center | Grape cell culture for treating inflammation |
US7695927B2 (en) * | 2005-03-18 | 2010-04-13 | Detroit R & D | Detection of hypertension using glucuronidated metabolic products |
RU2413735C2 (en) | 2005-03-31 | 2011-03-10 | Эдженсис, Инк. | Antibodies and related molecules binding with proteins 161p2f10b |
RS61229B1 (en) | 2005-04-04 | 2021-01-29 | Biogen Ma Inc | Methods for evaluating an immune response to a therapeutic agent |
WO2006109312A2 (en) * | 2005-04-15 | 2006-10-19 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
CN101248180B (en) | 2005-04-18 | 2013-09-25 | 米托米克斯公司 | Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers |
US20130022979A1 (en) | 2005-04-18 | 2013-01-24 | Genesis Genomics Inc. | 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER |
US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
US7189582B2 (en) | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
DE102005022047A1 (en) * | 2005-05-09 | 2006-11-30 | Dade Behring Marburg Gmbh | Binding partner of the placental growth factor, in particular antibodies directed against the placental growth factor, their production and use |
US9943481B2 (en) | 2005-05-26 | 2018-04-17 | Biorest Ltd. | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
JP2008546385A (en) | 2005-06-16 | 2008-12-25 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | Isolated cells and populations containing isolated cells for treating CNS disease |
ES2565670T3 (en) | 2005-06-20 | 2016-04-06 | Advanced Cell Diagnostics, Inc. | Nucleic acid detection methods in individual cells and identification of rare cells in large populations of heterogeneous cells |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
US7695975B2 (en) | 2005-06-23 | 2010-04-13 | Siemens Healthcare Diagnostics Inc. | Detection of adulterated samples |
EP1904526A4 (en) | 2005-07-07 | 2009-10-28 | Fulcrum Sp Ltd | Sp1 polypeptides, modified sp1 polypeptides and uses thereof |
CA2614531C (en) | 2005-07-07 | 2015-06-16 | Avraham Hochberg | Nucleic acid agents for downregulating h19, and methods of using same |
BRPI0616012A2 (en) | 2005-07-18 | 2011-05-31 | Protalix Ltd | mucosal or intestinal administration of biologically active macromolecules |
WO2007019541A2 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc. | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
EP1928479B1 (en) | 2005-08-24 | 2016-06-08 | Yeda Research And Development Co., Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
US7666593B2 (en) | 2005-08-26 | 2010-02-23 | Helicos Biosciences Corporation | Single molecule sequencing of captured nucleic acids |
EP1962719A4 (en) | 2005-08-29 | 2011-05-04 | Technion Res And Dev Of Foundation Ltd | Media for culturing stem cells |
SG165322A1 (en) | 2005-08-31 | 2010-10-28 | Schering Corp | Engineered anti-il-23 antibodies |
CA2621267A1 (en) | 2005-09-07 | 2007-03-15 | Nugen Technologies, Inc. | Improved nucleic acid amplification procedure |
US7608395B2 (en) | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
EP1926814B1 (en) * | 2005-09-22 | 2010-04-28 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
US8158801B2 (en) * | 2005-09-26 | 2012-04-17 | Life Technologies Corporation | Violet laser excitable dyes and their method of use |
WO2007041340A2 (en) * | 2005-09-30 | 2007-04-12 | The Trustees Of Columbia University In The City Of New York | Microfluidic cells with parallel arrays of individual dna molecules |
US20070202515A1 (en) * | 2005-10-12 | 2007-08-30 | Pathologica, Llc. | Promac signature application |
US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
EP1945816B1 (en) | 2005-10-21 | 2011-07-27 | GeneNews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
BRPI0618965B1 (en) | 2005-10-24 | 2021-01-12 | Evogene Ltd | method to increase a plant's tolerance to an abiotic stress condition, method to increase a plant's biomass, vigor and / or yield, method to increase the efficiency of fertilizer use and / or absorption of a plant |
AU2006306344A1 (en) * | 2005-10-24 | 2007-05-03 | Discoverx Corporation | Detection of intracellular enzyme complex |
US7842823B2 (en) * | 2005-10-27 | 2010-11-30 | The Regents Of The University Of California | Fluorogenic probes for reactive oxygen species |
CN101346393B (en) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | Modified siRNA molecules and uses thereof |
US20100028358A1 (en) | 2005-11-07 | 2010-02-04 | Wolfram Ruf | Compositions and Methods for Controlling Tissue Factor Signaling Specificity |
DE212006000071U1 (en) | 2005-11-18 | 2008-07-24 | Board of Regents, The University of Texas System, Austin | Quantification of fusion proteins and their activity as a result of chromosomal translocation |
AU2006321172B2 (en) | 2005-11-29 | 2012-02-23 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
WO2008002462A2 (en) * | 2006-06-23 | 2008-01-03 | Micronics, Inc. | Methods and devices for microfluidic point-of-care immunoassays |
US9056291B2 (en) | 2005-11-30 | 2015-06-16 | Micronics, Inc. | Microfluidic reactor system |
US7763453B2 (en) | 2005-11-30 | 2010-07-27 | Micronics, Inc. | Microfluidic mixing and analytic apparatus |
US8158360B2 (en) | 2005-12-08 | 2012-04-17 | Novartis Ag | Effects of inhibitors of FGFR3 on gene transcription |
US20070134814A1 (en) * | 2005-12-09 | 2007-06-14 | Kajander E O | Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease |
EP2674440B1 (en) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
CN101374860A (en) * | 2005-12-23 | 2009-02-25 | 技术转让合伙人公司 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
US7465544B2 (en) * | 2006-01-11 | 2008-12-16 | Wisconsin Alumni Research Foundation | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use |
EP1977312A2 (en) | 2006-01-16 | 2008-10-08 | Zlango Ltd. | Iconic communication |
JP5829373B2 (en) | 2006-01-27 | 2015-12-09 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Nogo receptor antagonist |
WO2007088051A2 (en) | 2006-01-31 | 2007-08-09 | Bayer Schering Pharma Aktiengesellschaft | Modulation of mdl-1 activity for treatment of inflammatory disease |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
CN101416063A (en) | 2006-02-06 | 2009-04-22 | 拉帕波特家族医学科学研究所 | Methods and kit for diagnosing T1DM |
PL1986661T3 (en) | 2006-02-08 | 2019-02-28 | Genzyme Corporation | Gene therapy for niemann-pick disease type a |
PL2676967T3 (en) | 2006-02-28 | 2019-12-31 | Biogen Ma Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
US20070231319A1 (en) | 2006-03-03 | 2007-10-04 | Yednock Theodore A | Methods of treating inflammatory and autoimmune diseases with natalizumab |
JP5107943B2 (en) | 2006-03-06 | 2012-12-26 | ゼティク テクノロジーズ リミテッド | Methods and compositions for identifying cellular phenotypes |
US7397546B2 (en) | 2006-03-08 | 2008-07-08 | Helicos Biosciences Corporation | Systems and methods for reducing detected intensity non-uniformity in a laser beam |
WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
PT2548951E (en) | 2006-03-23 | 2016-06-14 | Pluristem Ltd | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP2004858A4 (en) | 2006-03-28 | 2009-12-09 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Methods and kits for determining predisposition to warfarin resistance |
US20070232556A1 (en) * | 2006-03-31 | 2007-10-04 | Montine Thomas J | Methods and compositions for the treatment of neurological diseases and disorders |
MX2008012754A (en) * | 2006-04-07 | 2009-04-27 | Us Gov Health & Human Serv | Antibody compositions and methods for treatment of neoplastic disease. |
US8841134B2 (en) * | 2006-04-10 | 2014-09-23 | Bruker Biospin Corporation | Fluorescence resonance energy transfer detection with nanoparticles for in vitro and in vivo applications |
US20070281363A1 (en) * | 2006-04-13 | 2007-12-06 | Ewald Terpetschnig | Luminescent compounds |
FR2900341B1 (en) | 2006-04-27 | 2012-09-14 | Centre Nat Rech Scient | USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR THE TREATMENT OF CANCER |
US7732153B2 (en) | 2006-05-09 | 2010-06-08 | Beckman Coulter, Inc. | Nonseparation assay methods |
RU2008148308A (en) * | 2006-05-09 | 2010-06-20 | Маск Фаундейшн Фор Рисерч Дивелопмент (Us) | Determination of diastolic cardiac insufficiency using proteases and protease inhibitors in plasma |
US7799534B2 (en) * | 2006-05-09 | 2010-09-21 | Beckman Coulter, Inc. | Nonseparation assay methods |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
US20080076188A1 (en) * | 2006-06-19 | 2008-03-27 | Patsenker Leonid D | Luminescent compounds |
WO2008002920A2 (en) * | 2006-06-26 | 2008-01-03 | Epoch Biosciences, Inc. | Methods for generating target nucleic acid sequences |
US20080003230A1 (en) | 2006-07-03 | 2008-01-03 | Adair Charles D | Composition for modulating the expression of cell adhesion molecules |
EP2044090B1 (en) | 2006-07-10 | 2015-04-08 | The Regents of The University of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
US20080026394A1 (en) * | 2006-07-11 | 2008-01-31 | Antara Biosciences Inc. | Methods of detecting one or more cancer markers |
US8445222B2 (en) * | 2006-07-11 | 2013-05-21 | Musc Foundation For Research Development | Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling |
WO2008010934A2 (en) | 2006-07-14 | 2008-01-24 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
WO2008010228A2 (en) | 2006-07-20 | 2008-01-24 | Yeda Research And Development Co. Ltd. | Photosyntheticorganisms and compositions and methods of generating same |
EP2053961A4 (en) * | 2006-08-09 | 2013-05-01 | Biogen Idec Inc | Method for distribution of a drug |
JP5352460B2 (en) | 2006-08-15 | 2013-11-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Luminescent macrocyclic lanthanide complexes |
JP2008043332A (en) | 2006-08-17 | 2008-02-28 | Panomics Inc | Quantitative determination of nucleic acid from tissue slide |
EP2423332A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
EP2064319B1 (en) | 2006-08-28 | 2017-02-22 | Yeda Research and Development Co. Ltd. | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns |
US7951776B2 (en) | 2006-09-01 | 2011-05-31 | American Type Culture Collection | Methods for treatment of type 1 diabetes |
JP2008111824A (en) * | 2006-09-01 | 2008-05-15 | Nox Technologies Inc | NEOPLASM SPECIFIC tNOX ISOFORM AND METHOD THEREFOR |
US7985542B2 (en) | 2006-09-07 | 2011-07-26 | Institut Pasteur | Genomic morse code |
US7569396B1 (en) | 2006-09-08 | 2009-08-04 | Purplecow Llc | Caffeine detection using internally referenced competitive assays |
ES2457243T3 (en) * | 2006-09-08 | 2014-04-25 | The Chancellor, Masters And Scholars Of The University Of Oxford | Clinical diagnosis of liver fibrosis using human serum APOL1 as a biomarker |
US8050516B2 (en) * | 2006-09-13 | 2011-11-01 | Fluidigm Corporation | Methods and systems for determining a baseline during image processing |
US8055034B2 (en) * | 2006-09-13 | 2011-11-08 | Fluidigm Corporation | Methods and systems for image processing of microfluidic devices |
US20100129656A1 (en) | 2006-10-05 | 2010-05-27 | Technion Research & Develpment Foundation Ltd | Microtubes and methods of producing same |
US7888059B2 (en) * | 2006-10-05 | 2011-02-15 | Yeda Research And Development Co. Ltd. | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same |
EP2074230B1 (en) * | 2006-10-11 | 2012-11-28 | Janssen Pharmaceutica NV | Compositions and methods for treating and diagnosing irritable bowel syndrome |
EP1912067A1 (en) * | 2006-10-12 | 2008-04-16 | Eppendorf Array Technologies S.A. | Method for quantification of a target compound obtained from a biological sample upon chips |
EP2426199A3 (en) | 2006-10-20 | 2012-08-22 | Danisco US Inc. | Polyol oxidases |
US7776605B2 (en) * | 2006-10-26 | 2010-08-17 | Abbott Laboratories | Assay for cardiac troponin autoantibodies |
US20080305512A1 (en) * | 2006-10-26 | 2008-12-11 | Mattingly Phillip G | Assay for cardiac troponin autoantibodies |
WO2008051762A2 (en) * | 2006-10-26 | 2008-05-02 | Abbott Laboratories | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies |
WO2008049930A2 (en) | 2006-10-27 | 2008-05-02 | Janssen Pharmaceutica Nv | A method for profiling kinase inhibitors |
WO2008066655A2 (en) | 2006-11-02 | 2008-06-05 | Yale University | Assessment of oocyte competence |
US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
WO2008067552A2 (en) * | 2006-11-30 | 2008-06-05 | Fluidigm Corporation | Method and apparatus for biological sample analysis |
ATE555128T1 (en) | 2006-11-30 | 2012-05-15 | Res Dev Foundation | IMPROVED IMMUNOLOBULIN LIBRARIES |
US8232372B2 (en) | 2006-12-14 | 2012-07-31 | Schering Corp. | Engineered anti-TSLP antibody |
CA2672756C (en) | 2006-12-20 | 2018-11-20 | Evogene Ltd. | Polynucleotides and polypeptides involved in plant fiber development and methods of using same |
US8506499B2 (en) * | 2007-01-04 | 2013-08-13 | Musc Foundation For Research Development | Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling |
AU2008204338B2 (en) * | 2007-01-11 | 2014-03-06 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
WO2008089103A2 (en) | 2007-01-12 | 2008-07-24 | University Of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
ATE548454T1 (en) * | 2007-01-16 | 2012-03-15 | Yissum Res Dev Co | NUCLEIC ACID ACTIVE SUBSTANCES FOR STOPPING H19 FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
ES2378490T3 (en) | 2007-01-26 | 2012-04-13 | University Of Louisville Research Foundation, Inc. | Autoantibody detection methods to diagnose and characterize disorders |
US20100196403A1 (en) * | 2007-01-29 | 2010-08-05 | Jacob Hochman | Antibody conjugates for circumventing multi-drug resistance |
US8911996B2 (en) | 2007-01-31 | 2014-12-16 | Technion Research & Development Foundation Limited | Electrospun scaffolds and methods of generating and using same |
CA2676932C (en) | 2007-02-01 | 2015-11-24 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
PE20130588A1 (en) | 2007-02-02 | 2013-05-21 | Amgen Inc | HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE |
JP2010517693A (en) | 2007-02-06 | 2010-05-27 | グルメトリクス, インコーポレイテッド | Optical system and method for ratiometric measurement of blood glucose concentration |
US7751863B2 (en) | 2007-02-06 | 2010-07-06 | Glumetrics, Inc. | Optical determination of ph and glucose |
US8088097B2 (en) | 2007-11-21 | 2012-01-03 | Glumetrics, Inc. | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
US8143046B2 (en) | 2007-02-07 | 2012-03-27 | Danisco Us Inc., Genencor Division | Variant Buttiauxella sp. phytases having altered properties |
KR100855299B1 (en) * | 2007-02-16 | 2008-08-29 | 건국대학교 산학협력단 | Monoclonal antibodies specific against il-32 antigens, hybridoma producing the monoclonal antibodies and diagnostic systems using the monoclonal antibodies |
SG178804A1 (en) | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
DK2426144T3 (en) | 2007-02-23 | 2019-01-07 | Merck Sharp & Dohme | Manipulated Anti-IL-23P19 Antibodies |
BRPI0807991A2 (en) | 2007-02-28 | 2014-06-17 | Schering Corp | PREPARED ANTI-IL-23R ANTIBODIES. |
ES2662036T3 (en) | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Sequences that go to the core |
WO2008110006A1 (en) | 2007-03-12 | 2008-09-18 | Miraculins Inc. | Biomarkers of prostate cancer and uses thereof |
EP2514766A3 (en) | 2007-03-29 | 2013-06-05 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
EP2532746A3 (en) | 2007-03-30 | 2013-08-14 | EnGeneIC Molecular Delivery Pty Ltd. | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
KR20100015774A (en) | 2007-04-02 | 2010-02-12 | 라모트 앳 텔-아비브 유니버시티 리미티드 | Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease |
EP2132333B1 (en) | 2007-04-06 | 2011-11-23 | Becton, Dickinson and Company | Compositions and methods for the identification of a carbapenemase gene |
MX355608B (en) | 2007-04-09 | 2018-04-24 | Evogene Ltd | Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants. |
CA2683559C (en) | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
US8003314B2 (en) | 2007-04-16 | 2011-08-23 | Diagnostic Hybrids, Inc. | Methods for direct fluorescent antibody virus detection in liquids |
WO2008129548A2 (en) * | 2007-04-23 | 2008-10-30 | Segev Laboratories Limited | A system for delivering therapeutic agents into living cells and cells nuclei |
US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
EP2152905B1 (en) | 2007-05-01 | 2015-12-02 | Tel Hashomer Medical Research Infrastructure and Services Ltd. | Methods and kits for detecting fetal cells in the maternal blood |
AU2008247819B2 (en) | 2007-05-01 | 2013-02-14 | Research Development Foundation | Immunoglobulin Fc libraries |
WO2009009215A2 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
DK3360571T3 (en) | 2007-05-03 | 2021-01-04 | Agency For Science Tech And Research Astarstar | Antibodies that bind to an intracellular PRL-1 or PRL-3 polypeptide |
ES2660667T3 (en) | 2007-05-07 | 2018-03-23 | Protalix Ltd. | Large-scale disposable bioreactor |
WO2008141241A1 (en) * | 2007-05-10 | 2008-11-20 | Glumetrics, Inc. | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
WO2008150496A2 (en) * | 2007-05-31 | 2008-12-11 | Genelux Corporation | Assay for sensitivity to chemotherapeutic agents |
US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
WO2009000089A1 (en) * | 2007-06-28 | 2008-12-31 | University Of Saskatchewan | Immunomodulatory compositions and methods for treating disease with modified host defense peptides |
WO2009007980A1 (en) | 2007-07-11 | 2009-01-15 | Yeda Research And Development Co. Ltd. | Nucleic acid construct systems capable of diagnosing or treating a cell state |
ES2383568T3 (en) | 2007-07-12 | 2012-06-22 | Chemocentryx, Inc. | Heteroaryl pyridyl and phenyl benzenesulfonamides condensed as CCR2 modulators for the treatment of inflammation |
AU2008277257B2 (en) | 2007-07-15 | 2014-03-06 | Hillman, Yitzchak Mr | Disease treatment via antimicrobial peptides or their inhibitors |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
BR122020022199B1 (en) | 2007-07-24 | 2021-08-10 | Evogene Ltd | METHOD OF INCREASING THE TOLERANCE OF A PLANT TO ABIOTIC STRESS, BIOMASS AND/OR PRODUCTIVITY OF A PLANT, AND CONSTRUCTION OF ISOLATED NUCLEIC ACID |
WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
EP2537529B1 (en) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
JP5797403B2 (en) | 2007-08-03 | 2015-10-21 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | Human monoclonal antibody and method for producing the same |
US7790401B2 (en) | 2007-08-06 | 2010-09-07 | Siemens Healthcare Diagnostics | Methods for detection of immunosuppressant drugs |
US8420315B2 (en) | 2007-08-06 | 2013-04-16 | Orion Genomics Llc | Single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene |
US20120028880A1 (en) | 2007-08-08 | 2012-02-02 | Renata Pasqualini | Vegfr-1/nrp-1 targeting peptides |
WO2009023676A1 (en) | 2007-08-12 | 2009-02-19 | Integrated Dna Technologies, Inc. | Microarray system with improved sequence specificity |
WO2009023733A1 (en) * | 2007-08-13 | 2009-02-19 | Trustees Of Tufts College | Methods and microarrays for detecting enteric viruses |
CA2695969A1 (en) | 2007-08-15 | 2009-02-19 | Yeda Research & Development Co. Ltd. | Regulators of mmp-9 and uses therof |
AU2008299318A1 (en) | 2007-09-12 | 2009-03-19 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating tumors in immune-privileged sites |
EP2591789B2 (en) | 2007-09-19 | 2022-07-20 | Pluristem Ltd. | Adherent cells from adipose or placenta tissues and use thereof in therapy |
EP3136103B1 (en) | 2007-10-05 | 2018-08-29 | Affymetrix, Inc. | Highly multiplexed assays |
CA2702582C (en) * | 2007-10-15 | 2013-12-24 | Idexx Laboratories, Inc. | Feline pancreatic lipase |
US8088735B2 (en) | 2007-10-19 | 2012-01-03 | Rappaport Family Institute For Research In The Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
US20100240070A1 (en) * | 2007-11-07 | 2010-09-23 | Beckman Coulter, Inc. | Nonseparation Assay Methods Using Peroxide Generating Enzymes |
JP5264421B2 (en) * | 2007-11-22 | 2013-08-14 | 富士フイルム株式会社 | Test substance measuring carrier and method for producing the same |
WO2009069123A2 (en) | 2007-11-26 | 2009-06-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions comprising fibrous polypeptides and polysaccharides |
US7910378B2 (en) | 2007-12-14 | 2011-03-22 | Siemens Healthcare Diagnostics Inc. | Methods for detection of hydrophobic drugs |
CA2709517C (en) | 2007-12-27 | 2019-02-26 | Evogene Ltd. | Isolated polypeptides, polynucleotides useful for modifying water use efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants |
ES2535419T3 (en) | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Polo kinase expression silencing using interfering RNA |
BRPI0906429B1 (en) | 2008-01-10 | 2021-08-03 | Research Development Foundation | METHOD OF IDENTIFYING AN E. CHAFFEENSIS INFECTION IN AN INDIVIDUAL, USE OF ONE OR MORE SYNTHETIC POLYPEPTIDE AND KIT |
EP2574628B1 (en) | 2008-01-25 | 2015-05-20 | Amgen Inc. | Ferroportin antibodies and methods of use |
US20110052501A1 (en) * | 2008-01-31 | 2011-03-03 | Liat Dassa | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
CN101939019B (en) | 2008-02-07 | 2014-07-16 | 康奈尔大学 | Methods for preventing or treating insulin resistance |
US8034568B2 (en) | 2008-02-12 | 2011-10-11 | Nugen Technologies, Inc. | Isothermal nucleic acid amplification methods and compositions |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
US9469919B2 (en) | 2008-02-21 | 2016-10-18 | Technion Research & Development Foundation Ltd. | Method of attaching a cell-of-interest to a microtube |
US20090311695A1 (en) * | 2008-03-12 | 2009-12-17 | Talat Nasim | Method |
GB2470672B (en) | 2008-03-21 | 2012-09-12 | Nugen Technologies Inc | Methods of RNA amplification in the presence of DNA |
CA2719718C (en) | 2008-03-28 | 2019-07-02 | Mitomics, Inc. | Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor |
EP2107125A1 (en) | 2008-03-31 | 2009-10-07 | Eppendorf Array Technologies SA (EAT) | Real-time PCR of targets on a micro-array |
CA2720511A1 (en) | 2008-04-01 | 2009-10-08 | Biosearch Technologies, Inc. | Stabilized nucleic acid dark quencher-fluorophore probes |
JP5475753B2 (en) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | Lipid formulations for nucleic acid delivery |
CA2721380A1 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Silencing of csn5 gene expression using interfering rna |
WO2009129186A2 (en) | 2008-04-17 | 2009-10-22 | Glumetrics, Inc. | Sensor for percutaneous intravascular deployment without an indwelling cannula |
PL2288376T3 (en) | 2008-04-18 | 2016-07-29 | Collplant Ltd | Methods of generating and using procollagen |
AU2009239333A1 (en) | 2008-04-21 | 2009-10-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
EP2274592A4 (en) * | 2008-04-23 | 2011-09-07 | Luminex Corp | Method for creating a standard for multiple analytes found in a starting material of biological origin |
CN102066579A (en) | 2008-04-24 | 2011-05-18 | 纽约市哥伦比亚大学理事会 | Geometric patterns and lipid bilayers for DNA molecule organization and uses thereof |
DK2281034T3 (en) | 2008-04-30 | 2016-01-25 | Dupont Nutrition Biosci Aps | A method using alcohol dehydrogenase Pseudoglucanobacter saccharoketogenes |
EP2294087B1 (en) | 2008-05-01 | 2014-05-14 | Amgen, Inc. | Anti-hepcidin antibodies and methods of use |
JP2010043063A (en) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | Diagnosis and treatment of kawasaki disease |
CA2724343A1 (en) | 2008-05-15 | 2009-11-19 | Ribomed Biotechnologies, Inc. | Methods and reagents for detecting cpg methylation with a methyl cpg binding protein (mbp) |
BRPI0822661A2 (en) * | 2008-05-22 | 2015-06-30 | Centre Nat Rech Scient | Optically pure compounds for improved therapeutic efficiency |
MX2010012697A (en) | 2008-05-22 | 2011-03-15 | Evogene Ltd | Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility. |
BRPI0909541A2 (en) | 2008-05-27 | 2016-10-11 | Pluristem Ltd | '' method for treating inflammatory bowel disease '' |
US8663987B2 (en) | 2008-05-28 | 2014-03-04 | Ramot At Tel-Aviv University Ltd. | Mesenchymal stem cells for the treatment of CNS diseases |
WO2009152102A2 (en) * | 2008-06-10 | 2009-12-17 | The Regents Of The University Of California | Pro-fluorescent probes |
FI20085579A0 (en) * | 2008-06-12 | 2008-06-12 | Valtion Teknillinen | Detection of cannabis use |
US9952211B2 (en) | 2008-06-29 | 2018-04-24 | Realbio Technologies Ltd. | Liquid-transfer device particularly useful as a capturing device in a biological assay process |
US8211644B2 (en) * | 2008-07-13 | 2012-07-03 | Ribomed Biotechnologies, Inc. | Molecular beacon-based methods for detection of targets using abscription |
US9580513B2 (en) | 2008-08-08 | 2017-02-28 | Agency For Science, Technology And Research (A*Star) | VHZ for diagnosis and treatment of cancers |
US20120122800A1 (en) | 2008-08-08 | 2012-05-17 | Genisphere, LLC Hatfield, Pennsylvania | Long-Acting DNA Dendrimers and Methods Thereof |
US20110092961A1 (en) * | 2008-08-13 | 2011-04-21 | Searete Llc | Artificial cells |
AR073076A1 (en) | 2008-08-18 | 2010-10-13 | Evogene Ltd | USEFUL ISOLATED POLYPYPTIDES AND POLYUCLEOTIDES TO IMPROVE EFFECTIVENESS IN THE USE OF NITROGEN, TOLERANCE TO STRESS ABIOTIC, PERFORMANCE AND BIOMASS IN PLANTS. |
CN105708862B (en) | 2008-09-02 | 2020-11-06 | 普拉里斯坦有限公司 | Adherent cells from placental tissue and their use in therapy |
US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
WO2010029545A2 (en) | 2008-09-11 | 2010-03-18 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and methods for treating s. pneumoniae infection |
WO2010031006A1 (en) | 2008-09-12 | 2010-03-18 | Cryopraxis Criobiologia Ltda. | Ischemic tissue cell therapy |
SG10201504623VA (en) | 2008-09-24 | 2015-07-30 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
WO2010036323A1 (en) | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
EP2342356A4 (en) | 2008-09-29 | 2012-11-21 | Univ Ben Gurion | Amyloid beta-peptides and methods of use thereof |
DE102008049601A1 (en) | 2008-09-30 | 2010-04-01 | Siemens Healthcare Diagnostics Products Gmbh | Antibody for the determination of the prothrombin fragment F2 / F1 + 2 in a homogeneous immunoassay |
MX345298B (en) | 2008-10-30 | 2017-01-24 | Evogene Ltd | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield. |
AU2009313255B2 (en) | 2008-11-07 | 2014-08-07 | Research Development Foundation | Compositions and methods for the inhibition of Cripto/GRP78 complex formation and signaling |
WO2010055525A1 (en) | 2008-11-17 | 2010-05-20 | Technion Research & Development Foundation Ltd. | Method for predicting a patient's responsiveness to anti-folate therapy |
WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
WO2010061383A1 (en) | 2008-11-26 | 2010-06-03 | Biodalia Microbiological Technologies Ltd. | A method of in-situ enrichment of foods with fructan |
WO2010064231A1 (en) | 2008-12-02 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of analyzing a-i rna editing and nucleic acid constructs capable of same |
US20110287088A1 (en) | 2008-12-03 | 2011-11-24 | Research Development Foundation | Modulation of olfml-3 mediated angiogenesis |
US20120014927A1 (en) | 2008-12-03 | 2012-01-19 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
JP2012511032A (en) | 2008-12-05 | 2012-05-17 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | SPARC binding ScFv |
EP2633854B1 (en) | 2008-12-05 | 2015-09-16 | Yeda Research And Development Co. Ltd. | miRNA-9 or miRNA-9* for use in treating ALS |
EP2373997A1 (en) | 2008-12-09 | 2011-10-12 | Dako Denmark A/S | Method for evaluating pre-treatment |
WO2010068757A1 (en) | 2008-12-12 | 2010-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions |
WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
EP2808402A3 (en) | 2008-12-29 | 2015-03-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment |
DK2376528T3 (en) | 2008-12-29 | 2015-01-05 | Tel Hashomer Medical Res Infrastructure & Services Ltd | PEPTIDES AND COMPOSITIONS FOR PREVENTING cell adhesion, and methods of use thereof |
AR074925A1 (en) | 2008-12-29 | 2011-02-23 | Evogene Ltd | POLINUCLEOTIDES, CODED POLYPEPTIDES, AND METHODS TO USE THEM TO MODULATE TOLERANCE TO ABIOTIC STRESS, BIOMASS AND / OR PERFORMANCE IN PLANTS THAT EXPRESS THEM |
US8455263B2 (en) | 2008-12-30 | 2013-06-04 | Jin Po Lee | Quantitative analyte assay device and method |
WO2010076794A1 (en) | 2008-12-31 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Method of denitrifying brine and systems capable of same |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
IL196820A0 (en) | 2009-02-01 | 2009-11-18 | Yissum Res Dev Co | Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells |
US8691760B2 (en) | 2009-02-02 | 2014-04-08 | Ramot At Tel-Aviv University | Peptides, pharmaceutical compositions comprising same and uses thereof |
WO2010089707A1 (en) | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
EP2396661A4 (en) | 2009-02-11 | 2013-10-30 | Caris Mpi Inc | Molecular profiling of tumors |
EP2396429B1 (en) | 2009-02-11 | 2015-05-27 | Orion Genomics, LLC | Combinations of polymorphisms for determining allele-specific expression of igf2 |
WO2010096658A1 (en) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corin as a marker for heart failure |
EP2465920B1 (en) | 2009-02-26 | 2017-04-12 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolated populations of renal stem cells and methods of isolating and using same |
AU2010220157C1 (en) | 2009-03-02 | 2015-08-06 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
EP2404162B1 (en) | 2009-03-03 | 2017-12-27 | Access Medical System Co., Ltd. | Detection system and method for high sensitivity fluorescent assays |
HUE028729T2 (en) | 2009-03-09 | 2017-01-30 | Ramot At Tel-Aviv Univ Ltd | Compositions for prevention and treatment of neurodegenerative diseases |
WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
US9347947B2 (en) * | 2009-03-12 | 2016-05-24 | Siemens Healthcare Diagnostics Inc. | Immunoassays employing non-particulate chemiluminescent reagent |
JP2012520086A (en) | 2009-03-15 | 2012-09-06 | リボムド バイオテクノロジーズ インク | Molecular detection based on abstraction |
US20100240065A1 (en) * | 2009-03-18 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Prolyl Hydroxylase Compositions and Methods of Use Thereof |
US8481698B2 (en) * | 2009-03-19 | 2013-07-09 | The President And Fellows Of Harvard College | Parallel proximity ligation event analysis |
AU2010229490B2 (en) | 2009-03-24 | 2015-02-12 | University Of Chicago | Slip chip device and methods |
US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
EP2411522B1 (en) | 2009-03-27 | 2017-09-06 | MDNA Life Sciences Inc. | Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor |
TW201039841A (en) * | 2009-03-27 | 2010-11-16 | Gojo Ind Inc | Compositions and methods for screening and using compounds antagonizing spore-surface interactions |
EP2414542B1 (en) | 2009-03-30 | 2017-08-30 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
EP2344179A1 (en) | 2009-04-01 | 2011-07-20 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | A method of regulating proliferation and differentiation of keratinocyes |
WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
CA2795268A1 (en) | 2009-04-21 | 2010-10-28 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
GB0908770D0 (en) | 2009-04-24 | 2009-07-01 | Danisco | Method |
PL2424896T3 (en) | 2009-04-30 | 2016-03-31 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Anti ceacam1 antibodies and methods of using same |
WO2010124689A1 (en) | 2009-05-01 | 2010-11-04 | Dako Denmark A/S | New antibody cocktail |
CN102460174B (en) | 2009-05-14 | 2016-03-16 | 牛津大学之校长及学者 | One group of novel low abundance human plasma protein biomarker is used to carry out clinical diagnosis to liver fibrosis |
WO2010134073A1 (en) | 2009-05-19 | 2010-11-25 | Zetiq Technologies Ltd. | Kits for and methods of differential staining of cervical cancer cells and/or tissues |
CA2761767A1 (en) | 2009-05-19 | 2010-11-25 | Danisco A/S | Use of amylase and lipolytic enzyme in bread |
EP2432499A2 (en) | 2009-05-20 | 2012-03-28 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
CN102639146A (en) | 2009-05-27 | 2012-08-15 | 耶达研究及发展有限公司 | Proteasome inhibitors and uses thereof |
WO2010137013A1 (en) | 2009-05-27 | 2010-12-02 | Ramot At Tel Aviv University Ltd. | Crystallized photosystem i units from the pea plant and their use in solid state devices |
WO2010137021A2 (en) | 2009-05-27 | 2010-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
EP2435078A1 (en) | 2009-05-28 | 2012-04-04 | Yeda Research and Development Co. Ltd. | Methods of treating inflammation |
KR20120122869A (en) | 2009-06-02 | 2012-11-07 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases |
CA3095630A1 (en) | 2009-06-10 | 2010-12-16 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance |
EP2446267A1 (en) | 2009-06-24 | 2012-05-02 | Health Corporation - Rambam | Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders |
JP2012531197A (en) | 2009-06-25 | 2012-12-10 | デュポン ニュートリション バイオサイエンシーズ エーピーエス | protein |
ES2613498T3 (en) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | New lipid formulations for the delivery of therapeutic agents to solid tumors |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
JP6193570B2 (en) | 2009-07-17 | 2017-09-13 | バイオアトラ、エルエルシー | Simultaneously integrated selection and evolution of antibody / protein performance and expression in the production host |
WO2011011447A1 (en) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
EP2457089B1 (en) | 2009-07-21 | 2019-08-07 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | A method of diagnosing cancer |
GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
CA2769406A1 (en) | 2009-08-04 | 2011-02-10 | Biosystems International Sas | Lung cancer biomarkers |
EP2467470A2 (en) | 2009-08-17 | 2012-06-27 | Technion Research & Development Foundation Ltd. | Pericyte progenitor cells and methods of generating and using same |
WO2011021171A1 (en) | 2009-08-21 | 2011-02-24 | Beeologics, Llc | Preventing and curing beneficial insect diseases via plant transcribed molecules |
SG178845A1 (en) | 2009-08-21 | 2012-04-27 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
US9273059B2 (en) | 2009-08-24 | 2016-03-01 | Lumiphore, Inc. | Macrocyclic HOPO chelators |
CN102596179A (en) | 2009-08-27 | 2012-07-18 | 工业研究与发展基金会有限公司 | Liposomal compositions and uses of same |
WO2011027966A2 (en) | 2009-09-03 | 2011-03-10 | Seegene, Inc. | Td probe and its uses |
RU2595409C2 (en) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Anti-gitr antibodies |
EP2475381A2 (en) | 2009-09-08 | 2012-07-18 | Yeda Research and Development Co. Ltd. | Methods for hematopoietic precursor mobilization |
EP2475784A1 (en) | 2009-09-08 | 2012-07-18 | Ramot at Tel-Aviv University Ltd. | Methods of diagnosing amyotrophic lateral sclerosis (als) |
US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
US20120244185A1 (en) | 2009-09-16 | 2012-09-27 | Vaxart ,Inc. | Immunization strategy to prevent h1n1 infection |
US8735124B2 (en) | 2009-09-17 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
EP2478093A2 (en) | 2009-09-17 | 2012-07-25 | Yeda Research and Development Co. Ltd. | Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
CN102498127B (en) | 2009-09-17 | 2015-02-25 | 雷蒙特亚特特拉维夫大学有限公司 | Peptides for the treatment of oxidative stress related disorders |
CA2775092A1 (en) | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
WO2011038403A1 (en) | 2009-09-28 | 2011-03-31 | Yuling Luo | Methods of detecting nucleic acid sequences with high specificity |
JP2013506503A (en) | 2009-09-30 | 2013-02-28 | グルメトリクス, インコーポレイテッド | Sensor with antithrombogenic coating |
US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
US9377458B2 (en) | 2009-10-11 | 2016-06-28 | Biogen Ma Inc. | Anti-VLA-4 related assays |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
CN105368836A (en) | 2009-10-14 | 2016-03-02 | 耶路撒冷希伯来大学伊森姆研究发展公司 | Compositions for controlling varroa mites in bees |
CA2777663A1 (en) | 2009-10-16 | 2011-04-21 | University Of Medicine And Dentistry Of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
US20160186266A1 (en) | 2009-10-27 | 2016-06-30 | Carislife Sciences, Inc. | Molecular profiling for personalized medicine |
US8467843B2 (en) | 2009-11-04 | 2013-06-18 | Glumetrics, Inc. | Optical sensor configuration for ratiometric correction of blood glucose measurement |
KR20110050327A (en) | 2009-11-07 | 2011-05-13 | 주식회사 씨젠 | T h d primer target detection |
IL201999A (en) | 2009-11-08 | 2017-10-31 | Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel | Knock-out mouse of the mo-1 gene, a gene associated with morbid obesity |
EP2498806B1 (en) | 2009-11-12 | 2014-12-31 | Ramot at Tel-Aviv University Ltd. | Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes |
CA2783437C (en) | 2009-11-12 | 2020-08-04 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
US8592151B2 (en) * | 2009-11-17 | 2013-11-26 | Musc Foundation For Research Development | Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids |
GB0920089D0 (en) | 2009-11-17 | 2009-12-30 | Danisco | Method |
CN102770529B (en) | 2009-11-17 | 2018-06-05 | Musc研究发展基金会 | For the human monoclonal antibodies of people's paranuclein |
US9910040B2 (en) | 2012-07-09 | 2018-03-06 | Sevident, Inc. | Molecular nets comprising capture agents and linking agents |
US9733242B2 (en) | 2012-10-07 | 2017-08-15 | Sevident, Inc. | Devices for capturing analyte |
US20120273993A1 (en) | 2009-11-24 | 2012-11-01 | Collplant Ltd. | Method of generating collagen fibers |
ES2553712T3 (en) | 2009-11-30 | 2015-12-11 | Pluristem Ltd. | Adherent cells of the placenta and their use in the treatment of disease |
US8835120B2 (en) * | 2009-12-02 | 2014-09-16 | Abbott Laboratories | Assay for cardiac troponin-T (cTnT) |
US8652788B2 (en) * | 2009-12-02 | 2014-02-18 | Abbott Laboratories | Assay for diagnosis of cardiac myocyte damage |
US8183002B2 (en) | 2009-12-03 | 2012-05-22 | Abbott Laboratories | Autoantibody enhanced immunoassays and kits |
US20110136141A1 (en) | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Peptide reagents and method for inhibiting autoantibody antigen binding |
WO2011067745A2 (en) | 2009-12-06 | 2011-06-09 | Rosetta Green Ltd. | Compositions and methods for enhancing plants resistance to abiotic stress |
EP2510098B1 (en) | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
WO2011084357A1 (en) | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
AU2010336137B2 (en) | 2009-12-21 | 2015-08-06 | Seegene, Inc. | TSG primer target detection |
WO2011087707A1 (en) | 2009-12-22 | 2011-07-21 | Elitech Holding B.V. | Hypertheromostable endonuclease iv substrate probe |
GB0922377D0 (en) | 2009-12-22 | 2010-02-03 | Arab Gulf University The | Mutant LDL receptor |
CA3172119A1 (en) | 2009-12-28 | 2011-07-07 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
CN107254439B (en) | 2009-12-29 | 2022-01-11 | 加米达细胞有限公司 | Method for enhancing natural killer cell proliferation and activity |
CA2786374C (en) | 2010-01-05 | 2019-01-22 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
FI3339865T5 (en) | 2010-01-11 | 2023-04-15 | Assay for jc virus antibodies | |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
SG10201500015TA (en) | 2010-01-12 | 2015-02-27 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
US8697078B2 (en) | 2010-01-27 | 2014-04-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
WO2011094577A2 (en) | 2010-01-29 | 2011-08-04 | Micronics, Inc. | Sample-to-answer microfluidic cartridge |
ES2719502T3 (en) | 2010-01-29 | 2019-07-10 | Advanced Cell Diagnostics Inc | Nucleic acid in situ detection methods |
US8574832B2 (en) | 2010-02-03 | 2013-11-05 | Massachusetts Institute Of Technology | Methods for preparing sequencing libraries |
SG183174A1 (en) | 2010-02-04 | 2012-09-27 | Gilead Biologics Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
TWI504410B (en) | 2010-02-08 | 2015-10-21 | Agensys Inc | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
US9410131B2 (en) | 2010-02-11 | 2016-08-09 | Yeda Research And Development Co. Ltd. | Enzymatic systems for carbon fixation and methods of generating same |
WO2011104708A2 (en) | 2010-02-24 | 2011-09-01 | Ben Gurion University Of The Negev Research And Development Authority | Methods for inhibiting necrosis |
WO2011107939A1 (en) | 2010-03-01 | 2011-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors |
WO2011107994A1 (en) | 2010-03-04 | 2011-09-09 | Yeda Research And Development Co. Ltd. | Methods of measuring protein stability |
EP2545176B1 (en) | 2010-03-08 | 2016-05-11 | Yeda Research and Development Co. Ltd. | Recombinant protein production in heterologous systems |
MY163887A (en) | 2010-03-08 | 2017-11-15 | Monsanto Technology Llc | Polynucleotide molecules for gene regulations in plants |
WO2011111050A2 (en) | 2010-03-11 | 2011-09-15 | Jacob Edrei | Methods of generating hydrogen |
WO2011114251A1 (en) | 2010-03-18 | 2011-09-22 | Danisco A/S | Foodstuff |
EP2556085A2 (en) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
SG184466A1 (en) | 2010-04-06 | 2012-11-29 | Massachusetts Inst Technology | Gene-expression profiling with reduced numbers of transcript measurements |
US9125931B2 (en) | 2010-04-06 | 2015-09-08 | Massachusetts Institute Of Technology | Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers |
EP2557913B1 (en) | 2010-04-12 | 2016-08-03 | Ben Gurion University Of The Negev Research And Development Authority | Sulfotransferase of a red microalga and uses thereof |
US8927274B2 (en) | 2010-04-12 | 2015-01-06 | Technion Research & Development Foundation Limited | Populations of pancreatic progenitor cells and methods of isolating and using same |
WO2011129382A1 (en) | 2010-04-16 | 2011-10-20 | Abbott Japan Co. Ltd. | Methods and reagents for diagnosing rheumatoid arthritis |
RU2012148398A (en) | 2010-04-18 | 2014-05-27 | Иеда Рисеч Энд Девелопмент Ко. Лтд. | MOLECULES AND METHODS OF APPLICATION OF MOLECULES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ErbB / ErbB LIGANDS |
AU2011246876B2 (en) | 2010-04-28 | 2016-06-23 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
US20130053277A1 (en) | 2010-05-04 | 2013-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
EP2566500B1 (en) | 2010-05-05 | 2017-04-12 | Rappaport Family Institute for Research in the Medical Sciences | Ccl1 for use in therapy |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
MX2012012986A (en) | 2010-05-07 | 2013-03-05 | Abbvie Inc | Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor. |
US20120190563A1 (en) | 2010-05-07 | 2012-07-26 | Abbott Laboratories | Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor |
EP2569417B1 (en) | 2010-05-13 | 2018-04-18 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolated populations of adult renal cells and methods of isolating and using same |
EP2572197A4 (en) | 2010-05-18 | 2013-08-28 | Texas A & M Univ Sys | Method and composition for the diagnosis and monitoring of inflammatory diseases |
EP2575859B1 (en) | 2010-06-03 | 2018-09-19 | Ramot at Tel Aviv University, Ltd. | Methods of treating diabetes and compositions capable of same |
KR20130123357A (en) | 2010-06-07 | 2013-11-12 | 오스나트 에슈어-파비안 | Methods and kits for diagnosing conditions related to hypoxia |
EP2395354A1 (en) | 2010-06-10 | 2011-12-14 | Siemens Healthcare Diagnostics Products GmbH | Homogenous activity test for determining enzymatic reactions |
EP2582842A2 (en) | 2010-06-16 | 2013-04-24 | Yissum Research Development Company of The Hebrew University of Jerusalem | Method of diagnosing and treating cancer |
BR112012032126A2 (en) | 2010-06-16 | 2017-10-17 | Futuragene Israel Ltd Empresa Isralense | isolated polynucleotide, nucleic acid structure, nucleic acid structure system, isolated polypeptide, plant, insecticidal composition, and method for controlling or exterminating an insect |
US8329424B2 (en) | 2010-06-25 | 2012-12-11 | Siemens Healthcare Diagnostics | Reduction in false results in assay measurements |
US20130316338A1 (en) | 2010-06-29 | 2013-11-28 | The United States Government As Represented By The Department Of Veterans Affairs | CCR6 As A Biomarker of Alzheimer's Disease |
GB201011513D0 (en) | 2010-07-08 | 2010-08-25 | Danisco | Method |
EP2593468B1 (en) | 2010-07-12 | 2020-06-10 | The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Isolated polynucleotides and methods and plants using same for regulating plant acidity |
EP2407242A1 (en) | 2010-07-13 | 2012-01-18 | Dublin City University | Direct clone analysis and selection technology |
CN103108955B (en) | 2010-07-15 | 2015-11-25 | 工业研究与发展基金会有限公司 | For improving the nucleic acid construct of abiotic stress tolerance in plant |
EP2593480A2 (en) | 2010-07-15 | 2013-05-22 | Technion Research & Development Foundation Ltd. | Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
US9695410B2 (en) | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
DK3435087T3 (en) | 2010-07-16 | 2023-11-27 | Bioatla Inc | UNKNOWN PROCESSES FOR PROTEIN EVOLUTION |
CN103153467A (en) | 2010-07-16 | 2013-06-12 | 范德比尔特大学 | Low resource processor using surface tension valves for extracting, concentrating and detecting molecular species |
CA2804914A1 (en) | 2010-07-22 | 2012-01-26 | Nadir Askenasy | Regulatory immune cells with enhanced targeted cell death effect |
CA2806306A1 (en) | 2010-07-23 | 2012-01-26 | Luminex Corporation | Co-coupling to control reactivity of reagents in immunoassays |
US9120862B2 (en) | 2010-07-26 | 2015-09-01 | Abbott Laboratories | Antibodies relating to PIVKA-II and uses thereof |
US20130130311A1 (en) | 2010-07-27 | 2013-05-23 | Yeda Research And Development Co., Ltd. | Methods and systems for assessing clonality of cell cultures |
US9144585B2 (en) | 2010-07-27 | 2015-09-29 | Technion Research & Development Foundation Limited | Isolated mesenchymal progenitor cells and extracellular matrix produced thereby |
WO2012014207A2 (en) | 2010-07-27 | 2012-02-02 | Technion Research & Development Foundation Ltd. | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
US8901074B2 (en) | 2010-08-04 | 2014-12-02 | Ramot At Tel-Aviv University | Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases |
US8778699B2 (en) | 2010-08-04 | 2014-07-15 | Idexx Laboratories, Inc. | Detection of degradation products of canine NT-proBNP |
US10088490B2 (en) | 2010-08-20 | 2018-10-02 | Siemens Healthcare Diagnostics Inc. | Assay for analytes using multiple receptors |
SG187830A1 (en) | 2010-08-22 | 2013-03-28 | Univ Ramot | Induced pluripotent stem cells derived from human pancreatic beta cells |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
MX365161B (en) | 2010-08-30 | 2019-05-24 | Evogene Ltd | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance. |
WO2012032520A1 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease |
US10214722B2 (en) | 2010-09-07 | 2019-02-26 | Technion Research & Development Foundation Limited | Methods for expanding and maintaining human pluripotent stem cells (PSCs) in an undifferentiated state in a single cell suspension culture |
WO2012032510A1 (en) | 2010-09-07 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Primers for amplifying dna and methods of selecting same |
WO2012032519A2 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing parkinson's disease |
MX357746B (en) | 2010-09-08 | 2018-07-23 | Yeda Res And Development Co Ltd Star | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment. |
EP2614083A2 (en) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | An immunosuppressive drug combination for a stable and long term engraftment |
EP2616539A1 (en) | 2010-09-15 | 2013-07-24 | Ramot at Tel-Aviv University Ltd. | Methods of expanding and redifferentiating islet beta cells |
AU2011305696A1 (en) | 2010-09-20 | 2013-05-02 | Advanced Cell Diagnostics, Inc. | Biomarkers for differentiating melanoma from benign nevus in the skin |
US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
AU2011305445B2 (en) | 2010-09-24 | 2017-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
KR102504750B1 (en) | 2010-09-29 | 2023-03-02 | 어젠시스 인코포레이티드 | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
AU2011311665A1 (en) | 2010-10-04 | 2013-05-02 | Centre National De La Recherche Scientifique (Cnrs) | Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans |
EP2441520A1 (en) | 2010-10-12 | 2012-04-18 | Eppendorf AG | Real-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay |
US8951983B2 (en) | 2010-10-17 | 2015-02-10 | Yeda Research And Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
ES2562821T3 (en) | 2010-10-21 | 2016-03-08 | Advanced Cell Diagnostics, Inc. | Ultrasensitive method for in situ detection of nucleic acids |
KR20120042100A (en) | 2010-10-22 | 2012-05-03 | 주식회사 씨젠 | Detection of target nucleic acid sequences using dual-labeled immobilized probes on solid phase |
US20130216603A1 (en) | 2010-10-27 | 2013-08-22 | Nanocyte (Israel) Ltd. | Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
ES2688457T3 (en) | 2010-10-28 | 2018-11-02 | Yeda Research And Development Co. Ltd. | Methods of generating antibodies against metalloenzymes |
US20130227724A1 (en) | 2010-11-03 | 2013-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Transgenic plants with improved saccharification yields and methods of generating same |
US9410132B2 (en) | 2010-11-04 | 2016-08-09 | Ben-Gurion University Of The Negev Research And Development Authority | Acyl-CoA: diacylglycerol acyltransferase 1-like gene (PtDGAT1) and uses thereof |
TW201225972A (en) | 2010-11-15 | 2012-07-01 | Univ Ramot | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
US10117895B2 (en) | 2010-11-17 | 2018-11-06 | Ben-Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
US9574171B2 (en) | 2010-12-02 | 2017-02-21 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
US20120183960A1 (en) | 2010-12-07 | 2012-07-19 | Enterologics, Inc. | Method for identifying e. coli m-17 |
EP2652125B1 (en) | 2010-12-15 | 2017-04-26 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
CA3095614A1 (en) | 2010-12-22 | 2012-06-28 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing abiotic stress tolerance, yield, growth rate, vigor, biomass, oil content, and/or nitrogen use efficiency of plants |
AR084358A1 (en) | 2010-12-27 | 2013-05-08 | Lilly Co Eli | COMPOSITIONS AND METHODS FOR IDENTIFYING AND DIFFERING VIRAL COMPONENTS OF MULTIVALENT VACCINES OF THE “BOILING FEVER” (BOVINE RESPIRATORY DISEASE COMPLEX (BRDC)) |
BR112013016535A2 (en) | 2010-12-28 | 2016-09-20 | Bio Fd&C Co Ltd | plant extracts for the treatment and prevention of infections |
EP2471945A1 (en) | 2010-12-30 | 2012-07-04 | Siemens Healthcare Diagnostics Products GmbH | Method for determining coagulation inhibitors |
AU2011352207B2 (en) | 2010-12-31 | 2016-03-03 | Bioatla, Llc | Comprehensive monoclonal antibody generation |
MX352460B (en) | 2011-01-11 | 2017-11-24 | Seegene Inc | Detection of target nucleic acid sequences by pto cleavage and extension assay. |
EP3216878B1 (en) | 2011-01-17 | 2019-04-03 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
BR112013018516B1 (en) | 2011-01-20 | 2023-11-07 | Protalix Ltd | NUCLEIC ACID EXPRESSION CONSTRUCT, METHOD OF PRODUCING A RECOMBINANT HUMAN ALPHA-GALACTOSIDASE PROTEIN, HUMAN ALFAGALACTOSIDASE PROTEIN, PHARMACEUTICAL COMPOSITION, AND, USE OF A HUMAN ALPHAGALAACTOSIDASE PROTEIN OR A COMPOSITION |
US20120214152A1 (en) | 2011-01-28 | 2012-08-23 | Xiao-Jun Ma | Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions |
WO2012104851A1 (en) | 2011-01-31 | 2012-08-09 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
EP2673299B1 (en) | 2011-02-07 | 2017-05-10 | Research Development Foundation | Engineered immunoglobulin fc polypeptides |
US9212258B2 (en) | 2011-02-23 | 2015-12-15 | The Board Of Trustees Of The University Of Illinois | Amphiphilic dendron-coils, micelles thereof and uses |
WO2012114339A1 (en) | 2011-02-23 | 2012-08-30 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
CN103597078B (en) | 2011-03-02 | 2016-12-14 | 富途锐基尼以色列有限公司 | There is the antibiotic property transgenic plant of the T3SS albumen of functional disorder |
US9365828B2 (en) | 2011-03-03 | 2016-06-14 | Ramot At Tel-Aviv University Ltd. | Genetically modified muscle cells which express neurotrophic factors |
CA2829110C (en) | 2011-03-06 | 2019-01-15 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
EP2683835B1 (en) | 2011-03-08 | 2017-01-11 | King Abdullah University Of Science And Technology | Molecular biomarker set for early detection of ovarian cancer |
WO2012120518A1 (en) | 2011-03-08 | 2012-09-13 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (pku) |
AU2012229156A1 (en) | 2011-03-11 | 2013-10-31 | Board Of Regents Of The University Of Nebraska | Biomarker for coronary artery disease |
US20140086839A1 (en) | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
JP2014510084A (en) | 2011-03-17 | 2014-04-24 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | Bispecific and monospecific asymmetric antibodies and methods for their production |
EP2689008B1 (en) | 2011-03-22 | 2017-09-27 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
ES2611343T3 (en) | 2011-03-23 | 2017-05-08 | Elitech Holding B.V. | Functionalized 3-alkynyl pyrazolopyrimidine analogs as universal bases and methods of use |
US8969003B2 (en) | 2011-03-23 | 2015-03-03 | Elitech Holding B.V. | Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use |
CN103648517B (en) | 2011-03-24 | 2016-04-20 | 纽瑞姆制药(1991)有限公司 | Neuroprotective peptide |
WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
US20140005070A1 (en) | 2011-03-28 | 2014-01-02 | Novartis Ag | Markers associated with cyclin-dependent kinase inhibitors |
CN103534358B (en) | 2011-03-29 | 2015-03-25 | Seegene株式会社 | Detection of target nucleic acid sequence by PTO cleavage and extension-dependent cleavage |
SI2694106T1 (en) | 2011-04-01 | 2018-04-30 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
US9790262B2 (en) | 2011-04-05 | 2017-10-17 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
WO2012137202A1 (en) | 2011-04-05 | 2012-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci) |
ES2627154T3 (en) | 2011-04-06 | 2017-07-26 | Ramot At Tel-Aviv University Ltd. | Methods of monitoring and analysis of metabolic activity profiles, diagnostic and therapeutic uses thereof |
BR112013025811A2 (en) | 2011-04-08 | 2016-11-29 | Danisco Us Inc | "composition and method for removing a lipid based stain from a surface" |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
ES2768296T3 (en) | 2011-04-15 | 2020-06-22 | Pluristem Ltd | Methods and systems to collect cells |
CN103608675B (en) | 2011-04-20 | 2015-07-22 | 万迈医疗仪器有限公司 | Luminescent polymer cyclic amplification |
WO2012150598A2 (en) | 2011-05-03 | 2012-11-08 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
MX342067B (en) | 2011-05-04 | 2016-09-09 | Seegene Inc | Detection of target nucleic acid sequences by po cleavage and hybridization. |
US9192670B2 (en) | 2011-05-04 | 2015-11-24 | Ramot At Tel-Aviv University Ltd. | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease |
WO2012153333A1 (en) | 2011-05-09 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Regeneration and repair of mesenchymal tissue using amelogenin |
CN108342453A (en) | 2011-05-09 | 2018-07-31 | 富鲁达公司 | Detection of nucleic acids based on probe |
WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
WO2012156976A1 (en) | 2011-05-16 | 2012-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of producing artemisinin in non-host plants and vectors for use in same |
JP2014515476A (en) | 2011-05-20 | 2014-06-30 | アボットジャパン株式会社 | Immunoassay methods and reagents for reducing non-specific binding |
JP6457263B2 (en) | 2011-05-20 | 2019-01-23 | オリゴメリックス インコーポレイテッド | Tau protease composition and methods of use |
CA2836503C (en) | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
WO2012160526A2 (en) | 2011-05-23 | 2012-11-29 | Ofir Menashe | Formulations of microorganism comprising particles and uses of same |
CA2835283C (en) | 2011-05-24 | 2019-08-06 | Elitech Holding B.V. | Detection of methicillin-resistant staphylococcus aureus |
EP2715353B1 (en) | 2011-05-31 | 2016-08-24 | IDEXX Laboratories, Inc. | DETECTION OF DEGRADATION PRODUCTS OF FELINE NT-proBNP |
SG195190A1 (en) | 2011-05-31 | 2013-12-30 | Hutchison Biofilm Medical Solutions Ltd | Dispersion and detachment of cell aggregates |
EP3575792B1 (en) | 2011-05-31 | 2022-11-30 | Biogen MA Inc. | Method of assessing risk of pml |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
ES2670596T3 (en) | 2011-06-14 | 2018-05-31 | Yeda Research And Development Co. Ltd. | Combination therapy to prevent the formation of DCIS and progression to breast cancer |
RU2014101662A (en) | 2011-06-23 | 2015-07-27 | Каиима Био Агритех Лтд. | SOFT WHEAT, PLANTS OR PARTS THEREOF WITH PARTIALLY OR FULLY MULTIPLICATED GENOMES, HYBRIDS AND THEIR PRODUCTS, AND ALSO WAYS OF PRODUCING AND APPLICATION |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
WO2013010170A1 (en) | 2011-07-14 | 2013-01-17 | Lovell Mark A | Process for detection of alzheimer's disease from a serum sample |
CA2842321C (en) | 2011-07-18 | 2022-05-03 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
CA2841722A1 (en) | 2011-07-20 | 2013-01-24 | Kaiima Bio Agritech Ltd. | Maize plants having a partially or fully multiplied genome and uses thereof |
US20130030452A1 (en) | 2011-07-27 | 2013-01-31 | Health Corporation - Rambam | Devices for surgical applications |
CA2844012C (en) | 2011-08-04 | 2021-03-16 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
AU2012294814A1 (en) | 2011-08-05 | 2014-02-27 | Research Development Foundation | Improved methods and compositions for modulation of Olfml3 mediated angiogenesis |
WO2013021389A2 (en) | 2011-08-09 | 2013-02-14 | Yeda Research And Development Co.Ltd. | Downregulation of mir-7 for promotion of beta cell differentiation and insulin production |
WO2013025532A2 (en) | 2011-08-12 | 2013-02-21 | Siemens Healthcare Diagnostics Inc. | Detection of sex steroids |
EP2741602A1 (en) | 2011-08-14 | 2014-06-18 | Kaiima Bio Agritech Ltd. | Durum wheat plants having a partially or fully multiplied genome and uses thereof |
JP6317670B2 (en) | 2011-08-15 | 2018-04-25 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
WO2013025479A1 (en) | 2011-08-16 | 2013-02-21 | Emory University | Jaml specific binding agents, antibodies, and uses related thereto |
EP2753367A4 (en) | 2011-09-07 | 2015-10-14 | Yeda Res & Dev | Olfactory signature and odorant mixture having the same |
ES2657552T3 (en) | 2011-09-08 | 2018-03-05 | Yeda Research And Development Co. Ltd. | New risk biomarkers for lung cancer |
SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
CA2848685A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control comprising topical application of a glutamine synthetase polynucleotide |
UY34328A (en) | 2011-09-13 | 2013-04-30 | Monsanto Technology Llc | ? COMPOSITIONS AND METHODS TO CONTROL MALEZAS UNDERSTANDING A POLINUCLEOTIDE AND TRANSFER AGENT, AND THAT MODULATE PROTOPORPHYRINOGEN IX OXIDASE. |
BR112014005958A2 (en) | 2011-09-13 | 2020-10-13 | Monsanto Technology Llc | agricultural chemical methods and compositions for plant control, method of reducing expression of an accase gene in a plant, microbial expression cassette, method for making a polynucleotide, method of identifying polynucleotides useful in modulating expression of the accase gene and herbicidal composition |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
WO2013040057A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
CN104011068A (en) | 2011-10-21 | 2014-08-27 | 奥古雷克斯生命科学公司 | Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis |
EP2771464B1 (en) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Methods of treating cancer |
MX356814B (en) | 2011-11-03 | 2018-06-13 | Quark Pharmaceuticals Inc | Methods and compositions for neuroprotection. |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
US9736998B2 (en) | 2011-11-23 | 2017-08-22 | Danziger Dan Flower Farm | Otomeria plants |
US9617331B2 (en) | 2011-11-27 | 2017-04-11 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide |
EP2788009B1 (en) | 2011-12-08 | 2016-05-25 | Yeda Research and Development Co. Ltd. | Mammalian fetal pulmonary cells and therapeutic use of same |
WO2013093921A1 (en) | 2011-12-20 | 2013-06-27 | Collplant Ltd. | Collagen coated synthetic polymer fibers |
CN105833925B (en) | 2011-12-22 | 2018-11-13 | 瑞尔比奥技术有限公司 | sequential lateral flow capillary device for analyte determination |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
BR112014015959A8 (en) | 2011-12-22 | 2017-07-04 | Yeda Res & Dev | method for treating an individual in need of a non-syngeneic cell graft or tissue, method for treating an individual in need of an immature hematopoietic cell transplantation, method for inducing donor specific tolerance in an individual in need of a cell non-syngeneic or tissue graft, and method for treating an individual who needs a non-syngeneic cell or tissue graft |
WO2013098820A1 (en) | 2011-12-28 | 2013-07-04 | Kaiima Bio Agritech Ltd. | Cultivated sorghum plant having a partially or fully multiplied genome and uses of same |
EP2798081A1 (en) | 2011-12-29 | 2014-11-05 | Baylor Research Institute | Biomarkers for kawasaki disease |
US20150216998A1 (en) | 2012-01-01 | 2015-08-06 | Ramot At Tel-Aviv University Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
JP6190822B2 (en) | 2012-01-09 | 2017-08-30 | マイクロニクス, インコーポレイテッド | Microfluidic reactor system |
WO2013112216A1 (en) | 2012-01-24 | 2013-08-01 | Cd Diagnostics, Llc | System for detecting infection in synovial fluid |
WO2013114363A2 (en) | 2012-01-30 | 2013-08-08 | Yeda Research And Development Co.Ltd. | Antimicrobial agents |
US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
US8771964B2 (en) | 2012-02-02 | 2014-07-08 | Siemens Healthcare Diagnostics Inc. | Compositions and methods for detection of methadone metabolite |
WO2013118120A2 (en) | 2012-02-06 | 2013-08-15 | Rosetta Green Ltd. | Isolated polynucleotides expressing or modulating micrornas or targets of same, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant |
WO2013121426A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
HUE053068T2 (en) | 2012-02-14 | 2021-06-28 | Opko Biologics Ltd | Long-acting coagulation factors and uses thereof |
WO2013123409A1 (en) | 2012-02-17 | 2013-08-22 | NVS Technologies, Inc. | Polymer scaffolds for assay applications |
BR112014021067A2 (en) | 2012-02-19 | 2018-10-30 | Protalix Ltd | oral dosage unit forms and uses thereof for the treatment of gaucher disease |
WO2013124816A2 (en) | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | Generation of neural stem cells and motor neurons |
EP3401393B1 (en) | 2012-02-22 | 2020-02-19 | Exostem Biotec Ltd | Micrornas for the generation of astrocytes |
US9352042B2 (en) | 2012-02-24 | 2016-05-31 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
WO2013130811A1 (en) | 2012-02-29 | 2013-09-06 | Chemocentryx, Inc. | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
EP2833714A1 (en) | 2012-03-01 | 2015-02-11 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Male sterile garlic plants, hybrid offspring of same and methods of generating and using same |
WO2013133561A1 (en) | 2012-03-05 | 2013-09-12 | Seegene, Inc. | Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay |
EP3483184A1 (en) | 2012-03-07 | 2019-05-15 | Yeda Research and Development Co. Ltd | Compositions for inhibition of quiescinsulfhydryl oxidase (qsox1) and uses of same |
US9567392B2 (en) | 2012-03-20 | 2017-02-14 | Biogen Ma Inc. | JCV neutralizing antibodies |
WO2013140389A1 (en) | 2012-03-22 | 2013-09-26 | Ramot At Tel-Aviv University Ltd. | Plif multimeric peptides and uses thereof |
US20140178869A1 (en) | 2012-04-05 | 2014-06-26 | Advanced Cell Diagnostics, Inc. | Detection of immunoglobulin light chain restriction by rna in situ hybridization |
US9568431B2 (en) | 2012-04-16 | 2017-02-14 | Access Medical Systems, Ltd. | Luminescent immunoassays for quantitating analytes having a wide concentration range |
IN2014MN01886A (en) | 2012-04-18 | 2015-07-10 | Univ Ramot | |
MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
US20130280696A1 (en) | 2012-04-23 | 2013-10-24 | Elliott Millenson | Devices and methods for detecting analyte in bodily fluid |
US9439942B2 (en) | 2012-04-24 | 2016-09-13 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
CN104703622B (en) | 2012-04-26 | 2017-05-24 | 芝加哥大学 | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease |
ES2683707T3 (en) | 2012-05-02 | 2018-09-27 | Ibis Biosciences, Inc. | DNA sequencing |
EP3438285B1 (en) | 2012-05-02 | 2020-10-14 | Ibis Biosciences, Inc. | Dna sequencing |
JP6181158B2 (en) | 2012-05-09 | 2017-08-16 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | TACE prodomain variants as TNF-α inhibitors and their medical use |
MX2019001355A (en) | 2012-05-10 | 2023-01-17 | Bioatla Llc | Multi-specific monoclonal antibodies. |
EP2850086B1 (en) | 2012-05-18 | 2023-07-05 | Pacific Biosciences Of California, Inc. | Heteroarylcyanine dyes |
US8865158B2 (en) | 2012-05-22 | 2014-10-21 | Ramot At Tel-Aviv University Ltd. | Bacteriophages for reducing toxicity of bacteria |
MX360866B (en) | 2012-05-24 | 2018-11-09 | A B Seeds Ltd | Compositions and methods for silencing gene expression. |
SG11201408330XA (en) | 2012-05-24 | 2015-01-29 | Mountgate Group Ltd | Compositions and methods related to prevention and treatment of rabies infection |
CN104582770B (en) | 2012-06-01 | 2019-01-29 | 西奈山伊坎医学院 | Ceramide levels in the treatment and prevention of infection |
US9731048B2 (en) | 2012-06-03 | 2017-08-15 | Ben-Gurion University Of The Negev Research And Development Authority | Functionalized titanium binding peptides and implants coated with same |
KR102092025B1 (en) | 2012-06-04 | 2020-03-24 | 옵코 바이오로직스 리미티드 | Pegylated oxm variants |
CA2875710C (en) | 2012-06-22 | 2021-06-29 | John Wayne Cancer Institute | Molecular malignancy in melanocytic lesions |
US20150140679A1 (en) | 2012-06-27 | 2015-05-21 | Siemens Healthcare Diagnostics Inc. | Compositions and methods for liquid mixing assessment |
EP2870110A1 (en) | 2012-07-03 | 2015-05-13 | Nanospun Technologies Ltd. | Methods and devices for adsorption and biodegradation of petroleum |
ES2776365T3 (en) | 2012-07-09 | 2020-07-30 | Novartis Ag | Biomarkers associated with CDK inhibitors |
WO2014014788A2 (en) | 2012-07-18 | 2014-01-23 | President And Fellows Of Harvard College | Modification of surfaces for simulataneous repellency and targeted binding of desired moieties |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
IN2015DN00880A (en) | 2012-07-27 | 2015-06-12 | Univ Illinois | |
EP3594331A1 (en) | 2012-07-29 | 2020-01-15 | Yeda Research and Development Co. Ltd. | Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms |
WO2014020608A1 (en) | 2012-07-31 | 2014-02-06 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and treating motor neuron diseases |
US20150159222A1 (en) | 2012-07-31 | 2015-06-11 | Novartis Ag | Markers associated with human double minute 2 inhibitors |
BR112015001435B1 (en) | 2012-08-06 | 2022-01-18 | Brainstorm Cell Therapeutics Ltd | METHODS FOR GENERATION OF CELLS THAT SECRET BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF), GLIA-DERIVED NEUROTROPHIC FACTOR (GDNF), HEPATOCYTE GROWTH FACTOR (HGF) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN WHICH THESE CELLS DO NOT SECRET FACTOR NERVE GROWTH (NGF) |
CA2882745C (en) | 2012-08-23 | 2022-03-29 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
EP2850078B1 (en) | 2012-08-28 | 2018-04-25 | Pierce Biotechnology, Inc. | Benzopyrylium compounds |
US20140068814A1 (en) | 2012-09-03 | 2014-03-06 | A.B. Seeds Ltd. | Method of improving abiotic stress tolerance of plants and plants generated thereby |
EP2895197B1 (en) | 2012-09-12 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
WO2014057490A1 (en) | 2012-10-09 | 2014-04-17 | Ramot At Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
CN104854152A (en) | 2012-10-12 | 2015-08-19 | Nvs技术股份有限公司 | Polymers having orthogonal reactive groups and uses thereof |
JP6324974B2 (en) | 2012-10-12 | 2018-05-23 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | Antibody-based reagents that specifically recognize toxic oligomeric forms of tau |
WO2014072832A2 (en) | 2012-10-18 | 2014-05-15 | Oslo Universitetstssykehus Hf | Biomarkers for cervical cancer |
US20150354006A1 (en) | 2012-10-19 | 2015-12-10 | Novartis Ag | Markers for acute lymphoblastic leukemia |
US9395369B2 (en) | 2012-10-19 | 2016-07-19 | Regents Of The University Of Minnesota | Guinea pig cytomegalovirus (CIDMTR strain) |
EP2909230B1 (en) | 2012-10-19 | 2019-05-22 | Danisco US Inc. | Stabilization of biomimetic membranes |
AU2013336237A1 (en) | 2012-10-22 | 2015-06-11 | Sabag-Rfa Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
WO2014066590A1 (en) | 2012-10-24 | 2014-05-01 | Research Development Foundation | Jam-c antibodies and methods for treatment of cancer |
EP2912062A1 (en) | 2012-10-24 | 2015-09-02 | Yeda Research and Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
US9926564B2 (en) | 2012-10-29 | 2018-03-27 | Yeda Research And Development Co. Ltd. | Aptamers, multimeric aptamers and uses thereof |
WO2014078733A1 (en) | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
MX363326B (en) | 2012-11-20 | 2019-03-20 | Opko Biologics Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides. |
JP2016502536A (en) | 2012-11-29 | 2016-01-28 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | Methods to prevent tumor metastasis, treat and prognose cancer, and identify drugs that are putative metastasis inhibitors |
US9244083B2 (en) | 2012-11-30 | 2016-01-26 | Siemens Healthcare Diagnostics Inc. | Compositions and methods for detecting vitamin D |
US9121859B2 (en) | 2012-12-04 | 2015-09-01 | Siemens Healthcare Diagnostics Inc. | Compounds and methods for determination of FKBP-binding immunosuppressant drugs |
KR20150096788A (en) | 2012-12-21 | 2015-08-25 | 마이크로닉스 인코포레이티드. | Low elasticity films for microfluidic use |
WO2014100732A1 (en) | 2012-12-21 | 2014-06-26 | Micronics, Inc. | Fluidic circuits and related manufacturing methods |
JP2016509206A (en) | 2012-12-21 | 2016-03-24 | マイクロニクス, インコーポレイテッド | Portable fluorescence detection system and microassay cartridge |
WO2014106838A2 (en) | 2013-01-01 | 2014-07-10 | A.B. Seeds Ltd. | Methods of introducing dsrna to plant seeds for modulating gene expression |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
WO2014108850A2 (en) | 2013-01-09 | 2014-07-17 | Yeda Research And Development Co. Ltd. | High throughput transcriptome analysis |
JP6411372B2 (en) | 2013-01-17 | 2018-10-24 | ノベルラスディクス リミテッド | Method and system for identifying patient-specific driver mutations |
US9970929B2 (en) | 2013-01-18 | 2018-05-15 | Ark Diagnostics, Inc. | Voriconazole immunoassays |
WO2014116721A1 (en) | 2013-01-22 | 2014-07-31 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
US10077475B2 (en) | 2013-01-24 | 2018-09-18 | California Institute Of Technology | FRET-based analytes detection and related methods and systems |
EP2948566A4 (en) | 2013-01-24 | 2016-10-05 | California Inst Of Techn | Chromophore-based characterization and detection methods |
GB2547875B (en) | 2013-02-01 | 2017-12-13 | Univ California | Methods for meta-genomics analysis of microbes |
CA2899865C (en) | 2013-02-01 | 2023-10-10 | Kapil BHARTI | Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs) |
US9411930B2 (en) | 2013-02-01 | 2016-08-09 | The Regents Of The University Of California | Methods for genome assembly and haplotype phasing |
EP2950808B1 (en) | 2013-02-04 | 2019-08-21 | Ramot at Tel-Aviv University Ltd. | Generation of cytotoxic tumor specific cell lines and uses thereof |
ES2674704T3 (en) | 2013-02-13 | 2018-07-03 | Ark Diagnostics, Inc. | Posaconazole Immunoassays |
US20160008282A1 (en) | 2013-02-22 | 2016-01-14 | The Board Of Trustees Of The Universityof Illinois | Transdermal Drug Delivery Using Amphiphilic Dendron-Coil Micelles |
ES2662825T3 (en) | 2013-02-25 | 2018-04-09 | Seegene, Inc. | Detection of nucleotide variation in a sequence of target nucleic acids |
CA2902727C (en) | 2013-03-06 | 2020-08-18 | Protalix Ltd. | Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy |
EP2964668B1 (en) | 2013-03-06 | 2019-11-27 | Protalix Ltd. | Tnf alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same |
WO2014164479A1 (en) | 2013-03-11 | 2014-10-09 | Elitech Holding B.V. | Methods for true isothermal strand displacement amplification |
TWI582239B (en) | 2013-03-11 | 2017-05-11 | 諾華公司 | Markers associated with wnt inhibitors |
US10612019B2 (en) | 2013-03-13 | 2020-04-07 | Monsanto Technology Llc | Methods and compositions for weed control |
US10114015B2 (en) | 2013-03-13 | 2018-10-30 | Meso Scale Technologies, Llc. | Assay methods |
WO2014142575A1 (en) | 2013-03-13 | 2014-09-18 | Seegene, Inc. | Quantification of target nucleic acid using melting peak analysis |
AU2014249015B2 (en) | 2013-03-13 | 2020-04-16 | Monsanto Technology Llc | Methods and compositions for weed control |
KR102257912B1 (en) | 2013-03-13 | 2021-05-27 | 메소 스케일 테크놀러지즈, 엘엘시 | Improved assay methods |
US20140287945A1 (en) | 2013-03-14 | 2014-09-25 | NVS Technologies, Inc. | Surface oxidation for sequestering biomolecules and related methods |
EP2971086A1 (en) | 2013-03-14 | 2016-01-20 | ELITechGroup B.V. | Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use |
EP2970479B1 (en) | 2013-03-14 | 2019-04-24 | Novartis AG | Antibodies against notch 3 |
WO2014159242A1 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
US9273349B2 (en) | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
WO2014151683A1 (en) | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Gla domains as targeting agents |
US9347095B2 (en) | 2013-03-15 | 2016-05-24 | Bio-Rad Laboratories, Inc. | Digital assays for mutation detection |
US9789164B2 (en) | 2013-03-15 | 2017-10-17 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
EP2970909A4 (en) | 2013-03-15 | 2017-02-15 | The University of Chicago | Methods and compositions related to t-cell activity |
WO2014147622A1 (en) | 2013-03-21 | 2014-09-25 | Collplant Ltd. | Compositions comprising collagen and prp for tissue regeneration |
KR101403507B1 (en) | 2013-03-21 | 2014-06-09 | 주식회사 현일바이오 | Methods for Selectively Detecting Mycobacterium tuberculosis complex and Nontuberculous mycobacteria and Kits Using the Same |
ES2643321T3 (en) | 2013-03-24 | 2017-11-22 | Biokine Therapeutics Ltd. | A combination of a CXCR4 antagonist and cytarabine for use in the treatment of myeloid leukemia |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US20140308751A1 (en) | 2013-04-12 | 2014-10-16 | Siemens Healthcare Diagnostics Inc. | Assays for Analyte Homologs |
RU2015149680A (en) | 2013-04-21 | 2017-05-24 | Йеда Ресеарч Энд Девелопмент Ко. Лтд. | AGENTS TO SUPPRESS ACTIVITY AND / OR REDUCE THE NUMBER OF BCL-XL AND / OR BCL-W |
CN105531365A (en) | 2013-04-23 | 2016-04-27 | 耶达研究及发展有限公司 | Isolated naive pluripotent stem cells and methods of generating same |
EP2989119B1 (en) | 2013-04-25 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Use of inhibitory peptides for the treatment of inflammatory diseases |
US20160091485A1 (en) | 2013-04-25 | 2016-03-31 | The Broad Institute, Inc. | Markers for ezh2 inhibitors |
US10386377B2 (en) | 2013-05-07 | 2019-08-20 | Micronics, Inc. | Microfluidic devices and methods for performing serum separation and blood cross-matching |
US10190153B2 (en) | 2013-05-07 | 2019-01-29 | Micronics, Inc. | Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions |
WO2014182847A1 (en) | 2013-05-07 | 2014-11-13 | Micronics, Inc. | Device for preparation and analysis of nucleic acids |
US9328384B2 (en) | 2013-05-13 | 2016-05-03 | Elitechgroup B.V. | Droplet digital PCR with short minor groove probes |
WO2014188423A1 (en) | 2013-05-21 | 2014-11-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
CA2913155A1 (en) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
SG11201509636XA (en) | 2013-05-27 | 2015-12-30 | Rakuto Bio Technologies Ltd | Enzymatic system-containing cosmetic compositions |
EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | Method of assessing risk of pml |
ES2754177T3 (en) | 2013-06-12 | 2020-04-16 | Massachusetts Gen Hospital | Methods for multiplexed detection of target molecules and their uses |
SG10201710528WA (en) | 2013-06-18 | 2018-01-30 | Dnatrix Inc | Treatment of brain cancer with oncolytic adenovirus |
ES2938044T3 (en) | 2013-06-24 | 2023-04-04 | Univ Ramot | Omentum-based structure and delivery system |
US20160296609A1 (en) | 2013-06-28 | 2016-10-13 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
KR101863943B1 (en) | 2013-07-15 | 2018-06-01 | 주식회사 씨젠 | Detection of Target Nucleic Acid Sequence by PTO Cleavage and Extension-Dependent Immobilized Oligonucleotide Hybridization |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
BR112016000555B1 (en) | 2013-07-19 | 2022-12-27 | Monsanto Technology Llc | METHOD FOR CONTROLLING AN INFESTATION OF THE LEPTINOTARSA SPECIES IN A PLANT, INSECTICIDAL COMPOSITION AND CONSTRUCTION OF RECOMBINANT DNA |
WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
EP3027220A1 (en) | 2013-08-01 | 2016-06-08 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
EP3036005A4 (en) | 2013-08-21 | 2017-04-26 | The Board Of Regents Of The University Of Texas System | Compositions and methods for targeting connexin hemichannels |
EP3039030B1 (en) | 2013-08-29 | 2018-09-19 | Yeda Research and Development Co. Ltd. | Selective inhibitors of alpha2 isoform of na,k-atpase and use for reduction of intra-ocular pressure |
IL293871A (en) | 2013-08-30 | 2022-08-01 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
IL228284A (en) | 2013-09-03 | 2016-12-29 | Technion Res & Dev Foundation | Implants composed of cellular scaffolds and a vascular pedicle |
WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
ES2717446T3 (en) | 2013-09-17 | 2019-06-21 | Yeda Res & Dev | Peptides derived from ERK and uses thereof |
CN105960453A (en) | 2013-10-01 | 2016-09-21 | 卡迪马干细胞有限公司 | Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (ALS) |
BR112016007391A2 (en) | 2013-10-03 | 2017-08-01 | Oklahoma Med Res Found | biomarkers of activity, intensity and acute phase of systemic lupus erythematosus disease |
US9476884B2 (en) | 2013-10-04 | 2016-10-25 | University Of Massachusetts | Hybridization- independent labeling of repetitive DNA sequence in human chromosomes |
EP3058105B1 (en) | 2013-10-18 | 2019-05-22 | Seegene, Inc. | Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay |
KR102444140B1 (en) | 2013-10-21 | 2022-09-15 | 옵코 바이오로직스 리미티드 | Long-acting polypeptides and methods of producing and administering same |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
EP3060917B1 (en) | 2013-10-24 | 2019-05-15 | Siemens Healthcare Diagnostics Inc. | Assays for macromolecular analytes |
EP3060656A1 (en) | 2013-10-24 | 2016-08-31 | Yeda Research and Development Co., Ltd. | Polynucleotides encoding brex system polypeptides and methods of using same |
AU2014343214B2 (en) | 2013-10-31 | 2020-04-09 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia with a FLT3 mutation |
CA2929533C (en) | 2013-11-04 | 2023-06-06 | Monsanto Technology Llc | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2015070009A2 (en) | 2013-11-08 | 2015-05-14 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
IL245703B (en) | 2013-11-20 | 2022-07-01 | Univ Iowa Res Found | Methods and compositions for treating amyloid deposits |
MX2016006625A (en) | 2013-11-22 | 2016-12-02 | Univ Illinois | Engineered high-affinity human t cell receptors. |
WO2015079411A1 (en) | 2013-11-28 | 2015-06-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
EP3074044A2 (en) | 2013-11-28 | 2016-10-05 | Yeda Research and Development Co., Ltd. | Synaptojanin-2 inhibitors and uses thereof |
ES2697757T3 (en) | 2013-12-10 | 2019-01-28 | Yeda Res & Dev | Use of enzymes that catalyze the synthesis of pyruvate from formate and acetyl-CoA and bacteria that express the same |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
JP6559135B2 (en) | 2013-12-13 | 2019-08-14 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドSiemens Healthcare Diagnostics Inc. | Pretreatment agent in non-agglutination assay |
EP3083658B1 (en) | 2013-12-18 | 2019-05-08 | President and Fellows of Harvard College | Crp capture/detection of gram positive bacteria |
ES2670991T3 (en) | 2013-12-18 | 2018-06-04 | Siemens Healthcare Diagnostics Inc. | Endothelial Disease Detection |
WO2015094527A1 (en) | 2013-12-19 | 2015-06-25 | Danisco Us Inc. | Use of hydrophobins to increase gas transferin aerobic fermentation processes |
US11293929B2 (en) | 2014-01-07 | 2022-04-05 | Bioatla, Inc. | Proteins targeting orthologs |
JP7037884B2 (en) | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | New vaccines for HPV and HPV-related diseases |
MX368629B (en) | 2014-01-15 | 2019-10-08 | Monsanto Technology Llc | Methods and compositions for weed control using epsps polynucleotides. |
MX2016009954A (en) | 2014-01-29 | 2017-02-23 | Dana Farber Cancer Inst Inc | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd). |
US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
US20170042893A1 (en) | 2014-02-03 | 2017-02-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of casein kinase i inhibitors for depleting stem cells |
WO2015118537A2 (en) | 2014-02-05 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
EP3102607B1 (en) | 2014-02-06 | 2018-08-22 | Yeda Research and Development Co. Ltd. | Anti cd84 antibodies, compositions comprising same and uses thereof |
WO2015120273A1 (en) | 2014-02-07 | 2015-08-13 | The General Hospital Corporation | Differential diagnosis of hepatic neoplasms |
US20170101633A1 (en) | 2014-02-10 | 2017-04-13 | Protalix Ltd. | Method of maintaining disease stability in a subject having gaucher's disease |
WO2015121859A1 (en) | 2014-02-11 | 2015-08-20 | Brainstorm Cell Therapeutics Ltd. | Method of qualifying cells |
US20150232935A1 (en) | 2014-02-14 | 2015-08-20 | The General Hospital Corporation | Methods for diagnosing igg4-related disease |
US9540688B2 (en) | 2014-02-19 | 2017-01-10 | Personal Genomics, Inc. | Real-time sequencing method for single molecule |
WO2015131099A1 (en) | 2014-02-28 | 2015-09-03 | The General Hospital Corporation | Diagnosis of multiple myeloma and lymphoma |
WO2015132784A1 (en) | 2014-03-03 | 2015-09-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method and device for detection of pseudomonas aeruginosa |
WO2015147370A1 (en) | 2014-03-28 | 2015-10-01 | Seegene, Inc. | Detection of target nucleic acid sequences using different detection temperatures |
EP2923709A1 (en) | 2014-03-28 | 2015-09-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Multi-component-multistage malaria vaccine |
BR112016022711A2 (en) | 2014-04-01 | 2017-10-31 | Monsanto Technology Llc | compositions and methods for insect pest control |
CA2945438C (en) | 2014-04-10 | 2023-08-22 | Bonus Therapeutics Ltd. | Bone repair compositions |
DK4026917T3 (en) | 2014-04-14 | 2024-02-12 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Method and kit for determining cell or tissue death or the tissue or cell origin of DNA by DNA methylation analysis |
EP3132057B1 (en) | 2014-04-17 | 2019-10-16 | Yeda Research and Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
AP2016009504A0 (en) | 2014-04-27 | 2016-10-31 | Ccam Biotherapeutics Ltd | Humanized antibodies against ceacam1 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
EP3058085B1 (en) | 2014-04-28 | 2021-02-17 | Yeda Research and Development Co., Ltd. | Microbiome response to agents |
WO2015170325A2 (en) | 2014-05-04 | 2015-11-12 | Forrest Innovations Ltd. | Compositions and methods for reducing pathogen-induced citrus greening |
EP2942627A1 (en) | 2014-05-05 | 2015-11-11 | MicroBPlex, Inc. | Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof |
KR20170007773A (en) | 2014-05-07 | 2017-01-20 | 엔플렉스 피티와이 엘티디 | Synthetic thread based lateral flow immunoassay |
AU2015255883A1 (en) | 2014-05-08 | 2016-10-27 | Novodiax, Inc. | Direct immunohistochemistry assay |
WO2015172134A1 (en) | 2014-05-09 | 2015-11-12 | Biosearch Technologies, Inc. | Cosmic quenchers |
JP6695280B2 (en) | 2014-05-15 | 2020-05-20 | メソ スケール テクノロジーズ エルエルシー | Improved assay method |
WO2015179435A1 (en) | 2014-05-19 | 2015-11-26 | Bayer Healthcare Llc | Optimized humanized monoclonal antibodies against activated protein c and uses thereof |
US10294482B2 (en) | 2014-05-22 | 2019-05-21 | Yeda Research And Development Co. Ltd. | Recombinant microorganisms capable of carbon fixation |
WO2015186129A1 (en) | 2014-06-02 | 2015-12-10 | Technion Research & Development Foundation Limited. | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
EP3149155B1 (en) | 2014-06-02 | 2020-09-23 | Kadimastem Ltd. | Methods of inducing myelination and maturation of oligodendrocytes |
EP2955517A1 (en) | 2014-06-10 | 2015-12-16 | Siemens Healthcare Diagnostics Products GmbH | Process for the stabilisation of body fluid samples by the addition of detergent |
CA2953347A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
EP3145951A1 (en) | 2014-06-24 | 2017-03-29 | InSight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
JP6587288B2 (en) | 2014-06-25 | 2019-10-09 | テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド | Its use for the identification as well as the diagnosis and treatment of cancer stem cells |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
EP3160448A4 (en) | 2014-06-26 | 2018-11-14 | Ramot at Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
KR102309377B1 (en) | 2014-06-27 | 2021-10-05 | 지멘스 헬쓰케어 다이아그노스틱스 인크. | Binding partners specific for vitamin d epimers |
US9746484B2 (en) | 2014-06-27 | 2017-08-29 | Siemens Healthcare Diagnostics Inc. | Binding partners specific for vitamin D epimers in vitamin D assays |
WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
ES2799404T3 (en) | 2014-07-15 | 2020-12-17 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Isolated CD44 polypeptides and uses thereof |
CA2955414A1 (en) | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
CN106715719B (en) | 2014-07-21 | 2022-08-02 | 福尔生物治疗有限公司 | Method for determining drug response to patient specific mutations |
RU2021123470A (en) | 2014-07-29 | 2021-09-06 | Монсанто Текнолоджи Ллс | COMPOSITIONS AND METHODS FOR COMBATING PESTS |
CN108064274A (en) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | For cultivating the culture medium of multipotential stem cell |
EP4219710A3 (en) | 2014-08-01 | 2023-08-16 | Dovetail Genomics, LLC | Tagging nucleic acids for sequence assembly |
CN111624346A (en) | 2014-08-14 | 2020-09-04 | 米密德诊断学有限公司 | Kit for predicting and/or determining prognosis |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
CA2959775A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
EP2992895A1 (en) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
WO2016038609A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
EP3191592A1 (en) | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | Nmda receptor antagonists for treating gaucher disease |
AU2015318018B2 (en) | 2014-09-16 | 2017-05-11 | Synermore Biologics (Suzhou) Co. Ltd. | Anti-EGFR antibody and uses of same |
US10174320B2 (en) | 2014-09-21 | 2019-01-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Downregulating miR-132 for the treatment of lipid related disorders |
JP6954834B2 (en) | 2014-10-06 | 2021-10-27 | ケモセントリックス,インコーポレイティド | Combination therapy of CC chemokine receptor 9 (CCR9) inhibitor and anti-α4β7 integrin blocking antibody |
WO2016061111A1 (en) | 2014-10-13 | 2016-04-21 | Life Technologies Corporation | Methods, kits & compositions for determining gene copy numbers |
DE102015220401B4 (en) | 2014-10-20 | 2022-12-29 | Gen-Probe Incorporated | Erythrocyte Lysis Solution |
US20170306360A1 (en) | 2014-10-24 | 2017-10-26 | Danisco Us Inc. | Method for producing alcohol by use of a tripeptidyl peptidase |
CA2965438A1 (en) | 2014-10-24 | 2016-04-28 | Dupont Nutrition Biosciences Aps | Use of proline tolerant tripeptidyl peptidases in feed additive compositions |
WO2016075697A1 (en) | 2014-11-13 | 2016-05-19 | Enzootic Holdings Ltd. | Functional sex-reversal of decapod crustacean females |
EP3220945A2 (en) | 2014-11-17 | 2017-09-27 | Yeda Research and Development Co., Ltd. | Methods of treating diseases related to mitochondrial function |
EP3221470B1 (en) | 2014-11-17 | 2019-08-14 | Yeda Research and Development Co., Ltd. | Method of analyzing microbiome |
WO2016079219A1 (en) | 2014-11-19 | 2016-05-26 | Koninklijke Philips N.V. | Diagnostic method employing hnl |
EP3221455B1 (en) | 2014-11-20 | 2020-08-12 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells |
CN107208070B (en) | 2014-11-26 | 2021-09-07 | 技术创新动力基金(以色列)有限合伙公司 | Targeted elimination of bacterial genes |
CA2968808A1 (en) | 2014-11-27 | 2016-06-02 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
US10479997B2 (en) | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
US11279974B2 (en) | 2014-12-01 | 2022-03-22 | The Broad Institute, Inc. | Method for in situ determination of nucleic acid proximity |
EP4242329A3 (en) | 2014-12-08 | 2023-10-25 | Berg LLC | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
WO2016092555A2 (en) | 2014-12-11 | 2016-06-16 | Yeda Research And Development Co. Ltd. | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
WO2016094162A1 (en) | 2014-12-12 | 2016-06-16 | Elitechgroup B.V. | Methods and compositions for detecting antibiotic resistant bacteria |
EP3230468B1 (en) | 2014-12-12 | 2020-09-16 | ELITechGroup, Inc. | Methods and kits for detecting antibiotic resistant bacteria |
WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
KR101942955B1 (en) | 2014-12-23 | 2019-01-28 | 4디 파마 리서치 리미티드 | Immune modulation |
KR20170091157A (en) | 2014-12-23 | 2017-08-08 | 4디 파마 리서치 리미티드 | Pirin polypeptide and immune modulation |
JP6882981B2 (en) | 2014-12-30 | 2021-06-02 | セル キュア ニューロサイエンシズ リミテッド | RPE cell population and how to make it |
KR102359257B1 (en) | 2014-12-30 | 2022-02-07 | 셀 큐어 뉴로사이언시스 리미티드 | How to treat retinal disease |
ES2880346T3 (en) | 2014-12-30 | 2021-11-24 | Cell Cure Neurosciences Ltd | Evaluation of retinal pigment epithelial cell populations |
MX2017008567A (en) | 2015-01-04 | 2018-04-26 | Protalix Ltd | Modified dnase and uses thereof. |
WO2016116935A1 (en) | 2015-01-21 | 2016-07-28 | Yeda Research And Development Co. Ltd. | Use of rasa2 as a prognostic and therapeutic marker for melanoma |
PL3256589T3 (en) | 2015-01-22 | 2022-02-21 | Monsanto Technology Llc | Compositions and methods for controlling leptinotarsa |
AU2016219511B2 (en) | 2015-02-09 | 2020-11-12 | Research Development Foundation | Engineered immunoglobulin Fc polypeptides displaying improved complement activation |
WO2016134034A1 (en) | 2015-02-17 | 2016-08-25 | Dovetail Genomics Llc | Nucleic acid sequence assembly |
US10479825B2 (en) | 2015-02-25 | 2019-11-19 | Vanderbilt University | Antibody-mediated neutralization of Marburg virus |
WO2016135732A1 (en) | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
TWI719967B (en) | 2015-03-09 | 2021-03-01 | 美商艾澤西公司 | Antibody drug conjugates (adc) that bind to flt3 proteins |
WO2016145409A1 (en) | 2015-03-11 | 2016-09-15 | The Broad Institute, Inc. | Genotype and phenotype coupling |
EP3268475B1 (en) | 2015-03-11 | 2020-10-21 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Anti amphiregulin antibodies, compositions comprising same and uses thereof |
US10028659B2 (en) | 2015-03-26 | 2018-07-24 | Verily Life Sciences Llc | Aptamer-based sensors, implantable devices and detection system |
US11807896B2 (en) | 2015-03-26 | 2023-11-07 | Dovetail Genomics, Llc | Physical linkage preservation in DNA storage |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
CA2981142A1 (en) | 2015-03-27 | 2016-10-06 | University Of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
US9612534B2 (en) | 2015-03-31 | 2017-04-04 | Tokyo Electron Limited | Exposure dose homogenization through rotation, translation, and variable processing conditions |
EP3277308A1 (en) | 2015-03-31 | 2018-02-07 | Yeda Research and Development Co., Ltd. | Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof |
WO2016157192A1 (en) | 2015-04-01 | 2016-10-06 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Erodium crassifolium l'her plant extracts and uses thereof |
HUE057044T2 (en) | 2015-04-07 | 2022-04-28 | Ela Pharma Ltd | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto |
US20180258467A1 (en) | 2015-04-07 | 2018-09-13 | Polyskope Labs | Detection of one or more pathogens |
EP3081575A1 (en) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
US10519485B2 (en) | 2015-04-15 | 2019-12-31 | Biosearch Technologies, Inc. | Dual quencher probes |
CA2986202C (en) | 2015-04-27 | 2023-08-22 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions |
ES2911341T3 (en) | 2015-04-29 | 2022-05-18 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Antiphytopathogenic compositions |
US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
WO2016178207A1 (en) | 2015-05-04 | 2016-11-10 | Ramot At Tel-Aviv University Ltd. | Methods and kits for fragmenting dna |
EP3091026B1 (en) | 2015-05-08 | 2019-02-20 | Centrillion Technology Holdings Corporation | Disulfide-linked reversible terminators |
US20180161300A1 (en) | 2015-05-11 | 2018-06-14 | Yeda Research And Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
WO2016185471A1 (en) | 2015-05-17 | 2016-11-24 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Compositions and methods for treating cancer |
MX2017014771A (en) | 2015-05-18 | 2018-08-15 | Saga Diagnostics Ab | Detection of target nucleic acid and variants. |
WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
MX2017014787A (en) | 2015-05-21 | 2018-05-01 | Yeda Res & Dev | Bacterial populations for promoting health. |
KR20180014754A (en) | 2015-05-29 | 2018-02-09 | 옵코 바이오로직스 리미티드 | Pegylated oxine tomoldulin variant |
CN107750125A (en) | 2015-06-02 | 2018-03-02 | 孟山都技术有限公司 | For by the composition and method in delivery of polynucleotides to plant |
WO2016196782A1 (en) | 2015-06-03 | 2016-12-08 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
EP3302559B1 (en) | 2015-06-04 | 2022-01-12 | University of Southern California | Lym-1 and lym-2 targeted car cell immunotherapy |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
MA41010B1 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
ES2742514T3 (en) | 2015-06-15 | 2020-02-14 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MX2017016529A (en) | 2015-06-15 | 2018-03-12 | 4D Pharma Res Ltd | Compositions comprising bacterial strains. |
AU2016278067B2 (en) | 2015-06-15 | 2022-09-22 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
MA41060B1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
ES2917884T3 (en) | 2015-06-18 | 2022-07-12 | Yeda Res & Dev | Conditioning protocols and their use for tissue regeneration |
WO2016203476A1 (en) | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
KR102172937B1 (en) | 2015-06-19 | 2020-11-03 | 옵코 바이오로직스 리미티드 | Long-acting coagulation factor and its preparation method |
BR112017028035A2 (en) | 2015-06-26 | 2018-08-28 | Dupont Nutrition Biosci Aps | aminopeptidases for protein hydrolysates |
GB2556004A (en) | 2015-07-10 | 2018-05-16 | Univ West Virginia | Markers of stroke and stroke severity |
CN111375066B (en) | 2015-07-16 | 2023-04-25 | 百欧肯治疗有限公司 | Compositions and methods for treating cancer |
ES2963038T3 (en) | 2015-07-16 | 2024-03-25 | Yeda Res & Dev | Use of anti-third central memory T cells |
US10668094B2 (en) | 2015-07-19 | 2020-06-02 | Yeda Research And Development Co. Ltd. | Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure |
WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
CA2993023C (en) | 2015-07-22 | 2020-04-28 | Phytopharma International Ltd. | Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby |
US11230696B2 (en) | 2015-07-29 | 2022-01-25 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
WO2017021963A1 (en) | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
EP3331572A4 (en) | 2015-08-04 | 2019-05-01 | CD Diagnostics, Inc. | Methods for detecting adverse local tissue reaction (altr) necrosis |
EA201890442A1 (en) | 2015-08-05 | 2018-07-31 | Селл Кьюр Нейросайансес Лтд. | OBTAINING PHOTORECEPTORS FOR THE TREATMENT OF RETITAL DISEASES |
CN108138144A (en) | 2015-08-05 | 2018-06-08 | 细胞治疗神经科学有限公司 | The preparation of retinal pigment epithelium |
US10435457B2 (en) | 2015-08-06 | 2019-10-08 | President And Fellows Of Harvard College | Microbe-binding molecules and uses thereof |
EP3334449B1 (en) | 2015-08-10 | 2021-09-29 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using cd24 |
WO2017025967A1 (en) | 2015-08-13 | 2017-02-16 | Forrest Innovations Ltd. | Formulations and compositions for delivery of nucleic acids to plant cells |
WO2017031370A1 (en) | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
DK3341725T3 (en) | 2015-08-25 | 2021-09-06 | Prothena Biosciences Ltd | METHODS FOR DETECTING PHOSPHORYLATED ALPHA SYNUCLEIN |
US10526408B2 (en) | 2015-08-28 | 2020-01-07 | Research Development Foundation | Engineered antibody FC variants |
WO2017040813A2 (en) | 2015-09-02 | 2017-03-09 | University Of Massachusetts | Detection of gene loci with crispr arrayed repeats and/or polychromatic single guide ribonucleic acids |
US10765706B2 (en) | 2015-09-03 | 2020-09-08 | University Of South Florida | Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers |
CA3036409C (en) | 2015-09-08 | 2023-07-11 | Erik J. Sontheimer | Dnase h activity of neisseria meningitidis cas9 |
WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
WO2017053567A1 (en) | 2015-09-22 | 2017-03-30 | Delta Tm Technologies | Designing customized protein-specific buffer systems |
WO2017059108A1 (en) | 2015-09-29 | 2017-04-06 | Htg Molecular Diagnostics, Inc. | Methods for subtyping diffuse b-cell lymphoma (dlbcl) |
AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
EP3913068B1 (en) | 2015-10-12 | 2023-08-02 | Advanced Cell Diagnostics, Inc. | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto |
CN108368542B (en) | 2015-10-19 | 2022-04-08 | 多弗泰尔基因组学有限责任公司 | Methods for genome assembly, haplotype phasing, and target-independent nucleic acid detection |
EP3365376A1 (en) | 2015-10-25 | 2018-08-29 | Yeda Research and Development Co., Ltd. | Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same |
WO2017072763A1 (en) | 2015-10-26 | 2017-05-04 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
CA3187317A1 (en) | 2015-10-27 | 2017-05-04 | Jay Pharma, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method of inducing cardiomyocytes proliferation and treating heart diseases |
WO2017077539A1 (en) | 2015-11-03 | 2017-05-11 | Ariel-University Research And Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
AU2016354440B2 (en) | 2015-11-09 | 2023-09-28 | The Children's Hospital Of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
WO2017081689A1 (en) | 2015-11-11 | 2017-05-18 | Ramot At Tel-Aviv University Ltd. | Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
LT3209310T (en) | 2015-11-20 | 2018-04-25 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
JP6909230B2 (en) | 2015-11-30 | 2021-07-28 | カディマステム リミテッド | Methods for Differentiation and Purification of Pancreatic Endocrine Cells |
EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
CN108925136B (en) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor) |
CN109415437B (en) | 2015-12-02 | 2022-02-01 | 斯特库伯株式会社 | Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof |
JP2019507582A (en) | 2015-12-04 | 2019-03-22 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | SLC45A2 peptide for immunotherapy |
EP3389678B1 (en) | 2015-12-16 | 2022-06-15 | Ramot at Tel-Aviv University Ltd. | Particles comprising decellularized omentum |
JOP20200228A1 (en) | 2015-12-21 | 2017-06-16 | Novartis Ag | Compositions and methods for decreasing tau expression |
EP3393524B1 (en) | 2015-12-22 | 2022-04-06 | The Regents of The University of Colorado, A Body Corporate | Protecting rnas from degradation using engineered viral rnas |
US10561706B2 (en) | 2015-12-28 | 2020-02-18 | B. G. Negev Technologies And Applications | Isolated polypeptide and compositions comprising same |
CA3009127A1 (en) | 2016-01-06 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
WO2017122203A1 (en) | 2016-01-11 | 2017-07-20 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
MX2018008910A (en) | 2016-01-21 | 2019-03-28 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Parthenocarpic plants and methods of producing same. |
IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive yarn |
IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | Composition comprising sp1 and carbon based nanoparticles and uses thereof |
US11261433B2 (en) | 2016-01-31 | 2022-03-01 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
EP3411390A1 (en) | 2016-02-04 | 2018-12-12 | Yeda Research and Development Co. Ltd | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
WO2017139415A2 (en) | 2016-02-11 | 2017-08-17 | Qiagen Waltham, Inc. | Scavenger compounds for improved sequencing-by-synthesis |
WO2017139419A1 (en) | 2016-02-11 | 2017-08-17 | Qiagen Waltham, Inc. | Polyphenolic additives in sequencing-by-synthesis |
US20190142875A1 (en) | 2016-02-14 | 2019-05-16 | Yeda Research And Development Co. Ltd. | Microbiome-based diagnosis, prediction and treatment of relapsing obesity |
WO2017138008A2 (en) | 2016-02-14 | 2017-08-17 | Yeda Research And Development Co. Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
AU2017220830A1 (en) | 2016-02-16 | 2018-09-06 | Yeda Research And Development Co. Ltd. | Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth |
US20200200735A9 (en) | 2016-02-22 | 2020-06-25 | Ursure, Inc. | System and method for detecting therapeutic agents to monitor adherence to a treatment regimen |
EP3420108A4 (en) | 2016-02-23 | 2019-11-06 | Dovetail Genomics LLC | Generation of phased read-sets for genome assembly and haplotype phasing |
US11053476B2 (en) | 2016-02-23 | 2021-07-06 | Exostem Biotec Ltd. | Generation of cancer stem cells and use thereof |
WO2017147060A1 (en) | 2016-02-25 | 2017-08-31 | Dupont Nutrition Biosciences Aps | Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase |
US10889637B2 (en) | 2016-02-26 | 2021-01-12 | The Board Of Regents Of The University Of Texas System | Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies |
BR112018067522A2 (en) | 2016-03-01 | 2019-02-05 | Univ Of Rijeka Faculty Of Medicine | human poliovirus receptor (pvr) specific antibodies |
IL294121B2 (en) | 2016-03-03 | 2023-09-01 | Memed Diagnostics Ltd | Analyzing rna for diagnosing infection type |
DK3313423T3 (en) | 2016-03-04 | 2019-05-20 | 4D Pharma Plc | COMPOSITIONS INCLUDING BACTERIAL BLAUTIA STAMPS FOR TREATMENT OF VISCERAL HYPERSENSITIVITY |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
IL244649A0 (en) | 2016-03-17 | 2016-06-30 | Yeda Res & Dev | Methods of isolating barrel-like proteases and identifying peptides processed thereby |
CN109641935A (en) | 2016-03-25 | 2019-04-16 | 莫拉利达尔·瑞迪·穆拉 | Combinatorial compound and biomarker exploitation |
CN109195991B (en) | 2016-03-29 | 2023-10-31 | 斯特库比股份有限公司 | Dual function antibodies specific for glycosylated PD-L1 and methods of use thereof |
EP3436480A4 (en) | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
DE202017007129U1 (en) | 2016-04-27 | 2019-08-29 | Gen-Probe Incorporated | Lysis reagent for blood cells |
WO2017194589A1 (en) | 2016-05-10 | 2017-11-16 | Vib Vzw | Inhibition of tau-mediated early synaptic dysfunction |
IL262946B2 (en) | 2016-05-13 | 2023-03-01 | Dovetail Genomics Llc | Recovering long-range linkage information from preserved samples |
US11919971B2 (en) | 2016-05-16 | 2024-03-05 | President And Fellows Of Harvard College | Aqueous biomolecule coupling on CO2-plasma-activated surfaces |
WO2017203520A1 (en) | 2016-05-22 | 2017-11-30 | Yeda Research And Development Co. Ltd. | Methods of using pulmonary cells for transplantation and induction of tolerance |
IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of agents for treating drug resistant tumors |
WO2017208247A1 (en) | 2016-06-02 | 2017-12-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
JP7042755B2 (en) | 2016-06-05 | 2022-03-28 | バーグ エルエルシー | Systems and methods for patient stratification and potential biomarker identification |
WO2017212476A1 (en) | 2016-06-05 | 2017-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Novel molecules for the treatment of inflammation |
US20190160152A1 (en) | 2016-06-09 | 2019-05-30 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
CN109689894A (en) | 2016-06-19 | 2019-04-26 | 耶路撒冷希伯来大学伊萨姆研发有限公司 | Chemotherapy resistance is screened in human haploid cell |
US10961504B2 (en) | 2016-06-27 | 2021-03-30 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory T cells |
CN109416357B (en) | 2016-06-30 | 2022-07-15 | 西门子医疗系统荷兰有限公司 | Devices, systems, and methods for detecting an analyte in a bodily fluid sample comprising a plurality of cells |
WO2018001884A1 (en) | 2016-07-01 | 2018-01-04 | Carlsberg A/S | Method to screen for a mutant within a population of organisms by applying a pooling and splitting approach |
EP4184167A1 (en) | 2016-07-10 | 2023-05-24 | MeMed Diagnostics Ltd. | Early diagnosis of infections |
WO2018011795A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
WO2018011805A2 (en) | 2016-07-11 | 2018-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Systems and methods for growing cells in vitro |
BR112019000610A2 (en) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | long-acting coagulation factor vii and production methods thereof |
US20190224244A1 (en) | 2016-07-11 | 2019-07-25 | Bonus Therapeutics Ltd. | Cell compositions for tissue regeneration |
IL246722A0 (en) | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combination therapy to increase endogenous nitric oxide (no) synthesis |
TW201821093A (en) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | Compositions comprising bacterial strains |
KR20190031299A (en) | 2016-07-20 | 2019-03-25 | 주식회사 에스티큐브 | Methods of treating cancer using a combination of antibodies that bind to glycosylated PD-L1 |
WO2018015296A1 (en) | 2016-07-20 | 2018-01-25 | Vib Vzw | Therapeutic agents for neurological and psychiatric disorders |
WO2018020489A1 (en) | 2016-07-24 | 2018-02-01 | Yeda Research And Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
US10982252B2 (en) | 2016-08-08 | 2021-04-20 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacterial systems for analyzing ubiquitylated polypeptides |
EP3504553B1 (en) | 2016-08-10 | 2022-04-20 | Memed Diagnostics Ltd. | System and method for analysis of biological data |
ES2925527T3 (en) | 2016-08-14 | 2022-10-18 | Univ Ramot | Exosomes derived from mesenchymal cells to treat neurological disorders |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
JP2020501506A (en) | 2016-09-07 | 2020-01-23 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. | Anti-NKp46 antibody and therapeutic use thereof |
EP3512943B1 (en) | 2016-09-14 | 2023-04-12 | Yeda Research and Development Co. Ltd. | Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens |
US11385241B2 (en) | 2016-09-29 | 2022-07-12 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
IL248468A0 (en) | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing |
IL248385A0 (en) | 2016-10-18 | 2017-02-01 | Yeda Res & Dev | Treatment of a circadian rhythm disorder |
US20180128828A1 (en) | 2016-11-04 | 2018-05-10 | James W. Stave | Direct detection of microorganisms in patient samples by immunoassay |
EP3538093B1 (en) | 2016-11-09 | 2023-10-25 | Qiagen Sciences, LLC | Photoprotective mixtures as imaging reagents in sequencing-by-synthesis |
WO2018087759A1 (en) | 2016-11-10 | 2018-05-17 | Yeda Research And Development Co. Ltd. | Phosphotriesterases for treating or preventing organophosphate exposure associated damage |
IL266751B (en) | 2016-11-23 | 2022-07-01 | Chemocentryx Inc | Method of treating focal segmental glomerulosclerosis |
EP3545095A1 (en) | 2016-11-28 | 2019-10-02 | Yeda Research and Development Co., Ltd. | Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest |
WO2018100431A1 (en) | 2016-11-29 | 2018-06-07 | Genomic Vision | Method for designing a set of polynucleotide sequences for analysis of specific events in a genetic region of interest |
EP3548015A1 (en) | 2016-11-30 | 2019-10-09 | Yeda Research and Development Co. Ltd. | Methods of treating liver toxicity and disorders |
MX2018016003A (en) | 2016-12-01 | 2019-05-16 | Univ Ramot | Combined treatment for nerve injuries. |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
HUE059673T2 (en) | 2017-01-04 | 2022-12-28 | Mgi Tech Co Ltd | Nucleic acid sequencing using affinity reagents |
WO2018134824A1 (en) | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
RU2665631C2 (en) | 2017-01-25 | 2018-09-03 | Общество с ограниченной ответственностью "Секвойя Дженетикс" | Method of specific identification of dna sequences |
WO2018137705A1 (en) | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
EP3574114B1 (en) | 2017-01-26 | 2022-06-29 | Oklahoma Medical Research Foundation | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare |
IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods of culturing t cells and uses of same |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
WO2018167778A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and prognosing cancer |
WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
JP2020511539A (en) | 2017-03-16 | 2020-04-16 | リネージ セル セラピューティクス インコーポレイテッド | Method to measure the therapeutic effect of retinal disease treatment |
ES2963461T3 (en) | 2017-04-05 | 2024-03-27 | Yeda Res & Dev | Ex vivo culture system and methods of its use |
CN108823287B (en) | 2017-04-28 | 2019-04-12 | 厦门大学 | A method of detection target nucleic acid sequence |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Methods of treating psychiatric stress disorders |
EP3621991A2 (en) | 2017-05-10 | 2020-03-18 | Ariel Scientific Innovations Ltd. | Methods of purifying antibodies |
ES2939298T3 (en) | 2017-05-21 | 2023-04-20 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Combination of markers for cancer diagnosis |
KR20200019882A (en) | 2017-05-22 | 2020-02-25 | 4디 파마 리서치 리미티드 | Compositions Containing Bacterial Strains |
EP3634991A1 (en) | 2017-05-23 | 2020-04-15 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
MA41708A (en) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | COMPOSITIONS CONTAINING BACTERIAL STRAINS |
GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
CA3065301A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
CN111051346A (en) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1a1 |
EP3630973A1 (en) | 2017-05-31 | 2020-04-08 | Tropic Biosciences UK Limited | Methods of selecting cells comprising genome editing events |
US11542331B2 (en) | 2017-06-06 | 2023-01-03 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands |
ES2826394T3 (en) | 2017-06-09 | 2021-05-18 | Siemens Healthcare Diagnostics Products Gmbh | Activation assay for the diagnosis of heparin-induced thrombocytopenia |
WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
LT3638271T (en) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
ES2823053T3 (en) | 2017-06-14 | 2021-05-07 | 4D Pharma Res Ltd | Compositions comprising a bacterial strain of the genus Megasphaera and uses thereof |
US20200165671A1 (en) | 2017-07-13 | 2020-05-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Detecting tissue-specific dna |
US20200340057A1 (en) | 2017-07-13 | 2020-10-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dna targets as tissue-specific methylation markers |
WO2019012544A1 (en) | 2017-07-13 | 2019-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet pcr strategy for specific detection of tissue-specific circulating dna molecules |
WO2019018747A1 (en) | 2017-07-20 | 2019-01-24 | Trustees Of Boston University | Tenofovir detection assay |
WO2019016772A2 (en) | 2017-07-21 | 2019-01-24 | Novartis Ag | Compositions and methods to treat cancer |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combination therapy for the treatment of cancer |
ES2862434T3 (en) | 2017-08-02 | 2021-10-07 | Siemens Healthcare Diagnostics Products Gmbh | Binding test for the diagnosis of heparin-induced thrombocytopenia |
IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against transferrin receptor 1 (tfr1)-tropic arenaviruses |
ES2909351T3 (en) | 2017-08-17 | 2022-05-06 | Elitechgroup Inc | Duplex Fluorescence Stabilizing Quenchers for Nucleic Acid Probes |
US11692166B2 (en) | 2017-08-23 | 2023-07-04 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
BR112020003533A2 (en) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | b7-h4 antibodies and methods of using them |
JP7145895B2 (en) | 2017-09-01 | 2022-10-03 | 四川科倫博泰生物医薬股▲フン▼有限公司 | recombinant bispecific antibody |
CA3074291A1 (en) | 2017-09-05 | 2019-03-14 | GLAdiator Biosciences, Inc. | Delivery of payloads to stem cells |
WO2019055825A1 (en) | 2017-09-15 | 2019-03-21 | The Regents Of The University Of California | Inhibition of aminoacylase 3 (aa3) in the treatment of cancer |
AU2018336126A1 (en) | 2017-09-19 | 2020-04-30 | Tropic Biosciences UK Limited | Modifying the specificity of non-coding RNA molecules for silencing gene expression in eukaryotic cells |
KR102345601B1 (en) | 2017-09-29 | 2021-12-30 | 주식회사 씨젠 | Detection of target nucleic acid sequences by PTO cleavage and extension-dependent extension analysis |
EP3694545A4 (en) | 2017-10-11 | 2021-12-01 | Board Of Regents, The University Of Texas System | Human pd-l1 antibodies and methods of use therefor |
CA3078809A1 (en) | 2017-10-11 | 2019-04-18 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
JP2021502125A (en) | 2017-11-09 | 2021-01-28 | ピンテオン セラピューティクス インコーポレイテッド | Methods and Compositions for the Preparation and Use of Humanized Conformation-Specific Phosphorylated Tau Antibodies |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with improved properties |
CN111615332A (en) | 2017-11-29 | 2020-09-01 | 维德奥特有限公司 | Compositions, kits and methods for controlling amaranth weeds |
IL274979B1 (en) | 2017-11-29 | 2024-03-01 | Univ Ramot | Methods of preventing or treating neurogenic shock |
WO2019106680A1 (en) | 2017-12-03 | 2019-06-06 | Yeda Research And Development Co. Ltd. | Treatment of an ischemic heart disease |
CN109870581B (en) | 2017-12-04 | 2021-05-04 | 厦门万泰凯瑞生物技术有限公司 | Kit and method for quantitatively detecting HBsAg |
CA3085324A1 (en) | 2017-12-15 | 2019-06-20 | Syngenta Participations Ag | Non-antibody ligands for detecting target proteins |
EP3723785A1 (en) | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
WO2019130313A1 (en) | 2017-12-28 | 2019-07-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method to reproduce circadian rhythms on a microfluidic chip |
EP3735589A2 (en) | 2018-01-05 | 2020-11-11 | Vanderbilt University | Antibody-mediated neutralization of chikungunya virus |
EP3514541A1 (en) | 2018-01-17 | 2019-07-24 | Siemens Healthcare Diagnostics Products GmbH | Method of quantitative determination of a therapeutical tnf-alpha inhibitor |
IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
IL257269A (en) | 2018-01-31 | 2018-04-09 | Olender Tsviya | Endoplasmic reticulum targeting signal |
EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
WO2019155459A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Inhibitors of the 20s proteasome |
WO2019155041A1 (en) | 2018-02-12 | 2019-08-15 | Vib Vzw | Gβγ COMPLEX ANTIBODIES AND USES THEREOF |
WO2019165217A1 (en) | 2018-02-22 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd153 and/or cd30 in infection |
WO2019162945A1 (en) | 2018-02-23 | 2019-08-29 | Carmel Haifa University Economic Corporation Ltd. | Methods for treating memory impairment and cognitive dysfunction |
WO2019167047A1 (en) | 2018-02-28 | 2019-09-06 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of diagnosing and treating bladder cancer |
AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
WO2019175869A1 (en) | 2018-03-12 | 2019-09-19 | Yeda Research And Development Co. Ltd | Treatment of a heart disease |
US20210214445A1 (en) | 2018-03-23 | 2021-07-15 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
JP2021519283A (en) | 2018-03-29 | 2021-08-10 | テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド | Vesicles containing PTEN inhibitors and their use |
EP3774047A1 (en) | 2018-03-29 | 2021-02-17 | Yeda Research and Development Co. Ltd | Use of electric field gradients to control gene expression |
EP3775273B1 (en) | 2018-04-09 | 2023-01-18 | Advanced Cell Diagnostics, Inc. | Methods to further enhance signal amplification for the in situ detection of nucleic acids |
WO2019203623A1 (en) | 2018-04-20 | 2019-10-24 | Seegene, Inc. . | Method and apparatus for detecting a plurality of target nucleic acid sequences in sample |
JP7328324B2 (en) | 2018-04-24 | 2023-08-16 | アンプソース・バイオファーマ・シャンハイ・インコーポレイテッド | Antibodies against TIM-3 and uses thereof |
GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
US20210123016A1 (en) | 2018-05-02 | 2021-04-29 | Novartis Ag | Regulators of human pluripotent stem cells and uses thereof |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neoantigens |
WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
US20210121491A1 (en) | 2018-05-27 | 2021-04-29 | Biolinerx Ltd. | Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors |
EP3802526A1 (en) | 2018-05-29 | 2021-04-14 | ELITechGroup, Inc. | Carborhodamine compounds and methods of preparation thereof |
EP3802839A1 (en) | 2018-06-07 | 2021-04-14 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Nucleic acid constructs and methods of using same |
WO2019234750A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of regenerating and transforming cannabis |
TW202016144A (en) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | Compositions including cd3 antigen binding fragments and uses thereof |
US11873322B2 (en) | 2018-06-25 | 2024-01-16 | Yeda Research And Development Co. Ltd. | Systems and methods for increasing efficiency of genome editing |
AU2019297677A1 (en) | 2018-07-04 | 2021-02-25 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
WO2020012467A2 (en) | 2018-07-08 | 2020-01-16 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
JP7395517B2 (en) | 2018-07-11 | 2023-12-11 | イミュニティ ファルマ リミテッド | Peptide compounds and their therapeutic uses |
CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
US20210310082A1 (en) | 2018-07-31 | 2021-10-07 | Collplant Ltd. | Tobacco transgenic event and methods for detection and use thereof |
IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
CN113227359A (en) | 2018-08-24 | 2021-08-06 | 耶达研究及发展有限公司 | Methods of modulating polarization of M2 macrophages and uses thereof in therapy |
TW202019480A (en) | 2018-09-13 | 2020-06-01 | 美國德州系統大學評議委員會 | Novel lilrb4 antibodies and uses thereof |
CA3112135A1 (en) | 2018-09-20 | 2020-03-26 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral sclerosis |
WO2020065647A1 (en) | 2018-09-25 | 2020-04-02 | Biolinerx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
KR102220701B1 (en) | 2018-09-28 | 2021-03-03 | (주)나노헬릭스 | Multiplex identification method of pcr product using fluorescence-based multiple melting analysis |
US20220048940A1 (en) | 2018-09-28 | 2022-02-17 | Centrillion Technology Holdings Corporation | Disulfide-linked reversible terminators |
EA202191033A1 (en) | 2018-10-15 | 2021-12-21 | Юниверсити Оф Массачусетс | PROGRAMMED DNA BASE EDITING VIA NME2CAS9-DEAMINASE fusion proteins |
WO2020081204A1 (en) | 2018-10-18 | 2020-04-23 | Oklahoma Medical Research Foundation | Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity |
US20210403552A1 (en) | 2018-10-22 | 2021-12-30 | Shanghai GenBase Biotechnology Co., Ltd. | Anti-cldn18.2 antibody and uses thereof |
EP3870614A1 (en) | 2018-10-23 | 2021-09-01 | GlyCardial Diagnostics, S.L. | Antibodies specific for glycosylated apoj and uses thereof |
IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
CN111196851B (en) | 2018-11-20 | 2021-11-16 | 厦门万泰凯瑞生物技术有限公司 | Specific antibody aiming at human anti-mullerian hormone and application thereof |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
US20220089776A1 (en) | 2018-11-28 | 2022-03-24 | Oregon Health & Science University | Therapeutic factor xii antibody |
AU2019389175A1 (en) | 2018-11-30 | 2021-06-10 | Caris Mpi, Inc. | Next-generation molecular profiling |
CN113166246A (en) | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | Antibody and application thereof |
WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
EP3914734B1 (en) | 2019-01-25 | 2024-03-13 | President and Fellows of Harvard College | Compositions and method for synthesizing nucleic acids |
IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof |
IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
WO2020168162A1 (en) | 2019-02-15 | 2020-08-20 | Bio-Techne Corporation | Methods for multiplex detection of nucleic acids by in situ hybridization |
WO2020170239A1 (en) | 2019-02-21 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of generating organoids for high throughput screening of drugs |
EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
CN113692225B (en) | 2019-03-05 | 2023-04-18 | 以色列农业和农村发展部农业研究组织(范卡尼中心) | Genome-edited birds |
GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
EP3946611A2 (en) | 2019-03-31 | 2022-02-09 | Yeda Research and Development Co. Ltd | Anti-viral and anti-tumoral compounds |
JP2022528595A (en) | 2019-04-16 | 2022-06-15 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | Anti-FXI / FXIa antibody and its use |
AU2020265250A1 (en) | 2019-04-30 | 2021-11-18 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy |
IL266433B (en) | 2019-05-02 | 2020-11-30 | Sagi Irit | Compositions comprising the propeptide of lysyl oxidase and uses thereof |
EP3969619A1 (en) | 2019-05-13 | 2022-03-23 | Yeda Research and Development Co. Ltd | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases |
IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutated neopeptides |
EP3973049A1 (en) | 2019-05-22 | 2022-03-30 | Hadasit Medical Research Services and Development Ltd. | Methods of culturing human pluripotent cells |
GB2598520A (en) | 2019-05-28 | 2022-03-02 | Univ Shanghai Tech | Composition and methods to treat ectodermal dysplasia 2, Clouston type |
JP2022536326A (en) | 2019-06-12 | 2022-08-15 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | Method for producing oligodendrocytes |
EP3983540A1 (en) | 2019-06-16 | 2022-04-20 | Yeda Research and Development Co. Ltd | Method for stabilizing intracellular rna |
US20220251193A1 (en) | 2019-06-27 | 2022-08-11 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
JP2022538647A (en) | 2019-07-04 | 2022-09-05 | ウッコ インコーポレイテッド | De-epitoped alpha gliadin and its use for the management of celiac disease and gluten sensitivity |
WO2021005599A1 (en) | 2019-07-11 | 2021-01-14 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
EP3999851A4 (en) | 2019-07-16 | 2023-04-12 | Ramot at Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
AU2020317009A1 (en) | 2019-07-19 | 2022-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors containing Glypican 2 binding domains |
KR20220038415A (en) | 2019-07-26 | 2022-03-28 | 벤더르빌트 유니버시티 | Human monoclonal antibody to enterovirus D68 |
EP4004548A1 (en) | 2019-07-29 | 2022-06-01 | Yeda Research and Development Co. Ltd | Methods of treating and diagnosing lung cancer |
EP4004212A1 (en) | 2019-07-30 | 2022-06-01 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
WO2021028909A1 (en) | 2019-08-12 | 2021-02-18 | Yeda Research And Development Co. Ltd. | Dna repair blood test for predicting response of lung cancer patients to immunotherapy |
WO2021033176A1 (en) | 2019-08-22 | 2021-02-25 | Ariel Scientific Innovations Ltd. | Scaled-up methods for purifying antibodies |
EP4021463A1 (en) | 2019-08-27 | 2022-07-06 | Yeda Research and Development Co. Ltd | Treatment of bacterial vaginosis |
WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
WO2021051390A1 (en) | 2019-09-20 | 2021-03-25 | 上海吉倍生物技术有限公司 | Bcma-targeted antibody and chimeric antigen receptor |
IL269674B (en) | 2019-09-25 | 2020-08-31 | Roy Bar Ziv | Assembly of protein complexes on a chip |
WO2021062323A1 (en) | 2019-09-26 | 2021-04-01 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
CN114206931A (en) | 2019-09-30 | 2022-03-18 | 四川科伦博泰生物医药股份有限公司 | anti-PD-1 antibodies and uses thereof |
JP2022552282A (en) | 2019-10-09 | 2022-12-15 | エスティーキューブ アンド カンパニー | Antibodies specific for glycosylated LAG3 and methods of use thereof |
AU2020361455A1 (en) | 2019-10-10 | 2022-04-21 | Carlsberg A/S | Methods for preparing mutant plants |
WO2021080629A1 (en) | 2019-10-23 | 2021-04-29 | Elitechgroup, Inc. | Methods for true isothermal strand displacement amplification |
IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
US20240117386A1 (en) | 2019-10-31 | 2024-04-11 | Yeda Research And Development Co. Ltd. | Engineered autotrophic bacteria for co2 conversion to organic materials |
JP2023501004A (en) | 2019-11-11 | 2023-01-17 | アイビーアイ-エージー イノベイティブ バイオ インセクティサイズ リミテッド | Insect control nanobodies and their uses |
US20230022576A1 (en) | 2019-11-19 | 2023-01-26 | Protalix Ltd. | Removal of constructs from transformed cells |
IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | Method of treating alzheimer’s disease |
US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
EP4069865A4 (en) | 2019-12-02 | 2023-12-20 | Caris MPI, Inc. | Pan-cancer platinum response predictor |
EP4073246A4 (en) | 2019-12-12 | 2023-12-06 | President And Fellows Of Harvard College | Compositions and methods for light-directed biomolecular barcoding |
MX2022004919A (en) | 2019-12-13 | 2022-05-16 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anti-tslp antibody and uses thereof. |
CA3164996A1 (en) | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | Systems and methods for identifying cells that have undergone genome editing |
EP4077731A1 (en) | 2019-12-22 | 2022-10-26 | Yeda Research and Development Co. Ltd | Diagnosis of frontotemporal dementia |
CN113046420B (en) | 2019-12-26 | 2022-10-04 | 厦门大学 | Method for asymmetrically amplifying multiple target nucleic acids |
EP3842452A1 (en) | 2019-12-26 | 2021-06-30 | Universitat Autònoma de Barcelona | Scaffold proteins and therapeutic nanoconjugates based on nidogen |
CN113046421B (en) | 2019-12-26 | 2022-09-30 | 厦门大学 | Method for asymmetrically amplifying target nucleic acid |
IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods of treating atopic dermatitis |
US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
CN113061165A (en) | 2020-01-02 | 2021-07-02 | 厦门大学 | EB virus BNLF2b gene encoding polypeptide and detection use thereof |
IL272074A (en) | 2020-01-15 | 2021-07-29 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
WO2021152584A1 (en) | 2020-01-28 | 2021-08-05 | Ariel Scientific Innovations Ltd. | Methods of analyzing cell membranes |
WO2021152586A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Methods of treating cancer |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Articles of manufacture comprising anti pd-l1 antibodies and their use in therapy |
EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
WO2021156878A2 (en) | 2020-02-09 | 2021-08-12 | Nlc Pharma Ltd | Rapid detection test for sars-cov-2 |
IL272586A (en) | 2020-02-10 | 2021-08-31 | Yeda Res & Dev | Method for analyzing cell clusters |
AU2021220847A1 (en) | 2020-02-11 | 2022-09-01 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) |
CA3168337A1 (en) | 2020-02-17 | 2021-08-26 | Marie-Andree Forget | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
CN115698047A (en) | 2020-02-25 | 2023-02-03 | 非营利性组织佛兰芒综合大学生物技术研究所 | Leucine-rich repeat kinase 2 allosteric modulators |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
US20230127559A1 (en) | 2020-03-16 | 2023-04-27 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein |
MX2022011892A (en) | 2020-03-26 | 2022-10-18 | Univ Vanderbilt | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2). |
WO2021195385A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2) |
AU2021245409A1 (en) | 2020-03-29 | 2022-11-24 | Yeda Research And Development Co. Ltd. | Variants of beta-glucocerebrosidase for use in treating Gaucher Disease |
TW202203916A (en) | 2020-03-31 | 2022-02-01 | 美商卡默森屈有限公司 | Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies |
IL296698A (en) | 2020-03-31 | 2022-11-01 | Biomuse Ltd | Bacteria for the prevention and treatment of smoke-induced lung damage |
EP4133107A1 (en) | 2020-04-06 | 2023-02-15 | Yeda Research and Development Co. Ltd | Methods of diagnosing cancer and predicting responsiveness to therapy |
EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
US20230135456A1 (en) | 2020-04-13 | 2023-05-04 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
WO2021216728A1 (en) | 2020-04-22 | 2021-10-28 | President And Fellows Of Harvard College | Isothermal methods, compositions, kits, and systems for detecting nucleic acids |
WO2021229577A1 (en) | 2020-05-12 | 2021-11-18 | Collplant Ltd. | Collagen as a delivery tool for metal-based anti-viral agents |
JP7407973B2 (en) | 2020-05-15 | 2024-01-04 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | Antibody-drug conjugates, methods of their preparation, and uses thereof |
IL274811B (en) | 2020-05-20 | 2021-05-31 | Yeda Res & Dev | Indexing spatial information for a single-cell downstream applications |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
EP3939999A1 (en) | 2020-07-14 | 2022-01-19 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | Mage-a1 specific t cell receptor and uses thereof |
IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
US20230309480A1 (en) | 2020-08-18 | 2023-10-05 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
WO2022047359A1 (en) | 2020-08-31 | 2022-03-03 | Berg Llc | Protein biomarkers for pancreatic cancer |
IL277488A (en) | 2020-09-21 | 2022-04-01 | Yeda Res & Dev | Method for modulating weight |
EP4217370A2 (en) | 2020-09-23 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods and compositions for treating coronaviral infections |
IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | Method of diagnosing breast cancer |
EP4225902A1 (en) | 2020-10-05 | 2023-08-16 | Protalix Ltd. | Dicer-like knock-out plant cells |
KR20230104160A (en) | 2020-10-07 | 2023-07-07 | 프로탈릭스 리미티드 | long-acting deoxyribonuclease (DNASE) |
EP4228637A1 (en) | 2020-10-15 | 2023-08-23 | Yeda Research and Development Co. Ltd | Method of treating myeloid malignancies |
IL278401A (en) | 2020-10-29 | 2022-05-01 | Yeda Res & Dev | Polynucleotides for rna editing and methods of using same |
WO2022097157A2 (en) | 2020-11-09 | 2022-05-12 | 1E Therapeutics, Ltd. | Catalytic sequence based methods of treating or preventing bacterial infections |
GB202105804D0 (en) | 2020-11-20 | 2021-06-09 | Univ Cape Town | Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan |
AU2021387979A1 (en) | 2020-11-26 | 2023-03-30 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
CN117460543A (en) | 2020-12-04 | 2024-01-26 | 田纳西大学研究基金会 | Methods for diagnosing amyloid diseases |
IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling ubiquitination of mlkl for treatment of disease |
AU2021411103A1 (en) | 2020-12-28 | 2023-07-13 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
WO2022144883A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
EP4253413A1 (en) | 2020-12-31 | 2023-10-04 | Nona Biosciences (Suzhou) Co., Ltd. | Human lifr antigen binding protein, preparation method therefor, and application thereof |
JP2024502377A (en) | 2021-01-10 | 2024-01-18 | スーパーミート ザ エッセンス オブ ミート リミテッド | Pluripotent stem cell aggregates and microtissues obtained therefrom for cultured meat industry |
WO2022153286A1 (en) | 2021-01-14 | 2022-07-21 | Yeda Research And Development Co. Ltd. | Methods of producing vitamin d |
IL280340B (en) | 2021-01-21 | 2022-04-01 | Yeda Res & Dev | Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection |
GB2603166A (en) | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
CA3206117A1 (en) | 2021-02-09 | 2022-08-18 | Medilink Therapeutics (Suzhou) Co., Ltd. | Bioactive substance conjugate, preparation method therefor and use thereof |
JP2024506955A (en) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | How to make a vaccine |
JP2024506954A (en) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | Genetically modified bacteria for vaccine production |
IL305318A (en) | 2021-02-19 | 2023-10-01 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders |
WO2022183502A1 (en) | 2021-03-05 | 2022-09-09 | 上海吉倍生物技术有限公司 | Anti-cldn6 antibody and use thereof |
EP4304660A1 (en) | 2021-03-08 | 2024-01-17 | ImmunoGen, Inc. | Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer |
JP2024508597A (en) | 2021-03-09 | 2024-02-28 | 四川科倫博泰生物医薬股▲フン▼有限公司 | ROR1 binding protein and its uses |
IL281561A (en) | 2021-03-16 | 2022-10-01 | Yeda Res & Dev | Methods and devices for ex-utero mouse embryonic development |
CA3213424A1 (en) | 2021-03-30 | 2022-10-06 | Lior Moshe ZELCBUCH | Pseudomonas bacteriophage and uses thereof |
CA3214821A1 (en) | 2021-04-06 | 2022-10-13 | Guisong WANG | Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer |
EP4320443A1 (en) | 2021-04-06 | 2024-02-14 | BPGbio, Inc. | Protein markers for the prognosis of breast cancer progression |
WO2022216841A1 (en) | 2021-04-06 | 2022-10-13 | Berg Llc | Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer |
IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders |
CA3215979A1 (en) | 2021-04-19 | 2022-10-27 | Ghassan SAED | Methods for detecting or treating endometrial and ovarian hyperproliferative disorders |
CA3218291A1 (en) | 2021-05-12 | 2022-11-17 | Lior Moshe ZELCBUCH | Staphylococcus bacteriophage and uses thereof |
IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease |
WO2022259242A1 (en) | 2021-06-06 | 2022-12-15 | Yeda Research And Development Co. Ltd. | Combined treatment for cancer |
CA3230677A1 (en) | 2021-06-13 | 2022-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming human cells |
KR20240035997A (en) | 2021-06-16 | 2024-03-19 | 시드엑스 테크놀로지스 인코포레이티드 | Methods for selecting Matiola seeds |
NL2028466B1 (en) | 2021-06-16 | 2022-12-21 | Sakata Holland B V | Methods of sorting matthiola seeds |
WO2023275255A1 (en) | 2021-07-02 | 2023-01-05 | Tropic Biosciences UK Limited | Delay or prevention of browning in banana fruit |
CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
AU2022313138A1 (en) | 2021-07-18 | 2024-02-29 | Gamida-Cell Ltd. | Therapeutic nk cell populations |
WO2023002492A1 (en) | 2021-07-22 | 2023-01-26 | Yeda Research And Development Co. Ltd. | Codon optimization of nucleic acids |
WO2023016828A2 (en) | 2021-07-30 | 2023-02-16 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
WO2023012798A2 (en) | 2021-08-02 | 2023-02-09 | Yeda Research And Development Co. Ltd. | Antibodies for the treatment of cancer |
CA3226947A1 (en) | 2021-08-03 | 2023-02-09 | Muhammad YASSIN | Engineered tcr complex and methods of using same |
EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
WO2023018621A1 (en) | 2021-08-10 | 2023-02-16 | Gamida-Cell Ltd. | Engineered nk cells, methods of their production and uses thereof |
GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
WO2023043280A1 (en) | 2021-09-17 | 2023-03-23 | 주식회사 씨젠 | Detection of target nucleic acid sequence by using synthetic non-natural base-bearing tag oligonucleotide |
IL310714A (en) | 2021-10-26 | 2024-04-01 | Caribou Biosciences Inc | Exonuclease-coupled real-time endonuclease activity assay |
WO2023081070A1 (en) | 2021-11-02 | 2023-05-11 | University Of Massachusetts | Nme2Cas9 INLAID DOMAIN FUSION PROTEINS |
TW202323301A (en) | 2021-11-19 | 2023-06-16 | 英商米羅比奧有限公司 | Engineered pd-1 antibodies and uses thereof |
WO2023105526A1 (en) | 2021-12-08 | 2023-06-15 | Yeda Research And Development Co. Ltd. | Multipotent lung progenitor cells for lung regeneration |
GB202201137D0 (en) | 2022-01-28 | 2022-03-16 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
WO2023144798A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
EP4238988A1 (en) | 2022-03-01 | 2023-09-06 | Consejo Superior De Investigaciones Científicas | Antibodies against sars-cov-2 and uses thereof |
EP4239338A1 (en) | 2022-03-03 | 2023-09-06 | Siemens Healthcare Diagnostics Products GmbH | Global test for determining the status of the blood coagulation system |
WO2023192976A1 (en) | 2022-04-01 | 2023-10-05 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
GB202204813D0 (en) | 2022-04-01 | 2022-05-18 | Bradcode Ltd | Human monoclonal antibodies and methods of use thereof |
WO2023196866A1 (en) | 2022-04-06 | 2023-10-12 | Mirobio Limited | Engineered cd200r antibodies and uses thereof |
US20230357851A1 (en) | 2022-04-06 | 2023-11-09 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring frataxin-replacement therapy |
WO2023209708A1 (en) | 2022-04-25 | 2023-11-02 | Yeda Research And Development Co. Ltd. | Compositions for altering cyclic adp-ribose secondary messenger signalling |
WO2023240201A1 (en) | 2022-06-08 | 2023-12-14 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome |
WO2023239710A1 (en) | 2022-06-08 | 2023-12-14 | Onkure, Inc. | Benzopyrimidin-4(3h)-ones as pi3k inhibitors |
WO2023239940A1 (en) | 2022-06-10 | 2023-12-14 | Research Development Foundation | Engineered fcriib selective igg1 fc variants and uses thereof |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
WO2024038160A1 (en) | 2022-08-18 | 2024-02-22 | Vib Vzw | Means and methods to modulate neuron excitability |
EP4325224A1 (en) | 2022-08-18 | 2024-02-21 | Siemens Healthcare Diagnostics Products GmbH | Thrombocyte activation test for diagnosing heparin-induced thrombocytopenia |
WO2024054469A1 (en) | 2022-09-08 | 2024-03-14 | Onkure, Inc. | Isoquinolones as pi3k inhibitors |
WO2024064024A1 (en) | 2022-09-19 | 2024-03-28 | Onkure, Inc. | ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer |
WO2024064002A1 (en) | 2022-09-20 | 2024-03-28 | Onkure, Inc. | Hdac inhibitor oki-179 for the treatment of cancers resulting from a mapk pathway mutation |
WO2024068744A1 (en) | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3901654A (en) * | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
-
1975
- 1975-06-30 US US05/591,386 patent/US3996345A/en not_active Expired - Lifetime
- 1975-07-29 IL IL47835A patent/IL47835A/en unknown
- 1975-08-08 DE DE2535574A patent/DE2535574C2/en not_active Expired
- 1975-08-08 BR BR7505107A patent/BR7505107A/en unknown
- 1975-08-11 ES ES440173A patent/ES440173A1/en not_active Expired
- 1975-08-11 FR FR7525004A patent/FR2282115A1/en active Granted
- 1975-08-11 CH CH1042475A patent/CH621873A5/fr not_active IP Right Cessation
- 1975-08-11 CA CA233,197A patent/CA1042792A/en not_active Expired
- 1975-08-12 GB GB33581/75A patent/GB1526241A/en not_active Expired
- 1975-08-12 SE SE7509028A patent/SE427504B/en not_active IP Right Cessation
- 1975-08-12 GB GB18719/78A patent/GB1526242A/en not_active Expired
- 1975-08-12 JP JP50098013A patent/JPS6018940B2/en not_active Expired
- 1975-08-12 AU AU83881/75A patent/AU501140B2/en not_active Expired
- 1975-08-12 NL NLAANVRAGE7509587,A patent/NL185423C/en not_active IP Right Cessation
-
1976
- 1976-09-06 SE SE7509028A patent/SE426746B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NL185423C (en) | 1990-04-02 |
IL47835A (en) | 1978-08-31 |
US3996345A (en) | 1976-12-07 |
GB1526241A (en) | 1978-09-27 |
JPS5144628A (en) | 1976-04-16 |
SE427504B (en) | 1983-04-11 |
FR2282115B1 (en) | 1981-08-21 |
IL47835A0 (en) | 1975-10-15 |
NL7509587A (en) | 1976-02-16 |
DE2535574C2 (en) | 1986-01-16 |
AU501140B2 (en) | 1979-06-14 |
DE2535574A1 (en) | 1976-03-04 |
GB1526242A (en) | 1978-09-27 |
CH621873A5 (en) | 1981-02-27 |
SE7509028L (en) | 1976-02-13 |
JPS6018940B2 (en) | 1985-05-13 |
FR2282115A1 (en) | 1976-03-12 |
BR7505107A (en) | 1976-08-31 |
SE426746B (en) | 1983-02-07 |
SE7609841L (en) | 1977-03-09 |
ES440173A1 (en) | 1977-03-01 |
AU8388175A (en) | 1977-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1042792A (en) | Fluorescence quenching with immunological pairs in immunoassays | |
US4261968A (en) | Fluorescence quenching with immunological pairs in immunoassays | |
US4199559A (en) | Fluorescence quenching with immunological pairs in immunoassays | |
US4174384A (en) | Fluorescence quenching with immunological pairs in immunoassays | |
AU657134B2 (en) | Assay methods utilizing induced luminescence | |
US4272506A (en) | Purification of reagents by disulfide immobilization | |
US3998943A (en) | Double receptor fluorescent immunoassay | |
US4668640A (en) | Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins | |
CA1111763A (en) | Lipophilic particles non-covalently bonded to label and ligand for binding assay | |
US6251581B1 (en) | Assay method utilizing induced luminescence | |
US5391740A (en) | Fluoresence polarization immunoassay | |
US4160016A (en) | Receptor fluorescent immunoassay | |
US4161515A (en) | Double receptor fluorescent immunoassay | |
EP0668504B1 (en) | Quaternary ammonium immunogenic conjugates and immunoassay reagent | |
US5340716A (en) | Assay method utilizing photoactivated chemiluminescent label | |
US4218539A (en) | Enzyme conjugates and method of preparation and use | |
US4510251A (en) | Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers | |
US4255329A (en) | Double receptor fluorescent immunoassay | |
US5994143A (en) | Polymeric fluorophores enhanced by moieties providing a hydrophobic and conformationally restrictive microenvironment | |
GB2111476A (en) | Substituted carboxy- fluoresceins and their use in fluorescence polarization immunoassay | |
JPH034596B2 (en) | ||
US5661040A (en) | Fluorescent polymer labeled conjugates and intermediates | |
CH648414A5 (en) | ANTIENZYM-HOMOGEN-COMPETITIVBINDUNG TEST. | |
US4261974A (en) | Valproic acid immunogen conjugates and antibodies thereto | |
US6476199B1 (en) | Reagents for lysergic acid diethylamide immunoassay |